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Summary 
Human Immunodeficiency Virus (HIV) has been a worldwide threat to public health and 
the economy during the last three decades. About 35.3 million people were living with 
HIV at the end of 2012. Currently, no effective vaccine or cure is available despite the 
development of multiple antiretroviral drugs for HIV treatment. 
Extensive genetic variation and rapid evolution has been observed in the HIV genome, 
making HIV one of the fastest evolving organisms and particularly, challenging the 
development of drugs and vaccines. Because of this, drug resistance mutations emerging 
in the HIV genome can cause failure of antiviral therapy for all drug classes. The HIV 
genome only encodes fifteen viral proteins. During the HIV life cycle, fast viral 
replication and infection require a high level of interactions between HIV proteins, as 
well as interactions between HIV and human proteins. Therefore, a comprehensive 
analysis of HIV genomic diversity, interaction and coevolution can provide insights on 
the development of new drug classes and vaccines. 
The objectives of this Phd study were to investigate HIV genome-wide diversity, 
interaction and coevolution. We focused on the development of computational methods, 
which can be used for genome-wide analyses on large-scale datasets of genomic 
sequences, protein structures, anti-HIV inhibitors, HIV-human protein interactions and 
human immunological data. The structure of this thesis is organized as follows. 
Chapter 1 introduces the background knowledge about HIV genome, evolution, life cycle, 
antiretroviral treatment and functional cure. Information of HIV-1 genome-wide inter-
protein interactions is further reviewed. 
Chapter 2 presents the first study to evaluate the functional conservation of HIV-1 Gag 
proteins and to identify natural variations at the drug binding sites of Gag inhibitors. 
Using more than 10000 viral sequences, this study highlights natural variations of known 
drug binding sites and identifies the conserved drug targets in the HIV-1 Gag proteins. 
Chapter 3 extends the idea from Chapter 2 and presents the first study to characterize 
HIV genomic diversity using large-scale genomic datasets. We integrated data 
accumulated during the last three decades including approximately 3000 full-length 
genome sequences, all HIV protein structures, detailed HIV-human protein interaction 
data, human immunological data and all peptide inhibitors derived from the HIV genome. 
Using this large-scale data, we measured genomic diversity of major HIV clades, 
determined factors shaping HIV genomic diversity, identified potential HIV vaccine 
strains, demonstrated conserved drug-target regions and characterized known peptide 
inhibitors derived from HIV-1 full-length genome. 
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Chapter 4 evaluates HIV-1 Gag mutations emerging under drug selective pressure, for 
which we aimed to understand the impact of genome-wide coevolution in HIV drug 
resistance. We identified HIV-1 Gag mutations that were significantly associated with 
genotypic drug resistance to protease inhibitors (PIs). This study reports the first large-
scale analysis to evaluate PI-associated Gag mutations emerging during the PI treatment. 
Chapter 5 introduces a new ensemble coevolution system designed for predicting the 
intra- and inter-protein coevolution in the HIV-1 genome. This system integrates 27 
sequence-based methods published in the past decade. We designed a heuristic algorithm 
to identify a combination of four methods that outperformed any individual method in 
predicting HIV-1 intra- and inter-protein coevolution. 
Chapter 6 applies our ensemble coevolution system with the method combination 
optimized in Chapter 5 to model the HIV-1 Gag-protease coevolution networks. We 
showed that HIV-1 cleavage site mutations and Gag C-terminal mutations coevolving 
with protease drug resistance mutations. These PI-associated Gag positions may interact 
with human proteins, but they may not affect Gag inhibitors because drug binding sites 
are unlikely to coevolve with protease positions. 
Chapter 7 proposes ancestral polytrees as new graphical models to investigate large-scale 
interaction networks. We showed that ancestral polytrees were efficient to model 
mutation pathways in HIV-1 proteins. 
Chapter 8 discusses the ideas of my projects, as well as the strength and weakness of my 
studies. Data visualization and future perspectives of my projects are briefly discussed. 
Overall, this thesis contributes to the understanding of HIV genome-wide diversity, 
interaction and coevolution. 
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Samenvatting 
Het Humaan Immunodeficiëntie Virus (HIV) is in de afgelopen 30 jaar uitgegroeid tot 
een wereldwijde bedreiging voor de wereldgezondheid en  -economie, zo waren er op het 
einde van 2012 35.3 miljoen mensen besmet met HIV. Ondanks uitgebreid 
wetenschappelijk onderzoek naar HIV in de afgelopen 30 jaar.is er op dit moment nog 
altijd geen vaccinatie of genezing mogelijk. Wel zijn er verschillende antiretrovirale 
medicijnen ontwikkeld die de progressie naar het ziektestadium van AIDS vertragen door 
de virale replicatie te blokkeren op verschillende stages van de virale levenscyclus. 
Behandeling van HIV infectie is echter nog levenslang noodzakelijk.   
Het HIV genoom wordt gekenmerkt door een hoge mate van genetische variabiliteit en 
snelle evolutie, wat ervoor zorgt dat HIV als één van de snelst evoluerende organismen is. 
Deze evolutionaire flexibiliteit zorgt er op zijn beurt voor dat het moeilijk is om een 
algemeen werkend vaccin of medicijn te ontwikkelen. Mutaties in het virale genoom 
kunnen leiden tot de ontwikkeling van virale resistentie tegen antiretrovirale 
geneesmiddelen en uiteindelijk tot het falen van de behandeling.  Het virale genoom 
codeert voor 15 verschillende virale eiwitten, die de nodige interacties aangaan met 
zowel andere virale eiwitten als met eiwitten van de gastheercel om de replicatie van het 
virus en de effectieve infectie van gastheercellen te bewerkstelligen. Het is dus van 
belang om een beter inzicht te verkrijgen in de bestaande genetische diversiteit van HIV 
en de evolutionaire dynamiek van eiwit interacties, zodat de verkregen kennis kan 
bijdragen tot de ontwikkeling van nieuwe antiretrovirale geneesmiddelen en vaccins 
tegen HIV.   
Het doel van deze doctoraatsstudie was dan ook het in kaart brengen van diversiteit in het 
HIV genoom en het modeleren van co-evolutie. Er werd een sterke nadruk gelegd op de 
ontwikkeling en toepassing van computationele methoden die geschikt zijn voor analyses 
van grote datasets met informatie over HIV genoom sequenties, eiwitstructuren, 
geneesmiddelen, interacties tussen verschillende virale en humane eiwitten alsook 
beschikbare klinische en immunologische data van HIV patiënten. 
In het eerste inleidende hoofdstuk worden de verschillende algemene facetten van HIV 
geïllustreerd. In het kort worden de genoomstructuur, evolutie en levenscyclus van HIV 
beschreven evenals de aspecten rond bestaande preventiemaatregelen, antiretrovirale 
behandeling en potentiële genezing van HIV infectie. 
Het tweede hoofdstuk beschrijft een studie naar de natuurlijke variatie van HIV-1 Gag 
eiwitten en in het bijzonder van eiwit posities die belangrijk zijn voor de binding met 
HIV-1 antiretrovirale geneesmiddelen.  Door gebruik te maken van meer dan 10000 
virale sequenties werd amino zuur diversiteit in  gekende interactie- en bindingsdomeinen  
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voor verschillende Gag inhibitoren in het virale Gag eiwit en in mogelijke nieuwe 
doelwitten voor therapie in kaart gebracht.  
Het derde hoofdstuk vertrekt van een gelijkaardig idee als het tweede hoofdstuk maar 
presenteert de eerste studie die de genetische diversiteit van het hele HIV genoom 
bestudeert door gebruik te maken van grootschalige datasets. In de afgelopen 30 jaar is er 
een aanzienlijke hoeveelheid aan informatie verzameld over verschillende aspecten van 
HIV infectie. In deze studie hebben we verschillende bestaande datasets met elkaar 
geïntegreerd, met betrekking tot 3000 volledige HIV genoom sequenties, alle HIV eiwit 
structuren, gedetailleerde informatie over verschillende HIV-gastheer eiwit-interacties, 
klinische en immunologische data van HIV-patiënten en informatie over alle HIV peptide 
inhibitors die ontwikkeld zijn gebaseerd op het HIV genoom. Op basis van deze 
informatie hebben we de genetische diversiteit in het HIV genoom nauwkeurig 
beschreven, factoren geïdentificeerd die deze genetische diversiteit vorm geven, HIV 
stammen voorgesteld voor de ontwikkeling van een HIV vaccin en tot slot gekende HIV 
peptide inhibitoren, ontwikkeld op basis van het HIV-1 genoom, gekarakteriseerd. 
Hoofdstuk vier evalHIV-1 Gag mutaties die worden geselecteerd in verschillende HIV-1 
subtypen onder selectieve druk van bestaande antiretrovirale medicijnen. Verschillende 
mutaties in Gag werden geïdentificeerd die significant geassocieerd waren met 
genotypische drug resistentie tegen protease inhibitoren (Pis).  Deze studie rapporteert de 
eerste grootschalige analyse die PI-geassocieerde mutaties bestudeert die ontstaan tijdens 
de behandeling met PIs.  
Het vijfde hoofdstuk introduceert en beschrijft de ontwikkeling van een nieuw ensemble  
model dat toelaat om intra- en inter-eiwit co-evolutie in het HIV-1 genoom te analyseren. 
Dit systeem integreert 27 bestaande sequentie-gebaseerde predictie modellen, die 
gepubliceerd zijn in het afgelopen decennium. Er wordt vervolgens aangetoond dat dit 
samengestelde systeem een optimale combinatie van methoden identificeerde dat betere 
resultaten opleverde dan de meeste individuele modellen in het voorspellen van HIV-1 
intra- en inter-eiwit co-evolutie. 
Hoofdstuk zes past de optimale combinatie van methoden, geïdentificeerd in het 
ensemble model van het vijfde hoofdstuk,  toe om HIV-1 Gag-protease co-evolutie 
netwerken in HIV-1 subtype B te bestuderen. Er wordt aangetoond dat mutaties in het C-
terminale domein van Gag of in Gag klieving posities  co-evolueren met verschillende 
protease resistentie mutaties. Bovendien wordt er aangetoond dat deze Gag mutaties 
mogelijks kunnen interageren met verschillende humane eiwitten, maar niet met e 
bestaande Gag inhibitoren, omdat de drug bindingsdomeinen in het Gag eiwit over het 
algemeen niet mee evolueerde met de verschillende mutaties in het protease enzyme.. 
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Het zevende hoofdstuk presenteert verschillende “ancestral polytree networks” als 
potentiële nieuwe probabilistische grafische modellen voor het onderzoeken van 
grootschalige interactie netwerken op eiwit niveau. Er wordt aangetoond dat deze 
modellen efficiënt de verbanden tussen mutaties in verschillende HIV-1 eiwitten kunnen 
modelleren. 
Kort samengevat, hebben we in dit proefschrift HIV-1 genoom diversiteit, de associatie 
met therapie selectieve druk en factoren die een impact hebben op diversiteit onderzocht. 
Verder werd er ook een systeem op punt gesteld om HIV-1 co-evolutie te modeleren. Een 
ideale combinatie van individuele methoden werd geïdentificeerd die een betere predictie 
opleverde dan elk van de methoden afzonderlijk.  
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 Chapter 1 
General introduction 
 
                                                                                ―To err is human, to forgive, divine.‖ 
                                                                                                           — Alexander Pope  
 
1.1 Human immunodeficiency virus 
In 1981, a new disease recognized as Acquired Immune Deficiency Syndrome (AIDS) 
was spreading among young homosexual men in America, who were succumbing to 
uncommon opportunistic infections and rare malignancies [1]. In 1983, the discovery 
of a retrovirus, now termed human immunodeficiency virus (HIV), was recognized as 
the causative agent of AIDS [2]. Since then, HIV/AIDS has become one of the most 
devastating infectious diseases that have emerged in recent history. At the end of 2012, 
the WHO global health report showed that about 35.3 million people were living with 
HIV (http://www.who.int/gho/hiv/en/). Over 12 million children have been orphaned 
by AIDS and about 1600 babies acquire HIV from their infected mothers every day 
[1]. In the past three decades, the HIV pandemic has caused a great burden to the 
global wealth and health, especially in Sub-Saharan Africa where the highest rate of 
HIV infection has been recorded (http://www.unaids.org/). As the prospects of 
effective vaccine and curative treatments remain uncertain, HIV/AIDS will continue 
to be a significant threat to public health in the coming years. 
Based on genetic similarities, several HIV lineages have been identified including 
HIV type 1 (HIV-1) groups M, N, O, P and HIV type 2 (HIV-2) groups A-H. HIV-1 
group M causes the majority (>90%) of HIV global infections. HIV-1 group O has 
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infected a few tens of thousands of patients in West-Central Africa, HIV-1 group N 
has only been found in a small number of people in Cameroon and HIV-1 group P 
was recently reported in two patients originating from Yaounde, Cameroon [3]. Nine 
subtypes (A-D, F-H, J, K) have been classified in the HIV-1 group M. As a major 
subtype, HIV-1 subtype C accounts for nearly half (48%) of the HIV-1 global 
infections, while subtype B dominates infections in Europe and America. Besides 
HIV-1 subtypes, the recombination between different HIV-1 subtypes has generated 
more than 50 circulating recombinant forms (CRFs), contributing to the global HIV 
diversity [4]. 
HIV originated from multiple zoonotic transmissions from non-human primates 
(chimpanzee, western gorilla, sooty mangabey) to humans in West-Central Africa [3]. 
These zoonotic transmissions probably happened during the hunting and butchering of 
primates for bushmeat, as well as the capture, trade and keeping of monkeys as pets 
[5]. Moreover, simian immunodeficiency virus (SIV) has been identified as the 
ancestor of different HIV lineages in humans [3]. For instance, HIV-1 groups M and 
N originated independently from SIVcpz in chimpanzees living in West-Central 
Africa. HIV-1 groups O and P originated from SIVgor identified in Western lowland 
gorillas living in Cameroon. Notably, divergent SIVcpz lineages are the ancestors of 
SIVgor strains [3]. Accumulated evidence has shown that Kinshasa in the Democratic 
Republic of the Congo might be the birth of the global HIV-1 epidemic [6]. 
The estimated date of HIV origins has been traced back to the late 19
th
 or the early 
20
th
 century when many factors exerted a strong influence during the course of HIV 
transmission [3, 5]. The earliest direct evidence of HIV infection was identified 
retrospectively in a serum sample and a lymph node biopsy specimen collected from 
Kinshasa in 1959 and 1960, respectively [7]. The date for the cross-species 
transmission between HIV-1 group M and SIVcpz was estimated to be 1853 (95% 
confidence interval: 1799-1904). The estimated date of the group O origin was about 
1920 (1890-1940) and the transmission of HIV-1 group N probably took place around 
1921 (1885-1955) [3]. The transmission time of major HIV-1 subtypes and CRFs was 
largely after 1950s [8]. 
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1.2 HIV genome 
Fifteen viral proteins are coded by nine genes in the HIV genome (Figure 1.1). Three 
major genes, gag, pol and env, code for structural proteins (Matrix, Capsid, 
Nucleocapsid, p6), viral enzymes (Protease, Reverse transcriptase, Integrase) and 
envelope proteins (GP120, GP41). The remaining genes code for regulatory proteins 
(Tat, Rev) and accessory (so-called auxiliary) proteins (Vif, Vpr, Vpu/Vpx, Nef) [9]. 
Although both HIV-1 and HIV-2 originated from SIV [3], they have different gene 
maps (Figure 1.1). Particularly, Vpu in HIV-1 and Vpx in HIV-2 mark a distinct 
difference between these two HIV types. 
Interestingly, 11 of 16 HIV proteins are multimeric proteins folded with multiple 
protein units (chains) such as Matrix [10], Capsid [11], Protease [12], RT [13], 
integrase [14], Vif [15], Tat [16], Rev [17], GP120-GP41 [18] and Nef [19] (Figure 
1.1). Multimeric HIV proteins play crucial roles during the viral life cycle. For 
instance, Matrix and capsid multimers are needed to construct the viral structures of 
mature virions [10, 11]. Protease dimers catalyze the Gag and GagPol polyproteins 
during viral maturation [12]. Reverse transcriptase dimer is required to produce viral 
dsDNA during reverse transcription [13]. Integrase tetramer is essential for 
integrating viral dsDNA into host chromosomes during viral integration [14]. Rev 
multimers exports viral mRNA from nucleus to cytoplasm [17]. Envelope trimers 
formed with GP120 and GP41 interact with cellular receptors (e.g. CD4) during viral 
entry [18]. Nef dimers are required for the downregulation of receptors on plasma 
membrane surface [19]. We briefly summarize the HIV protein functions.  
Matrix: Matrix is a structural protein encoded by the gag gene, which provides the 
basic infrastructure of HIV particles. The matrix domain in the intact Gag polyprotein 
is destined to traffic Gag to the plasma membrane for viral budding and to recruit host 
factors (e.g. TIP47) [20]. Matrix anchors the lipid membrane through the 
myristoylated N-terminal domain which is critical for plasma membrane targeting and 
viral assembly [20]. When cleaved from Gag polyprotein during viral maturation, 
Matrix trimmers organize into ordered hexamers to build a structural layer beneath 
viral membrane, which protects the integrity of HIV particles [21]. To prevent the 
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nonspecific binding, matrix in the Gag polyprotein binds nucleic acids through a 
PIP2-dependent mechanism  [21].  
Capsid: Capsid is a structural protein encoded by the gag gene which provides the 
basic infrastructure of viral particles [21]. The hexamer and pentamer structure of 
Capsid constitutes the conical fullerene core of mature HIV particles [22]. The 
interaction between Capsid and host proteins allows for the packaging of host proteins 
(e.g. cyclophilin A) into HIV particles. Capsid also binds with the host restriction 
factor TRIM5α to prevent viral uncoating at the early stage [23]. 
Nucleocapsid: Nucleocapsid is a structural protein encoded by the gag gene [21, 24-
26]. To prevent viral RNA from nucleases, Nucleocapsid binds with the genomic viral 
RNA during viral packaging and coats the genomic RNA within viral core [27]. 
Nucleocapsid can also bind to host proteins such as the ESCRT-associated protein 
ALIX to promote viral budding [28]. Served as an RNA chaperone, nucleocapsid 
enhances nucleic acid-dependent steps in the HIV life cycle. For instance, it promotes 
the DNA strand exchange reactions during reverse transcription and stimulates viral 
integration during viral integration [29]. 
p6: p6 is a structural protein at the C terminus of gag gene [21]. p6 can recruit the 
host machinery to bud the virus outwards from the cell surface [30]. Viral protein Vpr 
and host proteins (e.g. AIP1/ALIX) bind to p6 during viral packaging [21]. 
Protease: The first viral enzyme encoded by the pol gene is protease. During viral 
maturation, protease cleaves Gag polyproteins at the cleavage sites to produce 
structural proteins (Matrix, Capsid, Nucleocapsid, p6). Protease cleaves the GagPol 
polyproteins to produce viral enzymes (Protease, Reverse transcriptase, Integrase). 
Moreover, the activity of protease depends on the concentration of GagPol 
polyproteins and the rate of protease-mediated autoprocessing is modulated by the 
adjacent p6 sequence [31]. 
Reverse transcriptase (RT): RT is another important enzyme encoded by the pol 
gene. To produce dsDNA from the viral single-stranded RNA genome, RT in the 
reverse transcriptase complex (RTC) catalyzes both the RNA-dependent and the 
DNA-dependent DNA polymerization reactions. During reverse transcription, RT 
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jumps from one template to another when two copies of single-stranded genomic 
RNAs exist per virion. The frequent template switch promotes the generation of novel 
recombinant DNA genome sequences derived from two parental RNA sequences [29]. 
Many mutations occur because HIV reverse transcription is highly error-prone. 
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Figure 1.1: Gene map and protein structure of HIV-1 and HIV-2 at the full-
length genome. Protein names on the gene map are annotated with their amino acid 
lengths (HIV-1 reference: HXB2, HIV-2 reference: BEN). HIV multimeric proteins 
are indicated by underlined names and extracellular proteins have their names colored 
blue. Red rings in the gene map indicate the locations where HIV-1 protease cleaves 
during viral maturation. The yellow ring in the env gene indicates the site for human 
proteases (furin, PC1) to cleave [32]. Protein domains indicated in the gene map are 
not to scale. Abbreviations: MA: matrix, CA: capsid, p2: spacer peptide 2, NC: 
nucleocapsid, p1: spacer peptide 1, PR: protease, RT: reverse transcriptase, IN: 
integrase, Vif: viral infectivity factor, Vpr: viral protein R, Tat: trans-activator of 
transcription, Vpu: viral protein U, Rev: regulator of virion expression, sp: signal 
peptide, GP120: surface glycoprotein GP120, GP41: transmembrane glycoprotein 
GP41, Nef: negative regulatory factor, gag: group-specific antigen gene, env: 
envelope gene, ORF: open reading frame. 
  
Integrase: Integrase is the third enzyme encoded by the pol gene. After the nuclear 
import of pre-integration complex (PIC), viral Integrase catalyzes two major reactions 
(3’-processing and strand transfer reactions) to insert the linear, double-stranded viral 
DNA into human chromosomes. In the mature viral particles, Integrase is cleaved 
from the GagPol polyprotein by viral Protease. Moreover, reverse transcriptase binds 
with integrase to prevent the catalytic activity of Integrase before viral integration 
[33]. As part of reverse transcriptase complex, Integrase also plays a role during 
reverse transcription [29]. 
GP120: Encoded by the env gene, the surface glycoprotein GP120 is exposed on the 
surface of HIV particles [34]. On the virion surface, there are less than 30 envelope 
spikes consisting of three molecules of GP120 and GP41 each, connected by non-
covalent interactions [29]. During viral entry, GP120 interacts with specific receptors 
(e.g. CD4) on cell surface [35]. Specifically, the binding of CD4 to the third and 
fourth loop regions of GP120 induces the conformational changes of GP120, which 
exposes the V3 loop of GP120 to interact with cellular coreceptors (e.g. CCR5). Many 
human neutralizing antibodies have been found to target GP120 in a strain-specific 
manner, while a few antibodies (e.g. PG9, PG16) have a broad neutralization activity 
against different HIV-1 strains [36-38]. 
GP41: The transmembrane glycoprotein GP41 is also encoded by the env gene. GP41 
contains a glycine-rich region which is essential for the membrane fusion activity [39]. 
Multiple functions of GP41 have been reported [39]: (1) the intracellular trafficking of 
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the Env protein is regulated by the cytoplasmic tail of GP41 (GP41CT) which 
interacts with various cellular proteins. (2) GP41CT interacts with the viral Matrix 
protein to regulate the Env incorporation into HIV virions. (3) GP41CT regulates the 
internalization exerted by the clathrin-mediated endocytosis. (4) GP41CT regulates 
cellular activation of host transcription factors (e.g. NF-kB). (5) GP41 interacts with 
host proteins to regulate the activity of actin cytoskeleton. (6) HIV-1 GP41 
membrane-proximal external region is targeted by human antibodies (e.g. 10E8) with 
a broad neutralization activity [40]. 
Vif: Viral infectivity factor is an accessory protein encoded by all lentiviruses except 
the equine infectious anemia virus [41]. Vif is famous to hijack the human ubiquitin 
ligase complex CBF-β to counteract the antiviral activity of host proteins, APOBEC-
3G and APOBEC-3F, both of which interfere with the correct assembly of HIV-1 
viral core [42, 43]. Vif also interacts with Gag polyprotein to modulate the Protease-
mediated proteolytic processing [41]. Vif is incorporated in HIV particles [41]. 
Vpr: Viral protein R is an accessory protein which plays multiple functions to 
enhance HIV replications in the non-dividing cells (e.g. macrophages). Vpr plays 
multiple functions such as the modulation of viral reverse transcription, the nuclear 
import of HIV-1 pre-integration complex, the transactivation of HIV-1 long terminal 
repeat (LTR) promoter, the induction of apoptosis and G2 cell cycle arrest (see review 
[44]). Vpr is incorporated in HIV particles [45]. 
Vpu: Viral protein U is a membrane-associated accessory protein with two major 
functions (CD4 downregulation, Tetherin antagonism) [46]. First, Vpu hijacks the 
human ubiquitin machinery to target CD4 and induces the downregulation of CD4 
receptors in the endoplasmic reticulum (ER). Second, Vpu antagonizes Tetherin, an 
interferon-regulated human restriction factor, to enhance the release of viral particles 
in a cell-type dependent manner. Vpu is not incorporated in HIV particles [47]. 
Vpx: Vpx is an accessory protein in HIV-2 but absent in HIV-1. Major functions of 
Vpx include: (1) Vpx induces the ubiquitin-proteasome-dependent degradation of 
SAMHD1 [48-50], which restricts the HIV-2 replication in myeloid cells. (2) Vpx is 
required for HIV-2 reverse transcription [51]. (3) Vpx assists the nuclear import of 
viral pre-integration complex (PIC) [48-50]. A major difference between Vpr in HIV-
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1 and Vpx in HIV-2 is that Vpr arrests the host cell cycle in the G2 phase, while Vpx 
targets the host restriction factor SAMHD1 for the proteasomal degradation [48]. 
Despite these, common attributes have been reported [49, 50]: (1) both are originated 
from the same ancestral gene; (2) both are incorporated into HIV particles via the 
interaction with p6 in gag precursors; (3) both are involved in the nuclear import of 
pre-integration complex. Vpx is not incorporated in viral particles. 
Rev: Rev is an accessory protein which controls the nuclear export of unspliced and 
partially spliced viral RNAs from nucleus to cytoplasm [52]. Rev multimers bind to 
the stem-loop structure of Rev response element (RRE) in the env coding region of 
viral RNA, forming a large oligomeric ribonucleoprotein (RNP) [29]. RNP complex 
interacts with the human export factor CRM1 (exportin 1 or Xpo1) and shuttles 
through the nuclear pore complex (NPC) from nucleus to cytoplasm. Overall, Rev 
activity exerts a strong influence on HIV-1 RNA transport, translation and packaging 
[53]. Rev is not incorporated in the viral particles [47]. 
Tat: Trans-activator of transcription is a regulatory protein which plays essential roles 
in viral replication. Tat exists in all lentiviruses and is the first eukaryotic transcription 
factor known to interact with TAR (transactivating response element) in RNA instead 
of DNA [29]. Tat interacts with many human proteins to execute multiple functions 
[29, 54, 55]: (1) Tat activates the transcription initiation and elongation of HIV-1 LTR 
promoter, preventing the premature termination of transcription and polyadenylation. 
(2) Tat acts as a nucleic acid chaperone to regulate the capping of HIV-1 mRNA. (3) 
Tat induces the T cell apoptosis, neurodegeneration and oxidative stress. (4) Tat 
regulates the expression of major histocompatibility complex (MHC) and 
downregulates several cell surface receptors. (5) Tat suppresses the activity of reverse 
transcriptase to prevent the premature synthesis of viral DNA. (6) Extracellular Tat 
upregulates the CXCR4 expression on CD4+ T cells, stimulates the expression of 
cytokines and interacts with cell-surface receptors to activate cellular signal 
transduction pathways. Tat is not incorporated in the viral particles. 
Nef: Negative regulatory factor is an accessory protein which enhances viral 
pathogenesis [56]. During the viral life cycle, Nef can play multiple roles [56]: (1) 
Nef downregulates CD4 receptors and MHC molecules; (2) Nef promotes the viral 
release and the cell-to-cell transmission; (3) Nef activates the apoptosis and involves 
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with the clathrin-dependent endocytic pathways. Nef is incorporated in the viral 
particles [56]. 
1.3 HIV evolution 
Extensive genetic variation has been observed at the HIV genome, making HIV one 
of the fastest evolving organisms [57]. Rapid HIV evolution is the result of multiple 
factors: (1) a high substitution rate (~0.2 errors per genome during each replication 
cycle) [57], (2) a high replication rate (~10
10
-10
12
 new particles per day) [57], (3) a 
high recombination rate (1.4±0.6×10
−5
 recombinations per site and generation)[58]. 
Because of these, HIV is famous for a high genomic diversity, which is associated 
with disease progression [59]. In fact, HIV genetic diversity of plasma isolates is 
reduced at any time point but increases during the course of infection [59]. Different 
processes have been reported to drive the HIV genetic diversity [57, 59]. For instance, 
The bottleneck accompanying HIV transmission can greatly reduce the genetic 
diversity [57], whereas natural selection is a less potent force to increase genetic 
diversity among hosts than within hosts [59]. Rapid HIV evolution generates T cell 
escape mutants to elude host cytotoxic T lymphocyte responses, causing a major 
barrier to develop effective HIV vaccines [57].  
Recombination: Recombination plays a central role in generating HIV genetic 
diversity during viral evolution. Genetic recombination occurs when the HIV reverse 
transcriptase switches between alternative genomic templates during reverse 
transcription. Moreover, recombination has been reported in all phylogenetic levels: 
among primate lentiviruses, among HIV-1 groups, among subtypes and within 
subtypes [57]. Circulating recombinant forms (CRFs) are the inter-subtype 
recombinants fixed in the patient populations. Until now, over 50 CRFs have been 
reported including the most prevalent CRF01_AE and CRF02_AG in the HIV 
epidemic [4]. Recombination is associated with natural selection and genetic drift to 
generate complex population dynamics, providing an efficient mechanism for HIV to 
escape the accumulation of deleterious mutations [60]. 
HIV reservoir: HIV reservoirs serve to maintain the pool of replicating virus in 
various cell types such as CD4+ T lymphocytes, follicular dendritic cells and 
macrophages [57]. HIV reservoirs protect HIV from anti-HIV inhibitors and promote 
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greater genetic diversity than non-reservoir virus due to the reservoir of archival 
strains [61]. Antiretroviral treatment can impair viral replication but has limited 
efficiency to eliminate HIV reservoirs [62]. It is partly because immune privileged 
tissues can drive anatomical compartments to act as sanctuary sites where HIV can 
still replicate beyond the reach of ant-HIV inhibitors [61]. The identified sanctuaries 
include the central nervous system, the gut-associated lymphoid tissue and the 
genitourinary tract [63]. Potential approaches have been proposed to eliminate HIV 
reservoirs. Most strategies are based on the principle of activating cells with HIV 
reservoir to induce viral expression from the HIV genome; for instance, the stem cell 
immune reconstitution and the activation-elimination strategy. Unfortunately, none of 
the published strategies has been proven to purge all latent virus complexity[62]. 
HIV evolution differs in different human tissues. HIV evolution has shown to be 
different in specific human tissues [64-68]. For instance, the HIV evolutionary rate 
can be differed between different brain compartments [65]. The higher evolutionary 
rate in the meninges and temporal lobe can be caused by the enhanced infection rate 
of macrophages during immune system failure [65]. Independent evolution of 
macrophage-tropism and increased charge in HIV-1 envelope proteins has also been 
found between the human brain and immune tissues [66]. Other tissues such as 
choroid plexus, bone marrow, lung and liver also provide different reservoirs for HIV 
pathogenesis [67].  
Due to high replication and mutation rates, HIV accumulates enormous mutations in 
its viral quasispecies - a group of viruses associated by similar mutations. By 
generating the viral quasispecies, HIV can induce the emergence of drug resistance 
mutations to cause the failure of HIV antiviral therapy. Overall, a better understanding 
of HIV evolution and diversity can benefit current antiviral treatment, as well as the 
drug and vaccine design.  To efficiently eradicate HIV reservoirs remains a challenge 
in the coming years. 
1.4 HIV life cycle 
In a therapy-naïve patient, HIV-1 produces about 10 billion nascent virions and 
infects 100 million cells per day [69]. Such fast replication is ensured by the HIV life 
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cycle which can be divided into six major stages: viral entry, reverse transcription, 
integration, transcription/translation, budding and maturation (Figure 1.2).  
Viral entry is the process of mature virions entering host cells, after which reverse 
transcriptase produces double-stranded DNA (dsDNA) from the viral genomic RNA. 
dsDNA is then imported into nucleus where viral integrase integrates the dsDNA into 
host chromosomes. Transcription makes large amounts of viral RNA copies from the 
integrated viral DNA. The export of viral RNAs from nucleus to cytoplasm allows for 
the translation of folded (precursor) proteins. During viral budding, viral genomic 
RNA and the Vif, Nef, Vpr, Gag, GagPol and Env proteins are assembled to build 
nascent HIV particles. During viral maturation, Gag and GagPol polyproteins are 
cleaved by viral Protease. Besides these major stages, the endocytosis, exocytosis and 
cell-to-cell transmission provide alternative pathways for viral entry and budding 
under certain conditions [70].  
HIV-human protein interactions play essential roles for HIV to hijack human cellular 
systems for viral replication [71-73]. For instance, Vif initiates the ubiquitination and 
degradation of the human protein APOBEC3G via the proteasomal pathway. Previous 
studies have investigated the global landscape of HIV–human protein interactions 
using the genome-wide siRNA libraries [74] and the quantitative scoring system 
MiST [75]. Our knowledge on HIV-human protein have also been enriched by the 
established databases such as the HIV-1 human protein interaction database [76] and 
the VirusMINT database [77].  
Besides interactions between HIV and human proteins, the efficient viral replication 
requires the interactions between HIV proteins, so-called HIV inter-protein 
interactions. Although HIV-1 genome only encodes 15 viral proteins, extensive HIV-
1 inter-protein interactions have been reported during different stages of the viral life 
cycle (Table 1.1). To our knowledge, there is no review which summarizes HIV-1 
inter-protein interactions. To understand the HIV-1 genome-wide interaction, this 
section summarizes the function of HIV-1 inter-protein interactions reported during 
the last three decades. Note that our study focuses on HIV-1 as few studies have 
reported HIV-2 inter-protein interactions (e.g. the p6 positions 15-40 interact with the 
vpx positions: 73-89 [78]). 
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Figure 1.2: Overview of HIV-1 life cycle. 
(1) Viral entry (viral fusion): mature virions target host cells through the binding with 
the cellular receptor CD4 and other chemokine co-receptors (e.g. CCR5, CXCR4).  
(2) Reverse transcription: reverse transcriptase in the reverse transcriptase complex 
(RTC) produces a double-stranded DNA (dsDNA) from a single-stranded RNA [79]. 
(3) Viral integration: the pre-integration complex (PIC) transports dsDNA into the 
nucleus through the nuclear pore complex (NPC) [80]. During the viral pre-
integration transcription, Rev, Tat and Nef are synthesized from un-integrated dsDNA 
[81]. Assisted by cellular cofactors (e.g. LEDGF/p75), PIC integrates dsDNA into 
host chromosome regions with a high transcriptional activity [80]. 
(4) Viral transcription: viral proteins (Tat, Nef) hijack the cellular transcription 
machinery to activate the viral mRNA synthesis from the integrated viral DNA [82]. 
Rev protein exports the viral mRNA and sliced precursors (vpr, vpu, nef, tat, vif, env, 
gag, gagpol) into the cytoplasm.  
(5) Viral translation: viral mRNAs are translated into precursor proteins in the cellular 
compartments. Viral mRNAs (gag, gagpol, vpr, vif) are translated in cytosolic 
polysomes [83]. In the cytoplasm, mature Vpr binds with host proteins (DCAF1, 
CDK1, Cyclin B) to induce the G2 cell cycle arrest. Vif induces the degradation of 
host APOBEC proteins [84] [85]. Nef plays multiple roles in different cellular 
compartments through HIV-host interactions [86]. In the rough ER, the cellular 
proteases (e.g. furin) cleave the env glycoproteins into GP120 and GP41, which 
subsequently assemble into the trimeric complex in the Golgi apparatus via non-
covalent interactions [87]. In the Endoplasmic reticulum (ER), the mRNA of Vpu is 
translated and mature Vpu in the complex with host proteins can retain the newly 
synthesized CD4 [88]. The dislocated CD4 is subsequently delivered to the 
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proteasome for degradation [88]. Most env proteins are retained in ER and 
subsequently ubiquitinated and degraded by proteasome [89]. Some of the env 
proteins travel to the Golgi complex to be proteolytically cleaved by the cellular furin 
or furin-like proteases [90]. Envelope complexes and viral proteins Vpr, Tat, and Nef 
travel to the extracellular membrane surface via the exosome secretory pathways [91].  
(6) Viral assembly and budding: Nascent viral particles are assembled and packaged 
with two mRNA genomes, viral proteins (Vif, Vpr, gag, gagpol, env) and cellular 
cofactors (e.g. actin, tRNA
Lys3
, cyclophilin A). Nascent viral particles pinch off from 
the cellular membrane to infect new host cells [83]. Mature Nef promotes the CD4 
degradation to prevent the Env-CD4 binding on the extracellular membrane of 
infected cells [92]. 
(7) Viral maturation: Protease cleaves Gag and GagPol polyproteins into structural 
proteins (Matrix, Capsid, Nucleocapsid, p6) and viral enzymes (Protease, RT, 
Integrase). After the protease-mediated proteolytic process, the immature viral 
particles become mature for new infections.  
(8) Endocytosis: As an alternative pathway, mature virions enter the host cells via 
cellular endocytosis. Mechanisms that govern HIV endocytosis remain unclear [93]. 
(9) Exocytosis: As an alternative pathway, nascent HIV virions are released through  
the exocytosis pathway [94]. 
Note that protein shapes and sizes are not to scale. 
 
Table 1.1: Summary of HIV-1 inter-protein interaction and their interaction 
positions 
Protein 1,Protein 2 Life stage Positions in Protein 1 Positions in Protein 2 Ref 
GP120, GP41 Entry,  
Budding, 
Translation 
53,72,73,220,223 542-562 [18] 
36-45, 491- 501  [95] 
 593,596,606,610,614,623 [96] 
 572,579 [97] 
 528,530,552,555, 
562,584,608,628 
[98] 
 593,596,597,601,610 [99]
 
 501,605 [100]
 
225,244  [101] 
66,69,72,73,104,107,109,111,
112,116,213,217 
 [102] 
44-47,84-86,215-219,222-
229, 91-95,241-245,485-492 
 [103] 
 596,597,618 [104] 
382,420,433,438  [105] 
44,53  [106] 
491,494,496,498  [107] 
 556,558,563,570,577 [108]
 
GP41, Matrix Entry, 
Budding 
 93 C-terminal 12,30 [109]
 
201 12,30,34 [110] 
201, 144 C-terminal 49 [111]
 
 292-296 34 [112]
 
 104 C-terminal 12,30 [113] 
 116-123 18,20,22,32,33 [114] 
 144 C-terminal 8-9,  16-18 [115] 
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 17 C-terminal  [109] 
 62 [116] 
  41-57,  56-68,  67-78 [117] 
 13-43 [118] 
  116-128 [119] 
 18,20,22,29,32,33 [120] 
GP120, Tat Entry 157-171 73-86 [121] 
RT, NC Reverse 
transcription 
 1-55 [122] 
 12-53 [123] 
 13C-terminal in p15 1-71 [124] 
RT, Integrase Reverse 
transcription; 
Integration 
 220-270,243,250,258 [125] 
1-242,387-560 201-288 [126] 
 130 [33] 
 46-65 [127] 
RT, Vif Reverse 
transcription 
 161-164,169-192 [128] 
  56C-terminal [129] 
RT, Tat Reverse 
transcription 
 47,49-52 [130] 
  60N-terminal [131] 
 1-86 [132] 
 49-57 [133] 
RT, Nef Reverse 
transcription 
 154-172 [134] 
Integrase, Nef   58-206 [135] 
Integrase, Rev Integration  1-30,49-74 [136] 
118-128,66-80 12-23, 53-67 [137] 
66-80,118-128  [138] 
Integrase,Matrix Integration 50-212 132 [139] 
Matrix, Vpr Integration 88-132  [140] 
Tat, Vpr Transcription 50-67 73 [141] 
RT, Gag Budding 183-305  [142] 
NC
Gag
, Vpr Budding 13-30,34-51 80-96 [143] 
NC
Gag
, Vif Budding  157-179 [144] 
48-55 68-81,89-100, 
162-173,177-189 
[145] 
Capsid
Gag
, Vif Budding 219-231  [146] 
Nef, P6* Budding 148-180  [147] 
Nef, GP41
Env
 Budding 181-210  [148] 
p6
Gag
, Vpr Budding  84-94 [149] 
 1-71 [150] 
32-46  [151] 
35-47  [152] 
15-18  [153] 
34-36  [154] 
p6*, Protease Maturation 65-68  [155] 
Protease, Vif Maturation 1-9  [156] 
 41-65 [157] 
 78-98 [158] 
 81-88,88-98 [159] 
 
1.4.1 Viral entry 
In this stage, HIV virions enter into the host cell cytoplasm and initiate the cell 
infection (Figure 1.2). Host cells which express the CD4 receptor on the cell surface 
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are targeted (e.g. helper T lymphocytes, macrophages, dendritic cells) by 
trimeric spikes formed by GP120 and GP41 (Figure 1.3). Different entry pathways 
and the involved host factors have been reviewed previously [87, 93, 160-163]. 
 
 
Figure 1.3: Schematic view of HIV-1 inter-protein interaction during viral entry. 
(A) Viral attachment: GP120 on the mature virion surface binds with CD4 which 
induces the aggregation of CD4 and co-receptors (e.g. CCR5) [164]. (B) Coreceptor 
binding: GP120 binds with chemokine co-receptors on the extracellular surface. (C) 
Interactions between GP120 and co-receptors induce conformation rearrangements in 
GP120 which expose the GP41 to form six-helix bundles. (D) The six-helix bundles 
pull viral core to enter the cytoplasm of host cells through the newly-created fusion 
pore. Protein shapes and sizes are not to scale. 
 
GP120−GP41 protein interaction: GP120 interacts with GP41 to form a 
trimeric spike through non-covalent interactions, allowing for the flexible structural 
rearrangement during viral entry [102]. When GP120 binds with the CD4 receptor, 
the non-covalent interaction between GP120 and GP41 is subsequently disrupted and 
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a series of conformation changes take place for viral entry [165]. The CD4-induced 
realignments in viral spikes induce the exposure of GP41 fusion peptide, which is 
inserted into the cell membrane thereafter (Figure 1.3). Early studies of GP120-GP41 
interactions showed that mutations in the C5 region of GP120 or the ectodomain of 
GP41 can disrupt the non-covalent interactions [18, 95, 100, 166]. A Science paper 
recently reported the first atomic-level structure of GP120-GP41 trimers, showing that 
an invariant 7-stranded β-sandwich in GP120 maintains GP120-GP41 interactions and 
regulates GP41 transitions [18].  
GP41
Env−MatrixGag protein interaction: Mutagenesis, biochemical and biophysical 
assays have shown that the N and C terminus of HIV-1 Matrix in Gag precursors 
(Matrix
Gag
) interact directly with the cytoplasmic tail of GP41 (GP41CT) [116]. 
GP41CT plays an essential role for the Env incorporation during viral budding [111, 
112, 167] and for the pre-bundle rearrangement of Env protein during viral entry [114, 
168, 169]. Major functions of GP41-Matrix interaction include: (1) Env proteins are 
incorporated into nascent virions through the interaction between GP41
Env
 and 
Matrix
Gag  
[108, 110, 111, 113, 116, 167]. (2) The maturation of viral core is associated 
with the activity of GP41CT [170]. (3) The stabilization of Env glycoproteins is 
enhanced by the GP41
Env
 -Matrix
Gag
 interaction in a cell-dependent manner [120, 169, 
171]. 
GP120−Tat protein interaction: Tat can bind with GP120 to enhance viral entry 
[121, 172]. This interaction involves several processes. Firstly, Tat is released to the 
extracellular space by infected cells [121, 173, 174]. Secondly, on the extracellular 
membrane of infected and uninfected cells in neighboring areas, the released Tat 
binds to chemokine receptors CCR2 and CCR3 but not CCR1, CCR4, and CCR5 
[175]. Thirdly, extracellular Tat directly interacts with GP120 on the cell surface, 
while Tat is dispensable for viral entry [121]. Moreover, the GP120-Tat interaction 
impacts on viral entry but not on Tat-mediated transactivation. When considering 
interaction domains, residue positions in the V1/V2 loop of GP120 interact with the 
second exon of Tat [121]. It remains unclear how GP120-Tat interaction exerts an 
influence on the conformation rearrangement of GP120. 
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No interaction between GP41 and Vif: An early study suggested that Vif may 
interact with GP41CT [176]. Two studies later showed that the GP41CT activity was 
independent of Vif, ruling out the possible GP41-Vif interaction during viral entry 
[177, 178]. 
1.4.2 Reverse transcription 
During reverse transcription, reverse transcriptase produces a double-stranded DNA 
from the single-stranded viral RNA [179-181]. After the viral entry, a series of 
processes take place to form the reverse transcriptase complex (RTC) in viral core 
(Figure 1.4). Where and when the reverse transcription happens is still debatable but 
recent evidence favors the hypothesis that reverse transcription takes place in the 
intact capsid core and is triggered by massive deoxyribonucleotides in the cytoplasm 
after viral entry [181-183]. During reverse transcription, the intact capsid core moves 
toward the nuclear pore on microtubules and RTC is turned into the pre-integration 
complex (PIC) [184] (Figure 1.2). Different aspects of HIV reverse transcription have 
been reviewed such as the enzymatic function of reverse transcriptase [34, 182], the 
maturation of RTC [79], the strand transfer process and recombinant events [180]. 
Here we focus on HIV-1 inter-protein interactions. 
RT−Integrase protein interaction: Integrase can physically interact with RT to 
enhance the initiation of reverse transcription [125, 185-188]. Mutagenesis analysis 
showed that Integrase mutants could severely impair reverse transcription and weaken 
the RT-Integrase interaction [33, 186]. Regarding RT-integrase interaction domains, 
the C terminus of Integrase (positions: 220-270) is important to bind with RT [33, 
186, 188]. The interaction domain in RT covers a board area including the finger-
palm domain (positions: 1-242) and the C terminus of the connection subdomain 
(positions: 387-560) [33]. It is now agreed upon that Integrase can interact with RT 
but the role of this interaction remains unclear. It has been shown that Integrase 
stimulates both initiation and elongation at the early steps of reverse transcription, 
while integrase exerts no effect on steps at or before template-primer annealing [189]. 
Integrase exerts no influence on the RT processivity, whereas RT can stimulate the 
Integrase-mediated strand transfer reaction in a concentration-dependent manner 
[126]. In another study, RT however inhibited the Integrase strand transfer reaction in 
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the cell-free assays [186, 188]. This discrepancy might be due to different HIV-1 
strains, cell lines or experiments. Further studies are still needed to address the 
functional interactions between Integrase and RT. 
RT−Nucleocapsid protein interaction: At the initiation stage of reverse 
transcription, RT interacts with Nucleocapsid to anneal the tRNA
Lys3
 onto the primer 
binding site of HIV genomic RNA [123, 190]. During reverse transcription, the RT-
Nucleocapsid interaction can: (1) promote the RT activity by reducing the rate of 
incorrect nucleotide incorporation [122, 191, 192]; (2) improve the 
ribonuclease activity of RNase H domain in RT [185]; (3) counteract the decreased 
strand transfer efficiency caused by RT mutations [124]. Two zinc fingers in 
Nucleocapsid are important to interact with the C terminus of the RNase H domain in 
RT [123, 124, 190, 192]. 
 
 
Figure 1.4: Schematic view of HIV-1 inter-protein interactions in reverse 
transcriptase complex. During reverse transcription, RTC can produce viral dsDNA, 
protect dsDNA from nuclease digestion and prevent viral self-integration [183]. 
Cellular cofactors can interact with RTC to facilitate reverse transcription [74]. 
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Question marks indicate unclear interaction positions. Note that protein shapes and 
sizes are not to scale. 
RT−Nucleocapsid protein interaction: At the initiation stage of reverse 
transcription, RT interacts with Nucleocapsid to anneal the tRNA
Lys3
 onto the primer 
binding site of HIV genomic RNA [123, 190]. During reverse transcription, the RT-
Nucleocapsid interaction can: (1) promote the RT activity by reducing the rate of 
incorrect nucleotide incorporation [122, 191, 192]; (2) improve the 
ribonuclease activity of the RNase H domain in RT [185]; (3) counteract the 
decreased strand transfer efficiency caused by RT mutations [124]. Two zinc fingers 
in Nucleocapsid are important to interact with the C terminus of RNase H domain in 
RT [123, 124, 190, 192]. 
RT−Vif protein interaction: RT was found to interact with Vif using the 
glutathione-S-transferse (GST) pulldown assay [128]. Vif is a component of RTC 
[129] and PIC [193]. A reduced RT activity was observed in the presence of Vif 
mutant [194], and the dsDNA synthesis is harmed by Vif defects in non-permissive 
cells [195, 196]. During the early stage of reverse transcription, the RT-Vif interaction 
can stimulate the tRNA
Lys3
 primer annealing by increasing the polymerization rate, 
decreasing the pausing of reverse transcription during ssDNA synthesis and 
increasing the RT processivity [129]. The C terminus of Vif can interact with RT 
[128], but the interaction domain in RT remains unclear. 
RT−Tat protein interaction: Direct RT-Tat interaction was confirmed by GST pull-
down and immune-precipitation assays [133]. A ratio of at least 2:1 between Tat and 
RT is required for the increased RT activity [197]. While the RT-Tat interaction is 
crucial for reverse transcription, biological mechanisms and interaction domains 
remain unclear. Tat can stimulate reverse transcription [130] and virus lacking Tat 
cannot initiate reverse transcription efficiently [131], whereas other studies have 
reported that Tat can suppress reverse transcription in cell-free assays [131, 132, 198]. 
Further studies are still needed to address the role of RT-Tat interaction and 
corresponding interaction domains. 
RT−Nef protein protein interaction: Direct interaction between RT and Nef was 
confirmed by co-precipitation assays [134]. The average ratio of Nef to RT is 
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estimated to be 1:10 in HIV-1 particles [199]. The RT-Nef interaction enhances the 
binding affinity of RT to RNA, a process which is independent of Nef binding to 
RNA [134]. Based on mutagenetic analyses, the p51 in RT was found to interact with 
the disorder loops in the C terminus of Nef [134]. 
RT−Vpr protein interaction: Peptides derived from Vpr (positions: 57-71 and 61-
75) can physically interact with RT and inhibit reverse transcription [200]. While 
direct evidence of full-length Vpr and RT interaction is still lacking, previous studies 
have shown that: (1) Vpr interacts with the tRNA
Lys3
 synthetase to influence the 
initiation of reverse transcription [201]. (2) Vpr is associated with the packed 
filaments in RTC [202]. (3) Vpr is cosedimented with the synthesized viral dsDNA 
[203]. (4) Both Vpr and RT are packed into the viral core. Further studies are needed 
to address the functional interactions between RT and Vpr. 
1.4.3 Viral integration 
As illustrated in Figure 1.5, HIV-1 integration involves: (1) the 3’-end processing, 
Integrase removes two nucleotides at the 3’ end of dsDNA in cytoplasm. (2) Nuclear 
import, PIC containing dsDNA is imported from cytoplasm into nucleus through the 
nucleus pore complex. (3) PIC targets the host chromosome domains with a high 
transcriptional activity. This process is assisted by cellular cofactors such as 
LEDGF/p75 – a cellular transcriptional coactivator serving as a tethering protein 
between the PIC and host chromosomes. (5) Strand transfer reaction: viral dsDNA is 
inserted into the host chromosomes via the strand transfer reaction exerted by viral 
Integrase. (6) Gap repair, the unpaired regions of DNA between HIV dsDNA and host 
dsDNA are repaired by cellular cofactors. Further details about nuclear import, pre-
integration transcription and host proteins (e.g. LEDGF/p75, INI1) have been 
reviewed in [81, 204, 205]. 
Integrase−Matrix protein interaction: The C terminus of Tyrosine-phosphorylated 
Matrix was reported to interact with the central domain of Integrase using immune-
precipitation and western-blot assays [139]. The Integrase-Matrix interaction 
facilitates the nuclear localization of viral dsDNA in the absence of mitosis [139]. 
Tyrosine phosphorylation of Matrix was necessary to interact with Integrase [139]. 
Replacing tyrosine with phenylalanine at the residue position 132 of Matrix can block 
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the nucleus import [139]. The core domain  of Integrase (positions: 50-212) is 
important for the Matrix binding [139]. 
Integrase−RT protein interaction: Integrase can physically interact with RT [33, 
125, 127, 187]. Two important roles of the Integrase-RT interaction have been 
reported during viral integration. First, RT serves as a regulator to inhibit the 
disintegration activity of Integrase [206]. Second, RT in PIC may inhibit the strand 
transfer activity of Integrase to prevent auto-integration before viral dsDNA reaches 
the host chromosome [187]. Auto-integration is a suicidal process that viral dsDNA 
integrates within itself [207]. Considering the interaction domains, the C terminus of 
Integrase is necessary and sufficient to interact with RT [33, 125]. Mutations 
(W243E, V250E, K258A) in the C terminus of Integrase could severely impair the 
Integrase-RT interaction [125]. Moreover, RT positions (L168, F171, Q174, I178) 
may interact with Integrase [127].  Notably, different interaction domains have been 
observed during viral integration and reverse transcription (Table 1.1). Further studies 
are needed to verify whether this difference is due to different cell-lines, HIV-1 
strains or conformation switch. 
 
Figure 1.5: Schematic view of HIV-1 inter-protein interactions during viral 
integration. (A) Viral uncoating: RTC turns into PIC with the recruitment of Matrix, 
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Rev and host factors (e.g. LEDGF/p75). PIC contains host factors and viral Integrase, 
Matrix, RT and Vpr and little to no Capsid. Meanwhile, Nef, Nucleocapsid, Tat and 
most Capsid proteins are dissociated from PIC [204]. (B) Nuclear import: PIC is 
imported from cytoplasm to nucleoplasm through the nuclear pore complex. (C) 
Chromosome localization: PIC is tethered to the targeting chromosome via the 
assistance of LEDGF/p75. (D) Integration: PIC integrates viral dsDNA into host 
chromosome. Question marks indicate unclear interaction positions. Note that protein 
shapes and sizes are not to scale. 
 
Matrix−Vpr protein interaction: Matrix was found to directly interact with Vpr in 
HIV-1 mature virions using coimmunoprecipitation and two-hybrid GAL4 assays
 
[140]. The Matrix-Vpr interaction may improve the stoichiometry of nucleophilic 
components in PIC and promote the nuclear import of dsDNA in non-dividing cells 
(e.g. monocyte-derived macrophages) [208]. The C terminus of Matrix may interact 
with Vpr [208], while the interaction domain in Vpr remains unclear. 
1.4.4 Viral transcription and translation 
After HIV-1 dsDNA is integrated into host chromosomes, viral regulatory proteins 
Tat, Rev and Nef can interact with cellular miRNA machinery to control the gene 
expression for the virus production (Figure 1.6). Previous studies have reviewed the 
biological processes of HIV-1 transcription in different cell lines [209] and the 
interaction between HIV proteins and cellular transcriptional factors [82, 210]. 
Tat−Vpr−cyclin T1/CDK9 complex: Vpr can interact with both Tat and cyclin T1 
[141]. Tat is a regulatory protein known to interact with cyclin T1 and its partner, 
CDK9, to promote viral transcription. In the presence of Vpr, a super-activation of the 
long terminal region (LTR) by Tat and cyclin T1/CDK9 was observed [141]. Vpr can 
strongly activate theHIV-1 LTR when both cyclin T1/CDK9 and Tat are present 
[141]. Vpr is known to the pre-integration transcription which synthesizes Rev, Tat 
and Nef before viral integration (Figure 1.2). Tat is dispensable for the Vpr-mediated 
activation of pre-integration transcription [211]. Moreover, the residue position R73 
in Vpr may interact with Tat [141], while the interaction domain in Tat remains 
unclear. 
Tat−Nef protein interaction: Physical interaction between Tat and Nef was 
identified using transient transfection, co-immunoprecipitation and GST pull-down 
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assays [212]. Both Tat and Nef are expressed before viral integration and localized in 
nucleus (Figure 1.2). Nef can enhance the Tat-mediated transactivation of HIV-1 
LTR [212]. On the cell membrane, Nef promotes the Tat-mediated viral transcription 
via an hnRNP-K-Nucleated signaling complex [213-215]. Nef exerts an influence on 
the Tat-mediated gene expression either by the direct interaction or the signaling 
pathways mediated by cellular cofactors. Interaction domains between Tat and Nef 
remain unclear. 
 
 
Figure 1.6: Schematic view of HIV-1 inter-protein interactions during viral 
transcription. To initiate viral transcription, the transactivator Tat binds to the TAR of 
RNA which is a regulatory element located at the downstream of HIV-1 LTR. Tat can 
recruit positive transcription elongation factors (e.g. Cyclin T1 (CycT1), cyclin-
dependent kinase 9 (CDK9)) to form a transcription complex. This complex then 
activates the CDK9 kinase leading to the hyperphosphorylation of RNA polymerase II 
(RNAP II). The hyperphosphorylated RNAPII interacts with Tat and other 
transcription elongation factors to transcribe the viral genomic RNA [216]. After the 
transcription of genomic RNA, Rev cooperates with the cellular factors Crom1 and 
RanGTP to export the genomic and sliced RNAs into cytoplasm. Question marks 
indicate unclear interaction positions. Note that protein shapes and sizes are not to 
scale. 
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Vpr−Vif protein interaction: Vif can physically interact with Vpr to degrade Vpr 
via the ubiquitin/proteasome pathway [217]. The downgradation of Vpr reduces the 
accumulation of infected cells at the G2 cell cycle arrest [217]. The interaction 
domains between Vpr and Vif remain unclear. 
Tat−INII−Integrase association: Direct interaction between Tat and Integrase has 
not been reported. Tat may associate with Integrase through a chromatin remodeling 
factor integrase interactor I (INII), also known as hSNF5. Being recruited into PIC 
[218], INII interacts with Integrase to enhance viral integration [219] and interacts 
with Tat to enhance the Tat-mediated transcription [220]. 
1.4.5 Viral budding  
As illustrated in Figure 1.7, the viral genomic RNA, envelope proteins and accessory 
proteins are assembled into nascent virions, which subsequently pinch off from 
extracellular membrane [221]. Previous studies have reviewed env trafficking and 
incorporation [222], HIV-1 genome packaging [223], APOBEC pathway [224], 
membrane lipids [225] and cellular cofactors in promoting viral budding [226]. Here 
we focus on the HIV-1 inter-protein interactions during viral budding. 
Vif−NCGag protein interaction: Vif can interact with nucleocapsid coded in the Gag 
precursor (NC
Gag
) [144, 145, 227, 228]. This interaction has been reported to impact 
the HIV-1 life cycle in three aspects: (1) Vif can inhibit the hybridization of tRNA
Lys3
 
and the Nucleotide-mediated formation of RNA dimers [229]; (2) Vif inhibits the 
protease-mediated proteolytic processing at the cleavage site between p2 and 
Nucleocapsid [230]. (3) NC
Gag
 becomes less stable in the viral core when Vif is 
absent [231]. The motifs at the C terminus of Vif interact with Gag [144], while the 
interaction domain in Nucleocapsid remains unclear. 
Vpr−p6Gag protein interaction: Vpr is incorporated into nascent HIV particles 
through its interaction with the p6 domain of Gag precursors (p6
Gag
) [149, 232, 233]. 
The Vpr-p6
Gag
 interaction allows for the Vpr incorporation on the lipid bilayer 
membrane [150, 234]. The motif near the C terminus of p6 [151-154] can interact 
with Vpr (position: 1-71 [150], 84-94 [231]).  
 
Chapter 1: General introduction 
  
 25   
 
Figure 1.7: Schematic view of HIV-1 inter-protein interactions during viral 
budding. Env trimmers are exported to extracellular membrane through a secretory 
pathway. Gag targets to the membrane rafts where sphingolipids, glycolipids and 
cholesterol are rich. (1) Matrix
Gag
-GP41 interaction: the N-myristoylation domain of 
Matrix
Gag
 interacts with GP41, allowing the incorporation of Gag into HIV particles. 
This interaction is mediated by the cellular cofactor TIP47 [235]. (2) Gag-Vif 
interaction. NC
Gag
 and Matrix
Gag
 can interact with Vif to assist the incorporation of 
Vif into HIV particles. (3) Vpr-p6
Gag
 interaction: Incorporation of Vpr into nascent 
virions depends on the Vpr-p6
Gag
 interaction. (4) NC
Gag
-Vpr interaction: NC
Gag
 can 
cooperate with p6
Gag
 to incorporate Vpr into HIV particles. This interaction also 
promotes the Vpr-RNA interaction during the RNA encapsulation. (5) Nef-p6*
Gagpol
 
interaction assists the Nef incorporation. Note the protein shapes and sizes are not to 
scale. 
 
Vpr−NCGag protein interaction: Vpr interacts with Nucleocapsid in the Gag 
precursor (NC
Gag
), which allows for the incorporation of Vpr into viral particles [143, 
236]. NC
Gag
 promotes the Vpr-RNA interaction during the encapsulation of genomic 
RNA [237]. Mutagenesis analysis has shown that the zinc fingers of NC
Gag
 [143] 
interact with the C terminus of Vpr (positions: 70-80) [237]. 
Env−Nef protein interaction: Nef can physically interact with the GP41 
cytoplasmic tail (GP41CT) [148]. Deletion of GP41CT abrogates the Nef-induced 
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increase of viral infectivity in CD4+ lymphocytes [148]. Mutagenesis analyses have 
shown that the C terminus of Nef (positions: 181-210) interacts with GP41CT [148]. 
Nef may improve HIV-1 infectivity by enhancing the Env incorporation because Nef 
induces the downregulation of CD4 to prevent Env-CD4 binding [92]. Moreover, Env 
protein is dispensable for the Nef-induced viral infectivity [238], whilst the accessory 
protein Nef is dispensable for viral budding and entry [239]. 
Nef−p6* protein interaction: p6* is a transframe peptide region which separates the 
Gag nucleocapsid domain from Protease. Nef interacts with the p6* domain of 
GagPol precursors in the intermediate compartment between the ER and trans-Golgi 
networks [147]. This interaction allows for Nef incorporation into nascent HIV 
particles [147, 240]. Moreover, the flexible loop in Nef (positions: 148-180) may 
interact with p6*
 
[147]. Nef mutants without this flexible loop cannot interfere with 
the processing of GagPol polyprotein and do not incorporate into HIV particles [147]. 
Matrix−GP41 protein interaction: Mediated by the cellular cofactor TIP47, the 
GP41 cytoplasmic tail (GP41CT) can interact with the N terminus of Matrix for Env 
incorporating into HIV particles [114, 235, 241]. Gag and Env proteins are 
colocalized in the plasma membrane and Golgi apparatus [242]. Matrix-GP41CT
 
interaction is critical for the envelope association with lipid rafts in the extracellular 
membrane [243]. The myristoylation of the N terminus in Matrix is required for Env 
incorporation [244]. 
Vpu−MatrixGag protein interaction: Vpu interacts with Matrix in the Gag precursor  
(Matrix
Gag
) [245]. This interaction may enhance the binding of Gag to the 
extracellular membrane [245]. The N terminus of Matrix
Gag
 is required to interact 
with Vpu [245], while interaction domain in Vpu remains unclear.  
RT−Gag protein interaction: RT is incorporated into virus-like particles through 
the RT-Gag interaction [142]. The thumb domain of p51 is required for RT 
incorporation, whilst the matrix and p6 in Gag precursors interact with RT [142]. Yet, 
it is rare for the production of mature RT in cytoplasm, as well as the transport of 
mature RT to the extracellular membrane. 
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1.4.6 Viral maturation 
After viral budding, immature virions undergo the maturation process during which 
multimerized Gag precursors are cleaved into mature proteins using viral protease 
[246]. Viral enzymes (protease, RT, integrase) in the GagPol precursors are not 
functional and must be cleaved and folded for viral activity [247]. Further details 
about the maturation process, the core morphology and structure can be found in [142, 
246]. Here we focus on HIV-1 inter-protein interactions observed during viral 
maturation. 
Protease−Vif protein interaction: Protease can directly interact with Vif [156]. This 
interaction can: (1) interfere the Protease dimerization [248]; (2) inhibit the Protease-
mediated proteolytic processing at the p2-Nucleocapsid cleavage site [230]; (3) 
prevent the Protease-mediated digestion of cellular proteins [248]. Moreover, the N 
terminus of Protease (positions: 1-9) interacts with the central domain of Vif 
(positions: 78-98) [248]. Mutations at Vif positions (36,47,101,117,124) were 
associated with protease drug resistance [249]. Vif-derived peptides (positions: 81-88, 
88-98) can inhibit the activity of Protease [159]. 
Protease−RT protein interaction: A direct interaction between Protease and RT 
was identified using immunoprecipitation, Western blot experiments and an enzyme-
linked immunosorbant assays [250]. Previous studies have shown that: (1) RT 
increases the catalytic activity of Protease without interfering with the protease 
dimerization [251]. (2) RT increases Protease activity in a dose-dependent, pH-
dependent and concentration-dependent manner [252]. (3) Protease inhibits the 
catalytic activity of RT whereas the activity of RNase H is not affected in the 
presence of Protease [250]. The interaction domains remain unclear. 
Integrase−Nef and Protease−Nef interactions: A physical interaction between 
Integrase and Nef has consistently been detected by different assays [135]. RT was 
reported to interact with Nef using GST pull-down and yeast two-hybrid assays. 
Protease-Nef was reported using yeast two-hybrid and immunoprecipitation assays. 
However, the biological function of Integrase-Nef interaction is unknown, neither 
interaction domains.  
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Figure 1.8: Schematic view of HIV-1 inter-protein interactions during viral 
maturation. (A) Schematic view of immature (left) and mature (right) HIV-1 
particles. Immature particles become mature after protease-mediated autoproteolytic 
processing. (B) Viral maturation. Seven steps are observed: (1) GagPol precursors 
aggregate in proximity using the Gag-Gag lattice interaction. GagPol dimerization 
within two Gagpol precursors induces the construction of Protease dimers with a low 
enzymatic activity [20]. (3) Protease intra-molecular autoprocessing: the cleave site 
between Nucleocapsid and sp1 is cleaved by Protease within the same Gagpol dimer. 
(4) Protease inter-molecular autoprocessing: Protease in one Gagpol dimer cleaves the 
sites (p6*-Protease, PR-p51, p51-p15, p15-IN) in the other Gag-Pol dimer. This 
process results in the production of Protease dimers and monomer HIV proteins 
(Integrase, p51, p15, p66). (5) Maturation of HIV-1 enzymes. Integrase and RT are 
folded and become mature. (6) Protease-mediated proteolytic processing. Mature 
Protease cleaves Gag precursors in a specific order: sp2-NC → sp1-p6 → MA-CA → 
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CA-sp2 → NC-sp1. This process frees MA, CA, sp1, sp2, NC and p6 from Gag 
precursors, during which RT interacts with Protease to enhance the proteolytic 
processing. The incorporated Vif binds with Protease dimers to inhibit the digestion of 
cellular cofactors. (7) After the maturation of HIV-1 structural proteins, a series of 
conformation changes turn immature particles into mature particles. Note that 50 to 
63 native HLA-II complexes are in the membrane of HIV-1 particles [253]. One HIV 
particle has an average of only 7–14 spikes [254], ~1400 Gag polyproteins [255], 
30−80 Vif proteins [256]. The protein shapes and sizes are not to scale. 
 
Integrase−Vpr association: While both Vpr and Integrase are components of PIC, a 
physical interaction between Integrase and Vpr has not been reported. Evidence has 
shown that: (1) Vpr can stimulate the strand transfer reaction of Integrase [257]. (2) 
Vpr directly binds to DNA or RNA in a non-specific manner [257] and enhances the 
binding of Integrase to viral DNA in PIC [237]. (3) The full-length Vpr or the C 
terminus of Vpr (positions: 52-96) can inhibit viral integration [257]. (4) Vpr-derived 
peptides (positions: 57-71, 61-75) can inhibit the activity of Integrase via a direct 
interaction [200]. Further investigations are still needed to show whether Integrase 
interacts with Vpr. 
Capsid−Integrase association: Direct interaction between Capsid and Integrase has 
not been reported. Yet, Integrase is required to sustain the interaction between Capsid 
and cyclophilin A, a cellular peptidyl-prolyl isomerase [258]. The stability of viral 
core formed by capsid was decreased in the presence of Integrase mutants (e.g. 
C130S). Mutations in Capsid exert a deleterious impact on both nuclear targeting and 
integration [259]. Nevertheless, a direct interaction between Capsid and Integrase 
remains unclear. 
1.4.7 Summary 
Investigation of HIV inter-protein interactions can enrich our understanding on HIV 
genome-wide interaction and evolution, possibly providing useful information on HIV 
vaccine and drug design. This section summarizes the known HIV-1 inter-protein 
interactions reported in the last three decades. Given that only 15 proteins are encoded 
in the HIV genome, a high level of HIV inter-protein interactions is expected. Indeed, 
15 HIV-1 proteins have shown different capacities to interact with each other during 
the viral life cycle (Figure 1.9). Accessory proteins (e.g. Nef) usually take multiple 
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functions with more opportunities to interact with others, while structural proteins (e.g. 
Capsid) are restricted to structural functions with lesser interactions. HIV inter-protein 
interactions in different stages of HIV life cycle provide many possible mechanisms 
to enhance viral replication. For instance, the interactions between Protease and Gag 
(Chapter 3), between GP41 and Matrix [260] can cause protease drug resistance, 
suggesting the crucial role of HIV genome-wide interaction and evolution.  
Nevertheless, detecting transient states of protein interactions has been proven 
difficult and the ideal experiments designed to capture these events will likely be 
complex and expensive. 
 
Figure 1.9: Mapping of the documented inter-protein interactions at the HIV-1 
genome. In the center, red links indicate the interaction domains between two proteins. 
Orange links indicate the direct interactions between two HIV-1 proteins but 
interaction regions have not been resolved (Table 1.1). In the circle, the N terminus, 
the central domain and the C terminus of HIV-1 proteins (Matrix, Capsid, NC, p6, 
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Protease, Integrase, Vpu, Rev, Vif and Vpr) are colored orange, purple and sky blue, 
respectively. The p51 and p15 domains in RT are colored brown and gray, 
respectively. In the GP120 protein region, the four variable domains (V1/V2, V3-V5) 
and five conserved domains (C1-C5) are colored by brown and sky blue, respectively. 
In GP41, two helix regions are colored brown and the others colored sky blue. On the 
out layer, the amino acid genetic diversity of HIV-1 subtype B genome is shown in 
green. The diversity values between 0 and 1 are mapped on five sub-layers. The data 
of protein interaction domains are available in Table 1.1. The genetic diversity data of 
HIV-1 subtype B genome is described in Chapter 2. 
Investigation of HIV genome-wide interactions faces difficulties in designing 
experiments that accurately detect the interaction complexes of HIV proteins during 
the different stages of the viral life cycle. HIV protein can use their intrinsically 
disordered structures to interact with other HIV proteins in transient states [29]. 
Because of the dynamic protein structures in different biological contexts, 
biochemistry experiments performed in cell-free settings may have underestimated 
the nature of potential interactions. For instance, before the viral maturation, HIV-1 
protein precursors (e.g. Gag) have flexible structures with varied interaction 
properties. After viral maturation, the products of Gag have relatively conserved 
domains to construct stable viral particles (Figure 1.8). 
 
Peptide inhibitors have been proposed to mimic the interaction domains by 
prohibiting protein interactions, leading to the inhibition of viral replication (Chapter 
2). Identification of key interaction domains in HIV-1 proteins may lead to new 
inhibitors with novel mechanisms of action. Although many HIV-1 inter-protein 
interactions have been identified in different experimental assays, the majority of the 
possible interaction domains still remain unclear (Table 1.1). We indeed observed 
discordance results of the biological mechanisms and interaction positions reported in 
different studies. Further studies are still needed to clarify the unclear protein 
interactions. Moreover, it has been shown that HIV-2 proteins may play different 
roles compared to HIV-1, while very few studies have investigated the HIV-2 protein 
interactions. It remains a challenge to explore the genome-wide interactions in both 
HIV-1 and HIV-2. 
While detecting HIV genome-wide interactions using the biochemistry experiments 
are expense and time-consuming, bioinformatics methods may provide alternative 
strategies. For instance, many protein-protein interaction models have been proposed 
in the last two decades. Sequence-based statistical analyses have also shown 
promising performance (Chapter 4, 5). Armed with large-scale sequence datasets and 
literature results, it is possible to model the genome-wide networks and explore all 
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potential interactions and coevolution at the HIV-1 genome. In this thesis, we 
conducted interesting projects and contributed to this research area. 
1.5 HIV antiretroviral treatment 
To date, a curative drug or effective vaccine to treat HIV is still uncertain. A high 
diversity of HIV strains exerts a difficulty in developing a global HIV vaccine [261]. 
During the past three decades, many attempts have been made to develop a vaccine 
with a protective efﬁcacy. Novel vaccine strategies and immunologic principles have 
been proposed [261-263]. As of May 2014, only three candidate vaccines have 
completed phase-III clinical trials (http://www.iavireport.org/). At the cost of 119 
million dollars, the RV144 vaccine trial conducted in Thailand was the only one trial 
which demonstrated that an HIV-1 vaccine may elicit a modest and transient 
protection against the HIV-1 acquisition [261]. To cover a wide range of challenging 
strains, RV144 tested the ―prime-boost‖ combination of two vaccines: ALVAC® HIV 
vaccine (the prime) and AIDSVAX® B/E vaccine (the boost) [264]. ALVAC is 
comprised of a canarypox virus vector engineered with three HIV-1 genes (gag, pol, 
env). Canarypox is a bird virus which cannot cause disease or replicate in humans 
[265]. In October 2003, a total of 16402 HIV negative volunteers aged 18-30 
participated in the randomized double-blind study groups receiving the prime-boost 
combination. A follow-up HIV test was conducted in July 2006. The results showed 
51 infections in the vaccine group compared to 74 in the placebo group, which 
indicates a 31.2% (95% confidence interval: 1.1 to 52.1%, p-value=0.04) reduction of 
HIV-1 acquisition. As debated intensively in the HIV community, RV144 
demonstrated a very slight but statistically significant degree of vaccine efficacy [266]. 
Moreover, a follow-up study showed no difference between the vaccine and placebo 
groups after 2.5 years [266]. Overall, the design of HIV vaccine still poses as one of 
the most difficult challenges in the coming years.  
With limited achievement from vaccine studies, extensive HIV research has been 
oriented to the discovery of anti-HIV drugs during the last three decades. Until May 
2014, over 25 drugs have been approved by FDA to treat HIV infected patients in 
clinical practice [267]. Most approved inhibitors are small molecules, except for one 
peptide inhibitor (T20). Most anti-HIV inhibitors have been designed to target viral 
Chapter 1: General introduction 
  
 33   
enzymes and envelope proteins (Figure 1.2). As shown in Table 1.2, the FDA-
approved inhibitors are classified into 5 different drug classes (see reviews [267, 
268]): (1) nucleoside analog reverse-transcriptase inhibitor (NRTI), (2) non-
nucleoside analog reverse-transcriptase inhibitor (NNRTI), (3) protease inhibitor (PI), 
(4) integrase inhibitor, and (5) entry (fusion) inhibitor (EI). HIV-1 inhibitors have 
been optimized to prohibit the virion production based on two mechanisms of action: 
competitive inhibition (drug molecules that outcompete natural substrates, e.g. PI, 
NRTI and IN drug classes) and non-competitive inhibition (drug molecules bind at the 
non-active sites and induce conformational changes to prevent the substrate binding. 
e.g. NNRTIs and CCR5-antagonists). In clinical practice, a highly active antiretroviral 
therapy (HAART) for efficient HIV treatment usually combines three or more anti-
HIV drugs. The HIV/AIDS guidelines in 2014 suggest the antiviral regimen to treat 
naïve patients, consisting of two NRTIs in combination with a third active drug from 
one of three classes: an NNRTI, a PI boosted with ritonavir or an integrase inhibitor 
(http://aidsinfo.nih.gov/guidelines). Figure 1.10 summarizes these 5 HIV drug classes. 
 
Figure 1.10: Overview of anti-HIV inhibitors approved by FDA. Five drug classes 
are indicated by colored bars with annotated inhibitors (see Table 1.2). The structure 
of protease-DRV complex is shown on right (PDB: 3OXW).  
 
NRTI: AZT (Zidovudine, Retrovir) was the first anti-HIV inhibitor approved by FDA 
in 1987, and it was developed as an anti-cancer inhibitor during 1960s. AZT is a 
nucleoside analog reverse-transcriptase inhibitor (NRTI) which targets the active site 
of reverse transcriptase. The discovery of AZT therapy was a breakthrough in the 
HIV/AIDS treatment, which has significantly prevented HIV transmission and 
provided a promising clinical and immunologic improvement [269]. In the past two 
decades, other potent NRTIs have also been developed such as abacavir (ABC), 
emtricitabine (FTC), didanosine (ddI), lamivudine (3TC), stavudine (d4T) and 
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tenofovir (TDF) (Table 1.2). Subscribed commonly in the first-line HIV therapy, 
NRTIs usually have a low genetic barrier with a high risk of developing drug 
resistance mutations. The structural basis of HIV-1 resistance to AZT suggests that 
RT mutations enhance the ATP-mediated excision of AZT monophosphate from the 3’ 
end of the DNA primer [270]. 
Table 1.2: Summary of FDA-approved HIV drugs (http://aidsinfo.nih.gov/). 
Drug class Name Abbreviation Approved date Brand name 
NRTI Zidovudine AZT Mar. 1987 Retrovir 
Didanosine ddI Oct. 1991 Videx 
Zalcitabine ddC June 1992 Hivid  
Stavudine d4T June 1994 Zerit 
Lamivudine 3TC Nov. 1995 Epivir 
Abacavir ABC Dec. 1998 Ziagen 
Tenofovir TDF Oct. 2001 Retrovir 
Emtricitabine FTC July 2003 Gilead Sciences 
NNRTI Nevirapine NVP June 1996 Viramune 
Delavirdine DLV April 1997 Rescriptor 
Efavirenz EFV Sept. 1998 Efavirenz 
Etravirine ETR Jan. 2008 Intelence 
Protease inhibitor Saquinavir SQV Dec. 1995 Invirase 
Ritonavir RTV Mar. 1996 Norvir 
Indinavir IDV Mar.1996 Crixivan 
Nelfinavir NFV Mar. 1997 Viracept 
Lopinavir LPV Sept. 2000 Kaletra 
Atazanavir ATV June 2003 Reyataz 
Fosamprenavir FPV Oct. 2003 Lexia 
Tipranavir TPV June 2005 Aptivus 
Darunavir DRV June 2006 Prezista 
Integrase inhibitor Raltegravir RAL Oct. 2007 Isentress 
Elvitegravir EVG Aug. 2012 Stribild 
Dolutegravir DTG Aug. 2013 Tivicay 
Entry inhibitor Enfuvirtide T20 Mar. 2003 Fuzeon 
Maraviroc MVC Aug. 2007 Selzentry 
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NNRTI: NNRTIs were discovered in the late 1980s and the first NNRTI inhibitor, 
nevirapine, was approved in 1996 [271]. Acting as non-competitive inhibitors, 
NNRTIs bind with the non-cleavage site of RT to induce conformation changes, 
which in turn affect the catalytic activity of RT and interrupt the viral replication 
[272]. NNRTIs are HIV-1 specific and HIV-2 is naturally resistant to all NNRTIs 
[273]. When comparing RT structures between HIV-1 and HIV-2, the difference was 
found at both conserved and non-conserved positions in the NNRTI binding pocket 
(positions: 101, 106, 138, 181, 188 and 190) [274]. As of January 2014, four NNRTIs 
have been approved: efavirenz (EFV), etravirine (ETR), delavirdine (DLV) and 
nevirapine (NVP). As the potency of NNRTIs can be diminished by drug resistance 
mutations, novel NNRTIs have been developed and several of them are currently 
under clinical trials [275].  
 
Figure 1.11: Overview of anti-HIV inhibitors in the HIV-1 life cycle. HIV 
inhibitors have been annotated in the HIV-1 life cycle. Descriptions and symbolic 
representations are described in Figure 1.2. Note that protein shapes and sizes are not 
to scale. 
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Protease inhibitor: In 1995, Saquinavir was approved as the first protease inhibitor, 
marking the start of an era for this new class of anti-HIV inhibitors. Protease 
inhibitors preventing viral maturation by targeting the protease cleavage site and 
competing with the protease substrates, namely Gag and GagPol polyproteins [12]. To 
date, 10 protease inhibitors have been approved by FDA: Saquinavir (SQV), 
Ritonavir (RTV), Indinavir (IDV), Nelfinavir (NFV), Lopinavir (LPV), Atazanavir 
(ATV), Fosamprenavir (FPV), Tipranavir (TPV) and Darunavir (DRV) (Table 1.2). 
Most of these PIs are prescribed along with a low dose of RTV because RTV acts as a 
booster for improving the bioavailability and half-life of other PIs [12]. Most clinical 
benefit has been shown when the protease inhibitors are considered as part of 
HAART. For instance, HIV RNA plasma levels were dramatically reduced when 
indinavir was combined with zidovudine and lamivudine in the majority of patients 
[12]. Yet, emerging protease drug resistance mutations challenge the potency of PIs 
[276]. Primary and secondary resistance mutations in protease have been documented 
by various clinical and experimental studies [12, 276, 277]. PI-associated mutations 
have been reported in the viral protease and the protease substrate Gag (Chapter 2). 
As an alternative mechanism for HIV to escape PI selective pressure, Gag mutations 
can be selected to alter structural confirmation of Gag to interact with the protease 
substrate-binding cleft (Chapter 4). 
Integrase inhibitor: In 2007, Raltegravir was approved as the first integrase inhibitor. 
In the class of integrase inhibitors, raltegravir, dolutegravir and elvitegravir have 
become key components of anti-HIV therapy [278]. To prohibit the strand transfer 
reaction, these Integrase inhibitors can compete with host dsDNA to bind with the 
catalytic core domain of Integrase during viral integration. Compared with other anti-
HIV drug classes, Integrase inhibitors have shown a good tolerability, a high safety 
profile and an absence of significant drug interactions [279]. Both raltegravir and 
elvitegravir have relatively low genetic barriers to drug resistance development, while 
it is not the case for dolutegravir [279]. Resistance mutations (Y143, Q148, N155) 
were consistently reported in all three Integrase inhibitors [278]. A better virologicval 
outcome of Integrase inhibitors was not significantly observed compared to protease 
inhibitors [279]. To develop new Integrase inhibitors, a promising class of Integrase 
inhibitors has been developed to target the Integrase multimerization and the 
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interactions between Integrase and LEDGF/p75 [280]. Several integrase inhibitors 
with promising antiviral activities have undergone in clinical trials [281]. 
Entry (fusion) inhibitor: Two entry inhibitors, Maraviroc (Selzentry, Celsentri) and 
Enfuvirtide (T20, Fuzeon), have been approved and many entry inhibitors have 
reached advanced stages of clinical trials [282]. Maraviroc is the first FDA-approved 
chemokine receptor antagonist or CCR5 inhibitor which targets the chemokine 
receptor CCR5 on the surface of CD4+ cells and macrophages [283]. CCR5 
antagonists can exhibit a potent inhibition of viral replication across different HIV-1 
strains. However, a significant concern was raised by the possibility that CCR5 
antagonists would accelerate the disease progression by promoting the emergence of 
viruses with chemokine receptor CXCR4 [282, 283]. The concept of co-
administration of CCR5 and CXCR4 antagonists has been halted due to the limited 
development of CXCR4 antagonists [282]. Enfuvirtide is a synthetic oligopeptide 
derived from the second helix domain (HR-2) of HIV-1 GP41. Enfuvirtide mimicks 
the HR-2 helix to block viral entry by preventing the interaction between the HR-1 
and HR-2 helices [284]. While Enfuvirtide has a high drug efficacy with the minimal 
systemic toxicity, the subcutaneous administration and high cost have limited its long-
term employment [282]. Following the success of Enfuvirtide, the second and third 
generations of GP41-derived peptide inhibitors (e.g. T1249) have been developed 
with promising antiviral activities in clinical and experimental studies [282, 284]. 
1.6 HIV functional cure 
In the past three decades, many researchers have tried to develop a cure for HIV [285]. 
One of the underlying challenges is the persistence of a competent replication pool of 
HIV in the resting CD4 T cells, which makes complete HIV eradication difficult [285]. 
HIV in latently infected cells is not dramatically affected by the intensification of 
current antiretroviral therapy [285, 286]. Recent HIV studies have reported possible 
treatments for reaching ―functional cure‖, which is defined as interventions to keep 
the viral load at a low or undetectable level and ensure no disease progression in the 
absence of anti-HIV drugs. The major benefit of stepping off anti-HIV therapies is the 
avoidance of drug induced side effects (e.g. bone demineralization, kidney failure, etc.) 
[287]. Although the functional cure has been investigated for many years, only a 
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small proportion of HIV infected patients have been reported to maintain viral 
suppression in the absence of antiviral treatments [288]. 
News broke in March 2013 about the functional cure of a Mississippi baby has 
received much attention in the HIV community. It was announced that an HIV-
infected baby from rural Mississippi whose medicine was stopped at 18 months of age 
has been living for a year without any detectable viral RNA [287]. On July 10, 2014, 
it was found that HIV rebound in the infected baby after antiretroviral therapy stopped 
for 27 months (http://www.nature.com/news/hiv-rebound-dashes-hope-of-mississippi-
baby-cure-1.15535). This dashed the hope to treat infants with hard antiviral 
treatments for HIV eradication. 
The Berlin patient is another example of a patient who is widely believed to have 
been cured of HIV-1 infection [286]. The 40-year-old man was infected with HIV-1 
and developed acute myeloid leukaemia. In February 2007, he received a bone-
marrow transplant from a donor who bears a homozygous mutation (△32) in the 
CCR5 chemokine receptor. This △32 mutation can naturally render the donor cells 
highly resistant to infections of most HIV-1 strains [289]. The antiviral treatment of 
this patient was stopped on the day of the first transplantation. In March 2008, he 
received a second transplantation with CCR5△32 stem cells from the same donor 
because of the relapse of acute myeloid leukemia. Surprisingly, the undetectable HIV 
viraemia has remained ever since [289]. Intensive efforts to identify residual HIV-1 
from liver and brain showed undetectable or barely detectable level of HIV-1 DNA or 
RNA [289]. Due to the high cost and risk, the bone marrow transplantation is still not 
a solution that could be implemented to treat HIV worldwide. Yet, this case study 
may indicate the most relevant factors that reduce or eliminate HIV latency, which 
could probably provide safe and suitable alternatives in the coming years [286]. 
1.7 Rationale and objectives of the study 
As of August 2014, a curative HIV drug or preventive vaccine remains elusive. It is 
also known that HIV drug resistance can impair the efficiency of all FDA-approved 
HIV inhibitors and challenges the development of novel inhibitors. A deep 
understanding of HIV genome-wide diversity, interaction and coevolution may 
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provide insights on the development of novel HIV inhibitors and vaccines. For 
instance, HIV-1 replication can be successfully blocked by targeting gag gene 
products, offering a promising strategy for new drug classes that complement 
contemporary HIV-1 treatment [290]. However, HIV-1 natural diversity is known to 
affect resistance pathways and therapy effectiveness. Natural polymorphisms are also 
associated with lack of response in clinical trials evaluating novel inhibitors such as 
Bevirimat [291]. The impact of sequence variability on drug binding sites has not 
been fully understood. It is therefore of interest to investigate HIV genome-wide 
diversity, shedding light on the drug resistance and novel drug design. 
Regarding the HIV genome-wide interaction, HIV-1 proteins can interact with each 
other and with human proteins (see Section 1.4). This information is valuable for HIV 
drug design. For instance, Maraviroc is the first FDA-approved chemokine receptor 
antagonist or CCR5 inhibitor that targets the protein interaction between GP120 and 
CCR5 [283]. Bear in mind that a large number of HIV-human protein interactions 
have been reported recently, potential drug targets may be mined through rational 
drug design and a detailed mapping of HIV genome-wide protein interactions may 
provide guidelines for the development of novel anti-HIV inhibitors.  
Coevolution in the HIV genome impacts different aspects of the HIV life cycle. The 
clinical relevance of HIV genome-wide coevolution is mostly involved with drug 
resistance. Many clinical cohort studies have shown that drug resistance mutations in 
drug target proteins are associated with treatment failure of HIV treatments. Recent 
discoveries also suggest that mutations in non-drug-target regions are also associated 
with treatment failure due to the genome-wide coevolution [260, 292]. For instance, 
amino acid substitutions in HIV Gag proteins have been recorded to compensate for 
the loss of binding affinity of protease mutants with the substrate Gag [293-295]. A 
recent study has shown that mutations at the GP41 cytoplasmic tail can confer PI drug 
resistance in two HIV-infected patients [260]. As indicated by Section 1.4.7, other 
genome-wide coevolution in the HIV genome may create new mechanisms for HIV to 
escape drug selective pressure. 
Recent in vitro and in vivo studies have continuously reported new experimental Gag 
inhibitors with promising antiviral activity. While the impact of sequence variability 
on drug binding sites is warranted but largely lacking, the aim of Chapter 2 is to 
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investigate natural variations of drug binding sites across major HIV subtypes and 
CRFs. Previous studies that reported findings on HIV genomic diversity were limited 
to reference genomes or small cohorts of less than 100 patients, largely infected with 
a single subtype. A genome-wide analysis of HIV diversity characterizing the HIV 
pandemic in large-scale patient populations is still lacking. Recent advances in whole-
genome sequencing, protein structure crystallization and establishment of large public 
databases provide large-scale data to gain new perspectives on HIV genome-wide 
diversity. For these reasons, the objectives of Chapter 3 were set to report the 
genome-wide diversity in patient populations and to identify driving factors that 
impact the HIV genome-wide diversity.  
Detection of HIV-1 coevolution has been shown to be essential for the understanding 
of drug resistance, functional interactions and evolutionary pathways in HIV-1 
proteins. Recent HIV-1 clinical studies indicated that treatment failure of protease 
inhibitors (PIs) was associated with coevolution between protease and Gag − a 
substrate of protease during the protease-mediated proteolytic process. However, it 
has not been reported which amino acid changes in Gag have been associated with 
drug resistance of protease inhibitors across different subtypes. For this reason, the 
aim of Chapter 3 is to answer this curious question. To provide standard methods for 
the coevolution analysis, most studies have analyzed HIV-1 protein coevolution using 
a single sequence-based method. However, a systematic comparison of these 
sequence-based methods has not been investigated, neither the possible advantages of 
integrating different methods to improve the prediction of HIV-1 coevolution. This 
research gap becomes the major focus of our study in Chapter 5. Moreover, the 
coevolution between the full-length Gag and protease remains unclear. By applying 
our method in Chapter 5, Chapter 6 wants to investigate the coevolution between the 
full-length Gag and protease residues to explore this new mechanism for HIV-1 viral 
escapes under drug selective pressure. In Chapter 7, our research turns to the study of 
polytree graphical models, which have been widely applied in various research fields. 
Previous studies have investigated the polytree graphical models under the framework 
of Bayesian networks – well-known probabilistic graphical models in statistics and 
machine learning. However, how to model the latent variables in polytree models has 
not been reported. The motivation of our Chapter 7 is to extend polytree models under 
the framework of Bayesian networks into ancestral polytree graphical models.  
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Figure 1.12: Structure of this Phd thesis. 
Based on the research questions described above, this Phd thesis investigates HIV 
genome-wide diversity, interaction and coevolution (Figure 1.12). To achieve this 
goal, our study in Chapter 2 begins with the investigation of natural variability in 
HIV-1 Gag, for the reason that a great number of inhibitors have been recently 
developed to target Gag. Reporting natural variability in drug binding sites can 
hopefully improve experimental Gag inhibitors. Based on similar ideas, our study in 
Chapter 3 extends to the investigation of the genetic variability in the HIV full-length 
genome and examines driving factors that shape HIV genome-wide diversity. As one 
can see it, Chapter 2 and 3 focus on exploring HIV genome-wide diversity and its 
impact on HIV inhibitors. Afterwards, our research interests are oriented towards the 
understanding of HIV-1 genome-wide coevolution. Specifically, Chapter 4 used the 
clinical data of our Leuven patient cohorts to report the PI-associated Gag emerging 
during the treatment of protease inhibitors. This chapter provides the clinical 
background of Gag-protease coevolution in HIV-1 infected patients who received PI-
based treatments. Subsequently, our investigation proposes an ensemble coevolution 
method (Chapter 5) and applies this method to model the Gag-protease coevolution 
networks (Chapter 6). Chapter 5 and 6 are sister projects that work on the 
computational methodology and the biological application, respectively. Our interests 
in Chapter 7 aim at creating new probabilistic graphical models to understand the 
drug resistance and protein signaling pathways, for our interests to model genome-
wide associations in following studies. In the appendix, we provide detailed 
information on HIV genome-wide protein interactions and natural polymorphisms. 
More specifically, the appendix visualizes the amino acid distribution and summarizes 
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the literature datasets of HIV-human protein interaction in the HIV full-length 
genome. 
Overall, we hope to provide new insights by investigating the following specific 
objectives: (1) investigate the sequence diversity of HIV-1 Gag, which encodes key 
HIV-1 structural proteins in the HIV-1 genome (Chapter 2); (2) investigate the HIV 
genome-wide diversity (Chapter 3); (3) evaluate the impact of HIV genomic diversity 
in drug resistance by analyzing HIV-1 Gag substitutions that were associated with 
protease drug resistance (Chapter 4); (4) design an ensemble coevolution system that 
integrates sequence-based statistical methods to model HIV intra- and inter-protein 
coevolution (Chapter 5); (5) use our ensemble coevolution system to model the 
networks of HIV-1 Gag-protease coevolution, which is a key component in HIV-1 
genome-wide coevolution (Chapter 6); (6) propose ancestral graphical models, which 
allow for fast learning of large-scale interaction networks (Chapter 7). The strength 
and weakness of my studies, as well as their future perspectives, is addressed in the 
final discussion and conclusion chapter (Chapter 8).  
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2.1 Summary 
HIV-1 replication can be successfully blocked by targeting gag gene products, 
offering a promising strategy for new drug classes that complement current HIV-1 
treatment options. However, naturally occurring polymorphisms at drug binding sites 
can severely compromise HIV-1 susceptibility to Gag inhibitors in clinical and 
experimental studies. Therefore, a comprehensive understanding of Gag natural 
diversity is needed. We analyzed the degree of functional conservation in 10862 full-
length Gag sequences across 8 major HIV-1 subtypes and identified the impact of 
natural variation on known drug binding positions targeted by more than 20 Gag 
inhibitors published to date. Complete conservation across all subtypes was detected 
in 147 (29%) out of 500 Gag positions, with the highest level of conservation 
observed in capsid protein. Almost half (41%) of the 136 known drug binding 
positions were completely conserved, but all inhibitors were confronted with naturally 
occurring polymorphisms in their binding sites, some of which correlated with HIV-1 
subtype. Integration of sequence and structural information revealed one drug binding 
pocket with minimal genetic variability, which is situated at the N-terminal domain of 
the capsid protein. This first large-scale analysis of full-length HIV-1 Gag provided a 
detailed mapping of natural diversity across major subtypes and highlighted the 
considerable variation in current drug binding sites. Our results contribute to the 
optimization of Gag inhibitors in rational drug design, given that drug binding sites 
should ideally be conserved across all HIV-1 subtypes. 
2.2 Introduction 
A curative therapy or preventive vaccine for HIV-1 infected patients remains elusive 
to date. Standard HIV treatment is confronted with the emergence of viral resistance 
to existing drug classes, necessitating the development of inhibitors with new 
mechanisms of action [1]. The Gag polyprotein, essential for HIV-1 morphogenesis, 
comprises four major domains (matrix, capsid, nucleocapsid, p6) and two small 
spacer peptides (p1, p2) [2]. Recently, HIV-1 inhibitors that target different stages of 
virion morphogenesis demonstrated promising antiviral activity, mainly by inhibiting 
capsid assembly, disrupting nucleocapsid binding with viral RNA/DNA or blocking 
proteolytic processing of polyproteins during maturation  [2-5]. 
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HIV-1 subtype B isolates were predominantly used for the in vitro experiments. Non-
B subtypes however account for 90% of HIV-1 infections worldwide [6] and amino 
acid (AA) compositions can differ up to 30% between subtypes [7]. Recently, 
treatment failure of patients in a phase II clinical study of the maturation inhibitor 
bevirimat was attributed to natural polymorphisms at drug binding positions, showing 
up in subtype-specific patterns [8]. Studies that extensively investigate the 
implications of HIV-1 diversity for Gag-directed drug development are lacking to 
date. In this large-scale analysis, we examined the distribution of naturally occurring 
sequence variability in full-length Gag sequences of major HIV-1 subtypes. 
Moreover, we evaluated the impact of HIV-1 subtypes on the conservation of Gag 
drug binding positions and multisite binding pockets published to date. 
2.3 Materials and Methods 
We retrieved 12543 gag nucleotide sequences spanning all 1500 base pairs from the 
HIV Los Alamos database (http://www.hiv.lanl.gov). Sequences were aligned against 
the HXB2 reference and manually curated using Seaview 4.3 [9]. Hypermutated 
sequences were detected using the Los Alamos hypermut tool [10]. HIV-1 subtype 
was determined by the Rega [11] and COMET subtyping tools 
(http://comet.retrovirology.lu/). Sequence quality was ensured by excluding duplicates 
and sequences with internal stop-codons, hypermutations, more than 1% ambiguous 
nucleotides, discordant subtype classification or an identical combination of patient 
code, sampling year and country. The analysis was restricted to the major subtypes 
and circulating recombinant forms (CRFs) characterizing the global HIV-1 subtype 
distribution [6]. For each individual subtype, amino acids that differed from the 
corresponding consensus AA and with prevalence ≥ 0.5% were defined as 
polymorphisms [12]. PDB data of protein-inhibitor complexes were collected from 
the RCSB Protein Data Bank [13], summarized in Additional file 1. The AA 
sequences in each PDB were aligned against the HXB2 reference. Drug binding 
pockets were defined by protein positions within a minimum Euclidean distance of 
less than 5Å between atoms of inhibitors and non-hydrogen atoms of residues [14]. 
Information on known Gag candidate inhibitors and binding positions was retrieved 
from more than 50 publications, summarized in Additional file 1. 
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To quantify the degree of positional conservation, a conservation index (CI) was 
calculated for each position by averaging pairwise scores between all AAs using the 
BLOSUM62 substitution matrix. Adapted from Karlin and Brocchieri [15], the 
conservation index (CI) of position x is calculated as: 
1 1
2
( ) 1 [ ( , ) / ( , ) ( , )]
( 1)
N N
i j i i j j
i j i
CI x S x x S x x S x x
N N   
 

 , where xi is the amino acid 
at position x in the i
th
 sequence of the multiple sequence alignment (MSA), N is the 
number of sequences in the MSA and S(xi, xj) is the substitution score of BLOSUM62 
between amino acids xi and xi. Given that denominators cannot be zero, a linear 
transformation was applied to S(xi, xj) by adding the absolute value of the minimum 
score | min(S)| + 1. CI measures were scaled between 0 and 1, with a CI value of 0 
indicating that AA variation was absent at that position. A highly conserved position 
was identified if its CI is below 0.01 for each HIV-1 subtype, a cutoff which 
corresponds approximately to cumulative polymorphism prevalence below 1% 
(Additional file 2). The Mann–Whitney U test was performed to compare CI 
distributions. Performance of the CI method is evaluated in Additional file 2 and our 
Matlab toolbox is available in Additional file 4. 
2.4 Results 
We analyzed 10862 full-length Gag sequences that fulfilled the quality criteria, 
encompassing 8 HIV-1 group M subtypes and CRFs: A1 (n = 1648), B (n = 4131), C 
(n = 2780), D (n = 443), F1 (n = 35), G (n = 49), CRF01_AE (n = 1714) and 
CRF02_AG (n = 62). Sequences were sampled from 61 countries between 1981 and 
2012. Table S2.1 summarizes more than 50 Gag inhibitors including their binding 
sites, target protein, mechanism of action, HIV-1 subtypes and PDB data. These 
candidate inhibitors were either small organic molecules or peptides and primarily 
targeted the capsid or nucleocapsid proteins. A total of 136 Gag positions were 
reported as drug binding positions, of which 53 interacted with more than one 
inhibitor. 
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Figure 2.1: Distribution of natural variations at 500 Gag positions of HIV-1 
group M (subtypes: A1, B, C, D, F1, G and CRF01_AE, CRF02_AG). The first 
position of each protein region is labeled with its protein name in a box. Annotated 
protein regions are indicated as colored bars: light-green for matrix (positions 1–132), 
light-blue for capsid (133–363), dark-green for p2 (364–377) and p1 (433–448), dark-
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blue for nucleocapsid (378–432) and grey for p6 (449–500). HXB2 indices for both 
full-length Gag and individual proteins are shown on top of the colored bars (e.g. 
„180|48‟ indicates the Gag position 180 and the capsid position 48). Known drug 
binding positions are marked with red stars. Consensus subtype B amino acid for each 
position is shown directly under the bar, and is highlighted green when the consensus 
AA differed in one or more subtypes. Natural polymorphisms are shown below the 
consensus subtype B amino acids; proportions (%) are colored blue for proportion ≥ 
5%; orange otherwise. Figure S2.3 provides the distribution of natural 
polymorphisms within each individual subtype. 
 
The AA distribution at 500 Gag positions among HIV-1 group M sequences is shown 
in Figure 2.1 and subtype-specific distributions are also visualized (Figure S2.3). 
Heterogeneity in consensus sequences was observed at 142 (28.4%) positions across 
subtypes, while pairwise comparisons of consensus sequences showed an average of 
11.6% difference between subtypes. On average, 43.6 ± 2.7% of positions harbored at 
least one polymorphism relative to its subtype consensus residue (Table 2.1). The 
capsid protein (29.4%) contained the lowest number of polymorphic positions 
followed by nucleocapsid (42.5%), matrix (59.9%), and p6 (65.6%). Moreover, of 147 
conserved positions in Gag, 67.8% were in capsid, 11.2% in nucleocapsid, 10.5% in 
matrix and 4.6% in p6. Pairwise AA diversity (Additional file 3) of full-length Gag 
sequences decreased from 17.0 ± 1.6% between subtypes to 9.0 ± 1.0% within 
subtypes (Table 2.2). The mean AA diversity was significantly lower for capsid (5.0 
± 0.8%) than for nucleocapsid (7.9 ± 2.8%), matrix (13.2 ± 2.0%) or p6 (14.7 ± 2.0%) 
(p-value<0.05) (Table 2.3). The CI distributions of full-length Gag characterized 
three conserved regions located at the nucleocapsid zinc-finger domains, the capsid 
N-terminal domain (NTD) and C-terminal domain (CTD) (Figure 2.2). 
Each Gag protein is demonstrated with its total AA and drug binding positions (e.g. 
Matrix [132/13]: 132 AA positions/13 drug binding positions). Natural polymorphism 
proportion (%) is indicated for each protein and subtype with respect to the total 
number of AAs and to the number of drug binding positions (e.g. 57.6/38.5 shows that 
for subtype B matrix, 57.6% of all 132 positions and 38.5% of 13 drug binding 
positions are polymorphic). Mean values across Gag domains and across HIV-1 
subtypes are indicated in the last row and column respectively. 
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Figure 2.2: Amino acid conservation in the HIV-1 full-length Gag. (A) Sliding 
window plots of CI values are shown for 8 HIV-1 subtypes (window size: 30AA, also 
see the plots of exact CI values in Figure S 2.9). Secondary structures are indicated 
for each protein region, with thick lines for helices and thin lines for random-coil 
structures. Positions conserved in all subtypes are colored blue (layer 1 in a small 
circle), known drug binding positions are colored red (layer 2) and regions where 
HIV-1 peptide inhibitors have been derived are colored green (layer 3). Figure S2.9 
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visualizes the conservation index of 500 Gag positions for 8 HIV-1 subtypes. (B) 
Distributions of CI values at 500 Gag positions across 8 HIV-1 subtypes and CRFs. 
Visualization software: Circos v0.64 (http://circos.ca/). 
 
 
Table 2.1: Natural polymorphism proportions in Gag domains and drug binding 
positions across 8 HIV-1 subtypes and CRFs (%) 
 B A1 C D F1 G 01_AE 02_AG Mean 
Matrix[132/13] 57.6/38.5 62.1/46.2 59.1/46.2 64.4/53.8 52.3/46.2 66.7/61.5 61.4/46.2 56.1/30.8 59.9/46.2 
Capsid[231/98] 27.3/30.6 34.2/33.7 29.4/29.6 27.7/27.6 31.2/37.8 30.3/28.6 28.1/28.6 27.3/27.6 29.4/30.5 
p2[14/8] 71.4/62.5 64.3/62.5 64.3/62.5 64.3/62.5 57.1/62.5 71.4/62.5 64.3/62.5 50.0/50.0 63.4/60.9 
NC[55/17] 56.4/58.8 41.8/35.3 38.2/41.2 36.4/29.4 34.5/23.5 54.5/58.8 43.6/35.3 34.5/41.2 42.5/40.4 
p1[16/0] 37.5/- 25.0/- 31.2/- 43.8/- 25.0/- 31.2/- 31.2/- 12.5/- 29.7/- 
p6[52/0] 76.9/- 69.2/- 69.2/- 55.8/- 65.4/- 61.5/- 69.2/- 57.7/- 65.6/- 
Mean 45.2/36.8 46.6/36.8 43.4/34.6 42.8/32.4 41.2/38.2 47.0/37.5 44.0/33.1 39.0/30.9 43.6/35.0 
 
Table 2.2: Inter- and intra-subtype diversity of Gag AA sequences in 8 HIV-1 
subtypes and CRFs (%) 
 Subtype B A1 C D F1 G 01_AE 02_AG 
Intra-subtype  8.96 8.34 9.89 8.91 9.45 10.90 7.58 8.26 
Inter-subtype B  17.54 18.38 12.70 16.52 18.46 17.22 18.61 
A1   17.65 16.73 16.93 17.27 12.71 14.69 
C    16.67 17.21 18.02 18.22 19.59 
D     16.55 17.56 16.85 18.72 
F1      15.93 16.48 17.68 
G       17.70 18.81 
01_AE        14.92 
 
Subtype-specific AA prevalence at the 136 drug binding positions is shown in Figure 
2.3. Most positions were located within capsid (72.1%) followed by nucleocapsid 
(12.5%), matrix (9.6%) and p2 (5.9%). Of these positions, 41.2% were conserved 
across all subtypes, while 20.6% showed a different consensus AA in one or more 
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subtypes. On average, 33.8% of drug binding positions harbored at least one 
polymorphism and 16.3% had at least one polymorphism above 5% prevalence. Non-
B subtypes displayed 32 polymorphisms at 20 binding positions that were absent in 
subtype B. Every inhibitor had at least one polymorphic binding position and 15 
inhibitors had more than 50% of drug binding positions showing natural 
polymorphisms. Among all inhibitors, PF-3450074 [16] targeted the most conserved 
binding positions at the capsid N-terminal domain, with only one being polymorphic 
(T107A/S ≤ 6.2%) (Table S2.2). 
Table 2.3: Pairwise AA diversity of Gag domains in 8 HIV-1 subtypes and CRFs (%) 
 Matrix Capsid p2 NC p1 p6 Gag 
B 12.36 4.56 20.65 10.31 4.77 15.74 8.84 
A1 10.69 5.46 13.97 4.75 5.60 17.17 8.18 
C 14.77 5.77 23.79 9.79 4.80 15.83 9.96 
D 12.74 4.87 25.62 9.43 8.89 10.17 8.68 
F1 12.71 5.37 29.24 9.00 6.71 15.32 9.32 
G 17.51 6.15 16.06 10.53 8.42 13.90 10.71 
01_AE 11.36 3.44 24.36 4.95 7.74 14.07 7.46 
02_AG 13.67 4.91 18.50 3.31 5.39 14.39 8.35 
Mean 13.17±2.01 5.04±0.79 21.49±4.83 7.92±2.77 6.39±1.60 14.70±1.99 9.02±1.09 
 
Finally, we analyzed known crystal structures of 9 protein-inhibitor complexes, with 8 
inhibitors targeting a total of 75 positions (binding pockets 1–4) in capsid and one 
targeting 23 positions in nucleocapsid (binding pocket 5) (Figure 2.4, Figure S2.4). 
Natural polymorphisms with prevalence ≥ 5% were observed in 28 positions of the 
binding pockets. Conserved positions were observed in 56% of the capsid binding 
pockets and 43% of the nucleocapsid binding pocket. Pocket 1 (0.0024) had the 
lowest average CI values compared to pocket 2 (0.008), 3 (0.0216), 4 (0.0337) or 5 
(0.0369).  
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Figure 2.3: Natural polymorphisms at 136 drug binding positions in 8 HIV-1 
subtypes and CRFs. For each Gag position, the HXB2 index is shown at the top, 
followed by the consensus amino acid and natural polymorphisms. Polymorphisms 
with proportions ≥ 5% are indicated with blue superscripts; orange otherwise. 
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Figure 2.4: Mapping of drug binding positions and binding pockets to HIV-1 
Gag protein monomers. The surface spectrum colors indicate the most to the least 
conserved positions in subtype B from blue CI = 0 to pink CI ≥ 0.1. (A) Secondary 
structures of 4 Gag proteins and 2 spacer peptides, annotated with five drug binding 
pocket locations. Gag proteins in cartoon representation are colored olive for matrix, 
blue for capsid, yellow for nucleocapsid, grey for p6, gold for p1 and p2. Bound 
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inhibitors are represented in green sticks. (B) Mapping of drug binding positions to a 
surface representation of Gag structure, with front and back views. Hypothesized 
binding positions of bevirimat are also annotated; known drug binding positions are 
colored red. (C) Surface representation of Gag conservation in HIV-1 subtype B 
(Figure S2.5 illustrates other subtypes). (D) Surface representations of five drug 
binding pockets in HIV-1 subtype B (Figure S2.4 shows other subtypes). Inhibitor 
names are annotated according to publication (Table S1). PDB entries of Gag 
proteins: matrix, 1HIW; capsid, 3NTE; p2, 1U57; nucleocapsid, 2M3Z; p6, 2C55. 
PDB data of capsid inhibitors: 2BUO, 2L6E, 2XDE, 4E91, 4E92, 2JPR and 4INB, 
each of which was superimposed to 3H4E using PDBs of 5 drug binding pockets: 
pocket 1, 2XDE; pocket 2, 4INB; pocket 3, 2BUO; pocket 4, 4E91; pocket 5, 2M3Z. 
PyMOL V1.5 (http://www.pymol.org/). 
 
2.5 Discussion and conclusions 
To our knowledge, our large-scale analysis provided the first detailed mapping of 
functional conservation of Gag across major HIV-1 subtypes, with implications for 
the rational design of Gag inhibitors. With more than 50 Gag inhibitors published to 
date, targeting virion morphogenesis is considered a potential new drug class for HIV-
1 treatment [2]. A clinical proof-of-concept was demonstrated in a phase II clinical 
trial of the maturation inhibitor bevirimat [17], which blocks proteolytic processing at 
the capsid-p2 cleavage site [18]. Lack of response was observed in 50% of patients 
and attributed to naturally occurring polymorphisms in the p2 region [8]. A single 
polymorphism V370A is sufficient for a 40-fold reduction in Bevirimat drug 
susceptibility [19], with A370 representing the consensus amino acid in several non-B 
subtypes. Natural diversity was also observed to affect drug effectiveness of other 
experimental Gag inhibitors [20-22]. Polymorphisms T190I, E230D and I256V, for 
instance, reduced drug susceptibility to the benzodiazepine and benzimidazole 
compounds [20]. Moreover, known HIV vaccine candidates containing subtype B 
Gag gene in HIV-derived vectors did not show sufficient protective efficacies in 
several large-scale clinical trials [23]. The high diversity of gag and env genes within 
and between subtypes can contribute to the challenges of designing a global HIV 
vaccine neutralizing all HIV-1 subtypes [24]. For the development of HIV vaccine 
and a potential new drug class targeting virion morphogenesis [2], an assessment of 
Gag functional conservation and polymorphisms at known drug binding positions is 
warranted.  
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We found that 23.4% of drug binding positions in the full-length Gag showed natural 
polymorphisms in non-B subtypes which could not be detected in subtype B. More 
importantly, all Gag inhibitors had at least one polymorphic binding position 
irrespective of subtype. We also found levels of Gag intra- and inter-subtype diversity 
(9.04% and 17.0%) that exceeded diversity estimates of key viral enzymes (< 7% and 
< 11%) targeted by standard HIV-1 treatment [12]. However, the most conserved Gag 
protein capsid has the same level of intra-subtype diversity as integrase (~5%) [12], 
favoring it as a conserved drug target. 
The capsid protein targeted by most candidate inhibitors accounted for 67.7% of 
conserved Gag positions and contained 72.1% of the 136 binding positions previously 
reported. Our sequence analysis identified two conserved capsid regions (Figure 2.2) 
located at the interaction interfaces between N-terminal domains (NTD-NTD) as well 
as between N-terminal and C-terminal domains (NTD-CTD) (). These interaction 
interfaces, crucial for the assembly and stabilization of pentamer and hexamer lattices 
[25], provide potential conserved drug targets. To reveal the ideal drug target, we 
described 4 crystalized drug binding pockets in capsid (Figure 2.4, Additional file 3: 
Figure S2.4). Inhibitors that target pockets 1–3 have shown promising antiviral 
activity against capsid multimerization in different subtype strains by altering NTD-
CTD interaction (pockets 1 and 3) or NTD-NTD interaction (pocket 2) [22, 26, 27]. 
Pocket 4 is less conserved and its polymorphic residues make direct contact with 
inhibitors, hindering the development of inhibitors that target this pocket [20]. 
Another potential drug target is the nucleocapsid protein, containing two critical zinc-
finger domains for binding with viral RNA genomes [2]. Our conservation analysis 
mapped the conserved nucleocapsid regions to zinc-finger domains (Figure 2.2 and 
Figure 2.5) and confirmed previous findings of absolute conservation of CCHC 
motifs at zinc-coordinating positions [28]. However, we detected considerable 
variation at other positions, which may alter drug binding and affect antiviral activity. 
Furthermore, nucleocapsid inhibitors tend to suffer from limited specificity and high 
toxicity due to the ubiquitous presence of zinc finger domains in many human 
proteins [4]. 
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Figure 2.5: Visualization of conserved regions in capsid and nucleocapsid. The 
capsid hexamer structure (PDB: 3H4E) is shown in top (A) and side (B) views, with 
the 6 capsid units (pink, blue), conserved NTD-NTD interaction domains (yellow) 
and conserved NTD-CTD interaction domains (red). (C) The structural complex of 
nucleocapsid and RNA (left, PDB: 1A1T) and the structural complex of nucleocapsid 
and inhibitor CAA (right, PDB: 2M3Z). The first zinc-finger domain (nucleocapsid 
positions: 14–29, Gag positions: 389–404) and the second zinc-finger domain 
(nucleocapsid positions: 35–50, Gag positions: 410–425) are colored red and orange, 
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respectively. Figure S2.7 and Figure S2.8 provide detailed structures of conserved 
Gag regions. 
Matrix inhibitors with broad spectrum antiviral activities were recently reported, but 
mutations at drug binding positions significantly reduced their effectiveness [29, 30]. 
We also observed many natural variants at their drug binding sites (Table S2.2), 
suggesting that further optimization of matrix inhibitors is needed. 
Studies that analyzed genetic variability and drug binding site heterogeneity in Gag 
using large-scale sequence populations are lacking. Previously, small subtype B 
sequence datasets were used to characterize Gag conservation (n = 125) [31] or 
positive selective pressure (n = 635) [32]. Polymorphisms at drug binding sites of 
capsid inhibitor PF-3450074 [16] and conservation of nucleocapsid zinc-finger 
domains [28] were also reported using fewer than 200 sequences. The only large-scale 
analysis that we found [33] quantified the drug binding site conservation of a single 
matrix inhibitor and lacked information on subtype-specific variations. By contrast, 
we presented here a large-scale and integrative analysis using 10862 full-length Gag 
sequences, 136 Gag inhibitor drug binding positions and 14 PDB structures. Natural 
polymorphisms of full-length Gag were detected across 8 major HIV-1 subtypes and a 
robust estimation of functional conservation was performed using CI analysis, which 
incorporated biochemical similarities between amino acids (Additional file 3). This 
sequence analysis predicted three conserved drug targets in Gag (Figure 2.2) which 
were confirmed by existing structural knowledge (Figure 2.5). 
This study is limited in that it neither addressed how to optimize known Gag 
inhibitors nor quantified the impact of newly identified polymorphisms on antiviral 
activities of investigated inhibitors. We collected all available PDBs of Gag-inhibitor 
structures from the RCSB protein data bank, but more crystallized complexes are 
needed to reveal novel mechanisms of action. Moreover, the limited number of 
available Gag sequences for subtypes F1, G and CRF02_AG (n < 100) may have 
affected the identification of polymorphic positions, but consistent conservation 
patterns were observed in Gag regardless of HIV-1 subtype (Figure 2.2). While we 
attempted to be as comprehensive as possible, additional inhibitors may have been 
reported. Conservation of their binding positions can nevertheless be deduced from 
our full-length Gag analysis. Future studies are also needed to address whether 
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interactions between Gag and protease can affect Gag drug binding sites, leading to 
compromised drug activities of Gag inhibitors [34]. 
In conclusion, our study presented a comprehensive mapping of functional 
conservation in Gag and strengthened the idea of capsid as a potential target for HIV-
1 therapeutics. Increased knowledge on HIV-1 natural diversity in drug binding 
pockets contributes to rational design of Gag inhibitors and it remains a challenge to 
design Gag inhibitors with drug binding sites conserved across HIV-1 subtypes. 
2.6 Additional ﬁle 1: Tables 
Table S2.1: Summary of experimental Gag inhibitors published to date 
 Inhibitor 
names 
Target 
protein 
Binding sites in target protein Detected effect HIV strain PDB Year Ref 
P
e
p
ti
d
e 
in
h
ib
it
o
r
s 
Matrix1 Matrix ? Inhibit assembly and 
maturation 
B  1994 [35] 
Capsid1 Capsid ? Inhibit assembly and 
maturation 
B  1994 [35] 
CAI Capsid D166,Y169,K182,N183,E187,E2
12,M215 
Inhibit capsid CTD 
interaction 
Cell-free 2BUO 2005 [36] 
CAC1/CAC1
M,H8 
Capsid I150,R154,Q155,R168,L173,Q17
9,N184,W185,M186,T189,L191,
V192,C199,T201,I202,L203,K20
4,A205,L212,E213,M215,M216,
A218,C219,Q220, 
V166,L173,E181, 
N194,D198,K200, 
G209,A210,T211,V222 
Inhibit capsid assembly B  2011 [37] 
NYAD series Capsid V165,F168,Y169,L172,R173,K18
2,N183,T186,L211,E212,M215[3
8] 
Inhibit capsid CTD 
interaction 
A,B,C,F,G,01A
E 
2L6E 2011 [26] 
P-1, P-2, P-3, 
P-4 
Capsid L151,R154, R184, M185, T188, 
K203(note that only the largest 
changesof  NMR in the presence 
of peptides were notified ) 
Inhibit CA 
polymerization 
B  2011 [39] 
CP4 Capsid T148, I150, L151, D152, V181, 
A185, T186, Q192, A208, L211, 
E212, T216 
Inhibit CA-hLysRS 
interaction 
Cell-free  2011 [40] 
HAGPIA CypA H54,R55,G72,Q63,N102,H126,W
121 
Inhibit CA-CypA 
interaction 
Cell-free 1AWR 1997 [41] 
Gagp6 
(p6:346-354) 
TSG101 T58,Y63,R64,Y68,N69,I70,T92,
M95,K98,V141,F142,S143 
Inhibit TSC101 UEV 
domain binding with 
Gag 
Cell-free 3OBU 2010 [42] 
S
m
a
ll
 o
rg
a
n
ic
 m
o
le
c
u
le
 
Compound14 Matrix ? Inhibit PI(4,5)P2-matrix 
interaction 
A,B,C,D,E,F,G  2012 [33] 
Compound7 Matrix L21,R22,W36,R76,T81,K98 Inhibit PI(4,5)P2-matrix 
interaction 
A,B,C,D,E,F,G  2013 [29] 
TD1,TD2,TD
3  
Matrix L21,R22,K26,K27,H33,W36,E73,
L75,R76,S77 
Inhibit MA-RNA 
interaction 
B  2013 [30] 
Bevirimat CA-SP1 ? Inhibit Gag maturation B  2003 [43] 
Bevirimat 
analogs 
(C-28, C-30) 
CA-SP1 H358,L363,A364 
A366,Q369,A370 T371 
Inhibit Gag maturation B  2011 [18] 
Vivecon 
(MPC-9055) 
CA-SP1 ? Inhibit Gag maturation A,B,C,D,E,F,G,
group O and N 
 2009 [44] 
PA1050040 CA-SP1 ? Inhibit Gag maturation -  2009 [46] 
MPI-461359 CA-SP1 ? Inhibit Gag maturation -  2010 [47] 
PF-46396 CA-SP1 ? Inhibit Gag maturation B,C,E[48]  2012 [49] 
Compound(16
) 
CA-SP1 A366, M367, Q369, V370, N372, 
I376 
Inhibit Gag maturation B  2012 [50] 
I-XW-053 Capsid S33,P34,E35,V36,V165,D166,F1 Inhibit NTD interaction A,B,C,D,E,F,G,  2012 [51] 
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68,Y169,K170,T171,L172,R173,
A174,E175,Q176,S178,Q179,E18
0,N183,T186 
group O 
PF-3450074 Capsid N57,M66,Q67,K70,I73,T107 Inhibit capsid NTD 
interaction 
A,B,C,D,E 2XDE 2010 [16] 
BM4 Capsid W23,V27A/I,K30R,F32,S33G,T5
8I,H62 
Inhibit capsid NTD 
interaction 
B 4E92 2012 [22] 
BD3 Capsid W23,V24,V27A/I,F32,V36T,T58I
,V59,G61E,H62 
Inhibit capsid NTD 
interaction 
B 4E91 2012 [22] 
Inhibitor4 Capsid W80,M96,E98,W117,H120,P122,
P123,I124,I129,R132 
Inhibit capsid NTD 
interaction 
B 4E91 2013 [52] 
BMMP Capsid ? Inhibit Gag-Gag 
interaction 
B  2011 [53] 
Compound3,4
,5 
Capsid ? Inhibit capsid NTD 
interaction 
Cell-free  2013 [54] 
Compound27 Capsid ? Inhibit capsid NTD 
interaction 
Cell-free  2013 [55] 
CAP-1 Capsid W23,V27,E28,A31,F32,V59,H62,
A64,A65,I141 
Inhibit capsid CTD 
interaction 
B 2JPR 2007 [56] 
CAI-
compound  
series 
Capsid V165,Y169,N183,L211,M215 Inhibit capsid CTD 
interaction 
A,B,C,D,F,G, 
group O 
 2011 [57] 
Benzodiazepi
ne series 33 
Capsid V27,A31,F32,V59,H62,A65,Y14
6 
Inhibit capsid NTD 
interaction 
Cell-free  2012 [58] 
Inhibitor3 Capsid W23,V24.V27,E28,K30,A31,F32,
S33,P34,V36,I37,F40,K56,V59,G
60,G61,H62,A65,M66,K69,I134,
K138,N139,I141,V142 
Inhibit capsid NTD 
interaction 
B 4INB 2013 [27] 
CAA NC V13,K14,F16,I24,A25,K26,R32,
G35,W37,K38,Q45,M46,K47 
Inhibit NC-RNA/DNA 
interaction 
B 2M3Z 2013 [59] 
WDO-217 NC ? Zinc ejection B,HIV-2,SIV  2012 [60] 
Compound6,
Compound8 
NC F16,R32,K34,W37,Q45,M46,K47 Inhibit NC(11-55)-
RNA interaction 
B  2012 [61] 
Compound45 NC C49,T50,E51 Inhibit NC-
oligonucleotide  
B  1999 [62] 
SL3ligands NC zinc fingers(15-28,36-49) Inhibit NC-RNA/DNA 
interaction 
B  2012 [63] 
mONs NC zinc fingers Inhibit NC-DNA 
interaction 
Cell-free  2011 [64] 
SAMT NC zinc fingers Inhibit NC-RNA/DNA B  2010 [65] 
NV038 NC zinc fingers Zinc ejection B,HIV-2,SIV  2010 [66] 
CO7 NC zinc fingers Inhibit NC-DNA 
interaction 
Cell-free  2009 [67] 
Thioesters NC zinc fingers Inhibit NC-RNA 
interaction 
B  2004 [68] 
YS1332D NC zinc fingers Inhibit NC-RNA 
interaction 
B  2003 [69] 
DIBA NC zinc fingers Zinc ejection B,HIV-2,SIV  2001 [70] 
PATEs NC zinc fingers Target zinc fingers B  2001 [69] 
NSC 624151 NC zinc fingers Target zinc fingers A,B,C,D,F,HIV-
2,SIV 
 1996 [71] 
SRR-SB3 NC zinc fingers Target zinc fingers B,HIV-2,SIV  1996 [72] 
NOBA NC zinc fingers Target zinc fingers Cell-free  1998 [73] 
Enantiomers NC zinc fingers Inhibit NC-RNA 
interaction 
Cell-free  2003 [74] 
2-
Mercaptobenz
amide 
Thioesters 
NC zinc fingers Target zinc fingers Cell-free  2005 [75] 
thiolcarbamat
es (TICAs), 
NC zinc fingers Target zinc fingers B  2002 [76] 
Azodicarbona
mide (ADA) 
NC zinc fingers Target zinc fingers B,HIV-2  2000 [77] 
 
Notations: (a) peptide inhibitors – amino acid sequences which were designed to 
inhibit HIV replication, (b) small organic molecule – low molecular weight organic 
compounds that were designed to bind Gag proteins. Sequences of peptide inhibitors 
are: 
(1) Matrix1[matrix sites: 47-59]: NPGLLETSEGCRQ,  
(2) Capsid1[capsid sites:124-133]: IPVGEIYKRW,  
(3) CAI: ITFEDLLDYYGPK(Bio
1
)CL,  
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(4) CAC1M [capsid sites:175-193] SESAASSVKAWMTETLLVANTSS,  
     H8[capsid sites:158-176] KEPFRDYVDRFYKTLRAEQ,  
(5) NYAD-201[capsid sites:178-192] AQEVKXWMTXTLLVA 
     (X= (S)-alpha- (2‟-pentenyl)alanine),  
(6)  P-1[capsid sites: 181-192] VKNWMTETLLRQ,  
(7) CP4: cyclo(D-Ala-Ile-Fpa-Arg-Tyr-Trp-D-Ala-D-Ala-Glu)-Lys 
(8) HAGPIA [capsid sites:87-92] HAGPIA 
(9) Gagp6[p6 sites:5-13]: PEPTAPPEE 
As for the information of clinical trials, Bevirimat is under Phase IIb[17], Vivecon 
was under phase IIa (discontinued) [44], PA1050040 was under phase I [45] and 
Azodicarbonamide (ADA) was under phaseI/II (discontinued) [4]. 
 
Table S2.2: Summary of natural variants at drug binding sites of Gag inhibitors 
Inhibitors Ref Tar
get 
HIV-1 subtypes 
B(n=4131) A1(n=1648) C(n=2780) D(n=443) F1(n=35) G(n=49) 01_AE(n=1714) 02_AG(n=62) 
CAI [36] CA  F169Y1.2,G
183A1.2,G1
83N20.9,G1
83S2.4,E187
D11.7 
D187E14.1 N183A4.8
,N183G7.
0,N183T7.
0,E187K2.
7 
G183N30.
3,G183S3.
0,D187E8.
8, 
G183N3
7.5,G183
H2.1,G1
83S12.5,
D187E10
.4 
Y169F1.3,N183
H2.9 
N183G4.9,N1
83H1.6,E187
D14.8 
CAC1/CA
C1M,H8 
[37] CA R154K29.1,
K199R6.0,T
216I2.4,T21
6S1.1,A194
S12.3,T200
S2.5,T210S
2.7 
K154R3.2,V
191I17.1,K1
99R1.5,R20
3K8.1,A204
G6.0,S200A
3.7,S200G1.
3,S200T10.1
,T210S18.7 
K154R26.3
,V191I10.0
,K199R1.2,
R203K16.2
,A204G12.
9,T200N4.
4,T200I5.0,
T200S2.1,
T200V2.4,
T210S30.9,
L211I1.4 
R154K9.1,
Q179T3.4,
V191I4.3,I
201L3.2,A
204G4.1,T
216S3.4,T
200I4.1,T
210S6.6 
R154K33.
3,V191I8.
8,K199R2.
9,K203R5.
9,A204G5
.9,L205M
2.9,Q219R
2.9,G220E
2.9,A194S
8.8,T200I
2.9,A209
G2.9,T210
S18.2,L21
1I2.9 
R154K46
.8,Q179T
2.1,V191
I4.3,R20
3K31.9,
A204G4.
2,A204S
2.1,T200
N2.1,T20
0I2.1,T2
10S20.8 
R154K12.7,V19
1I3.0,K199R1.2,
K203R5.7,A204
S2.7,S200A5.8,
S200T3.4,T210
S5.3 
R154K27.9,V
191I3.3,V191
T1.6,K199R3.
3,R203K33.3,
A204G3.3,L2
05M3.3,T216
S1.6,A194S3.
3,S200A13.1,
S200H1.6,S20
0I1.6,S200T1
4.8,T210S5.0 
NYAD 
series 
[26] CA  F169Y1.2,G
183A1.2,G1
83N20.9,G1
83S2.4 
L211I1.4 N183A4.8
,N183G7.
0,N183T7.
0 
G183N30.
3,G183S3.
0,L211I2.
9 
G183N3
7.5,G183
H2.1,G1
83S12.5 
Y169F1.3,N183
H2.9 
N183G4.9,N1
83H1.6 
P-1, P-2, 
P-3, P-4 
[39] CA R154K29.1 K154R3.2,R
203K8.1 
K154R26.3
,R203K16.
2 
R154K9.1, R154K33.
3,T188S5.
9,K203R5.
9 
R154K46
.8,T188S
2.1,R203
K31.9 
R154K12.7,K20
3R5.7 
R154K27.9,R
203K33.3 
Bevirimat 
analogs 
(C-28, C-
30) 
[18] CA Q6H1.9,V7
A20.8,V7I1.
7,V7M6.2,V
7T1.1,T8S1.
3 
Q6H1.8,V7
A16.5,V7I1.
9,V7L1.4,Q
8N1.3,Q8H3
.1 
Q6R1.0,Q6
L1.7,A7T1
5.5,A7V22.
7,N8Q1.1,
N8G14.1,N
8S7.1,N8T
1.5 
A1T2.3,A
7V18.8,T8
N15.4,T8S
8.8 
Q6K5.9,A
7I3.0,A7L
3.0,A7T6.
1,A7V42.
4,T8A3.3,
T8N3.3,T
8Q16.7,T8
S6.7 
Q6N2.1,
Q6H10.4
,Q6K2.1,
A7I2.1,A
7M2.1,A
7V10.4,S
8N2.1,S8
T16.7 
Q6N7.5,Q6H30.
3,Q6K1.3,Q6S2.
7,A7T4.0,A7V2
8.1 
V7A31.1,V7T
1.6,Q8H16.4 
CP4 [40] CA T148A2.1,T
148I2.5,T14
8S3.6,T148
V22.3,A208
G15.6,T216I
2.4,T216S1.
1 
G208A1.6 V148T1.8,
G208A5.5,
L211I1.4 
A208Q2.0
,A208G38
.9,T216S3
.4 
V148T2.9,
G208A5.9
,L211I2.9 
V148T4.
2,D152G
2.1 
V148I2.5,V148
T10.2 
V148T18.0,G
208A1.6,T216
S1.6 
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Compoun
d7 
[29] MA K76R42.8,T
81A9.1,T81
L1.0,K98R1
.0 
R76K36.7,T
81A4.5 
R22K5.0,R
76I3.8,R76
K41.5,R76
V1.3 
K76R7.2,
K98Q3.4 
R22K8.8,
W36R2.9,
R76K38.2,
T81A3.0,
T81L6.1 
L21M2.1
,K76R39.
6,T81A1
2.5,T81P
2.1,K98
Q6.4,K9
8T4.3 
K76R17.4,T81A
9.2,T81L4.1,K9
8Q1.6 
K76R18.0,T8
1A3.3 
TD1,TD2,
TD3 
[30] MA K26R8.2,K2
6N2.3,K26S
2.1,L75I4.9,
L75F7.5,K7
6R42.8 
K26R6.6,K2
6N1.8,K26S
1.1,L75I12.8
,L75F4.5,L7
5V1.8,R76K
36.7 
R22K5.0,K
26R1.7,E7
3K5.1,L75I
2.8,L75F8.
5,R76I3.8,
R76K41.5,
R76V1.3 
N26R6.7,
N26G3.0,
N26H12.0
,N26K24.
2,N26S24.
2,K27Q2.
0,E73K4.8
,I75L24.9,
I75M2.0,I
75V2.0,K
76R7.2 
R22K8.8,
K26R2.9,
W36R2.9,
L75I5.9,L
75F2.9,R7
6K38.2 
L21M2.1
,K26R39.
6,K27N4
.2,E73Q4
.2,L75I4
2.6,K76R
39.6 
K26R7.7,L75I6.
1,L75F1.6,L75Y
1.2,L75V4.2,K7
6R17.4 
K26R1.6,K26
N3.3,K26S3.3
,L75I4.9,L75
V1.6,K76R18.
0 
PF-
3450074 
[16] CA T107S2.8   T107S2.9 T107A4.2,
T107S6.2 
T107S1.
2 
  
I-XW-053 [51] CA K170R4.5,T
171V2.6,S1
78T10.4,E1
80D36.1 
S33N4.7,F1
69Y1.2,T17
1A4.7,T171
C9.8,T171I1
.2,T171V7.7
,T178S17.4,
E180D25.5,
E180P1.1,G
183A1.2,G1
83N20.9,G1
83S2.4 
S33N15.9,
V36I11.4,
K170R3.2,
T171A1.2,
T171V4.0,
T178S15.1,
D180E38.4 
S33N7.7,T
171V8.8,S
178T5.0,Q
179T3.4,D
180N2.7,
D180E11.
1,N183A4
.8,N183G
7.0,N183T
7.0 
S33N2.9,
V36I2.9,K
170R9.1,T
171A9.1,T
171C3.0,T
171V6.1,T
178S26.5,
E180D11.
8,G183N3
0.3,G183S
3.0 
S33N6.2,
T171A4.
2,T171C
2.1,T171
V2.1,T17
8S10.4,Q
179T2.1,
E180D29
.2,G183
N37.5,G
183H2.1,
G183S12
.5 
N33S2.7,Y169F
1.3,T178S16.1,
E180D1.6,N183
H2.9 
E35K1.6,T171
A1.6,T171V1.
6,T178S3.3,E
180D13.1,N18
3G4.9,N183H
1.6 
BM4 [22] CA V27I25.1, I27V2.3,K3
0R13.3,S33
N4.7,I58V6.
4 
I27V13.9,S
33N15.9 
I27V17.0,
S33N7.7 
W23M2.9,
I27V33.3,
K30R2.9,
S33N2.9 
V27I16.7
,K30N2.
1,S33N6.
2 
V27I7.0,N33S2.
7 
I27V3.3,K30R
1.6,I58V1.6 
BD3 [22] CA V27I25.1, I27V2.3,I58
V6.4,V59I1.
9 
I27V13.9,
V36I11.4,
V59I3.0 
I27V17.0 W23M2.9,
I27V33.3,
V36I2.9 
V27I16.7 V27I7.0,G61D2.
0 
I27V3.3,I58V
1.6 
Inhibitor4 [52] CA M96I8.6,M9
6L3.4,M96
V3.5,E98D1
1.0,N120H1
7.9,N120S2
3.2,P123A1.
8,I124V3.6,
R132K5.8 
M96I8.9,M9
6L12.2,S120
N7.5,S120G
16.0,I124F1.
8,I124V2.4,
R132G2.0,R
132K5.5 
M96I20.2,
M96L5.1,
M96S1.1,E
98D6.0,S1
20A3.1,S1
20N16.6,S
120G19.4,
S120H1.2,
P123A2.2,I
124V35.7 
M96I15.2,
E98D7.0,S
120A2.5,S
120N38.0,
S120G1.1,
S120H2.3,
I124V6.3,
R132K7.3 
M96I32.4,
M96L2.9,
E98D2.9,S
120A2.9,S
120G14.7,
P122Q2.9,
V124I2.9,I
129M2.9,
R132G2.9,
R132K2.9 
I96M2.1,
E98D20.
8,E98G2.
1,W117R
2.1,S120
N10.6,S1
20G6.4,P
123A2.1,
I124V10.
4 
M96I13.5,M96L
8.5,E98D2.1,N1
20G10.8,N120S
35.8,P123A8.4,
P123S4.1,I124V
1.8 
M96I1.6,M96
L1.6,E98D1.6,
S120N1.6,S12
0G4.9,I124T1.
6,I124V14.8,I
129M1.6, 
CAP-1 [56] CA V27I25.1, I27V2.3,A3
1G24.5,V59
I1.9,I141L5.
6 
I27V13.9,
A31N5.6,A
31G16.2,V
59I3.0 
I27V17.0,
E28K2.9,
A31G6.3 
W23M2.9,
I27V33.3,
E28G2.9,
A31G2.9 
V27I16.7
,A31G2.
1,A31S2.
1 
V27I7.0,G31S1.
1,A64G1.5 
I27V3.3,A31
N1.6,A31G11.
5 
CAI-
compound 
series 
[57] CA  F169Y1.2,G
183A1.2,G1
83N20.9,G1
83S2.4 
L211I1.4 N183A4.8
,N183G7.
0,N183T7.
0 
G183N30.
3,G183S3.
0,L211I2.
9 
G183N3
7.5,G183
H2.1,G1
83S12.5 
Y169F1.3,N183
H2.9 
N183G4.9,N1
83H1.6 
Benzodiaz
epine 
series 33 
[58] CA V27I25.1 I27V2.3,A3
1G24.5,V59
I1.9,S146N1
.9 
I27V13.9,
A31N5.6,A
31G16.2,V
59I3.0 
I27V17.0,
A31G6.3 
I27V33.3,
A31G2.9 
V27I16.7
,A31G2.
1,A31S2.
1,S146C
4.2 
V27I7.0,G31S1.
1,S146R1.9,S14
6K1.6 
I27V3.3,A31
N1.6,A31G11.
5 
Chapter 2: Functional conservation of HIV-1 Gag 
  
73 
Inhibitor3 [27] CA  K30R13.3,A
31G24.5,S3
3N4.7,V59I
1.9,N139H5.
6,I141L5.6 
A31N5.6,A
31G16.2,S
33N15.9,V
36I11.4,V5
9I3.0 
E28K2.9,
A31G6.3,
S33N7.7,I
134V1.4 
W23M2.9,
E28G2.9,
K30R2.9,
A31G2.9,
S33N2.9,
V36I2.9 
K30N2.1
,A31G2.
1,A31S2.
1,S33N6.
2,N139H
2.1 
G31S1.1,N33S2
.7,G61D2.0,N13
9H1.2 
K30R1.6,A31
N1.6,A31G11.
5 
CAA [59] NC V13I15.3,I2
4L11.6,I24T
1.5,I24V1.8,
K26R48.5 
R26K6.0 V13I33.7,F
16Y1.7,I24
L22.7,R26
K25.0 
I13L13.2,I
13V9.1,I2
4L14.5,I2
4T13.3,K2
6R31.7 
V13I35.3,I
24L11.8,I
24V2.9,K
26R42.4 
K14R2.1,
F16Y2.1,
L24I2.1,
R26K2.1,
Q45L2.1,
M46I2.1,
K47R18.
8 
R26K3.6 I13L1.6,I13V
1.6,L24V1.6,
R26K1.6,Q45
L1.6 
Compoun
d6,Compo
und8 
[61] NC K34R17.9 F16Y1.7,K3
4R11.9 
R34K40.1 K34R2.9 F16Y2.1,
K34R6.2,
Q45L2.1,
M46I2.1,
K47R18.8 
K34R2.9 R34K29.3,Q45L
1.6 
 
Compoun
d45 
[62] NC T50N4.7,T5
0I2.2,T50S4
.0,E51G1.6 
T50D1.3,T5
0E1.4,E51D
1.2 
T50N3.1  T50N2.9,
T50E2.9,T
50P2.9 
T50M2.1
,T50S2.1
,E51D2.1
,E51Q2.1 
T50N4.6 T50N3.3,E51
V1.6 
Bevirimat [43] CA-
p2 
Q6H1.9,V7
A20.8,V7I1.
7,V7M6.2,V
7T1.1,N9Q1
.6,N9G8.4,N
9S6.7,N9T2.
6,I13M2.3,I
13V14.1 
Q6H1.8,V7
A16.5,V7I1.
9,V7L1.4,H
9N11.5,H9Q
29.5,H9G1.1
,I13V7.8 
Q6R1.0,Q6
L1.7,A7T1
5.5,A7V22.
7,N9Q4.9,
N9H6.0,N9
S20.7,M13
L12.2 
A7V18.8,
N9Q3.4,N
9G13.6,N
9K12.7,N
9S14.7,N9
T2.3,N9V
4.8,I13A1.
6,I13L6.3,
I13M3.6,I
13V18.8 
Q6K5.9,A
7I3.0,A7L
3.0,A7T6.
1,A7V42.
4,N9G3.0,
N9H12.1,
N9K6.1,N
9S21.2,V1
3I44.1,V1
3L2.9 
Q6N2.1,
Q6H10.4
,Q6K2.1,
A7I2.1,A
7M2.1,A
7V10.4,
G9N4.3,
G9D2.1,
G9S2.1,
G9T2.1,I
13A2.2,I
13M2.2,I
13V17.8 
Q6N7.5,Q6H30.
3,Q6K1.3,Q6S2.
7,A7T4.0,A7V2
8.1,H9N5.6,H9
Q35.9,H9G2.6,
H9P1.3,H9S1.5,
I13M1.3,I13V15
.4 
V7A31.1,V7T
1.6,Q9N3.3,I1
3V34.4 
Inhibitor names, references and targets are indicated in the first three columns. The 
proportions of natural variations for subtype B, A1, C, D, F1, G, 01AE and 02AG 
were summarized from the 4
th
 to 11
th
 columns. Natural polymorphisms for each 
inhibitor are summarized for each subtype and they are annotated in the form of 
“wildtype+position+mutation+proportion”. For instance, “R154K29.1” indicates the 
most prevalent amino acid R at position 154 switches to amino acid K, with the 
proportion 29.1% in sequence dataset. Note that the most prevalent amino acid is 
defined as wildtype in our analysis. 
2.7 Additional ﬁle 2: Notes 
Mathematical model of conservation index 
We analyzed the degree of positional conservation in the multiple sequence alignment 
(MSA), taking into account of stereochemical variability between amino acids. 
Adapted from the conservation analysis in Karlin and Brocchieri  [15, 78], a 
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conservation index (CI) was calculated for each position by averaging pairwise 
dissimilarity scores between all AAs using BLOSUM62 matrix [79].  
Amino acid substitution matrices (e.g. BLOSUM62) are designed for estimating the 
occurrence of each possible pairwise substitution over evolutionary time. While the 
genetic code allows the translation of similar codons into the same synonymous or 
similar AAs, mutating one AA to another AA with substantially different biochemical 
properties can affect protein folding or activity [80]. In a substitution matrix, the 
nondiagonal pairwise scores how likely an AA is to be substituted by another in a 
homologous protein and the diagonal scores indicate how likely one AA is to be 
substituted at all [81]. For instance, a negatively charged residue like aspartic acid D 
is more likely to be replaced by the other negatively charged residue glutamic acid E, 
than it is to be mutated into positively charged histidine H. In BLOSUM62 matrix, D 
to E is scored 2, while D to H is -1. Adapted from Karlin and Brocchieri [15, 78], 
conservation index (CI) of position x  is calculated as: 
1 1
( , )2
( ) 1
( 1) ( , ) ( , )
N N
i j
i j i i i j j
S x x
CI x
N N S x x S x x  
 

  
Where ix  is the amino acid form at the position x of the i
th
 sequence in the MSA, N  
is the number of sequences in MSA, ( , )i jS x x is the similarity score between amino 
acid form ix  and jx . Suggested in Karlin and Brocchieri [15, 78], we adapted the 
similarity matrix BLOSUM62 to provide the similarity scores for ( , )i jS x x . Since 
denominators should not be zero, the values of BLOSUM62 M  are linearly 
transformed into positive by adding the absolute value of minimum score 
| min( ) | 1M  . In our analysis, the conservation index of positions with less than 20% 
gaps is calculated, and the amino acid comparisons were restricted to 20 amino acids 
(e.g. ARNDCQEGHILKMFPSTWYV). Note that if no natural variations exist at 
conserved position x , then ( ) 0CI x   otherwise, 0 ( ) 1CI x  . Given BLOSUM62 as 
the similarity matrix for ( , )i jS x x , it can be shown that 0 ( ) 0.9278CI x  . Besides, 
the relationship between conservation index and pairwise diversity can be described 
by the Proposition 1, which explains that conservation index is equal to or less than 
pairwise diversity. Note that pairwise diversity is defined as: 
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1 1
2
1 ( )
( 1)
N N
i j
i j i
x x
N N

  
 

 , where   denotes the Kronecker symbol, ( )i jx x   
equals 1 if ix is identical to jx ; otherwise 0. 
 
Proposition 1. Suppose x  is a position in MSA and ix  is a polymorphism at x , 
( )iP x  is the prevalence of ix , let ( )CI x  and  ( )Diversity x denote conservation index 
and pairwise diversity, respectively, then:          
( ) ( )CI x Diversity x  
Proof: Assume that an amino acid similarity matrix S  (e.g. BLOSUM62) satisfies 
( , ) ( , )i i i jS x x S x x . We have: 
( , )
1 ( ) 1
( , ) ( , )
i j
i j
i i j j
S x x
x x
S x x S x x
     
It can then be concluded that: 
                                     
1 1
1 1
1 1
( , )2
( ) 1
( 1) ( , ) ( , )
( , )2
[1 ]
( 1) ( , ) ( , )
2
(1 ( ))
( 1)
( )
N N
i j
i j i i i j j
N N
i j
i j i i i j j
N N
i j
i j i
S x x
CI x
N N S x x S x x
S x x
N N S x x S x x
x x
N N
Diversity x

  
  
  
 

 

  





 
The above section explained relationship between CI(x) boundary and pairwise 
diversity; we now discuss the properties of the relationship between CI(x) and 
accumulative polymorphism prevalence. Let ( )C x  be the cumulative polymorphism 
prevalence at position x , a trivial observation can be found as: 
22( ) ( ) min [1, ( ( ) ( ))]
1
N
CI x Diversity x C x C x
N
  

. This is derived from the 
following equations that
2
( ) ( ) ( )
1 a b a
N
Diversity x P x a P x b
N 
  

  and 
( ) 0.5
( ) ( )
P x a
C x P x a
 
   , where a and b are two AA forms at position x  in MSA.  
Theoretical results did not yield a precise value for the upper boundary of CI(X) using 
C(X). We therefore used our HIV-1 Gag datasets to show the relationship between 
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( )CI x  and cumulative polymorphism prevalence regarding the identification of 
conserved positions. Given the cutoff 0.01 for both ( )CI x  and cumulative 
polymorphism prevalence, we compared the results from both measurements. 
Suppose 1S  is the set of conserved positions given the cutoff of ( )CI x , 2S  is the set 
of positions with cumulative polymorphism prevalence less than 0.01. We found that 
only 5 out of 147 positions in 1S  were different from 2S , and 6 out of 149 positions 
in 2S  were different from 1S . The two measurements reach up to 95.9% (6/149) 
common predictions. In other words, using ( )CI x  tests to identify conserved sites at 
cutoff 0.01 can approximately guarantee cumulative polymorphism prevalence below 
0.01.  
Herein, we provide an adapted example from Valdar [81] to compare conservation 
index with other state-of-the-art conservation methods (i.e. Shannon entropy, Jensen-
Shannon diversity, relative entropy, property relative entropy, sum of pairs [82]). We 
used our Matlab package to calculate Shannon entropy and the python software from 
Capra and Singh [82] to calculate the other measurements (default settings).  
Table S2.3: Comparison of conservation methods given a simple sequence 
example 
Example Pos1 Pos2 Pos3 Pos4 Pos5 Pos6 Pos7 Pos8 Pos9 
Seq1 E D D D D D I P D 
Seq2 E D D D D D I P V 
Seq3 E D D D D D I P Y 
Seq4 E D D D D D I P A 
Seq5 E D D D D D L W T 
Seq6 E D D D E E L W K 
Seq7 E D D D E E L W P 
Seq8 E D D D E E L W C 
Seq9 E D D D E F V S R 
Seq10 E D E F F F V S H 
Methods          
Conservation index 0 0 0.0665 0.1636 0.3107 0.4006 0.1580 0.5874 0.6730 
Shannon Entropy 0 0 0.1412 0.1412 0.4097 0.4472 0.4581 0.4581 1 
Property entropy 0 0 0.0418 0.1253 0.1896 0.1703 0.1998 0.4889 0.6355 
Jensen-Shannon 0.8367 0.8299 0.8007 0.7621 0.7102 0.6567 0.6507 0.6075 0.5497 
Relative Entropy 0.9447 0.9481 0.9048 0.8257 0.7117 0.6143 0.6238 0.6070 0.5363 
Property relative entropy 3.1713 3.1713 3.0608 2.8399 2.6729 2.4370 2.2060 1.7668 1.1429 
Sum of pairs 5.0000 5.5500 5.1500 3.9722 2.5444 1.9166 1.7277 1.4666 -1.4888 
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Given the above example with 10 sequences (Seq1 to Seq10), the following order 
ranks the positions (Pos1 to Pos9) from the most conserved to the least conserved: 
Pos1 = Pos2 > Pos3 > Pos4 > Pos5 > Pos6, and Pos7 > Pos8 > Pos9. The most 
conserved positions are Pos1 and Pos2 where there is no mutation. AA change from D 
to E is more tolerable than from D to F, thus Pos3 is more conserved than Pos4. Pos4, 
with fewer mutations, is more conserved than Pos5. Pos7 which possesses all 
hydrophobic I, L and V are more conserved than Pos8 containing P, W, S from 
different AA groups (aromatic side group, hydrophobic group, polar uncharged side 
group). Pos9 is the most variable position with all different AAs.  
We found that CI was a robust estimation of the conserved sites for three reasons: (1) 
positions with no natural variations in the MSA have equal CIs. This is not the case 
with Jensen-Shannon diversity score, for instance. (2) Positions with higher natural 
variations have higher CIs. This is not the case with property entropy, for instance. (3) 
The biochemical similarities between amino acids are taken into account. This is not 
the case with Shannon entropy where all amino acids are treated equally. Regarding 
the difference between state-of-the art methods, it has been described extensively in 
[81] [82]. Given 4130 full-length HIV-1 subtype B Gag sequences, Figure S2.1 
demonstrates the distribution of conservation scores in HIV-1 subtype B Gag using 
conservation index, Shannon entropy and relative entropy. Figure S2.2 demonstrates 
the comparison of Shannon entropy and conservation index using full-length protease 
sequences sampled from 723 HIV-1 subtype B patients, downloaded from HIV Los 
Alamos Database. 
Figure S2.1 and Figure S2.2 demonstrate that the three methods show similar 
patterns in full-length Gag conservation analysis, indicating that conservation index 
may characterize AA conservation and yield similar patterns to entropy measurements. 
Note that positional conservation methods based on substitution matrices were 
criticized for not accounting for gaps [81], gaps were treated as missing data in our 
analysis and only positions with less than 20% gaps were analyzed. Regarding the 
performance, it is possible that other state-of-the-art methods provide equally ideal 
estimations of positional conservation by taking into account stereochemical 
sensitivity, reviewed in [81]. Taken together, our data show that conservation index 
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provides sufficient statistical power to quantify positional conservation using the 
BLOSUM substitution matrix. 
 
Figure S2.1: Amino acid conservation in HIV-1 full-length Gag analyzed by 
conservation index, Shannon entropy and relative entropy. The plots of the exact 
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conservation values (A-C) and fitted polynomial curves (D) are provided. 
 
 
Figure S2.2: HIV-1 protease conservation analyzed by conservation index and 
Shannon entropy.  
 
 
 
Inter- and intra-subtype diversity 
The amino acid inter- and intra-subtype diversity was calculated by pairwise amino 
acid comparisons [12]. Herein we describe the mathematical models. Suppose D is a 
multiple sequence alignment containing N amino acid sequences, L is the number of 
positions in D. Intra-subtype diversity ( )
IntraDiversity D for dataset D is calculated as: 
1 1 1
2 1
( ) 1 ( )
( 1)
N N L
Intra t t
i j
i j i t
Diversity D D D
N N L

   
  

   
Where t
iD is the t
th
 amino acid form of the sequence i in dataset D,   denotes the 
Kronecker symbol, ( )t ti jD D  equals 1 if 
t t
i jD D is true; otherwise 0. Similarly, we 
can calculate the inter-subtype diversity between two sequence datasets. Suppose 1D  
and 2D  are the multiple sequence alignments from two subtypes (e.g. subtype B and 
subtype C). Both have the number of sequences, N and M, respectively. The inter-
subtype diversity between two subtypes ( 1, 2)
InterDiversity D D  is defined as: 
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( 1, 2) 1 ( 1 2 )
N M L
Inter t t
i j
i j t
Diversity D D D D
N M L

  
  

   
In our analysis, we calculated the pairwise diversity at positions on sequences with 
less than 20% gaps and gaps were treated as missing data. To solve the heavy 
computation of large sequence datasets (1000 sequences lead to half a million 
pairwise calculations), our Matlab toolbox implemented parallel computation with 
optimized memory strategy (http://www.mathworks.com/matlabcentral/fileexchange/47155-
amino-acid-conservation-zip). 
 
 
 
 
 
 
2.8 Additional ﬁle 3: Figures 
Figure S2.3: The distribution of natural polymorphisms at 500 Gag positions on 
8 HIV-1 subtypes. HXB2 indices at each individual protein are shown in the first 
column, followed by HXB2 indices in the full-length Gag. Drug binding positions are 
marked with red stars. The colors in the second column distinguish the Gag domains: 
light green for matrix (position: 1-132), light blue for capsid (133-363), dark green for 
p2 (364-377) and p1 (433-448), dark blue for nucleocapsid (378-432) and gray for p6 
(449-500). The remaining columns list the consensus amino acid for each subtype 
followed its natural variation(s) and the corresponding proportion(s) in blue 
(prevalence above 5%) and orange (prevalence at or below 5%). 
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Figure S2.4: Surface representation of five drug binding pockets in 8 HIV-1 
subtypes. For each subtype figure, surface spectrum colors indicate each position‟s 
CI, from the most conserved (blue CI = 0 ) to the least conserved positions (pink CI ≥ 
0.1). Crystallized inhibitors are shown in sticks view inside their binding pockets. 
Visualization software: PyMOL V1.5 (http://www.pymol.org/). 
Chapter 2: Functional conservation of HIV-1 Gag 
  
89 
 
Chapter 2: Functional conservation of HIV-1 Gag 
  
90 
 
Figure S2.5: Surface representation of conservation index of full-length Gag in 8 
HIV-1 subtypes. 4 Gag proteins (monomers) and 2 spacer peptides are annotated and 
displayed in schematic view at the top.  Drug binding sites (red) are mapped onto 
HIV-1 Gag protein structures. For each subtype figure, surface spectrum colors 
indicate each position‟s CI, from the most conserved (blue CI = 0) to the least 
conserved positions (pink CI ≥ 0.1).  Crystallized inhibitors are shown in sticks view 
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inside their binding pockets.  Visualization software: PyMOL V1.5 
(http://www.pymol.org/). 
 
Figure S2.6: The structure of capsid hexamer superimposed with 8 crystallized 
inhibitors. The capsid hexamer structure is shown in the top, side and bottom views 
from Fig S1(A) to S1(C). The drug binding pockets are annotated in each figure. 
Three figures on the left side show the N-terminal domains (NTD, position: 1-146) 
and C-terminal domains (CTD, position: 151-231), colored blue and pink, 
respectively. Red circles indicate drug binding pockets, whose targets are within the 
interfaces of NTD-NTD, NTD-CTD or CTD-CTD interactions. Three figures on right 
side map the CIs to the structure and visualize the conservation of the drug binding 
pockets. It shows that drug binding pocket 1 in NTD is situated on the NTD-CTD 
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interaction interface, drug binding pocket 2 in NTD is situated on the NTD-NTD 
interaction interface, drug binding pocket 3 in CTD is situated on the NTD-CTD 
interaction interface, and drug binding pocket 4 is inside NTD. Note that drug binding 
pockets 1 and 3 are situated on the opposite sides of the same NTD-CTD interface. 
The superimposed crystallized inhibitors were mapped onto the capsid hexamer using 
PyMOL V1.5 (PDB: 3H4E). Visualization software: PyMOL V1.5 
(http://www.pymol.org/). Inhibitor references are available in Additional file 1. 
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Figure S2.7: Conserved NTD and CTD domains in HIV-1 capsid. The capsid 
hexamer structure is shown in top (A), side (B) and bottom (C) views. Conserved 
NTD-NTD interaction domains are colored yellow (capsid positions: 30-70, Gag 
positions: 162-202). Conserved NTD-CTD interaction domains are colored red 
(capsid positions: 155-176, Gag positions: 287-308). PDB: 3H4E. Visualization 
software: PyMOL V1.5 (http://www.pymol.org/). 
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Figure S2.8: Conserved zinc-finger domains in HIV-1 nucleocapsid. The 
structures of nucleocapsid–RNA and nucleocapsid–inhibitor complexes are shown in 
top (A), side (B) and bottom (C) views. The first zinc-finger domain is colored red 
(nucleocapsid positions: 14-29, Gag positions: 389-404) and the second zinc-finger 
domain (nucleocapsid positions: 35-50, Gag positions: 410-425) are colored orange. 
PDB: 1A1T, 2M3Z. Figure S2.7 and Figure S2.8 visualize the conserved regions 
identified as three minimum conserved regions using our conservation analysis 
(Figure 2.2). Visualization software: PyMOL V1.5 (http://www.pymol.org/).  
 
Figure S 2.9: Plots of CI values at 500 Gag positions across 8 HIV-1 subtypes and 
CRFs. Each subplot shows the results of A1, B, C, D, F1, G, CRF01_AE and 
CRF02_AG, respectively. 
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3.1 Summary 
The HIV pandemic is characterized by extensive genetic variability, which has 
challenged the development of HIV drugs and vaccines. Although HIV genomes have 
been classified into different types, groups, subtypes and recombinants, a 
comprehensive study that maps HIV genome-wide diversity at the population level is 
still lacking to date. This study aims to characterize HIV genomic diversity in large-
scale sequence populations, and to identify driving factors that shape HIV genome 
diversity. A total of 2996 full-length genomic sequences from 1705 patients infected 
with 16 major HIV groups, subtypes and circulating recombinant forms (CRFs) were 
analyzed along with structural, immunological and peptide inhibitor information. 
Average nucleotide diversity of HIV genomes was almost 50% between HIV-1 and 
HIV-2 types, 37.5% between HIV-1 groups, 14.7% between HIV-1 subtypes, 8.2% 
within individual HIV-1 subtypes and less than 1% within single patients. Along the 
HIV genome, diversity patterns and compositions of nucleotides and amino acids 
were highly similar across different groups, subtypes and CRFs. Current HIV-derived 
peptide inhibitors were predominantly derived from conserved, solvent accessible and 
intrinsically ordered structures in the HIV-1 subtype B genome. We identified these 
conserved regions in Capsid, Nucleocapsid, Protease, Integrase, Reverse transcriptase, 
Vpr and the GP41 N terminus as potential drug targets. In the analysis of factors that 
impact HIV-1 genomic diversity, we focused on protein multimerization, 
immunological constraints and HIV-human protein interactions. We found that amino 
acid diversity in monomeric proteins was higher than in multimeric proteins, and 
diversified positions were preferably located within human CD4 T cell and antibody 
epitopes. Moreover, intrinsic disorder regions in HIV-1 proteins coincided with high 
levels of amino acid diversity, facilitating a large number of interactions between 
HIV-1 and human proteins. This first large-scale analysis provided a detailed mapping 
of HIV genomic diversity and highlighted drug-target regions conserved across 
different groups, subtypes and CRFs. Our findings suggest that, in addition to the 
impact of protein multimerization and immune selective pressure on HIV-1 diversity, 
HIV-human protein interactions are facilitated by high variability within intrinsically 
disordered structures. 
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3.2 Introduction 
As the causative agent of AIDS, the Human Immunodeficiency Virus (HIV) 
represents a worldwide threat to public health and the economy. The HIV pandemic is 
characterized by extensive genomic diversity caused by multiple factors including 
multiple zoonotic transmissions into human populations, high rates of viral evolution 
and recombination [1]. HIV has two major types, HIV-1 and HIV-2, which are further 
divided into groups, subtypes and recombinant forms. Globally, over 90% of HIV 
infections belong to HIV-1 group M viruses, which have been classified into 9 
subtypes (A-D, F-H, J, K) and more than 50 circulating recombinant forms (CRFs) [1]. 
The high genetic diversity of the HIV genome has challenged the development of 
drugs and vaccines [2]. 
The HIV genome contains nine genes that encode fifteen viral proteins. Three major 
genes, gag, pol and env, code for structural proteins (Matrix, Capsid, Nucleocapsid, 
p6), enzymes (Protease, Reverse transcriptase (RT), Integrase) and envelope proteins 
(GP120, GP41), respectively. The remaining genes code for regulatory (Tat, Rev) and 
accessory proteins (Vif, Vpr, Vpu/Vpx, Nef) [3]. These viral proteins exhibit multiple 
functions and interact with various human proteins during the HIV life cycle [4, 5]. 
During the past three decades, many antiviral inhibitors have been designed to prevent 
HIV replication by targeting different viral proteins [6]. These anti-HIV peptides and 
small-molecule inhibitors either act by blocking active sites of viral enzymes or 
interrupting protein interactions [6]. For instance, the fusion inhibitor T20 
(Enfuvirtide, Fuzeon), a peptide derived from the GP41 heptad repeat region, can 
efficiently inhibit viral entry by interrupting interactions between the GP41 helices [7]. 
For all existing drug classes, mutations in the HIV genome can cause drug resistance 
[8]. Therefore, inhibitors have been preferentially developed to target conserved 
regions of different viral proteins [9]. HIV genetic diversity also challenges the 
development of a global HIV vaccine [10]. While the vaccine trial STEP was unable 
to show preventive vaccination in subtype B infected cohorts [11], the Thai trial 
RV144 showed for the first time that prime-boost vaccination provided a modest 
efficacy in patients infected with CRF01_AE [12]. For vaccine and drug design, it 
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remains important to investigate the genomic diversity of different HIV groups, 
subtypes and CRFs at a population level. 
Despite a large body of knowledge on different aspects of HIV pathogenesis, a large-
scale analysis that reveals the genome-wide diversity within and between different 
HIV groups, subtypes and CRFs is still lacking. Although previous HIV genomic 
studies have reported subtype distribution, genetic variability, disease progression, 
evolutionary rate, positive selective pressure and the origin of HIV [11-27], most 
studies reported their findings using either reference genomes or small cohorts of less 
than 100 patients or sequences in a single subtype. HIV-1 subtype B which dominates 
infections in developed countries is the most studied subtype, largely due to historical 
reasons [28]. For instance, the adaptive evolution during acute infection was 
evaluated only in 11 individuals infected with HIV-1 subtype B [14]. In light of using 
HIV consensus sequences as vaccine candidates, an analysis on the genetic difference 
between consensus sequences and circulating strains was limited to subtypes B and C 
using less than 100 sequences [2], while other subtypes also prevail worldwide [29].  
The last three decades have seen an accumulation of HIV data including full-length 
genomic sequences, protein crystal structures, HIV-human protein interactions, 
human T-cell epitope information and antiretroviral peptide inhibitors derived from 
the HIV genome. By integrating distinct but complementary sources of large-scale 
HIV datasets, this study aims to characterize HIV genome-wide diversity and to 
determine multiple factors that shape HIV genomic diversity. 
3.3 Materials and Methods 
HIV genome sequence dataset: In August 2013, we retrieved 3607 nucleotide 
genomic sequences of major HIV-1 and HIV-2 clades (HIV-2 group A and B, HIV-1 
group N, O, P, subtype A1, B, C, D, F1, G, H, J, K, CRF01_AE, CRF02_AG) from 
the HIV Los Alamos database (www hiv      g v  ). The quality criteria for removing 
duplicates and sequences with hypermutations, stop codons, ambiguous nucleotides or 
subtype misclassification were described in [9]. The sequence dataset that fulfilled the 
quality criteria comprised 2996 genomic sequences, sampled from 1684 HIV-1 and 21 
HIV-2 patients between 1982 and 2013. Information on genomic sequence datasets is 
summarized in Table 3.1. 
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Nucleotide genomic sequences were aligned using MUSCLE [30]. Protein regions 
encoded by their respective open reading frames (ORFs) were concatenated according 
to the reference strains (HIV-1: HXB2, HIV-2: BEN). For each HIV protein coding 
region, the translation of nucleotide to amino acid sequence alignments was optimized 
by our nucleotide to amino acid alignment toolbox. This toolbox maximizes amino 
acid matches, including in overlapping reading frames, based on the BLOSUM62 
substitution matrix. Sequence alignments were further curated using Seaview v4.3 
[31]. Our alignment toolbox and genomic sequences are available in Additional file 3. 
Table 3.1: Information of HIV-1 and HIV-2 full-length genome sequence datasets 
Type HIV-1 HIV-2 
Group M N O P A B 
Subtype/CRF A1 B C D F1 G H J K 01_AE 02_AG 
Number of genome  159 1425 554 65 25 27 4 2 2 581 81 11 25 4 25 6 
Number of patient  134 657 429 57 22 23 4 2 2 250 71 9 22 2 16 5 
Average length in 
nucleotides* 
8500 8600 8600 8500 8500 8600 8600 8600 8600 8500 8500 8500 8700 8600 8600 8600 
*: Only the HIV coding regions are counted. 
HIV-derived peptide inhibitor dataset: HIV-derived peptide inhibitors have their 
amino acid sequences derived from HIV proteins. We searched for English articles in 
PubMed published between January 1983 and September 2013 using the keywords 
“HIV peptide i hibit r”, “HIV [pr tei    me] peptide” and “HIV [pr tei    me] 
inhibitor”  References from primary studies, review articles and peptide design papers 
were also reviewed. If more than one peptide inhibitor were reported in one 
publication, only the most promising peptide inhibitors as indicated by the abstract of 
articles were collected. If data on the same inhibitors was reported by more than one 
publication, only the latest results were retained. Table S 3.1 summarizes the 121 
peptide inhibitors with corresponding information on peptide sequences, peptide-
derived regions, target proteins, inhibitory activities and references. 
PDB, HIV-human protein interaction, CD4/CD8/antibody epitope datasets: As of 
February 2014, we queried HIV PDB data from the RCSB Protein Data Bank using 
sequence search; PDB quality was then examined using PDBREPORT [32] (Table 
3.2). We extracted HIV-human protein interactions (interaction type: physical 
interaction) from the NCBI HIV-1 human protein interaction database [33]. From the 
HIV Los Alamos database (http://www.hiv.lanl.gov/content/immunology/), we 
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extracted the human CD4 T cell and antibody epitopes in HIV-1. For human 
CTL/CD8 T cell epitopes, we included the best-defined CTL epitopes of the A-list 
described in [34] (Table 3.3). 
Table 3.2: Summary of protein structures and PDB data for HIV-1 and HIV-2 
proteins 
Gene gag pol 
Protein Matrix Capsid p2 Nucleocapsid p1 p6 Protease RT Integrase 
Number of units 3 5,6 1 1 1 1 2 2 4 
HIV-1 
AA length 132 231 14 55 16 52 99 560 288 
Multimer 1HIW # 3H4E - - - - 1A30 1N6Q 1K6Y 
Monomer - -  1U57 1A1T - 2C55 - - - 
HIV-2 
AA length 135 229 17 52 14 64 99 559 292 
Multimer - 2WLV - - - - 3S45 1MU2 - 
Monomer 2K4E - - 2E1X - - - - 3F9K 
 
Gene vif vpr tat rev vpu/vpx* env Nef  
Protein Vif Vpr Tat Rev Vpu/Vpx GP120 GP41 Nef  
Number of units 2,3,4 1 2 2,6 1 3 3 2  
HIV-1 
AA length 192 96 101 116 82 481 345 206  
Multimer - - - 3LPH - 4NCO 2XRA -  
Monomer 4N9F 1M8L 1K5K - 1VPU - - 4EMZ  
HIV-2 
AA length 215 102 130 107 113 503 354 263  
Multimer - - - - - - - -  
Monomer - - - - - - - -  
#: PDB code from the RCSB Protein Data Bank;  *: Vpu in HIV-1 and Vpx in HIV-2, 
-: either the data is not available or do not exist. For multerimeric HIV proteins, 
structures with different units can coexist such as pentamers and hexamers of Capsid 
[35], dimers and hexamers of Rev [36] and dimers, trimers and tetramers of Vif [37]. 
Table 3.3: Summary of antibody, CD4+, CD8+ T cell epitope positions in the HIV-1 
genome 
 
Antibody epitope position CD4+ epitope position CD8+ epitope position 
Matrix 20-31 1-107,118-132 11-44,74-101,124-132 
Capsid 
64-75 
1-219 
3-56,61-92,94-104,108-117,121-153,161-
189,197-205, 217-231 
p2 
 
2-14 1-10 
NC 
 
1-55 28-36,50-55 
p1 
 
1-16 1-10 
p6 
 
1-43 33-41 
Protease 
 
53-70 3-11,30-42,57-66,68-90 
RT 249-263,295-304,521-531 
36-53,97-111,156-181,195-
209,249-272,276-317,338-
352,384-398,411-443 
18-26,33-43,73-82,93-101,107-115,118-135, 
137-166,173-187,202-210,244-252,260-279, 
293-301,309-318,333-350,356-366,375-383, 
392-401,436-457,495-505,520-528 
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Integrase 
 16-30,79-93,171-234,242-267 
28-36,66-74,78-93,114-121,123-132,135-
143,165-194,197-211,219-227,260-271 
Vif 
 
65-76,81-96 17-26,28-39,48-66,79-89,102-111,158-168 
Vpr 
 
32-96 29-42,48-67 
Tat 47-60 17-55,64-80 30-49 
Rev 
 
9-56 14-23,57-75 
Vpu 
 
19-34 5-13,29-37 
GP120 
101-121,131-166,182-
191,206-215,269-292,390-
413,424-444,468-481 
1-34,41-55,57-103,125-
159,164-237,239-276,278-
327,333-481 
1-39,48-56,74-82,169-177,179-196,268-
277,280-300,345-353,386-397 
GP41 
14-32,50-104,128-172 
36-77,82-186,189-206,221-
233,303-345 
46-54,66-82,95-103,187-201,259-291,294-
311,320-327,332-345 
Nef 
90-98 
3-59,64-102,104-128,140-
154,162-206 13-27,37-45,68-100,105-145,180-191 
Protein secondary structure: For HIV-1 proteins (Rev, GP41) whose crystalized 
structures are not fully resolved in the PDB data, we used the sequence-based method 
PSIPRED V3.0 [38] to estimate protein secondary structures. For the other HIV-1 
proteins with available PDB data (Table 3.2), we assessed protein secondary 
structures using both PSIPRED V3.0 [38] and 2Struc [39]. 2Struc is a software 
platform which integrates 8 PDB-based methods: DSSP_CONT, DSSP, KAKSI, 
PALSSE, P-SEA, STICKS, STRIDE and XTLSSTR [39]. Alpha-helix, beta-strand 
and random-coil structures were estimated using the majority voting of above 9 
methods. Prediction similarities between these 9 methods are shown in Figure S 3.11. 
Protein intrinsic disorder: Protein disordered regions are exploited by the virus to 
invade cellular host systems [40]; these regions are often structurally unstable without 
their partner molecules [41]. We estimated the intrinsically disordered structures of 
HIV-1 subtype B proteins using three software packages: MetaPrDOS [41], VSL2P 
[42] and PreDisorder v1.1 [43]. A disorder score (a numerical value between 0 and 1) 
of each amino acid position was estimated by 17 methods in these 3 software 
packages. An amino acid position was estimated as intrinsically disordered if its 
disorder score was above the cutoff value of 0.5 [41-43]. The intrinsically disordered 
positions were identified based on the majority voting of 17 methods. Prediction 
similarities between these 17 methods are shown in Figure S 3.12. 
 
Table 3.4: Cutoffs for determining solvent exposed residues 
Amino acid A R N D C Q E G H I 
ASA(Å
2
) 39.91
 #
 62.79 52.71 50.64 34.63 63.68 59.14 55.65 43.91 48.39 
Amino acid L K M F P S T W Y V 
ASA(Å
2
) 55.76 52.23 63.85 50.23 45.29 37.80 46.01 76.61 71.12 47.58 
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#: For each amino acid, the cutoff is calculated using the 25% of the maximum ASA in all 
HIV-1 proteins, as described in [44]. 
Solvent accessible surface area: We estimated protein solvent accessible surface 
areas (ASA) using Chimera V1.6.1 [45] (default parameters). Provided with PDB data 
in Table 3.2, we calculated the ASA at each amino acid of all HIV-1 protein units. 
For each of the 20 amino acids, a distribution of its ASA scores over 15 HIV-1 
proteins was obtained and the maximum ASA was identified therein. An amino acid 
at a specific position was considered buried if its ASA was lower than 25% of the 
maximum ASA for the corresponding amino acid [44] (Table 3.4). 
Phylogenetic analysis: Our phylogenetic analysis was performed using 1384 
nucleotide genomic sequences of 14 HIV groups and pure subtypes (thus excluding 
CRFs), obtained from the earliest sampling time (one sequence per patient). To 
prepare the alignment, we also removed ambiguous regions containing multiple 
insertions, deletions and hypervariable positions (HXB2 index: 1126-1182, 6866-
7003, 7106-7154, 7773-7842, 7981-8032, 8897-9383). Maximum-likelihood 
phylogenetic trees were obtained using the multi-threaded FastTree V2.1 [46]. Our 
software parameters were set to 100 bootstrap replicates, the fully optimized GTR 
(generalized time-reversible) model, the continuous gamma distribution and the 
exhaustive nearest-neighbor interchange approach. The consensus phylogenetic tree 
with bootstrap supports was obtained using the seqboot tool in Phylip V3.69 
(http://evolution.genetics.washington.edu/phylip.html). 
Quantification of genetic diversity: Sequence diversity was calculated based on the 
pairwise nucleotide (NT) and amino acid (AA) comparisons [9, 47]. When calculating 
the amino acid diversity of HIV genome, we concatenated the amino acid sequences 
of 15 HIV protein coding regions in the full-length genome. Suppose the sequence 
dataset D contains L sequences with N positions, genetic diversity at position n is 
calculated by: , ,
1 1
2
( ) 1 ( )
( 1)
L L
n n i n j
i j i
GD D D D
L L

  
  

 , where ,n iD is the NT or AA 
form of the position n  at the i
th
 sequence in the dataset D,   represents the Kronecker 
symbol, 
, ,( )n i n jD D   
equals 1 if 
,n iD is identical to ,n jD ; otherwise 0. Given the 
sequence dataset D, intra-clade genetic diversity ( )AGD D  is defined as the average 
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genetic diversity of all positions: 
, ,
1 1 1
1 2
( ) 1 ( )
( 1)
N L L
n i n j
n i j i
AGD D D D
N L L

   
  

  . 
Suppose two sequence datasets D1 and D2 aligned with the same reference genome 
have the number of sequences
 1
L  and 2L  respectively. The inter-clade genetic 
diversity between D1 and D2 is defined as: 
1 2
, ,
1 1 11 2
1 1
( 1, 2) 1 ( 1 2 )
L LN
n i n j
n i j
RGD D D D D
N L L

  
  

  . Furthermore, only positions 
for which less than 20% of sequences had gaps were considered and gaps were treated 
as missing data. Intra- and inter-clade genetic diversity was measured using one 
genomic sequence per patient, while intra-patient diversity was calculated using more 
than one genomic sequence sampled from individual patients. The Mann–Whitney U 
test was performed to compare the distributions of genetic diversity and a significant 
difference was identified if a p-value was less than 0.05. Our Matlab implementation 
of genomic diversity analysis is available in Additional file 3. 
3.4 Results 
Genome-wide diversity within and across HIV types, major groups and subtypes 
We quantified the nucleotide and amino acid diversity of the HIV genome using 2996 
full-length sequences sampled from 1705 patients (Table 3.1). The amino acid 
diversity was 53.8% (95% confidence interval (CI): 53.0-54.6%) between HIV-1 and 
HIV-2, 41.1% (CI: 25.6-54.3%) between HIV-1 groups, 18.0% (CI: 15.6-19.6%) 
between HIV-1 subtypes, 12.0% (CI: 8.6-14.4%) within HIV-1 subtypes and 1.1% 
(CI: 0.3-2.2%) within HIV-1 patients (Figure 3.1A). Similarly, nucleotide genomic 
diversity was found to be the highest when comparing HIV-1 and HIV-2 (mean: 
48.32%, CI: 47.8-48.9%), followed by HIV-1 inter-group (37.5%, CI: 26.0-45.7%), 
HIV-1 inter-subtype (14.7%, CI: 12.2-15.8%), HIV-1 intra-subtype (8.2%, CI: 5.3-
10.0%) and HIV-1 intra-patient diversity (0.6%, CI: 0.2-1.4%) (Figure S 3.1). As 
expected, the trend in HIV genomic diversity corresponds with the phylogenetic 
relationships between groups and pure subtypes in HIV-1 and HIV-2 (Figure 3.1B). 
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Figure 3.1: (A) Distribution plots of amino acid diversity in the HIV genome. The 
plots show the genomic diversity within HIV-1 infected patients (HIV-1 intra-patient, 
blue), within HIV-1 subtypes (HIV-1 intra-subtype, green), between HIV-1 subtypes 
(HIV-1 inter-subtype, red), between HIV-1 group M and group N (HIV-1 inter-group, 
yellow), between HIV-1 group M and group O/P (HIV-1 inter-group, black) and 
between HIV-1 and HIV-2 (pink). Figure S 3.1 shows distribution plots of nucleotide 
genomic diversity. 
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(B) Maximum likelihood phylogenetic tree of HIV groups and pure subtypes. Green 
cones indicate HIV-1 subtypes in group M, while orange cones denote other HIV 
groups. All phylogenetic branches have bootstrap supports of more than 85% except 
one containing subtypes J, H and C. Branch lengths from the root to HIV-1 and HIV-
2 are shortened for visualization purposes. SIV strains were not included in our 
phylogenetic tree. Software: FigTree V1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/). 
(C) Distribution plots of amino acid diversity in 6 major HIV-1 subtypes and CRFs (B, 
A1, C, D, CRF01_AE, CRF02_AG). X- and y-axes indicate the amino acid diversity 
and the proportions of sequence pairs, respectively. Six subplots in the first and 
second rows show the intra-subtype amino acid diversity of 6 HIV-1 subtypes and 
CRFs. Three subplots in the third row show the distribution of inter-subtype genomic 
diversity (B vs A1, B vs C, B vs 01_AE). One genomic sequence per patient (Table 
3.1) was used for our analysis. Figure S 3.2 shows the distribution of the other inter-
clade genomic diversity.  
(D) Average inter- and intra-clade genomic diversity of HIV-1 and HIV-2. The top 
right matrix demonstrates results for amino acid diversity, the bottom left matrix for 
nucleotide diversity. HIV subtypes and groups are shown on the left side of the matrix. 
 
 
We next quantified genomic diversity within and between individual HIV clades. The 
distributions of inter-clade genomic diversity had mean values that were significantly 
higher than those of intra-clade genomic diversity (p-value < 0.05) (Figure 3.1C, 
Figure S 3.2). Within each HIV clade, amino acid diversity was consistently higher 
than nucleotide diversity (Figure 3.1D). CRF01_AE showed the lowest genomic 
diversity (nucleotide: 5.7%, amino acid: 8.7%) among the 10 HIV-1 subtypes with at 
least 10 sequences available (Figure 3.1D). Moreover, the estimated geographical 
distribution of HIV-1 genomic diversity (Figure S 3.5) showed a good agreement 
with the reported geographical distribution of HIV-1 subtypes [29]. 
Sequence variability was not uniformly distributed along the full-length HIV genome, 
but similar patterns were consistently observed in HIV group, subtype and CRF 
genomes at the nucleotide and amino acid levels (Figure 3.2A, B). Among all HIV 
proteins, Integrase was the most conserved protein (mean ± deviation: 4.5±1.1%), 
while GP120 varied the most (21.3±2.5%) (Table 3.5). Pairwise comparisons of 
genetic diversity between subtype B and the other clades identified conserved regions 
in the Capsid, Nucleocapsid, Protease, RT, Integrase, Vpr and the N terminus of GP41 
(Figure 3.2C). Despite the different degrees of sequence diversity along the full-
length genome, the nucleotide and amino acid compositions were comparable across 
the 16 group and subtype genomes (Figure 3.3A, B).  
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Figure 3.2: (A) Amino acid diversity along the full-length HIV genome using the 
sliding windows (window size: 100AA; also see the plots of exact diversity values in 
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Figure S 3.3). Each colored plot shows the density of amino acid diversity for one 
HIV group, subtype or CRF genome, indicated by the figure legend. Six layers are 
shown beneath the plots: (1) HIV-1 protein regions (HXB2 reference) are 
concatenated and shown with abbreviated names (e.g. MA: matrix); (2) peptide-
inhibitor-derived region; (3) CD8+ T cell epitope position; (4) CD4+ T cell epitope 
position; (5) antibody epitope position; (6) HIV-2 protein region (BEN reference). 
(B) Nucleotide diversity along the full-length HIV genome using sliding windows 
(window size: 300 nucleotides; also see the plots of exact diversity values in Figure S 
3.4). Each colored plot shows the density of nucleotide diversity for one HIV group, 
subtype or CRF genome, indicated by the figure legend. Annotated HIV-1 and HIV-2 
reference genomes are shown beneath; each track contains one open reading frame 
(ORF). Long terminal regions in the HIV genome are not shown. 
(C) Contour map of inter-clade amino acid diversity between HIV-1 subtype B and 
the other HIV genomes. Inter-clade amino acid diversity was calculated by a sliding 
window of 30 amino acids over the HIV genome (low: ≤1 AA difference, high: ≥25 
AA differences). Five colored layers beneath the contour map are annotated in (A). 
 
 
Table 3.5: Average AA diversity of viral proteins within individual HIV clades (%) 
 Clade # MA CA NC p6 PR RT IN Vif Vpr Tat Rev Vpu/Vpx* GP120 GP41 Nef 
HIV-1 Subtype A1 13.07 7.3 7 19.89 5.59 6.44 4.76 13.63 9.86 18.14 16.83 23.04 23.34 13.38 14.64 
Subtype B 12.9 4.95 10.83 14.99 8.21 6.04 4.91 14.71 11.29 19.32 18.34 20.04 23.93 15.59 17.79 
Subtype C 16.11 5.77 9.39 15.52 6.15 5.84 4.45 10.61 10.64 15.37 16.10 20.21 22.89 14.19 14.96 
Subtype D 14.78 5.08 10.85 13.16 7.68 6.98 4.80 11.57 11.74 17.89 15.87 19.40 23.58 13.61 14.42 
Subtype F1 13.69 5.71 10.07 16.72 8.84 6.42 4.76 11.04 9.26 17.01 15.70 18.27 20.24 13.39 14.02 
Subtype G 17.33 5.54 7.40 17.21 6.60 7.30 4.17 14.36 10.33 15.51 18.39 19.25 23.87 12.98 14.15 
Subtype H 18.81 3.61 8.48 17.65 4.55 5.95 5.71 15.46 9.11 19.28 19.80 18.31 21.51 12.33 16.34 
CRF01_AE 10.06 3.00 4.92 13.37 4.34 3.75 2.39 9.32 7.97 13.57 13.34 12.80 17.40 9.62 11.78 
CRF02_AG 13.57 5.69 3.78 13.63 5.56 5.67 4.06 13.44 7.70 13.58 15.49 16.42 23.37 12.09 15.45 
Group N 10.52 6.40 7.06 10.01 5.93 6.78 3.09 11.02 4.87 12.15 12.77 35.01 21.43 9.15 12.64 
Group O 14.52 7.45 9.89 22.17 8.20 6.51 5.77 16.17 12.16 21.61 21.25 27.12 28.65 19.35 17.96 
HIV-2 Group A 10.15 4.67 11.82 11.02 7.14 6.89 6.78 12.74 22.55 22.59 22.75 10.40 18.55 16.47 21.98 
Group B 12.14 3.54 13.15 15.4 5.76 6.4 6.19 12.71 12.66 20.44 15.82 11.45 21.20 15.29 20.59 
#: Only HIV groups or subtypes with more than 2 genome sequences are listed (Table 
3.1). *: Vpu in HIV-1 and Vpx in HIV-2. 
 
 
Multiple factors shape HIV-1 genomic diversity 
We next evaluated three potential factors (protein multimerization, immunological 
constraints, HIV-human protein interactions) that shaped the HIV genomic diversity. 
Firstly, we calculated the average diversity at amino acid positions of the 15 HIV-1 
proteins (Figure 3.3C). For every HIV-1 group, subtype and CRF, the average amino 
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acid diversity was significantly higher in the monomeric proteins (Nucleocapsid, Vpr, 
Vpu, p6) than in the multimeric proteins (Matrix, Capsid, Protease, RT, Integrase, Vif, 
Tat, Rev, GP120, GP41, Nef) (p-value < 0.01) (Table 3.6). This suggests that the 
protein multimerization imposes a constraint on the HIV-1 sequence variability. 
Secondly, we evaluated the amino acid variation in the known CD4 T cell, CD8 T cell 
and antibody epitopes (Table 3.3). By measuring the diversity of 3066 amino acid 
positions, we identified 919 (30%) variable positions with amino acid diversity above 
12.9% (the average amino acid diversity within subtype B) using 657 subtype B 
genomic sequences. Univariate analysis showed that these variable positions were 
preferably located within antibody epitopes (OR 1.43, CI: 1.15-1.79, Fisher‟s exact 
test, p-value = 0.0015) and CD4 T cell epitopes (OR 1.73, CI: 1.18-2.96, p-value = 
0.0438), but not within CD8 T cell epitopes (OR 1.11, CI: 0.82-1.51, p-value = 0.498) 
(Figure 3.2A). 
 
Table 3.6: Comparison of average genetic diversity of HIV monomeric and 
multimeric proteins 
HIV-1 clade A1 B C D F1 G H 
Monomers 14.6% 14.4% 14.4% 14.3% 14.1% 14.1% 13.9% 
Multimers 12.7% 13.1% 12.5% 12.5% 12.3% 12.3% 12.3% 
P-value 
#
 5.4E-7 1.3E-5 3.8E-10 1.9E-11 5.2E-11 6.6E-11 4.9E-10 
 
HIV-1 clade J K 01_AE 02_AG N O P 
Monomer 12.9% 13.0% 12.7% 12.5% 12.7% 13.0% 12.8% 
Multimer 11.3% 11.3% 11.1% 11.1% 11.1% 11.4% 11.1% 
P-value 1.1E-9 2.0E-9 6.3E-12 8.2E-11 9.1E-13 4.0E-14 8.9E-14 
#: Mann-Whitney U-test. Monomeric proteins: Nucleocapsid, Vpr, Vpu, p6.  
Multimeric proteins: Matrix, Capsid, Protease, RT, Integrase, Vif, Tat, Rev, GP120, 
GP41, Nef. 
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Figure 3.3: (A) Nucleotide composition for HIV-1 and HIV-2. X-axis represents the 
HIV groups, subtypes and CRFs. Y-axis shows the average proportions of nucleotides 
(A, T, C, G) using the HIV genomic sequence datasets (one sequence per patient, 
Table 3.1). 
(B) Amino acid composition for HIV-1 and HIV-2. X-axis represents HIV groups, 
subtypes and CRFs. Y-axis shows the average proportions of amino acids using the 
HIV protein sequence datasets (one sequence per patient, Table 3.1). 
(C) Distribution plots of amino acid genetic diversity for 15 HIV-1 subtype B proteins. 
Each subplot demonstrates a viral protein. X- and y-axes indicate the amino acid 
diversity and the proportions of amino acid diversity, respectively. Red lines inside 
distribution plots indicate mean values of amino acid diversity at individual proteins. 
(D) Top and side views of 3D HIV-human protein interaction networks. HIV-1 
proteins with protein names annotated are indicated by green spheres. Human proteins 
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that interact with only one HIV-1 protein are indicated by blue spheres in the outer 
circle (one human protein one sphere). Human proteins that interact with more than 
one HIV-1 protein are indicated by purple spheres above the plane of HIV-1 proteins. 
The height of the layers above the plane indicates the number of HIV proteins that a 
human protein interacts with. Below, human proteins are clustered if they interact 
with a set of more than one HIV-1 protein. Abbreviation names have been described 
in the abbreviation list. Visualization software: Geomi V2.0 
(http://sydney.edu.au/engineering/it/~visual/geomi2/). 
 
  
Thirdly, we mapped 1352 interactions between 1052 human and 15 HIV-1 proteins 
using the HIV-human protein interaction dataset (Figure 3.3D, see Materials). The 
following three observations support the hypothesis that the amino acid diversity of 
HIV-1 proteins is associated with HIV-human protein interactions. (1) Univariate 
analysis showed that HIV-1 proteins with higher amino acid diversity interact with 
more human proteins (Pe rs  ‟s c efficie t = 0.74, p-value = 0.0017). Polynomial 
regression analysis further identified a second-order model that fitted the correlation 
between these two variables (Figure 3.4A, adjusted R-squared: 0.82). (2) Intrinsically 
disordered structures in HIV-1 proteins can interact with multiple interaction partners 
[40]. Univariate analysis showed a significant correlation between the average amino 
acid diversity and the average disorder scores of HIV-1 proteins (Pe rs  ‟s 
coefficient=0.64, p-value = 0.015, Figure 3.4B). (3) The levels of HIV-human protein 
interactions clustered according to the functional roles of the HIV-1 proteins, which 
have different functional roles and requirements for interactions with human proteins 
(Figure 3.4C). HIV regulatory proteins (Tat, Rev) and envelope proteins (GP120, 
GP41) had the largest number of interactions with different human proteins (568 for 
the regulatory proteins, 322 for the envelope proteins), while viral enzymes had the 
least number of interactions (Figure 3.4C). The average amino acid diversity of 
envelope proteins (20.4%) and regulatory proteins (18.8%) was higher than that of 
accessory proteins (16.0%), structural proteins (9.0%) and viral enzymes (5.9%) 
(Figure S 3.6). Our findings suggest that HIV-1 proteins with higher genetic 
diversities have larger intrinsically disordered structures and interact with more 
human proteins. 
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Figure 3.4: (A) Plot of polynomial regression between the HIV-1 protein diversity (x-
axis) and the number of HIV-human protein interactions (y-axis). The second-order 
model is:
28346 1223 57.96y x x   , (adjusted R-squared: 0.82, root-mean-square 
error: 42.31). 
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(B) Plot of average protein disorder score and average amino acid diversity in HIV-1 
proteins. Red circles indicate the number of HIV-human protein interactions at 
individual viral proteins, for visualization purpose, scaled between 20 and 200 
interactions (proteins with fewer than 20 interactions are scaled to the same size as 
those with 20, proteins with more than 200 interactions are scaled to the same size as 
those with 200). Average amino acid diversities of HIV-1 proteins are calculated 
using subtype B sequences (one genomic sequence per patient, Table 3.1). 
(C) Clustering of HIV-1 proteins and schematic view of HIV-1 viral particle. On the 
left, each colored circle represents a viral protein positioned according to the clusters 
of protein functions. The size of each red circle indicates the number of HIV-human 
protein interactions involving each HIV-1 protein (see (B)). On the right, the 
schematic view of mature viral particle is visualized at the bottom with annotations 
indicated in the inserted figure legend. Above, surface representations show the 
structures of HIV-1 proteins that are grouped according to their functional roles. 
Different units in HIV-1 multimeric proteins are indicated with different colors and 
HIV-1 monomeric proteins are colored pink. HIV-1 protein structures are scaled 
according to their precise protein sizes for direct comparison. Visualization: PyMOL 
V1.5 (http://www.pymol.org/). 
 
 
Peptide inhibitors are mainly derived from conserved subtype B genomic regions 
We investigated the 121 HIV-derived peptide inhibitors reported between 1993 and 
2013 (Table S 3.1). Figure 3.5A illustrates the GP41 structure and the GP41-derived 
region of T20 as an example of HIV-derived peptide inhibitors. Peptide inhibitors had 
on average a length of 25 AAs (range: 3 to 73), a charge of +0.27 at pH 7.2 and a 
molecular weight of 2953 g/mol. Most common amino acids in these peptide 
inhibitors were leucine, glutamic acid and isoleucine (Figure S 3.7). Comparisons 
between the 121 peptide sequences and the consensus sequences of 16 HIV group, 
subtype and CRF genomes showed the highest sequence similarity with subtype B 
(79.8%) (Figure 3.5B). Aspartic acid to asparagine (25.7%) was the most common 
amino acid substitution between the consensus subtype B sequence and the peptide 
inhibitor sequences (Figure 3.5C). 
We characterized peptide-derived regions in the subtype B genome. Of the 894 amino 
acid positions from which the 121 peptide inhibitors were derived, 41.2% were 
located in helix structures and 60.2% displayed less than 5% genetic diversity in the 
subtype B genome. Forty-two inhibitors had IC50 or EC50 values less than 1 μM and 
were derived from 249 amino acid positions in the HIV-1 genome (Table S 3.1). In 
the subtype B genome, these 249 positions displayed significantly lower amino acid 
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diversity compared to the genome-wide diversity (Figure 3.5D, 10.1% vs 12.9%, p-
value = 0.019), and were likely to be from conserved (amino acid diversity < 5%, OR: 
1.43 (1.09-1.88), p-value = 0.016), solvent exposed (OR: 2.47 (1.88-3.24), p-value = 
3.9E-11) and intrinsically ordered structures (disorder score < 0.4, OR: 1.75 (1.21-
2.51), p-value = 0.0019) (Figure 3.5E). 
Integrated findings from our analyses on HIV-1 genomic diversity, HIV-derived 
peptide inhibitors and protein structures are visualized in Figure 3.6. The HIV 
genomic sequence datasets and our toolbox developed for data visualization, genomic 
diversity analysis and HIV genomic alignment are freely available in Additional file 3. 
 
Figure 3.5: (A) Cartoon representation of GP41 structure. The red structure indicates 
the region from which peptide inhibitor T20 was derived (PDB: 3H01). 
(B) Bar plot of sequence similarities between peptide inhibitor sequences and the 
sequences of HIV-derived regions in the consensus genome of different HIV clades. 
X-axis presents the HIV groups, subtypes and CRFs. Y-axis shows the sequence 
similarity between peptide inhibitor sequences and the sequences of HIV-derived 
regions in the consensus genomes of HIV groups, subtypes or CRFs. 
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(C) Amino acid replacements between peptide inhibitor sequences and HIV-derived 
regions in the subtype B genome. The percentage values (%) are colored using heat 
maps. 
(D) Distribution (bee-swarm) plots of amino acid diversity in the full-length subtype 
B genome (black crosses), peptide-derived regions (blue diamonds) and peptide-
derived regions of those inhibitors whose IC50/EC50 are less than 1 μM (red circles). 
Each shape represents the amino acid diversity at one protein position. Two-sample 
Kolmogorov-Smirnov tests were performed to compare diversity distributions 
(significance level: 0.05). 
(E) Plot of amino acid diversity (x-axis), disorder score (y-axis) and solvent 
accessible surface area of peptide-inhibitor-derived regions (contour map, darker red 
indicates larger accessible surface areas). GP41 inhibitor T20 is also annotated. For 
individual peptide inhibitors, the average amino acid diversity, disorder score and 
solvent accessible surface areas are shown in Figure S 3.8, Figure S 3.9 and Figure 
S 3.10, respectively. 
 
 
3.5 Discussion and conclusions 
To our knowledge, this study provides the first large-scale analysis that investigates 
the genomic variability of 16 major groups, subtypes and CRFs in HIV-1 and HIV-2. 
While previous studies have reported the diversity of HIV genomes in small cohorts 
of patients (n < 250)[11-24, 48], our analyses evaluated HIV genome-wide diversity 
using 2996 full-length genomic sequences sampled from 1705 patients worldwide. 
We evaluated three important aspects of HIV genomic diversity using the integrated 
datasets of genomic sequences, protein structures, HIV-human protein interactions, 
human immune epitopes and HIV-derived peptide inhibitors. Firstly, we quantified 
HIV genomic diversity at the individual and population levels. Secondly, we reported 
possible associations between HIV-1 amino acid diversity and protein 
multimerization, immunological constraints and HIV-human protein interactions. 
Thirdly, we mapped conserved regions in the HIV genome and characterized 
experimental and clinically used HIV-derived peptide inhibitors [7]. 
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Figure 3.6: HIV-1 genomic diversity and protein structures. All 15 HIV-1 proteins 
are mapped in the circle with 8 layers, showing the schematic view of HIV-1 peptide 
inhibitors (layer 1), the protein secondary structures (layer 2, dark blue: helices, light 
blue: beta-strands, white: random-coil structures), protein disorder scores (layer 3), 
amino acid diversity of residue positions (layer 4), human CD4+/CD8+/antibody 
epitope regions (layer 5, three sub-layers from inside to outside represent CD8+ T cell, 
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CD4+ T cell and antibody epitope regions), HXB2 reference indices (layer 6), 
peptide-inhibitor-derived regions (layer 7) and the protein structures are colored 
according to the amino acid diversity of residue positions (layer 8, low: 0%, high: 
≥30%). Three major genes (gag, pol, env) are annotated in the center. Structures of 
multimeric HIV-1 proteins are shown outside the circle and different protein units are 
colored separately. The list of PDB data is available in Table 3.2. Visualization: 
Circos V0.64 (http://circos.ca/). 
 
Quantification of HIV genomic diversity: HIV-1 genomic diversity is the lowest 
within single patients and increases in the following order when different patients are 
considered: within subtypes, between subtypes, between groups and between HIV 
types (Figure 3.1). A nucleotide genomic diversity was quantified to be 48.3% 
between HIV-1 and HIV-2, 37.5% between HIV-1 groups, 14.7% between HIV-1 
subtypes, 8.2% within HIV-1 subtypes, and 0.6% within single patients infected with 
HIV-1. These results are in good agreement with previous studies which analyzed less 
than 100 sequences [13, 23]. Our study quantified genomic diversity at the population 
level using the largest sequence dataset ever analyzed, thereby resulting in robust and 
accurate estimations. As shown in Figure 3.2, the degree of HIV genetic diversity 
varied along the full-length genome. A comparison of the amino acid diversity of HIV 
proteins revealed the highest diversity in the envelope proteins, followed by the 
regulatory, accessory, structural and enzymatic proteins (Figure 3.4, Table 3.5). 
Estimated amino acid diversities for Gag (intra-subtype: 6.6 ± 1.2%), Pol (5.7 ± 0.9%) 
and Env (18.7 ± 2.7%) displayed higher values than previous reports analyzing fewer 
than 100 sequences of subtypes A and B [24]. Using large-scale sequence datasets, 
our study thus provides a better estimation of genetic diversity in HIV proteins. 
HIV genomic diversity is shaped by multiple factors: HIV genomic diversity is 
driven by the high rates of viral replication, recombination and mutation [49], but 
other factors also play a role in shaping HIV genomic diversity. To evaluate potential 
factors, we correlated HIV amino acid diversity with protein multimerization, human 
immunological constraints and HIV-human protein interactions. Firstly, we found that 
the average amino acid diversity was significantly lower in the multimeric than in the 
monomeric proteins, suggesting that protein multimerization places a constraint on 
HIV-1 sequence variability. Previous findings on other protein families have also 
shown that multimeric proteins are relatively conserved and have less tolerance for 
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amino acid substitutions [50-52]. Secondly, we showed that CD4 T cell and antibody 
epitope positions in the HIV-1 genome were likely to have high amino acid diversities, 
supporting the hypothesis that human immune system imposes a diversifying selective 
pressure on the HIV-1 genome [26]. Thirdly, we mapped 1352 HIV-human protein 
interactions between 15 HIV-1 proteins and 1052 human proteins. A strong 
association was found between the amino acid diversity of HIV-1 proteins and the 
number of HIV-human protein interactions (Figure 3.4). HIV-1 proteins with higher 
genetic diversities tended to interact with more human proteins. This is likely 
associated with structurally disordered regions in HIV-1 proteins (Figure 3.4B), 
which provide the structural flexibility for HIV to interact with multiple human 
proteins [40]. For instance, GP120 uses five hypervariable loops (Figure S 3.13) to 
interact with various human proteins [53]. An intricate landscape of HIV-human 
protein complexes is made by HIV to exploit human cellular machineries during the 
HIV infection and production [54]. Despite the high variability of HIV, it is surprising 
that the nucleotide and amino acid compositions were remarkably constant across all 
HIV-1 and HIV-2 clades (Figure 3.3A, 3B), suggesting that other constraints may be 
active to restrict the HIV genetic diversity [25]. 
Conserved drug targets in the HIV-1 genome: Many peptide inhibitors derived 
from HIV-1 proteins have shown promising antiviral activities and some of these 
inhibitors are currently under clinical trials [55, 56]. Our study summarized HIV-
derived peptide inhibitors published between 1993 and 2013 (Figure S 3.13-Figure S 
3.22, Table S 3.1), and mapped the positions of these inhibitors to the HIV-1 genome 
(Figure 3.6). We showed that most peptide inhibitors were derived from the regions 
of HIV-1 subtype B proteins (Figure 3.5B), which had conserved, solvent exposed 
and intrinsically ordered structures (Figure 3.5E). This information enhances current 
understanding of HIV-derived peptide inhibitors, which may provide valuable 
guidelines for the design of novel peptide inhibitors [57, 58]. In the full-length 
genome, we identified conserved regions in Capsid, Nucleocapsid, Protease, RT, 
Integrase, Vpr and N-terminal domain of GP41 (Figure 3.2). These conserved regions 
have been targeted by known anti-HIV inhibitors (Figure 3.6). For instance, over 40 
experimental inhibitors with promising antiviral activities have been designed to 
target Capsid and Nucleocapsid [9]. HIV enzymes (Protease, RT, Integrase) are 
targeted by most of the FDA-approved antiretroviral drugs. Peptide inhibitor T20 
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targets the N-terminal heptad domain of GP41 [59]. Overall, our sequence analysis 
mapped the conserved drug target regions in the HIV-1 genome, providing useful 
information for drug design. 
Implications for HIV vaccine development: HIV subtype- and geography-specific 
vaccination has been proposed to contend with the challenges imposed by the high 
HIV genetic diversity [2]. Previous vaccine trials were carried out in regional 
populations dominated by a single HIV-1 subtype or CRF. For instance, the STEP [11] 
and RV144 [12] vaccine trials targeted patient populations mainly infected by subtype 
B and CRF01_AE, respectively. Particularly, the RV144 trial in 2009 showed the first 
sign that a prime–boost strategy achieved a modest vaccine efﬁc cy (31.2%) in the 
heterosexual population, which was at risk for infections with CRF01_AE [12, 48]. In 
our analysis, CRF01_AE has the lowest genomic diversity among the 12 analyzed 
HIV groups, subtypes and CRFs (Figure 3.1D, Figure 3.2A, 2B). It is thus tempting 
to speculate that the low diversity of CRF01_AE may have contributed to the success 
of the RV144 trial. As conserved epitopes are ideal targets for potential vaccines to 
contend with the high HIV diversity [24, 60], our study highlighted position-specific 
conservation along the full-length HIV genome (Figure 3.6). Moreover, HIV-1 
consensus sequences have been considered as potential vaccine candidates to 
minimize genetic diversity between vaccine candidates and circulating strains [2]. 
Previous analyses on fewer than 100 Matrix and GP160 sequences reported that 
genetic diversity between subtype-specific consensus sequences and circulating 
strains was only half of the genetic diversity between circulating strains from the 
same subtype [2]. We found that in the full-length HIV genome, this effect was much 
smaller as we only observed a 32.5% reduction of the genomic diversity (8.3% vs. 
12.3%, Figure S 3.23). As the most explored vaccine target protein, GP120 has the 
highest genetic diversity among all HIV proteins (Table 3.5), presenting a challenge 
in the search for broadly neutralizing antibodies and vaccines [61]. Furthermore, we 
mapped the global distribution of HIV-1 genomic diversity (Figure S 3.5). Our results 
showed the highest HIV genomic diversity in Central Africa, the birthplace of HIV [1, 
29], which suggested the difficulty of implementing HIV vaccines in this region. 
Limitations and future perspectives: The limited number of genomic sequences in 
HIV-1 subtypes H, J and K, group P and HIV-2 group B (n<10) may have affected 
Chapter 3: An integrated map of HIV genome-wide diversity 
  
122 
our estimation of sequence diversity, but consistent patterns were detected in the full-
length genome across different HIV groups and subtypes (Figure 3.2). Our structural 
analysis focuses on HIV-1 proteins because most PDB data is available for HIV-1 but 
not for HIV-2. Information on positions involved in HIV-human protein interactions 
is largely lacking, restricting our analysis from exploring the genetic diversity of 
protein interaction positions. Beside the multiple factors described in our study, other 
driving forces may shape HIV genetic diversity [25] and the genetic diversity data 
reported in our study can be useful for further investigations. Despite an extensive 
search, anti-HIV peptide inhibitors other than the ones described here may have been 
developed, but major changes in our conclusions regarding the known peptide-derived 
regions are not expected. Future studies are still needed to clarify how to improve 
vaccines and anti-HIV inhibitors based on the information of HIV genomic diversity. 
The increased knowledge of genome-wide diversity from our study may contribute to 
a better rational design of HIV vaccines and inhibitors. 
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3.6 Additional ﬁle 1: Figures 
 
Figure S 3.1: Distribution plots of nucleotide (A) and amino acid (B) genomic diversity 
among HIV types, groups and subtypes. See figure captions in Figure 3.1. Mean value 
of genomic nucleotide diversity: 48.32% (CI: 47.80-48.89%) between HIV-1 and 
HIV-2, 37.48% (CI: 25.98-45.70%) between HIV-1 groups, 14.72% (CI: 12.19-
15.79%) between HIV-1 subtypes, 8.20% (CI: 5.32-9.95%) within HIV-1 subtypes 
and 0.6% (CI: 0.2-1.4%) within HIV-1 patients. Mean value of amino acid genomic 
diversity: 53.75% (95% CI: 52.97-54.57%) between HIV-1 and HIV-2, 41.11% (CI: 
25.58-54.28%) between HIV-1 groups, 18.02% (CI: 15.59-19.60%) between HIV-1 
subtypes, 11.99% (CI: 8.63-14.36%) within HIV-1 subtypes and 1.1% (CI: 0.3-2.2%) 
within HIV-1 patients. For visualization purpose, we did not plot the long peak region 
of HIV-1 intra-patient nucleotide diversity which is above 1% in the proportion of 
genomic diversity. 
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Figure S 3.2: (A) Distribution plots of amino acid diversity between HIV-1 subtype B 
and other clades (HIV-1 subtypes, HIV-1 and HIV-2 groups) in the protein coding 
regions of the full-length genome. Each graph displays the distribution plots of 
diversity within subtype B (green), diversity within the other subtype/group (blue) and 
diversity between subtype B and the other subtypes/groups (red). The x- and y-axes 
indicate the HIV amino acid diversity and the proportions, respectively. (B) 
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Distribution plots of amino acid diversity between subtype C and other clades (HIV-1 
subtypes, HIV-1 and HIV-2 groups). 
 
 
Figure S 3.3: Amino acid diversity along the full-length HIV genome. Twelve subplots 
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individually show the nucleotide diversity results for subtype B, A1, C, D, F1, G, CRF01_AE, 
CRF02_AG, and HIV-2 group A and B, HIV-1 group N, O. 
 
Figure S 3.4. Nucleotide diversity along the full-length HIV genome. Twelve 
subplots individually show the nucleotide diversity results for subtype B, A1, C, D, 
F1, G, CRF01_AE, CRF02_AG, and HIV-2 group A and B, HIV-1 group N, O. 
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Figure S 3.5: Global distribution of HIV-1 genomic diversity. Countries with no 
sequences available (NA) are colored white. Amino acid genomic diversity in 
individual countries was mapped onto the global cartographic map in Natural Earth 
V2.0.0 (http://www.naturalearthdata.com/). Countries with infections by different 
groups or subtypes had higher genomic diversity, with the highest being found in 
Central Africa. Our results are consistent with the known distribution of HIV-1 
subtypes described in [29], implying that the strains included in our study may capture 
the global HIV-1 diversity. 
 
 
Figure S 3.6: Average amino acid diversity of HIV-1 protein clusters and 
number of HIV-human protein interactions. The five protein clusters include: viral 
enzymes (PR, RT, IN), accessory proteins (Vif, Vpu, Vpr, Nef), envelope proteins 
(GP120, GP41) and regulatory proteins (Tat, Rev). Proteins are clustered according to 
their functional roles in the HIV-1 life cycle [4]. 
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Figure S 3.7: Amino acid composition of HIV-1 subtype B genome (blue circles), 
HIV-1 peptide-derived regions (black diamonds) and the HIV-1 peptide inhibitor 
sequences (red stars). 
 
    
Figure S 3.8: Average genetic diversity of peptide-derived regions in HIV-1 
subtype B. The x-axis indicates the length of peptide inhibitor sequences. The y-axis 
indicates the average genetic diversity of the known peptide-derived regions of HIV-1 
subtype B genome. 
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Figure S 3.9: Solvent accessible surface area (ASA) of peptide-derived regions in 
HIV-1 subtype B. The x-axis shows the length of peptide inhibitor sequences. The y-
axis shows the average ASAs (Å) of known peptide-derived regions of HIV-1 subtype 
B genome. Horizontal lines mark the average ASAs of 55 Å and 95 Å, covering most 
peptide inhibitors with IC50/EC50<1μM. 
 
 
Figure S 3.10: Protein intrinsic disorder scores of peptide-derived regions in 
HIV-1 subtype B. X-axis indicates the length of peptide inhibitor sequences. Y-axis 
indicates the average protein intrinsic disorder scores in the known peptide-derived 
regions of HIV-1 subtype B genome. The horizontal line at the value of 0.5 indicates 
the cutoff of the disorder score for determining disordered (≥0.5) or ordered (<0.5) 
structural regions.   
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Figure S 3.11: Similarity of prediction results between the consensus and the 9 
protein secondary structure methods. Consensus assignments were obtained using 
the majority voting strategy among the 9 individual methods. Given 15 HIV-1 
proteins in the full-length genome of HIV-1 subtype B, similarities between two 
methods were calculated by the percentages of common predictions of alpha-helix 
(top-right part of matrix) and beta-strand (left-bottom part of matrix) structures. 
 
Figure S 3.12: Prediction similarities of the consensus and 17 methods for 
protein intrinsically disorder prediction. Prediction similarities were calculated by 
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the percentages of common predictions of ordered (disorder tendency score < 0.5) or 
disordered (disorder tendency score ≥ 0.5) positions in HIV-1 protein structures. 
Consensus predictions were obtained using the majority voting strategy among the 17 
individual methods. The consensus method has the highest average prediction 
similarities compared to the other methods. 
 
 
 
 
Figure S 3.13: Structure of the HIV-1 GP120-CD4-Fab 48d complex (PDB: 2B4C, 
3U4E) and mapped GP120 peptide-derived inhibitors. On the structure, CD4 and 
Fab 48d structures are colored orange and pink, respectively. The GP120 and peptide 
inhibitor sequences is annotated beneath the protein structures. Peptide inhibitors are 
mapped to the GP120 functional domains (bottom), including 5 variable domains 
(V1-V5) and 5 conserved domains (C1-C5) [62]. 
The V1 to V3 and V5 loops have been identified as the minimal functional units of 
GP120 to mediate CXCR4-dependent infection [62]. The V3 loop is the major target 
for neutralizing antibodies and V3-derived peptides offer promising anti-HIV 
activities [63]. GP120-derived peptides can inhibit the interactions between GP120 
and T-cell surface glycoproteins (e.g. CD4, CD19), chemokine co-receptors (e.g. 
CCR5, CXCR4) and monoclonal antibodies [63]. The inhibition activity of GP120-
derived peptides can be strain-dependent and cell-dependent (Table S 3.1). 
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Figure S 3.14: GP41 structure and mapped GP41-derived peptide inhibitors. The 
protein cartoon representation of GP41 protein is shown on top and the peptide 
inhibitor sequences are annotated beneath the structures. SIV GP41 structure is 
visualized (PDB: 2EZS) since the crystal structure of HIV-1 GP41 has not yet been 
fully resolved (February 2014). 
GP41 forms a trimer with GP120 in a viral spike on the surface of HIV particles 
(Figure 3.5). Three C-terminal heptad repeats (CHRs) bind with three N-terminal 
heptad repeats (NHRs) to form a 6-helix bundle, which fuses the viral with cellular 
membrane to create a fusion pore during viral entry [64, 65]. Peptides derived from 
either NHR or CHR can mimic the viral structures to prevent viral entry. T20 
(Enfuvirtide, Fuzeon, DP178), derived from NHR of HIV-1 subtype B strain LAI, is 
an 36AA L-peptide inhibitor which targets multiple sites on GP41 and GP120 [59]. 
Most GP41 peptide inhibitors have been derived from the conserved pre-hairpin 
structure [66]. GP41-derived L-peptides have many defects such as proteolytic 
degradation, limited potency and toxicity [67]. To overcome the defects of L-peptides, 
D-peptides have been proposed as promising fusion inhibitors (reviews [68, 69]). For 
instance, the D-peptide inhibitors PIE12 [70] and IQN17 [71] have shown good anti-
HIV activities by mimicking the heptad repeat regions in GP41. 
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Figure S 3.15: HIV-1 Integrase tetramer (PDB: 1K6Y) and mapped integrase-
derived peptide inhibitors. The protein cartoon representation of Integrase domains 
is shown on top and the peptide inhibitor sequences are annotated beneath the 
structures. For visualization purpose, we used the integrase monomer from the 
prototype foamy virus (PDB: 3OY9). The HIV-1 integrase structure has an N-terminal 
domain (NTD), a catalytic core domain (CCD) and a C-terminal domain (CTD), 
which are connected by flexible links [4]. Integrase plays multiple roles during viral 
reverse transcription and integration [72]. The key role of integrase is to insert viral 
dsDNA into human chromatins, creating a viral reservoir for viral infection [73]. 
Integrase-derived peptides can inhibit integrase-mediated catalytic functions, 
integrase inter-domain interactions and/or integrase-human protein interactions (Table 
S 3.1). Peptide inhibitors derived from CCD can i hibit i tegr se dimeriz ti  , 3‟-end 
DNA processing and strand transfer during viral integration [74]. 
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Figure S 3.16: HIV-1 reverse transcriptase (RT) structure (PDB: 3DLK) and 
mapped RT-derived peptide inhibitors. The surface representation of reverse 
transcriptase domains is shown on right and the peptide inhibitor sequences are 
annotated on the left side of the structure.Reverse transcriptase forms a heterodimer to 
synthesize dsDNA from the viral genomic RNA [75]. RT structures are comprised of 
the finger, palm, thumb, connection, RNaseH and P51 functional domains [76]. 
Peptide inhibitors derived from the connection (Pep-7 [77], Peptide1 [78]) and thumb 
domain (P24[79], P27[79], PAW[79]) can block the dimerization of p66 and p51. 
Nanoparticle delivery systems can improve the delivery of RT peptide inhibitors [79]. 
 
Figure S 3.17: HIV-1 Protease homodimer structure (PDB:1A30) and mapped 
protease-derived peptide inhibitors. The protein cartoon representation of protease 
is shown on top, and the peptide inhibitor sequences are annotated beneath the 
structure. Beta-sheets of the N-terminal and C-terminal domains are crucial for 
protease dimerization [80, 81]. HIV-derived peptide inhibitors that mimic the N- and 
C-terminal domains have been investigated as potential protease inhibitors. These 
include the cross linked interfacial peptide PF1 [82] and the PR-derived peptide p-S8 
[83]. Peptides derived from protease 83-93 can inhibit protease folding [84-86]. 
 
Figure S 3.18: HIV-1 Tat structure (PDB: 1JFW) and mapped Tat-derived 
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peptide inhibitors. The protein cartoon representation of Tat is shown on top. The 
peptide inhibitor sequences are annotated beneath the structure. 
The regulatory protein Tat can bind with GP120 to enhance viral entry [87]. Peptide 
sequences derived from the Tat positions 48-57 can interrupt the Tat-GP120 
interaction in a concentration-dependent manner [87]. The peptide inhibitor Tat11 can 
interrupt nuclear import by interacting with the host importin beta protein [88]. 
Moreover, the Tat-mediated transcription can be blocked by the inhibition of Tat-TAR 
interactions, which involves the arginine rich motif of Tat and the 3-nt bulge of the 
TAR RNA hairpin (U23, A27, U38) [89]. 
 
Figure S 3.19: HIV-1 Vpr structure (PDB:1M8L) and mapped Vpr-derived 
peptides. The protein cartoon representation of Vpr is shown on top and the peptide 
inhibitor sequences are annotated beneath the Vpr structure. 
An interaction between Vpr and RT has not been reported, nor an interaction between 
Vpr and Integrase. However, peptide inhibitors derived from Vpr domains (positions: 
57-71, 61-75) can interfere with the activity of both RT and Integrase [90]. Two 
studies have independently shown that Vpr-derived peptides (positions: 55-69, 60-74) 
can inhibit the strand transfer and the 3‟-end-processing reactions conducted by 
Integrase [91, 92]. 
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Figure S 3.20: HIV-1 Rev tetramer structure (PDB: 3LPH) and mapped Rev-
derived peptide inhibitors. The protein cartoon representation of Rev is shown on 
top and the peptide inhibitor sequences are annotated beneath the Rev structure. 
Rev can target the Rev response element (RRE) in the viral RNA genome during 
nuclear export, while Rev-derived peptides can interrupt the Rev-RRE interaction 
[93]. Rev can physically bind with Integrase to form a pre-integration complex so that 
viral integration can be postponed until the completion of nucleocytoplasmic shuttling 
[94, 95]. Two Rev-derived peptides (positions: 1-30, 49-74) can inhibit the Integrase 
3‟-end processing and the strand-transfer in cell-free assays [94]. Moreover, direct 
interactions between two Rev domains (positions: 12-23, 53-67) and integrase 
domains (positions: 118-128, 66-80) have been reported [96]. Two shorter Rev 
peptides (positions 13-23, 53-67) have also shown the inhibitory activity [97]. The 
Integrase-derived peptides INr-1 and INr-2 can stimulate viral genome integration and 
interrupt the Rev-Integrase protein interaction [98]. 
 
Figure S 3.21: Monomer structure of HIV-1 Capsid (PDB: 2NTE) and mapped 
Capsid-derived peptide inhibitors. The protein cartoon representation of Capsid is 
shown on top and the peptide inhibitor sequences are annotated beneath the structure. 
Capsid pentamers and hexamers constitute the internal shell of viral particles [35]. 
The alpha-helical structure of the C-terminal domain (CTD, positions: 146-231) 
participates in the capsid multimerization [99]. Peptide inhibitors derived from the 
CTD can interrupt the multimerization of HIV-1 Capsid by mimicking the capsid 
multimerization interfaces. The peptide inhibitor CAC1 derived from the CTD 
domain can disassociate CTD dimers (Kd = 50 uM) [100]. Since peptide inhibitors 
must penetrate the viral membrane to prevent the Capsid multimerization, cell-
penetrating peptides have been designed to improve the peptide potency in cell culture 
experiments [101, 102]. For instance, the peptide inhibitor CAI [103] has been 
converted into a cell-penetrating peptide NYAD-1, which improves the binding 
affinity and inhibits the post entry stage [101]. The cell-penetrating peptides NYAD-
201 and NYAD-202 have shown promising anti-HIV activities [102]. 
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Figure S 3.22: HIV-1 Vif structure (PDB: 4N9F) and mapped Vif-derived peptide 
inhibitors. Peptide inhibitor sequences are annotated beneath the Vif structure. The 
N-terminal domain, the central domain and the C-terminal domain of Vif are colored 
blue, green and yellow, respectively. The Vif-derived peptide Vif41-65 (positions: 41-
65) can inhibit protease activity [104]. The Vif positions (36, 47, 101, 117, 124) are 
associated with PI treatment [105]. Two Vif-derived peptides 30-65 and 78-98 have 
also been shown to inhibit the protease activity [106]. The N terminus of Protease 
(positions: 1-9) interacts with the central domain of Vif (positions: 78-98) [107]. Two 
Vif-derived peptides (positions: 81-88, 88-98) inhibit the protease activity [106, 108]. 
 
Figure S 3.23: Distribution plots of amino acid diversity between the consensus 
and the circulating genomes (blue), and within circulating genomes (black). The 
x-axis indicates HIV-1 subtypes B, A1, C, D, CRF01_AE and CRF02_AG, each of 
which contains more than 50 sequences in our datasets. The y-axis indicates amino 
acid genomic diversity. For each subtype, the consensus sequence is obtained by 
retaining the most prevalent residue at each position. For each of the 6 HIV-1 
subtypes (A1, B, C, D, 01_AE, 02_AG), the average amino acid diversity between 
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circulating strains (12.3±1.5%) was significantly higher than that between the 
consensus and the circulating strains (8.3±1.3%, P-value<0.001). 
 
3.7 Additional ﬁle 2: Tables 
Table S 3.1: Summary of 121 peptide inhibitors derived from HIV-1 proteins. (1) 
Peptide position: HIV-1 proteins and HXB2 positions from which the peptide 
inhibitors were derived. The numbering of the GP41 peptide positions refers to the 
Env protein; (2) Peptide name: we used the peptide names as indicated in the 
published articles; (3) Sequence: peptide amino acid sequence, with additional 
molecule functional groups where relevant; (4) Target: target protein with which 
peptide inhibitors bind; (5) IC50/EC50/Kd: experimental outcomes of peptide 
performance in Kd, IC50 or EC50. The superscript „d‟ i dic tes Kd and „E‟ i dic tes 
EC50. Others without superscripts are IC50 values. GP120 i hibit rs: „ ‟ i dic tes 
neutralizing activity, IN inhibitors: „s‟ i dic tes i tegr se str  d tr  sfer, „3e‟ i dic tes 
i tegr se 3‟-e d pr cessi g  „~‟ i dic tes  ppr xim te v  ues; (6) HIV strain: HIV 
strains used for evaluation of peptide inhibitory activity. If multiple HIV-1 strains 
were used, subtype or group information is given in both of the columns (5) and (6). 
(7) Cell line: cell lines used in the experiments. 
Peptide 
position(1) 
Peptide 
name(2) 
Sequence(3) Target(4) IC50/EC50/Kd(5) HIV  strain(6) Cell line(7) Ref 
GP41[638–673] T20(enfuvirt
ide) 
YTSLIHSLIEESQNQQEKN
EQELLELDKWASLWNWF 
GP41 B:2.7±0.4nM, 
IIIB:28nM[109], 
BCF02>2000nM[109]  
B:HXB2, 
B:IIIB [109], 
C: BCF02 [109]  
293T [109],[66] 
GP41[638–673] T-20EK YTSLIEELIKKSEEQQKKN
EELKKLEEWAKKWNWF 
GP41 B:1.2nM NL4-3D36G MT-2 [110] 
GP41[621-652] CP621-652 QIWNNMTWMEWDREINN
YTSLIHSLIEESQNQ 
GP41 HXB2:8.6±2.5nM, 
NL4-3:5.8±0.6nM 
HXB2,NL4-3 TZM-bl [111] 
GP41 [621-
652] 
CP32M VEWNEMTWMEWEREIEN
YTKLIYKILEESQEQ 
GP41 BCF02:10nM[109], 
IIIB:5nM[109]  
IIIB[109], 
BCF02[109] 
MT-2 [109], 
[112] 
GP41[628-661] NCS-C34-
Chol 
WMEWK(NCS)REINNYTSL
IHSLIEESQNQQEKNEQEL
LGSGN-Chol 
GP41 8.4±2.2nM HXB2, SF162, 
CNE28,NL4-3 
HEK293T [113] 
GP41[528-581] 17-70 STMGAASMTLTVQARQLL
SGIVQQQNNLLRAIEAQQ
HLLQLTVWGIKQLQARIL 
GP41 391±33nM HXB2 TZM-bl [114] 
GP41[630-659] SJ-2176 EWDREINNYTSLIHSLIEES
QNQQEKNEQEGGC 
GP41 P24-NC:101uME 
CPE:142nME 
Cell fusion:156nME 
IIIB MT-2 [115] 
GP41[512-544] IFFA AVGIGALFLGFLGAAGST
MGARSMTLTVQARQL 
GP41  IIIB SupT1, TF228 [116] 
GP41[628-
639,641-661] 
ABT WEEWDREINNYT(MPA)LI
HELIEESQNQQEKNEQELL 
GP41 1.01-66.39nM NL4-3,subtype 
A,B,C 
TZM-bl [117] 
GP41[626-663] T1144 TTWEAWDRAIAEYAARIE
ALLRALQEQQEKNEAALR
EL 
GP41 0.4nM Bal TZM-bl [118] 
GP41[638-673] 
[626-663] 
TLT35 T20 (GGGGS)6 T1144 GP41 IIIB:11.06±3.12nM,
Bal: 
2.24±0.68nM,Range: 
1.83-27.87nM 
IIIB,Bal, 
Subtype:A,B,C,E
,F,G,O 
MT-2 [118, 119] 
GP41[626-657] C32-e5.0 Ac-
TTWEAWDRAIAEYAARIE
ALIRAAQEQQEKNC-NH2 
GP41 6.4±1.4nMd   [120, 121] 
GP41[626-664] C39-e5.0 Ac-
TTWEAWDRAIAEYAARIE
ALIRAAQEQQEKNEAELR
ELC-NH2 
GP41 9.9±1.8nMd   [120, 121] 
GP41[628-661] C34 WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELL 
GP41 >2uM[109]  BCF02[109] 293T [109],[122
, 123] 
GP41[636-661] A c−βA  −
P26 
A c−βA  −NNYTSLIHSLIE
ESQNQQEKNEQELL 
GP41 NL4-
3D36G:130±12nM, 
IIIB:14.9±2.99nM 
NL4-3D36G, 
IIIB 
MT-2, 
HL2/3,TZM-b 
[124] 
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GP41[626-661] MT-C34 MTWMEWDREINNYTSLIH
SLIEESQNQQEKNEQELL 
GP41 0.5±0.1nM NL4-3 HL2/3 [125] 
GP41[626-649] MT-
SC22EK 
MTWEEWDKKIEEYTKKIE
ELIKKS 
GP41 A:3.8-4.6nM 
B: 1.6-9.3nM 
C:1.3-10.8nM 
AE:3.4-15.1nM 
BC:0.8-6.5nM 
A,B,C,A/E,B/C TZM-bl [126] 
GP41[625-661] C37 GGHTTWMEWDREINNYT
SLIHSLIEESQNQQEKNEQ
ELLGHHHHHH 
GP41 HXB2: ~1nM 
JR-FL:~1.5nM 
HXB2,NL4-
3,JR-FL, Ba-L 
293T [127] 
GP41[628-673] C46(364H-
3L 
multimer) 
WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELLELD
KWASLWNWF 
GP41 JR-FL:23nM, 
Bal:120nM, 
117III: >100nM, 
HXB2:12nM 
JR-FL,Bal, 
117III,IIIB,HXB
2 
U87,293T [128] 
GP41[628-656] (Caca29)2 (CAcaWMEWDREINNYTSL
IHSLIEESQNQQEKN)2 
GP41 5.71nM - - [129] 
GP41[628-649] (CAcaSC22
EK)2 
(CAcaWEEWDKKIEEYTKK
IEELIKKS)2 
GP41 4.9nM - - [129] 
GP41[629-662] SC35E(SBn
)5H9 
Ac-
WEEWEKKIHEYTAKIELIK
KSEEQQKKNEEELKK-NH2 
GP41 1.02±0.33nM ??? TZM-bl [130] 
GP41[628-673] V2o WMTWDREIDNITQTISSAI
EESQNQNEKNEQELLKLN
QWDIFSNWF 
GP41 HXB2:0.42±0.15nM, 
BaL:0.51±0.11nM,SI
Vmac251:5.0±3.3nM 
HXB2,BaL,SIV
mac251 
293T [131] 
GP41[553-590] DP-107 NNLLRAIEAQQHLLQLTV
WGIKQLQARILAVERYLK
DQ 
GP41 2.7uM IIIB MT4 [132] 
GP41[627-662] SFT(Sifuvirt
ide) 
SWETWEREIENYTRQIYRI
LEESQEQQDRNERDLLE 
GP41 A:1.81nM, 
B:10.35nM, 
C:3.84nM[133] 
Subtype A,B,C MT-2 [133-135] 
GP41[559-581] IQN23 Ac-
RMKQIEDKIEEIESKQK
KIENEIARIKKL-
IEAQQHLLQLTVWGIK
QLQARIL-NH2 
GP41 15±7nM HXB2 293T [136] 
GP41[546-581] N36 SDIVQQQNNLLRAIEAQQ
HLLQLTVWGIKQLQARIL 
GP41 180±70nME NL4-3 293T, MT-2 [137] 
GP41[546-581] N36Fd SDIVQQQNNLLRAIEAQQ
HLLQLTVWGIKQLQARIL-
GYIPEAPRDGQAYVRKDG
EWVLLSTFL 
GP41 NL4-3: 
56.34±9.24nM,IIIB:9
9nM; Bal: 
182.9nM,93IN101:1.
21nM 
IIIB,NL4-3, 
BaL,93IN101 
MT-
2,PMBC,TZM-
bl 
[65] 
GP41[559-586] N28Fd IEAQQHLLQLTVWGIKQL
QARILAVERY-
GYIPEAPRDGQAYVRKDG
EWVLLSTFL 
GP41 NL4-
3:26.95±0.02nM, 
IIIB:39nM 
IIIB,NL4-3, 
BaL, 93IN101 
MT-
2,PMBC,TZM-
bl 
[65] 
GP41[536-581] N46 TLTVQARQLLSGIVQQQN
NLLRAIEAQQHLLQLTVW
GIKQLQARIL 
GP41 >1uM (IIIB) IIIB, 92US657, 
94UG103 
MT-2,H9, [138] 
GP41[536-581] N46FdFc TLTVQARQLLSGIVQQQN
NLLRAIEAQQHLLQLTVW- 
GIKQLQARILGYIPEAPRD
GQAYVRKDGEWVLLSTFL
-(H)6 
GP41 310±25nM IIIB, 92US657, 
94UG103 
MT-2,H9, [138] 
GP41[626-663] T2635 TTWEAWDRAIAEYAARIE
ALIRAAQEQQEKNEAALR
EL 
GP41 6.24nM~393.0nM LAI TZM-bl [139] 
GP41[626-663] T-2544 MTWEAWDRAIAEYAARIE
ALIRAAQEQQEKNEAALR
EL 
GP41 7nM IIIB PBMC, 
MT-2 
[140] 
GP41[626-661] T-651 MTWMEWDREINNYTSLIH
SLIEESQNQQEKNEQELL 
GP41 8nM IIIB PBMC, 
MT-2 
[140]  
GP41[628-683] P5 WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELLELD
KWASLWNWFNITNWLWY
IK 
GP41 ~60nM LAI, JR-CSF Hela,PBMC [141] 
        
IN[95-109] Alpha-1 QETAYFLLKLAGRWP-
CONH2 
IN 3.5uM  - [142] 
IN[171-187] Alpha-5 HLKTAVQMAVFIHNFKR-
CONH2 
IN 3.0uM  - [142]  
IN[196-209] Alpha-6 AGERIVDIIATDIQ-CONH2 IN 2.0uM  - [142]  
IN[95-107] Alpha-1s QETAYFLLKLAGR-CONH2 IN 150uM  - [142]  
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IN[196-205] Alpha-6s AGERIVDIIA-CONH2 IN 30uM  - [142]  
IN[82-89] Beta-3 GYIEAEVI-CONH2 IN >1mM  - [142] 
IN[95-109] H104 QETAYFLLKLALRWP-
CONH2 
IN - - - [143] 
IN[97-108] NL-6 TAYFLLKLAGRW IN 2.7uMs,  
21 uM3E 
- - [144] 
IN[99-104] NL6-5 YFLLKL IN 20uMs, 3E - - [144] 
IN[129-139] NL-9 ACWWAGIKQEF IN 56uMs,  
95uM3E 
- - [144]  
IN[173-188] INS K188E WTAVQMAVFIHNFKRE IN 5.2±0.2uM HXB2 HEK293T [145] 
IN[92-108] INH1 ATGQETAYFLLKLAGKA-
CONH2 
IN 150uMs, 250uM3E NL4 –3 CEM-12D7 [146] 
IN[167-187] INH5 DQAEHLKTAVQMAVFIHN
YKA-CONH2 
IN 4.7uMs, 11uM3E   [146]  
IN[147-176] K159 SQGVVESMNKELKKIIGQ
VRDQAEHLKTAY 
IN 16nMS,16nM3E HXB2D - [147],[148
],[149] 
IN[151-176] EAA26 VESMNEELKKIIAQVRAQ
AEHLKTAY 
IN - - - [148],[150
] 
IN[171-
187,196-209] 
a5-Cmpi-a6 HLKTAVQMAVFIHNFKR-
Cmpi-AGERIVDIIATDIQ-
NH2 
IN 460±30nM   [151] 
        
CA[175-194] CAC1 Ac-
EQASQEVKNWMTETLLV
QNA-CONH2 
CA 50uMd BH10 - [100] 
CA[207-217] Capsid1 PAATLEEMMTA CA   H9 [152] 
CA[175-193] CAC1M SESAASSVKAWMTETLLV
ANTSS 
CA 8±1uMd HXB2 U87-CD4-
CXCR4 
[153] 
CA[175-194] CAC1C ESASSSVKAWMTETLLVQ
NA 
CA 19±8uMd HXB2 U87-CD4-
CXCR4 
[153] 
CA[178-192] NYAD-201 AQEVKXWMTXTLLVA (X
= (S)-2-alpha- (2‟-
pentenyl)alanine) 
CA IIIB: 4.29±0.62uM, 
MN: 3.03±0.61uM, 
SF2: 5.06±1.37uM, 
RF: 2.84±0.63uM, 
Bal: 4.73±1.92uM, 
89.6: 5.21±0.87uM 
IIIB,MN,RF,SF2
,BaL,89.6 
MT-2,PBMC [102] 
CA[178-192] NYAD-202 AQAVKXWMTXTLLVA (X
= (S)-alpha- (2‟-
pentenyl)alanine) 
CA IIIB: 2.36±0.33uM, 
MN: 2.47±0.71uM, 
SF2: 4.48±0.84uM, 
RF: 2.64±0.39uM, 
Bal: 2.23±0.44uM, 
89.6: 3.471±0.22uM 
IIIB,MN,RF,SF2
,BaL,89.6 
MT-2,PBMC [102]  
CA[181-192] P-1 VKNWMTETLLRQ CA 3.8±3.5uMd BH10 - [99] 
CA[124-133] peptide 1 IPVGEIYKRW CA 37±10uMd   [154] 
        
RT[285-301] PAW GTKWLTEWIPLTAEAEC RT 700±200nM
d LAI PBMC [79] 
RT[285-299] P27 GTKWLTEWIPLTAEC RT 50±10nMd LAI PBMC [79]  
RT[285-296] P24 GTKWLTEWIPLC RT 700±50nMd LAI PBMC [79] 
RT[395-404] Pep-7 KETWETWWTE RT 138nMd BH10 - [77],[155] 
RT[389-407] Peptide1 FKLPIQKETWETWWTEY
WE 
RT 1.2uMd LAV MT-4 [78] 
        
PR [83-93] p-S8 NIIGRNLLTQI PR 2.58±0.78uM[84] - -
 [84],[85],[
83, 86] 
PR[1-5,95-99] PF1 PQITL-(G)3-CTLNF PR 40uM(HIV1),20uM(
HIV2) 
HIV1,HIV2  [82] 
        
MA[71-87] 8L CH3CO-
GSEELRSLYNTIAVLGC-
NH2 
MA NL4-3: 2.3±0.3uME 
JR-CSF: 7.8uM 
NL4-3, JR-CSF MT-
4,PM1/CCR5 
[156] 
MA[81-97] 9L CH3CO-
TIAVLYSVHQRIDVKGC-
NH2 
MA NL4-3: 2.1±0.5uME 
JR-CSF: 0.58uM 
NL4-3, JR-CSF MT-
4,PM1/CCR5 
[156] 
MA[47-59] 4/5m NPGLLETSEGCRQ MA 615ug/ml IIIB H9 [152] 
        
RT [166-185] 4286 KILEPFRKQNPDIVIYQYM
D 
IN 4.8uM3E,4.5uMS BH10 - [157] 
RT [516-535] 4321 ELVNQIIEQLIKKEKVYLA
W 
IN 6.9uM3E,5uMS BH10 - [157]  
RT [176-195] 34 PDIVIYQYMDDLYVGSDL
EI 
IN 10uMS, 
6uM3E 
HXB2 -  
RT [366-385] 53 KQLTEAVQKITTESIVIWG
K 
IN 7±1uM3E,4±1uMS HXB2 - [158] 
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RT [396-415] 56 ETWETWWTEYWQATWIP
EWE 
IN 6±1uM3E,2±1uMS HXB2 - [158]  
RT [486-505] 65 LQDSGLEVNIVTDSQYAL
GI 
IN 2uMS, 
11uM3E 
HXB2 - [158] 
RT [526-545] 64 ELVNQIIEQLIKKEKVYLA
W 
IN 14uMS, 
15uM3E 
HXB2 - [158] 
IN[46-65] #4330 KGEAMHGQVDCSPGIWQ
LDC 
RT 4.2±0.2uMRDDP, 
6.8±0.7uMDDDP 
HXB2R - [159] 
        
Vpr [33-47] Vpr 33-47 HFPRIWLHSLGQHIY IN 41uMs, 
187uM3e 
BH10 - [90] 
Vpr [53-67] Vpr 53-67 TWAGVEAIIRILQQL IN 144uMs, 
>200uM3e 
BH10 - [90] 
Vpr [57–71] Vpr 57-71 VEAIIRILQQLLFIH RT/IN 0.22uM BH10 - [90] 
Vpr [61-75] Vpr 61-75 IRILQQLLFIHFRIG RT/IN 0.7uMrddp, 1.3uMdddp BH10 - [90]  
Vpr[55-69] Vpr-1 AGVEAIIRILQQLLF IN - HXB2, 
JR-CSF 
MT-4 [91]  
Vpr[64-75] Vpr-3 R8 Ac-LQQLLFIHFRIG-
RRRRRRRR-NH2 
IN 4±0.1nMs[91],  
8±1nM3e[91], 
60±10nMs[92],  
130±20nM3e[92] 
HXB2 
[91],[92], JR-
CSF[91]  
MT-4 [91],[92] 
Vpr[58-75] Vpr-4 R8 Ac-EAIIRILQQLLFIHFRIG-
RRRRRRRR-NH2 
IN 5±2nMs, [91] 
6±6 nM3e[91] 
40±10nMs[92] 
90±10nM3e[92] 
HXB2[91],[92], 
JR-CSF[91]  
MT-4[91],[92] [91],[92]  
Vpr [65-79] Vpr 65-79 QQLLFIHFRIGCQHS IN 14uMs, 
76uM3e 
BH10 - [90] 
Vpr[58-75] Vpr-15 Ac-
EAEIRIKQQLLFIHFRIG-
RRRRRRRR-NH2 
IN 31±10nMS, 
40±1nM3E 
HXB2, 
JR-CSF 
MT-4 [91]  
        
Vif[30-65] Peptide4 YVSGKARGWFYRHHYESP
HPRISSEVHIPLGDARLV 
PR 230-250uM IIIB Hut 78 [106] 
Vif[78-92] Peptide6 DWHLGQGVSIEWRKK PR 110uM IIIB Hut 78 [106] 
Vif[88-98] Peptide7 EWRKKRYSTQV PR 25uM[106], 
3.31uM[108] 
IIIB Hut 78 [106], 
[108] 
Vif[41-65] Vif41-65 RHHYESPHPRISSEVHIPLG
DARLV 
PR/IN  
 
HXB-2 PBL [104] 
        
p6* [1-8] TFP FLREDLAF PR 98±10uMI HXB2  [160] 
p6* [4-6] - EDL PR 50±9uMI HXB2  [160]  
PR[1-5]Tat [49-
61]p6*[53-
56]PR[95-99] 
P27 PQITL-RKKRRQRRRPPQV- 
SFNF- CTLNF 
PR 0.23-0.32uM/5uM A01 patient, 
LAI[161] 
MT-2,H9 [161], 
[162] 
        
Rev [1-30] Rev1-30 MAGRSGDSDEELLKTVRL
IKFLYQSNPPPS 
IN 6.5±0.2uMd HXB2 - [94]  
Rev [13-23] Rev13-23 LKTVRLIKFLY IN 2.8±0.1uMd HXB2 HeLa [94],[96] 
Rev [49-74] Rev49-74 QRQIRSISGWILSTYLGRPA
EPVPLQ 
IN 11.2±0.5uMd HXB2 - [94]  
Rev [53-67] Rev53-67 RSISGWILSTYLGRP IN 6.9±0.1uMd HXB2 HeLa [94],[96]  
CA[229-
231]p2[1-3] 
6a RVL-FEA-Nle PR NL4-3: 2.60±0.4nM, 
MDR769: 
4.40±0.7nM 
NL4-3, 
MDR769 
- [163] 
        
GP120[280-
302] 
NTM RSANFTDNAKTIIVQLNQS
VEIN 
CD4 
receptor 
 BH-10 - [164] 
GP120[424-
433] 
Peptide 1 INMWQEVGKA CD4 28uM IIIB - [165] 
GP120[365-
373] 
Peptide 2 SGGDPEIVT CD4  6uM IIIB - [165]  
GP120[312-
317] 
SPC3 [GPGRAF]8-K4-K2-K-βA chemokin
e receptors 
α β 
7.7±0.4uM LAI Xenopus 
oocyte 
[166] 
GP120[293-
334] 
V3-BH10 EINCTRPNNNTRKSIRIQRG
PGRAFVTIGKIGNMRQAH
CNIS 
IgG, 
MAbs,CD
19 
- IIIB,MN MT-4, 
PMBC 
[167] 
GP120[290-
334] 
V3-89.6 ESVVINCTRPNNNTRRRLS
IGPGRAFYARRNIIGDIRQA
HCNIS 
IgG, 
MAbs,CD
19 
- IIIB,MN MT-4, 
PMBC 
[167]  
GP120[290-
320,323-334] 
V3-ELI ESVKITCARPYQNTRQRTP
IGLGQSLYTTRSRSIIGQAH
CNIS 
IgG, 
MAbs,CD
19 
- IIIB,MN MT-4, 
PMBC 
[167]  
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GP120[298-
321] 
62.19 RPNNNTRKRIRIQRGPGRA
FVAIE 
F39F,447-
52D Fab 
31%n IIIB,89.6 MT-2 [168] 
GP120[296-
313,315-331] 
V3B-FP CTRPNNNTRKSIRIGPGQT
FYATGDIIGDIRQAHC 
 >50%n BZ167, DJ263, 
NL43 
[169] 
GP120[421-
436,298-321] 
C4–V3 
T303C–
E322C 
KQIINMWQEVGKAMYA-
RPNNNCRKSIHIGPGRAFY
TTGCG 
chemokin
e receptors 
- IIIB,NL4-3, 
JRFL 
293T,Rabbit [63] 
GP120[326-
340] 
15K IRKAHCNISRAKWND CXCR4,C
CR5 
  293T,PBMC,
MDM 
[170] 
GP120[326-
340] 
15D IRKAHCNISRADWND CXCR4,C
CR5 
  293T,PBMC,
MDM 
[170]  
GP120[157-
171] 
CT319 CSFNITTEIRDKVKK Tat  HXB2 U937 [171] 
        
IN[170-191], 
IN[214-228], 
IN[259-273] 
CCD170-
191,CTD214-
228,CTD259-
274 
(1)EHLKTAVQMAVFIHNF
KRKGGI,(2)QKQITKIQNFR
VYYR 
(3)VVPRRKVKIIRDYGK 
Transporti
n-SR2 
- - -  [172] 
IN[161-174] NLS(IN) IIGQVRDQAEHLKC-NH2 Importin-
alpha 
 -  [173] 
        
Tat[48-57] R10 RRRRRRRRRR  50uMe IIIB MAGI [87] 
Tat[49-58] Tat11 RKKRRGRRRC-NH2  5nMd  Colo-205 [88] 
Tat[11-50] - WKHPGSQPKTACTNCYCK
KCCFHCQVCFITKALGISY
GRK 
CXCR4  NL4-3 293T [174, 175] 
        
Rev[34-47] Rev 8 Ac-RRRRERQRKRRRRR-
OH 
RRE ~150nM - - [93] 
        
MA[11-47] p17(11-47) GELDRWEKIRLRPGGKKK
YKLKHIVWASRELERFAV
N 
Ca2+/Ca
M 
- - -  [137] 
        
GP41[577-586]  QARVLAVERY IgA  IIIB,ADA TZM-bl [176] 
GP41[628–683] Peptide P5 WMEWDREINNYTSLIHSLI
EESQNQQEKNEQELLELD
KWASLWNWFNITNWLWY
IK 
GP41-
Antibody 
61±1.5uM HXB2 Hela-CD4-
LTR-LacZ 
[141] 
 
3.8 Additional ﬁle 3: Software 
This document briefly describes the manual of functions and algorithms included in 
our software. We present the software for full-length genome alignment, the intra- and 
inter-clade genome diversity analysis and the data visualization. Our example datasets 
are available in the toolbox package. 
Motivation: Extensive full-length sequences of HIV genomes have been accumulated 
in the past few years. To our best knowledge, a toolbox developed for analyzing full-
length HIV genome has not been reported. Here, we offer a Matlab toolbox for HIV 
full-length genomic analysis. We provide an alignment tool that optimizes HIV amino 
acid alignments given the input files of nucleotides genomic sequences. Classical 
alignment tools either perform nucleotide or amino acid alignments. In order words, 
nucleotide (amino acid) sequences are optimized when nucleotide (amino acid) 
Chapter 3: An integrated map of HIV genome-wide diversity 
  
143 
sequences are inputs. Most classical tools do not optimize amino acid alignments 
based on nucleotide genomic sequences, because of the overlapping regions in three 
open reading frames. Considering different lengths and locations of 15 HIV proteins 
in 3 open reading frames of the HIV genome, our tool has been developed to optimize 
the genomic alignment using the reference mapping strategy. 
Protocol: HIV-1 and HIV-2 genome encodes 15 proteins in three open reading 
frames. The number of nucleotides in one HIV genomic sequence is usually between 
8500 and 8800. We have developed a tool to improve codon sequence alignments. 
Briefly, the input of our toolbox requires the nucleotide sequence alignment, which 
can be prepared using many classical nucleotide alignment tools (e.g. SeaView [31], 
Mega [177], Mafft [30]). Next, our toolbox uses the reference genome to assemble the 
nucleotide sequence alignment from each protein coding region. Thereafter, the 
alignments in protein regions are optimized by maximizing the matched codons based 
on the amino acid substitution matrix. 
We first describe our algorithm for improving the amino acid alignments from 
nucleotide sequences in one protein coding region. 
 
Algorithm: Alignment of codon sequences 
Input:    One MSA file with nucleotide genomic sequences 
Output: One MSA file with aligned amino acid sequences 
Step 1: Arrange the nucleotide positions into codon triples. /*--A-B---C--- => --ABC------- */ 
Step 2: Refine small nucleotides into codon columns. /*-AAA--BBB- => --AAA--BBB-- */ 
                                                                                      /*-AAA-BBB-- => --AAA--BBB-- */ 
Step 3: Refine codon positions to the left or right side if substitution scores are improved. 
Step 4: Optimize the codon alignments at the insertion and deletion regions. 
Step 5: Transform codon sequence alignments into amino acid alignments. 
In our toolbox, the function called “TransferNucleotide2AminoAcidAlignment.m” 
implements the above algorithm. A simple example is given to run the alignment tool. 
Note that MSAInputFile is the path of the MSA input file and MSAOutputFile is the 
path of the MSA output file. 
 
Example: 
[ Seq,SeqTitle,SeqID ] = ExtractSequenceOut(  MSAInputFile  ); % collect the nucleotide input 
Seq = TransferNucleotide2AminoAcidAlignment( Seq,SeqTitle );%optimize codon alignments 
[a,b] = WriteSequence2Fasta( Seq, SeqTitle, MSAOutputFile  ); % output improved alignments 
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Secondly, six steps are performed to align full-length HIV genomic sequences. An 
example is provided in the file called “StartFile_FullGnomeAlignmentTool.m”. 
 
Procedure for HIV genomic alignment: 
(1) We collect the information of HXB2 genome reference. 
(2) We concatenate each HIV-1 protein region in the full-length genome based on HXB2. 
(3) We perform the codon sequence alignment of HIV-1 proteins using full-length alignment tool. 
(4) We examine sequence quality using other sequence visualization software, such as Seaview. 
(5) We transform the sequences from nucleotide forms to amino acid forms. 
(6) We assemble the concatenated protein sequences into full-length amino acid genomes. 
Thirdly, “AnalysisGenomeIntraSubtypeDiversity.m” implements the computation of 
the intra-clade genomic diversity. “AnalysisGenomeInterSubtypeDiversity.m” 
implements the computation of the inter-clade genomic diversity.  
We implemented our toolbox in Matlab 2013a under the Linux system. A simple 
example to use our toolbox is provided in: “MeasureGenomeGeneticDiversity.m”. If 
you have encountered the difficulty of using the toolbox in different Matlab versions 
or computer systems, please consult Guangdi Li (liguangdi.research@gmail.com). 
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4.1 Summary 
HIV-1 Gag amino acid substitutions associated with protease inhibitor (PI) treatment 
have mainly been reported in subtype B, while information on other subtypes is scarce. 
Using sequences from 11613 patients infected with different HIV-1 subtypes, we 
evaluated the prevalence of 93 Gag amino acid substitutions and their association with 
genotypic PI resistance. A significant association was found for 13 Gag substitutions, 
including A431V in both subtype B and CRF01_AE. K415R in subtype C and S451G 
in subtype B were newly identified. Most PI-associated Gag substitutions are located 
in the flexible C-terminal domain, revealing the key role this region plays in PI 
resistance. 
4.2 Introduction 
An amino acid substitution is commonly defined as an amino acid change between 
two consecutive sequences based on longitudinal data [1, 2]. Amino acid substitutions 
in HIV-1 protease, commonly called resistance mutations if they confer HIV-1 drug 
resistance, are known to emerge under selective pressure of protease inhibitors (PIs) 
[3]. As an alternative mechanism, HIV-1 can escape PI selective pressure by the 
selection of substitutions in the protease substrate Gag [1, 4-7]. Such Gag 
substitutions arising during PI-based treatment have mostly been characterized in 
HIV-1 subtype B (Table 4.1), while only a few studies have focused on non-B 
subtypes using small cohorts of patients (Table 4.2). Gag variability has been shown 
to impact PI susceptibility in a subtype-dependent manner [4, 6], warranting a 
comprehensive analysis of PI-associated Gag substitutions across different subtypes. 
Here, we identified novel Gag substitutions in HIV-1 non-B subtypes using 
longitudinal data from patients failing PI-based therapy. Moreover, we evaluated the 
prevalence of the newly identified and the previously reported Gag substitutions in 
different HIV-1 subtypes and investigated their association with genotypic PI 
resistance using a large sequence dataset. 
 
Table 4.1: Summary of HIV-1 subtype B Gag substitutions observed during PI-
based treatment. 
Gag protein Gag position Gag substitutions * Reference 
Matrix 12 E12K [8] 
Matrix 62 G62R [9]  
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Matrix 75 L75R [8] 
Matrix 76 R76K [4] 
Matrix 79 Y79F [10] 
Matrix 81 T81A [10] 
Matrix 125 S125K [9] 
Matrix 132 Y132F [9] 
Capsid 219 H219Q [8, 11] 
p2 370 V370A, V370I, V370M [12] 
p2 373 S373Q [5, 13] 
p2 374 A374G,A374N,A374P,A374S,A374T [5, 14]  
p2 375 T375N [5] 
Nucleocapsid 390 V390D [8] 
Nucleocapsid 409 R409K [8] 
Nucleocapsid 431 A431V [7, 13, 15-23] 
p1 435 G435E, G435R [1, 17, 24] 
p1 436 K436E, K436N, K436R [14, 17, 18, 24, 25] 
p1 437 I437A, I437T, I437V [2, 14, 17, 18, 20, 23-26] 
p1 438 W438R [17] 
p1 440 S440C [24] 
p6 449 L449F, L449P, L449Q, L449V 
[2, 13-15, 18, 20, 23, 24, 
27-32]  
p6 451 S451I, S451N, S451T [32, 33]  
p6 452 R452K, R452S [15, 18, 23, 34] 
p6 453 P453L, P453T 
[14, 16, 18, 20, 21, 23, 
28, 29, 31, 34] 
p6 459 P459I [35] 
*: Only Gag substitutions associated with FDA-approved PIs in HIV-1 subtype B are 
summarized. The substitution is expressed relative to the subtype B consensus 
sequence (http://www.hiv.lanl.gov/). 
 
Table 4.2: Summary of Gag amino acid substitutions in HIV-1 non-B subtypes 
observed during PI-based treatment. 
Gag amino acid substitutions in non-B 
subtypes * 
Number of patients infected 
by non-B subtypes 
Reference 
A431V A or F 
#
 (n=4) [21] 
K436R, N451S C (n=1) [21] 
L363F, A364G, A374T, I376V, M378V, R380K, 
K436E, G443R 
G (n=2), 01_AE (n=1),  
02_AG (n=4) 
[14] 
V128A/T/I, Q130R, Y132F, V135M, V362I, 
A373T, A374T, A375T, I376A/V/M, K380R, 
S381G, N382K, E428D/Q, Q430R/G/V/I, 
A431V, K436R, L449I, N451S, R452K, P453I 
G (n=21) [36] 
N375S, G381R A1 (n=2) [2] 
G381S, G446E 02_AG (n=1) [2] 
V135I, I376V, L486F 01_AE (n=1) [2] 
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P453L/T/I F 
#
 (n=61) [37] 
M138L, F363L, L363W, A374T, V374A, 
R387K, N389T, K411Q, K415R, G420A, 
P422Q, T427P, P445L, S451G, R452G, P453L, 
P453Ins, I469T, P472S, P474L, E477Q 
A1 (n=1), C (n=6), D (n=1), 
F1 (n=1), J (n=1), 01_AE 
(n=1), 02_AG (n=1) 
Our study 
*: Non-B Gag substitutions reported during PI-based treatment either in the literature 
or in our study. The substitutions also identified in subtype B are indicated in bold.  
#: Information of HIV-1 subtype or sub-subtype was ambiguous or not available. 
 
4.3 Findings 
We first investigated the emergence of non-B Gag substitutions during PI-based 
treatment in a cohort of 1068 patients followed at the University Hospital of Leuven, 
for which virological outcome and treatment information were available [38]. Our 
protocol and quality control of viral sequencing and viral load tests have been 
described previously [39, 40]. The sequences with associated information are 
available through Euresist (http://www.euresist.org). For 69 patients infected with 
HIV-1 non-B subtypes and receiving PI-based treatment for at least three months, 
sequence information for Gag, protease and reverse transcriptase (RT) was available 
at baseline and at treatment failure, which was defined according to the guidelines of 
the European AIDS Clinical Society (EACS) (http://www.eacsociety.org/). Under 
drug selective pressure, 21 different substitutions at 18 Gag positions were identified 
among 12 patients, of whom 11 harbored Gag substitutions in the presence of (pre-
existing or simultaneously acquired) drug resistance mutations in protease or RT 
(Figure 4.1, Table 4.3). Gag substitution P453Ins (insertion: EPTAPP) emerged in 
patient 343 in the absence of PI and RTI resistance mutations. Some substitutions 
were from a less to a more common amino acid such as M138L. Specifically, patients 
failing LPV/r-based regimens developed one of the following Gag substitution 
patterns: L363W+E477Q, F363L+N389T+P422Q+P455L, K411Q, P472S+P474L, 
K415R+I469T, M138L, A374T or G420A. Patients failing DRV/r-based regimens 
developed Gag substitution patterns P453Ins or T427P+R452G. Patients failing an 
ATV/r-based regimen developed Gag substitution patterns: P453L or 
V374A+R387K+S451G+P453Ins. A patient failing a regimen containing FPV/r and 
SQV/r developed L363W. Longitudinal data from 34 PI-naïve patients infected with 
non-B subtypes revealed the emergence of one Gag substitution (V370A) in a single 
patient. Overall, when analyzing all subtypes, the proportion of PI-treated patients 
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with Gag substitutions was much higher than that of PI-naïve patients (17.4% (12/69) 
vs 2.9% (1/34), p-value = 0.037). 
 
Table 4.3: Summary of Gag, protease and RT substitutions in 12 patients of the 
Leuven cohort. 
Patient 
ID 
Subtype Sampling 
day 
Gag 
substitution 
Protease variants  
and PI resistance 
mutations 
RT variants and RTI resistance mutations 
123 A1 2002-10-08 363L+477E 10V 49R+103N+108I+118V+173[S,L]+179I+184V 
+189[I,V]+215[N,T,Y,S]+225[H,P]+238[K,T] 
+248T+303L +348[N,I] 
2003-12-10 363L+477Q 10V+20T 49[K,R]+103N+108I+118V+173L+179L+184M 
+189I+215Y+225P+238T+248T+303[W,L]+348na 
2004-10-27 363W+477Q 10V+20T 49K+103N+108I+118[I,V]+173L+179L+184M 
+189I+215Y+225P+ 238T+248[T,I]+303L+348na 
 
343 C 2010-03-17 453P 64I+70[K,R] 40[E,D]+49[K,R]+106[M,V]+123[S,G]+126[K,R] 
+165[T,I]+175N+277[K,R]+281R 
2012-11-30 453PTAPPE 64[I,L]+70K 40E+49K+106V+123S+126K+165I+175[N,Y] 
+277K+281[K,R] 
 
357 C 2004-07-26 363F+389N 
+422P+445P 
74S 13[R,K]+86D+148V+154[R,K]+280[Y,C] 
2005-09-05 363L+389T 
+422Q+445L 
74S 13K+86[D,G]+148[V,I]+154K+280C 
 
445 C 2007-06-27 411K 60[D,E]+66I 3S+28K+32E+36A+49K+60I+65K+67D+70K 
+75[I,V]+101K+103N+123[N,S]+173V+177D 
+184M+190G+207[E,G]+211R+214L+215[T,I]+ 
219K+277[K,R]+ 278Q+281R 
2008-01-02 411K 60E+66I 3S+28K+32E+36A+49K+60I+65R+67D+70K 
+75V+101K+103N+123S+173V+177D+184M 
+190G+207E+211R+214L+215[T,I]+219K 
+277R+278[Q,R]+281K 
2011-07-15 411Q 60D+66[I,M] 3S+28E+32K+36E+49[K,R]+60V+65K+67N 
+70R+75V+101K+103K+123S+173A+177E 
+184V+190A+207E+211K+214[L,F]+215T 
+219K+277R+278Q+281K 
2012-04-04 411Q 60D+66I 3[N,S,D,G]+28[K,E]+32K+36E+49K+60V+65K 
+67N+70R+75V+101[K,E]+103K+123S+173A 
+177E+184V+190A+207E+211K+214[L,F] 
+215T+219[K,E]+277R+278Q+281K 
 
834 C 2003-02-12 472P+474P 20R+62V 103N+173T +184V 
2007-01-04 472S+474L 20R+62V 103K+173A +184M 
 
1039 C 2010-08-12 427T +452R 62[I,V]+72I+ 
74S+82[I,V] 
8[I,V]+28E+39E+48[T,S]+53[E,D]+67D 
+121[H,D]+123[N,S,D,G]+135I+142[I,V] 
+166[K,R]+184M+208H+214F+241V 
+286[T,A]+324[E,D] +334Q 
2011-02-14 427T +452R 62I+72I+ 74S+82V 8V+28E+39E+48T+53E+67[N,D]+121D+123S 
+135I+142[I,V]+166[K,R]+184[I,M]+208H 
+214F+241V+286A+324E+334[Q,H] 
2011-04-01 427T +452R 62[I,V]+72I+ 
74S+82[I,V] 
8V+28E+39E+48[T,S]+53[E,D]+67[N,D]+121D 
+123S+135I+142I+166[K,R]+184V+208[H,Y] 
+214F+241V+286A+324E+334na 
2011-08-08 427T +452G 62V+72I+74S+82I 8V+28K+39E+48T+53E+67D+121D+123S+135L 
+142I+166K+184V+208H+214F+241V+286A 
+324E+334Q 
2013-04-22 427P+452G 62[I,V]+72[I,M] 8V+28E+39[K,E]+48T+53E+67D+121D+123S 
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+74S+ 
82[I,V] 
+135[T,I,S,L]+142I+166K+184V+208H 
+214[L,F]+241[V,L]+286A+324E+334Q 
 
1075 C 2005-11-07 363L 10I+18H+33F+ 
43T+48V+54A+ 
62V+74S+82A+89I 
35T+41L+44D+67N+84[T,S]+101K+106M+ 
118I+184V+190A+210W+215Y+219N+227L 
2006-03-01 363W 10I+18H+33F+43T 
+48V+54A+62V 
+74S+82A+89I 
35T +41L+44D+67N+84T+101[K,E] 
+106[I,M,V]+118I+184[M,V]+190A+ 
210W+215Y+219N+227L 
2006-05-15 363L 10I+18[Q,H]+33F 
+43T+48V+54A+ 
62V+74S+82A+89I 
35[T,I]+41L+44D+67N+84T+101[K,E] 
+106V+118I+184[M,V]+190A+210W 
+215Y+219N+227L 
 
552 D 2002-02-18 415K+469I 13I+14K+62I 
+72I+93[I,L] 
20[K,R]+136N+275K+294P+297A 
2003-07-28 415K+469T 13I+14K+62I 
+72I+93L 
20[K,R]+136N+275[K,R]+294P+ 
297A+334R+335G 
2004-03-22 415K+469T 13I+14K+62[I,V] 
+72[I,V]+93L 
20[K,R]+136N+275K+294P+297A +334R+335E 
2009-02-11 415K+469T 13[I,V]+14[K,R] 
+62I+72[I,V] 
+93[I,L] 
20K+136N+275K+294T+297[T,A]+334R+335E 
2011-01-24 415R+469T 13[I,V]+14[K,R] 
+62[I,V]+72[I,V] 
+93[I,L]  
20K+136[N,H]+275K+294na+297na+ 
334na+335na 
 
27 F1 2008-07-24 453P 10V+62V+69Y 207E+276V 
2010-07-14 453L 10V+62V+69Y 207K+276[I,V] 
2011-01-12 453L 10V+62V+69[H,Y] 207[K,E]+276V 
 
666 J 2001-06-13 138M+374A 10I+20R+35E+54I 
+60[N,S]+62V+ 
82V+89M 
67D+70K+101K+174[K,R]+184M+200I+288A 
+294T+322T 
2003-11-12 138L+374A 10I+20R+35E+54I+ 
60S 
+62V+82V+89M 
67D+70K+101K+174[K,R]+184V+200[T,I,A,V] 
+288[A,S]+294T+322T 
2004-11-03 374T 10I+20R+35D+54V+ 
60S+62V+82A+89L 
67N+70R+101E+174K+184M+200I+288A+294P 
+322A 
 
407 01_AE 2009-11-02 374V+387R 
+451S+453P 
79P 11K+184I+200A+281R+286A+ 
304[E,A]+325L+326I 
2010-03-22 374A+387K 
+451G+ 
453EPTAPP 
79H 11[K,T]+184[I,M]+200[A,V]+281K+286[T,A] 
+304A+325I+326V 
 
652 02_AG 2008-01-31 420G 20I 11R+27[T,S]+35I+106V+207G+276I+291D+292I 
+294T+311R 
2008-08-19 420A 20I 11[K,Q,R]+27T+35[T,I]+106[I,V]+207[E,G] 
+276[I,V]+291[E,D]+292[I,V]+294[T,P]+311[K,R] 
For the first sequence, PI/RTI drug resistance mutations, detected by the drug 
resistance interpretation algorithms HIVdb v7.0 [41] and/or Rega V9.1 [42], are 
colored red. The other protease and RT variants are indicated in black. Ambiguous 
nucleotide letters are decomposed and translated into amino acids, which are indicated 
by brackets. Gag substitutions and PI/RTI resistance mutations with therapy changes 
are mapped in Figure 4.1. “na” indicates that the sequence does not cover the 
corresponding position. 
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Figure 4.1: Gag substitutions and PI or RTI resistance mutations in 12 patients 
from the Leuven cohort. Each subplot shows the data of one patient regarding the 
viral load, the treatment period and the emerging Gag substitutions and the PI/RTI 
resistance mutations. X- and Y-axes indicate the time (weeks) and the level of plasma 
HIV RNA (log10 copies/mL), respectively. For each subplot, red dots indicate the 
level of viral load and the dash line indicates the viral load cutoff at 50 copies per mL. 
Beneath the viral load plot, each treatment period is annotated by a colored bar with 
vertical black lines indicating the sequence sampling time. The blue, pink, green and 
yellow bars show PI-based treatments containing LPV/r, FPV/r, ATV/r and DRV/r, 
respectively. The grey bar indicates treatments lacking PIs. Multiple substitutions or 
mutations are shown using the plus symbol “+”. Amino acids translated from 
ambiguous nucleotide letters are indicated by brackets. For patient 343, the insertion 
EPTAPP at position P453 is annotated as P453Ins. For patient 1075, the sets of PI or 
RTI resistance mutation are abbreviated (Mut 1-4) and listed in the subplot. Table 4.3 
provides the full list of Gag, protease and RT substitutions in these 12 patients. 
 
For our second analysis, we compiled a comprehensive list of 93 Gag substitutions at 
55 positions in B and non-B subtypes observed in PI-treated patients, based on 
literature results or our first analysis as described above (Table 4.1, Table 4.2). Next, 
we systematically evaluated the prevalence of these variants in major HIV-1 subtypes 
using 10865 full-length Gag sequences retrieved from the HIV Los Alamos database 
(one sequence per patient) (Table 4.4). Sequence alignment and quality control have 
been described previously [43]. We found that the prevalence of 62 (66.7%) Gag 
variants at 39 positions was above 1% in at least one subtype or CRF (A1, B, C, D, F1, 
G, CRF01_AE, CRF02_AG). Among the 55 Gag positions, only 363 and 455 were 
highly conserved with less than 1% overall amino acid variation in every subtype and 
CRF in our dataset (Figure 4.2A). Moreover, 77 of these 93 variants (82.8%) were 
found at 42 positions located in the Gag C-terminal domain (positions: 362-500). 
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Figure 4.2: Prevalence of Gag amino acid variants reported in patients failing 
PI-based therapies and their mapping to HIV-1 protein structures.  
(A) Prevalence of amino acid variations at 55 Gag positions in 8 HIV-1 subtypes (A1, 
B, C, D, F1, G, 01_AE and 02_AG) given the Los Alamos full-length Gag sequence 
dataset (Table 2). Only Gag positions where amino acid substitutions have been 
observed during PI-based treatment are shown. For each position, the HXB2 index is 
shown at the top, followed by the most prevalent amino acids (bold) and amino acid 
variations in our sequence datasets. Amino acids with blue superscripts have 
prevalence above 10% and other amino acids have orange superscripts.  
(B) Structural representation of Gag polyprotein and mapping of the 13 PI-associated 
Gag substitutions identified in Table 3. The annotation of Gag polyproteins is shown 
at the top. Individual Gag protein structures are shown at the bottom. Gag 
substitutions are annotated and colored accordingly. Red surfaces indicate PI-
associated Gag substitutions at the Gag C-terminal domain; other substitutions are 
shown in green. PDB data of Gag protein structures: matrix, 1HIW; capsid, 3NTE; p2, 
1U57; nucleocapsid, 2M3Z; p6, 2C55. Visualization software: PyMOL V1.5 
(http://www.pymol.org/). 
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As treatment information of the 10865 full-length gag nucleotide sequences was 
largely lacking, our third analysis aimed to evaluate whether these 93 Gag variants 
were significantly associated with genotypic PI resistance. Among the 11613 
sequences pooled from the Leuven and the Los Alamos datasets (Table 4.4), 6645 
spanned both the gag and the full-length protease regions, and were translated into 
amino acid sequences for our analysis. Using the drug resistance interpretation 
algorithms HIVdb V7.0 [41] and Rega V9.1 [42], 660 sequences were concordantly 
estimated to be partially or fully resistant to at least one PI, and 5657 sequences were 
concordantly estimated to be fully susceptible to all PIs (Table 4.5). Sequences with 
discordant estimates of PI susceptibility were excluded from our analysis. Fisher’s 
exact tests were then used to compare the amino acid prevalence between these PI-
susceptible and PI-resistant datasets. Of the 93 Gag variants, 16 at 13 amino acid 
positions were associated with (partial or full) PI resistance in at least one HIV-1 
subtype (p-value < 0.05, Table S4.1). After multiple testing correction using the false 
discovery rate approach described in [44], 13 Gag variants at 10 positions remained 
significantly PI-associated within individual subtypes (adjusted p-value < 0.05), 
including 11 variants located in the Gag C-terminal domain (Figure 4.2B, Table 4.6). 
Our analysis successfully identified the known PI-associated Gag substitution A431V, 
strengthening the validity of our approach. As the only PI-associated Gag substitution 
found in more than one subtype, A431V had a high prevalence in the PI-resistant 
strains of subtype B (13.5%) and CRF01_AE (18.2%) (Table 4.6). Interestingly, of 
the 21 Gag substitutions observed in our first analysis, K415R and S451G were newly 
identified to be significantly associated with genotypic PI resistance in subtypes C and 
B respectively, suggesting a possible involvement in PI-resistance. 
Table 4.4: Summary of Leuven and Los Alamos sequence datasets. 
Subtype 
Los Alamos dataset Leuven dataset Total 
number of 
patient 
 Number of Gag 
sequence * 
Number of Gag 
sequence 
Number of PI-
naïve patient 
Number of PI-
treated patient 
A1 1648 167 72 19 1739 
B 4131 639 313 57 4501 
C 2780 198 58 24 2862 
D 443 42 20 9 472 
F1 35 38 25 4 64 
G 49 1 1 0 50 
J 3 8 1 2 6 
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01_AE 1714 72 45 5 1764 
02_AG 62 139 71 22 155 
Total 10865 1304 606 142 11613 
*: Number of Gag sequences in different HIV-1 subtypes (one sequence per patient). 
Table 4.5: Summary of PI-resistant and PI-susceptible sequence datasets 
Subtype 
Number of PI-susceptible 
gag-protease sequences * 
Number of PI-resistant 
gag-protease sequences # 
Total 
A 185+72=257 6+3=9 266 
B 1820+313=2133 434+31=465 2598 
C 1728+58=1786 119+18=137 1923 
D 98+20=118 1+0=1 119 
F 21+25=46 3+0=3 49 
G 33+0=33 14+0=14 47 
01_AE 1112+45=1157 22+2=24 1181 
02_AG 55+71=126 3+4=7 133 
Total 5657 660 6317 
*: Number of PI-susceptible Gag-protease sequences used in this study. These 
sequences were amino acid sequences translated from nucleotide sequences obtained 
from the Los Alamos + Leuven datasets. PI-susceptible sequences were estimated to 
be fully susceptible to all PIs by both the HIVdb v7.0 [41] and the Rega V9.1 [42] 
algorithms. 
#: Number of PI-resistant Gag-protease sequences used in this study. These sequences 
were amino acid sequences translated from nucleotide sequences obtained from the 
Los Alamos + Leuven datasets. PI-resistant sequences were estimated to be partially 
or fully resistant to at least one PI by both the HIVdb v7.0 [41] and the Rega V9.1 [42] 
algorithms. All the Los Alamos sequences encode the full-length Gag polyprotein. 
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Table 4.6: Prevalence of PI-associated Gag substitutions in individual HIV-1 
subtypes. 
Gag substitutions 
* 
Subtype 
Prevalence 
#
 
P-value Adjusted 
p-value 
PI-resistant 
dataset 
PI-susceptible 
dataset 
V128I B 5.8%(7/121
&
) 0.9%(6/638) 0.002 0.024 
Y132F B 10.7%(13/122) 3.4%(22/639) 0.004 0.035 
K415R C 2.5%(3/119) 0.0%(0/1727) <0.0001 0.012 
Q430R C 2.5%(3/119) 0.1%(1/1727) 0.003 0.046 
A431V B 13.5%(23/170) 0.1%(1/787) <0.0001 <0.0001 
01_AE 18.2%(4/22) 0.7%(8/1111) <0.0001 0.007 
I437V B 8.9%(15/168) 1.7%(13/784) <0.0001 <0.0001 
L449F B 5.6%(21/377) 0.5%(7/1352) <0.0001 <0.0001 
L449V B 4.8%(18/377) 0.9%(12/1352) <0.0001 <0.0001 
S451G B 3.4%(13/378) 1.3%(17/1348) 0.008 0.041 
S451T B 2.1%(8/378) 0.0%(0/1348) <0.0001 <0.0001 
R452S B 3.4%(13/384) 0.3%(4/1374) <0.0001 <0.0001 
P453T C 21.8%(26/119) 3.1%(53/1722) <0.0001 <0.0001 
P453L B 18.5%(71/384) 7.1%(99/1399) <0.0001 <0.0001 
*: A list of Gag substitutions whose prevalence differs significantly between 
sequences estimated to be (fully or partially) PI-resistant and sequences estimated to 
be PI-susceptible (see full reports in Table S4.1). One-tailed Fisher’s exact tests were 
performed, and p-values were adjusted using multiple testing correction via the false 
discovery rate (FDR) approach [44]. 
#: Statistical analyses were only performed on individual subtype (B, C, G, 01_AE) 
datasets, which contained more than 10 (partially or fully) PI-resistant sequences. 
Table 4.5 summarizes the subtype distribution of PI-resistant and PI-susceptible 
sequence datasets. 
&: The numerator indicates the number of sequences for which the corresponding 
Gag position is covered; the denominator indicates the number of sequences 
displaying the respective amino acid substitutions. 
 
4.4 Discussion and conclusions 
To our knowledge, this study presents the first large-scale sequence analysis to 
establish statistical significance of PI-associated Gag substitutions in HIV-1 non-B 
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subtypes. Our longitudinal analysis of a clinical cohort of patients failing PI-based 
therapy confirmed that PI-treated patients developed more Gag substitutions than PI-
naïve patients. The majority of these Gag substitutions emerged in the context of pre-
existing or simultaneously acquired PI or RTI resistance mutations, confirming the 
important role of the known resistance mutations, while in some patients Gag 
substitutions emerged in the absence of resistance mutations (Figure 4.1, Table 4.3). 
Such Gag substitutions may therefore contribute to the virological failure of PI-based 
treatments. Based on two widely used genotypic interpretation algorithms, our 
comparative analysis found that only 13 (13.8%) of the 93 Gag substitutions emerging 
under PI selective pressure were significantly associated with genotypic PI resistance 
(Table 4.6). Particularly, the novel Gag substitutions K415R and S451G were 
identified in both our longitudinal and cross-sectional sequence analyses. This 
suggests that they may play a role in viral escape from PI selective pressure, partially 
contributing to the observed virological failure. Since virological outcome and 
treatment information is lacking for most sequences extracted from the HIV Los 
Alamos database, this limits our analysis to address the clinical impact of the newly 
identified substitutions with large-scale data.  
Using small cohorts, previous studies suggested that different subtypes may develop 
different Gag substitutions [6, 45, 46]. We confirmed this hypothesis since only 9 of 
the 58 Gag substitutions reported in non-B subtypes (Table 4.2) were also observed in 
subtype B (Table 4.1). Among non-B Gag substitutions, 4 were significantly 
associated with genotypic PI resistance, of which only A431V was PI-associated in 
subtype B as well (Table 4.6). However, further evaluations on subtypes A2, D, F2, J, 
K and other CRFs are still needed due to the restriction of our study to particular 
subtypes. Interestingly, a predominant presence of PI-associated Gag substitutions at 
the flexible C-terminal domain of Gag (Figure 4.2B) leads us to suggest the 
hypothesis that PI-associated Gag substitutions tend to emerge in the structural 
flexible regions. These Gag substitutions can emerge along with protease drug 
resistance mutations as shown in our longitudinal sequence analysis (Figure 4.1, 
Table 4.3) and previous studies [15, 18]. Future studies are still needed to investigate 
the significance of coevolution between Gag substitutions and protease resistance 
mutations. 
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Overall, our findings showed different PI-associated substitutions in the Gag C-
terminal domain across different subtypes, providing a roadmap to elucidate the role 
of Gag amino acid substitutions in the development of PI resistance. 
4.5 Additional table 
Table S4.1: Prevalence in individual HIV-1 subtypes of Gag amino acid variants 
observed during PI therapy.  
Gag amino 
acid 
variant 
Subtype 
* 
Amino acid prevalence 
p-value 
# 
Adjusted 
p-value PI-resistant 
dataset 
PI-susceptible 
dataset 
12E C 0.8%(1/119) 0.2%(4/1724) 0.286 1 
12K B 25.4%(31/122) 25.3%(158/624) 0.923 1 
62G C 1.7%(2/117) 0.2%(4/1700) 0.054 0.741 
62R B 4.1%(5/121) 4.1%(26/639) 0.599 1 
76K C 48.3%(57/118) 44.7%(769/1719) 0.999 1 
76R 01_AE 9.1%(2/22) 19.1%(212/1112) 0.958 1 
79F G 14.3%(2/14) 48.5%(16/33) 0.998 1 
79Y 01_AE 9.1%(2/22) 33.7%(374/1111) 0.999 1 
81A B 15.6%(19/122) 7.5%(48/639) 0.021 0.165 
81A 01_AE 4.5%(1/22) 10.9%(121/1112) 0.929 1 
125K B 4.1%(5/122) 1.6%(10/636) 0.087 0.559 
128A B 0.8%(1/121) 2.8%(18/638) 0.966 1 
128A G 15.4%(2/13) 9.7%(3/31) 0.532 1 
128I B 5.8%(7/121) 0.9%(6/638) 0.002 0.024 
128I C 7.7%(9/117) 11.8%(201/1709) 0.964 1 
128I G 15.4%(2/13) 0.0%(0/31) 0.101 1 
128I 01_AE 4.5%(1/22) 0.7%(8/1089) 0.172 1 
130R B 2.5%(3/122) 1.3%(8/639) 0.263 0.925 
130R G 7.1%(1/14) 0.0%(0/33) 0.313 1 
132F B 10.7%(13/122) 3.4%(22/639) 0.004 0.035 
132F G 21.4%(3/14) 0.0%(0/33) 0.035 0.925 
135I B 1.6%(2/122) 0.3%(2/657) 0.121 0.625 
135I C 0.8%(1/119) 0.2%(3/1728) 0.236 1 
135M B 0.8%(1/122) 0.0%(0/657) 0.158 0.694 
135M G 7.1%(1/14) 0.0%(0/32) 0.319 1 
138M B 10.7%(13/122) 8.4%(55/657) 0.369 1 
138M C 0.8%(1/119) 0.2%(3/1721) 0.236 1 
219Q B 28.1%(34/121) 21.2%(141/665) 0.458 1 
219Q C 9.2%(11/119) 18.3%(314/1715) 0.999 1 
219Q 01_AE 22.7%(5/22) 22.8%(253/1112) 0.768 1 
362I B 17.7%(22/124) 21.9%(149/680) 0.978 1 
362I C 2.5%(3/119) 1.6%(27/1727) 0.317 1 
362I G 21.4%(3/14) 0.0%(0/33) 0.035 0.925 
363F B 0.8%(1/124) 0.0%(0/680) 0.155 0.694 
364G C 0.8%(1/119) 0.1%(1/1728) 0.126 1 
370A B 17.8%(23/129) 14.7%(106/720) 0.491 1 
370I B 3.9%(5/129) 2.4%(17/720) 0.254 0.925 
370M B 4.7%(6/129) 6.1%(44/720) 0.83 1 
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370V 01_AE 36.4%(8/22) 31.3%(348/1111) 0.768 1 
373A B 4.9%(7/143) 4.8%(37/766) 0.6 1 
373Q B 0.7%(1/143) 2.0%(15/766) 0.938 1 
373S C 5.9%(2/34) 2.4%(27/1114) 0.229 1 
373T B 3.5%(5/143) 4.0%(31/766) 0.719 1 
374G B 2.8%(4/142) 1.1%(8/756) 0.114 0.625 
374G C 1.5%(1/65) 0.2%(1/591) 0.191 1 
374N B 8.5%(12/142) 5.4%(41/756) 0.168 0.706 
374P B 2.8%(4/142) 5.2%(39/756) 0.938 1 
374S B 1.4%(2/142) 3.0%(23/756) 0.929 1 
374T B 13.4%(19/142) 14.2%(107/756) 0.819 1 
374V B 0.7%(1/142) 2.5%(19/756) 0.97 1 
374V C 9.2%(6/65) 14.7%(87/591) 0.955 1 
375A B 28.0%(40/143) 17.2%(131/761) 0.089 0.559 
375A C 1.8%(2/111) 2.2%(34/1513) 0.727 1 
375N B 15.4%(22/143) 19.2%(146/761) 0.973 1 
375N B 15.4%(22/143) 19.2%(146/761) 0.973 1 
375S B 6.3%(9/143) 11.4%(87/761) 0.989 1 
375T C 0.9%(1/111) 0.5%(7/1513) 0.436 1 
375T G 14.3%(2/14) 0.0%(0/22) 0.171 1 
376A B 0.7%(1/144) 0.3%(2/763) 0.407 1 
376A G 15.4%(2/13) 3.0%(1/33) 0.227 1 
376M B 3.5%(5/144) 2.1%(16/763) 0.249 0.925 
376M C 2.5%(3/118) 0.3%(5/1724) 0.012 0.251 
376M G 7.7%(1/13) 3.0%(1/33) 0.512 1 
376V B 15.3%(22/144) 18.0%(137/763) 0.945 1 
376V C 9.3%(11/118) 6.8%(118/1724) 0.282 1 
376V G 23.1%(3/13) 12.1%(4/33) 0.412 1 
378V B 1.3%(2/153) 1.0%(8/769) 0.52 1 
378V C 0.8%(1/119) 0.9%(15/1726) 0.66 1 
380K B 29.4%(45/153) 25.0%(192/769) 0.771 1 
380K 01_AE 4.5%(1/22) 10.5%(117/1111) 0.922 1 
380R G 7.1%(1/14) 15.2%(5/33) 0.91 1 
381G C 22.7%(27/119) 18.1%(310/1714) 0.488 1 
381G G 28.6%(4/14) 24.2%(8/33) 0.688 1 
381S B 2.6%(4/153) 2.3%(18/770) 0.527 1 
382K B 1.3%(2/153) 1.2%(9/768) 0.575 1 
382K G 7.1%(1/14) 0.0%(0/33) 0.313 1 
387K B 4.6%(7/152) 5.5%(42/769) 0.764 1 
387R 01_AE 27.3%(6/22) 20.5%(223/1090) 0.526 1 
389N B 2.7%(4/150) 4.2%(32/758) 0.884 1 
389N C 4.4%(5/114) 2.1%(35/1682) 0.12 1 
389T C 9.6%(11/114) 17.8%(300/1682) 0.998 1 
389T G 8.3%(1/12) 0.0%(0/2) 0.867 1 
415R B 0.6%(1/169) 1.7%(13/786) 0.937 1 
415R C 2.5%(3/119) 0.0%(0/1727) <0.0001 0.012 
427P B 1.2%(2/168) 0.6%(5/784) 0.363 1 
427P C 0.8%(1/119) 0.0%(0/1725) 0.065 0.771 
430R C 2.5%(3/119) 0.1%(1/1727) 0.003 0.046 
430R G 15.4%(2/13) 0.0%(0/33) 0.093 1 
431V B 13.5%(23/170) 0.1%(1/787) <0.0001 <0.0001 
431V C 1.7%(2/119) 0.2%(4/1728) 0.054 0.741 
431V G 23.1%(3/13) 0.0%(0/33) 0.03 0.925 
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431V 01_AE 18.2%(4/22) 0.7%(8/1111) <0.0001 0.007 
435E B 0.6%(1/170) 0.0%(0/785) 0.179 0.715 
436R B 4.7%(8/170) 4.8%(38/787) 0.637 1 
436R C 3.4%(4/119) 4.1%(71/1724) 0.75 1 
436R G 15.4%(2/13) 15.2%(5/33) 0.716 1 
436R 01_AE 31.8%(7/22) 27.0%(300/1112) 0.702 1 
437V B 8.9%(15/168) 1.7%(13/784) <0.0001 <0.0001 
437V C 1.7%(2/119) 0.6%(11/1726) 0.208 1 
438R B 0.6%(1/170) 0.3%(2/787) 0.446 1 
449F B 5.6%(21/377) 0.5%(7/1352) <0.0001 <0.0001 
449I B 1.9%(7/377) 1.0%(13/1352) 0.132 0.644 
449P B 6.9%(26/377) 8.0%(108/1352) 0.871 1 
449P C 2.5%(3/119) 3.0%(52/1727) 0.716 1 
449V B 4.8%(18/377) 0.9%(12/1352) <0.0001 <0.0001 
451G B 3.4%(13/378) 1.3%(17/1348) 0.008 0.041 
451N B 13.0%(49/378) 14.7%(198/1348) 0.962 1 
451S C 42.0%(50/119) 38.5%(663/1721) 0.992 1 
451S G 14.3%(2/14) 6.1%(2/33) 0.395 1 
451T B 2.1%(8/378) 0.0%(0/1348) <0.0001 <0.0001 
452G B 0.8%(3/384) 0.1%(2/1374) 0.074 0.542 
452G G 7.7%(1/13) 0.0%(0/33) 0.298 1 
452K B 1.0%(4/384) 0.9%(13/1374) 0.535 1 
452S B 3.4%(13/384) 0.3%(4/1374) <0.0001 <0.0001 
453I B 0.8%(3/384) 0.2%(3/1399) 0.12 0.625 
453I G 15.4%(2/13) 0.0%(0/33) 0.093 1 
453Ins C 25.7%(35/136) 24.0%(413/1722) 0.3561 1 
453L B 18.5%(71/384) 7.1%(99/1399) <0.0001 <0.0001 
453L C 3.4%(4/119) 10.4%(179/1722) 0.999 1 
453T B 4.4%(17/384) 4.7%(66/1399) 0.699 1 
453T C 21.8%(26/119) 3.1%(53/1722) <0.0001 <0.0001 
453T 01_AE 40.9%(9/22) 14.1%(157/1112) 0.026 0.386 
469I B 3.1%(12/383) 2.9%(46/1570) 0.508 1 
469I C 1.7%(2/116) 1.1%(19/1660) 0.411 1 
469T G 14.3%(2/14) 0.0%(0/33) 0.102 1 
472P 01_AE 9.5%(2/21) 13.1%(121/927) 0.821 1 
472S B 0.9%(4/426) 1.6%(28/1795) 0.893 1 
472S C 1.8%(2/114) 7.6%(119/1560) 0.999 1 
474L B 0.5%(2/430) 0.3%(6/1811) 0.475 1 
474P B 0.7%(3/430) 1.7%(30/1811) 0.968 1 
474P 01_AE 4.5%(1/22) 21.2%(218/1028) 0.996 1 
486F B 0.2%(1/433) 0.5%(9/1806) 0.884 1 
486F C 0.8%(1/119) 0.1%(1/1728) 0.126 1 
*: We only examined the sequence datasets of subtypes B, C, G and CRF01_AE, 
which contained more than 10 sequences estimated to be partially or fully PI-resistant 
(see Table 4.5). 
#: One-tailed Fisher’s exact tests were performed on amino acid variants that occurred 
more than once in individual subtype datasets. For each HIV-1 subtype, the obtained 
p-values were adjusted using multiple testing corrections via the false discovery rate 
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approach (software: Matlab 2013a, also see reference [44]). Amino acid variants are 
colored dark gray if their p-values and adjusted p-values were less than 0.05. Amino 
acid variants are colored gray if their p-values were less than 0.05 but adjusted p-
values were above 0.05. Amino acid variants whose p-values are equal to 1 are not 
shown. 
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5.1 Summary 
A key challenge in the field of HIV-1 protein evolution is the identification of 
coevolving amino acids at the molecular level. In the past decades, many sequence-
based methods have been designed to detect position-specific coevolution within and 
between different proteins. However, an ensemble coevolution system that integrates 
different methods to improve the detection of HIV-1 protein coevolution has not been 
developed. We integrated 27 sequence-based prediction methods published between 
2004 and 2013 into an ensemble coevolution system. This system allowed 
combinations of different sequence-based methods for coevolution predictions. Using 
HIV-1 protein structures and experimental data, we evaluated the performance of 
individual and combined sequence-based methods in the prediction of HIV-1 intra- 
and inter-protein coevolution. We showed that sequence-based methods clustered 
according to their methodology, and a combination of four methods outperformed any 
of the 27 individual methods. This four-method combination estimated that HIV-1 
intra-protein coevolving positions were mainly located in functional domains and 
physically contacted with each other in the protein tertiary structures. In the analysis 
of HIV-1 inter-protein coevolving positions between Gag and protease, protease drug 
resistance positions near the active site mostly coevolved with Gag cleavage positions 
(V128, S373-T375, A431, F448-P453) and Gag C-terminal positions (S489-Q500) 
under selective pressure of protease inhibitors. This study presents a new ensemble 
coevolution system which detects position-specific coevolution using combinations of 
27 different sequence-based methods. Our findings highlight key coevolving residues 
within HIV-1 structural proteins and between Gag and protease, shedding light on 
HIV-1 intra- and inter-protein coevolution. 
5.2 Introduction 
Recent structural analysis showed that the fullerene core of HIV-1 particles is formed 
by capsid hexamers and pentamers through both intra- and inter-protein interactions 
[1]. HIV-1 capsid protein is encoded by the gag gene, which contains matrix, capsid, 
p2, nucleocapsid, p1 and p6 domains. In a spherical shell of an immature virus, Gag 
polyproteins are arranged radially in a curved hexameric lattice bound together by 
protein interactions [2]. The HIV-1 matrix and capsid proteins are cleaved from Gag 
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and reorganized into tubular lattices of mature particles during the protease-mediated 
proteolytic processing [3]. Mutations near Gag cleavage sites (GCS) can affect the 
protease binding affinity [4], suggesting that HIV-1 intra- and inter-protein 
interactions play a key role during the viral life cycle. Previous sequence analyses 
have reported the association between human HLA alleles and Gag codons [5], intra-
protein coevolution in capsid [6] and immunologically vulnerable sectors in Gag [7]. 
However, a systematic study of HIV-1 intra- and inter-protein coevolution of Gag and 
protease proteins is largely lacking. 
Many studies have revealed position-specific coevolution in HIV-1 proteins using 
sequence-based methods [5, 6, 8-12]. For instance, coevolving positions were found 
to be proximal in capsid structure [6]. HIV-1 drug-resistance mutations in protease, 
reverse transcriptase and integrase tend to coevolve under the drug selective pressure 
[8-10, 13]. Important coevolving residues were also found in HIV-1 Env [11], Vif 
[12] and Gag [5]. To model coevolution within and between proteins [11, 14, 15], 
position-specific sequence analysis has been used to detect pairs of correlated amino 
acid positions, so-called statistical couplings [16] (also called co-variations [17] or 
correlated substitutions [18]). A deep understanding of genetically coevolving 
residues has enriched our insights in protein folding [17], protein-protein interaction 
[19], allosteric communication [20] and ligand binding [21] (see review [22]). Since 
the first sequence-based method was proposed in 1970 [23], more than 30 methods 
were published and most of them were based on the principle of information theory, 
physicochemical properties, molecular phylogenetics and Bayesian statistics [15, 22, 
24] . Thanks to the increase of crystalized structures in public databases, the 
performance of sequence-based methods is usually evaluated based on structural 
information, such as protein contact map [25], because spatially proximate positions 
tend to coevolve [26] and sequence evolution is associated with structural dynamics 
[27]. Nevertheless, state-of-the-art methods in different studies showed significant 
variability, while evaluation of long-range coevolving residues continues to be 
difficult in most scenarios [15, 22, 24] . 
The supervised ensemble approach in statistics and machine learning aims at creating 
a robust method through the integration of multiple predictive models [28]. It relies on 
the philosophy that the aggregation of information from several sources is usually 
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superior to a single individual source for decision-making (e.g. jury, peer-review, 
voting for political candidates) [28]. Well-known ensemble methods such as random 
forest [29] and AdaBoost [30] provide robust predictions with outstanding 
performance in many applications. Other ensemble methods have also been designed 
for solving various problems [31-33]. For instance, the ensemble machine system 
XCS was made to improve self-adaptation of evolutionary algorithms [31]. While 
more than 27 sequence-based methods have been proposed for position-specific 
coevolution prediction, an ensemble coevolution system that integrates multiple 
methods to improve the prediction of HIV protein coevolution has not been 
investigated. 
Here, we present the first ensemble coevolution system (ECS) to detect HIV-1 
position-specific coevolution by integrating 27 sequence-based methods published 
between 2004 and 2013 (Table 5.1). This new software platform allows for parallel 
coevolution predictions and systematic combinations of sequence-based methods. We 
collected extensive HIV-1 sequences and experimental and clinical data to evaluate 
the performance of individual methods and combinations of methods. Using our 
coevolution system, we identified combinatorial approaches with superior 
performance at predicting HIV-1 coevolution. We thereafter investigated intra- and 
inter-protein coevolving positions in HIV-1 Gag and protease using an optimized 
combinatorial approach that integrated four sequence-based methods. 
Table 5.1: Summary of 27 sequence-based methods in our ensemble coevolution 
system. 
Methods* Statisitcal methodology Updated Ref 
ASC/APC Mutual information 2007 [34] 
BN Bayesian network 2007 [35] 
CTMP Continuous-time Markov model, phylogenetic tree 2007 [36] 
CoMap Compensation coefficient, phylogenetic tree 2007 [37] 
Complementary AA complementary matrix, Pearson coefficient 2006 [38] 
CMPro 2D recursive neural networks 2012 [39] 
DCA Maximum entropy model 2011 [25, 26] 
DNcon Deep network, Bolzmann machines 2012 [40] 
GREMLIN Maximum entropy model 2013 [41] 
Interdependency Entropy, mutual information 2004 [42] 
LogR Bayesian networks, APC 2010 [43] 
MI Mutual information 2012 [44-46] 
MIBP Mutual information,physicochemical properties 2011 [47] 
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Mutagenetic Maximum likelihood mixed trees 2005 [10] 
NBZPX2 Normal binary, ZRES 2012 [46] 
NCPS Mutual information, sequence similarity 2009 [48] 
NNcon Neural networks 2009 [49] 
PCC Mutual information, Pearson’s coefficients 2010 [18] 
PSICOV Sparse inverse covariance 2012 [50] 
PhysicoMI Mutual information, physicochemical properties 2012 [6] 
PhyCMAP Random forest, integer linear programming 2013 [51] 
RCW Mutual information 2007 [52] 
Spidermonkey MCMC Bayesian network, phylogenetic tree 2008 [53] 
SCA Statistical free energy couplings 2009 [54] 
SVMcon Support vector machine 2006 [55] 
ZRES Mutual information 2009 [56] 
*: A comprehensive description of the methodology and our experimental settings are 
provided in section 2 of Text S1. 
 
5.3 Materials and Methods 
HIV-1 protein sequence datasets for sequence-based coevolution prediction 
As of February 2013, we retrieved 3171 HIV-1 subtype B gag and protease nucleotide 
sequences from the Los Alamos HIV database (http://www.hiv.lanl.gov) (HXB2 
nucleotide positions: 1186-2549, one sequence per patient). For each Gag and 
protease protein, we aligned sequences against the HXB2 reference and manually 
curated the alignment using Seaview V4.3 [57]. To improve sequence quality, we 
used the criteria described in our recent study [58] to remove duplicates and 
sequences with any hypermutation, stop codon, ambiguous nucleotide or subtype 
misclassification. Afterwards, patient treatment information of the retrieved sequences 
was obtained from the corresponding sequence publications. Sequence data obtained 
from treatment-naive patients were used to detect intra-protein statistical couplings 
given that wild-type HIV-1 protein structures were used for evaluation. Sequence data 
obtained from patients receiving protease inhibitor (PI) treatment were used to detect 
inter-protein statistical couplings given that HIV-1 clinical datasets with PI treatment 
information were used for evaluation. Overall, we obtained five intra-protein 
sequence datasets: matrix (n=605), capsid (n=656), nucleocapsid (n=768), p6 
(n=1030), protease (n=1762), as well as two inter-protein sequence datasets, protease-
p6 (n=788) and protease-GCS (Gag cleavage sites) (n=292). 
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Sequence-based statistical methods for position-specific coevolution predictions 
We integrated 27 known sequence-based statistical methods (Text S1) into one 
software platform for position-specific coevolution predictions. Summarized in Table 
5.1, these methods were mainly designed based on the principles of information 
theory, phylogenetic analysis, parametric or non-parametric statistical tests, Bayesian 
maximum likelihood and codon substitution models. Given the inputs of multiple 
sequence alignments (MSAs) and phylogenetic trees, sequence-based methods predict 
coevolving residues and rank them according to the method-specific measurements 
with either parametric or non-parametric statistical tests (Text S1). The predictions 
were ranked according to each method. Parameter settings used in our study were 
either default or optimized according to method manuals or publications (Text S1). 
To prepare the inputs of the phylogenetic-based methods, we constructed unrooted 
maximum likelihood phylogenetic trees using the following procedure. Given the 
nucleotide MSAs, neighbor-joining phylogenetic trees were obtained by IQPNNI V 
3.3 [59] (nucleotide substitution model: general time reversible (GTR) model, 
bootstrap resampling: 1000 replicates). These neighbor-joining phylogenetic trees 
were used as starting trees in RAxML V7.0.4, which subsequently optimized the 
unrooted maximum likelihood phylogenetic trees (nucleotide substitution model: 
GTRGAMMA, 100 bootstrap replicates) [60]. 
 
HIV-1 protein structural and experimental datasets for evaluating predictive 
performance of sequence-based methods 
We retrieved PDB data of HIV-1 proteins from the RCSB Protein Data Bank 
(www.pdb.org). The quality of crystalized structures was assessed using 
PDBREPORT [61] (default parameters). The PDB dataset included: 1HIW (matrix), 
3H4E (capsid), 1A1T (nucleocapsid), 2C55 (p6) and 1TW7 (protease). We also 
collected extensive experimental and clinical data of PI-associated Gag-protease 
mutations from literature, which was queried in PubMed using the keywords “HIV 
Gag mutation”, “HIV Gag protease”, “HIV protease mutations Gag”, “HIV Gag 
evolution” or “HIV protease cleavage”. References in primary studies and reviews 
were also searched. The data is summarized in Table S 5.1. 
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True positives for intra-protein coevolving positions were assessed according to their 
proximity in protein contact maps. To construct contact maps for each protein, 
Euclidean distances between the Cβ atoms of residue pairs were calculated given the 
atomic coordinates in PDB [51]. In cases where a HIV-1 protein has multiple 
functional domains (e.g. matrix, capsid, protease), Euclidean distances between 
residue pairs were calculated within and between functional domains and the 
minimum value for each pair was used for assignment [25]. The predicted intra-
protein couplings were assigned as true positives if they were long-range pairs of 
residues in contact: (1) at least 6 amino acids apart in the sequence [51]; (2) not 
located at the same alpha-helix or beta-strand secondary structures [49] and (3) less 
than 8 Å between residue pairs on the protein contact map [25]. The predicted intra-
protein couplings, which had residues less than 6 amino acids apart in the sequence or 
were located in the same alpha-helix or beta-strand secondary structures, were not 
counted during the evaluation. Above criteria were set to evaluate long-range 
coevolving positions in protein tertiary structures by not counting predictions of 
neighboring AA positions. 
For the protease-p6 and protease-GCS coevolution, the predicted inter-protein residue 
pairs were considered as true positives if any corresponding Gag-protease mutation 
patterns were reported in the experimental and clinical datasets (Table S 5.1). For 
each row of multiple residue patterns in Table S 5.1, pairwise combinations of 
protease-p6 or protease-GCS residues were used for the validation of true positives. 
For both intra- and inter-protein predictions, false positives were the couplings in the 
top-ranked long-range predictions that were not identified as true positives. We did 
not evaluate negative predictions because the sequence-based methods were not 
designed to predict residue positions that are not coevolving [22]. 
 
Statistical measurements for method evaluation 
Predictions of sequence-based methods were evaluated by five statistical 
measurements.  
Precision-recall curve (AUC): For intra- and inter-protein coevolution predictions, 
we assessed the area under the precision-recall curve (AUC) [62] as the relative 
effectiveness of sequence-based methods. Optimized by the binomial model, an 
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unbiased estimator of AUC was calculated by taking into account biases introduced 
by small sample sizes and class imbalance in favor of negative examples [62]. 
Notably, AUC is independent of the cutoffs of the top-ranked long-range couplings 
and is equal to one if all the true positives are ranked higher than the false positives. 
Accuracy: For intra- and inter-protein coevolution predictions, accuracy was 
calculated as the number of true positives divided by the total number of top-ranked 
predictions [40, 55, 63]. Particularly, the accuracy of the L/2 or L top-ranked 
predictions was evaluated, where L was the number of residue positions in the MSA 
input. In most instances, the cutoff for positive predictions of coevolving pairs of 
residues or couplings was set to the L top-ranked couplings. In some instances 
(mentioned specifically), it was set to the L/2 top-ranked predictions [63]. Thus, 
positive predictions for coevolution are the L top-ranked couplings, unless it is 
specified that L/2 is used as a cutoff. 
Harmonic distance: For intra-protein coevolution predictions, the harmonic distance
dX was measured as a weighted harmonic average difference between the Euclidean 
distance distribution of the predicted couplings and the all-pair Euclidean distances 
[51, 63]. Being popular in Critical Assessment of Protein Structure Prediction 
(CASP), the harmonic distance dX  is defined as:
15
1
( ( ) ( )) /d n nnX P d P a n  , 
where ( )nP d  is the percentage of predicted couplings with Euclidean distances 
between 4(n−1) and 4n, ( )nP a  is the percentage of all contact pairs with Euclidean 
distances between 4(n−1) and 4n [51]. A higher value of the harmonic distance dX  
indicates a better prediction performance of a method. 
Average Euclidean distance: For intra-protein coevolution predictions, average 
Euclidean distance was measured for the top-ranked long-range couplings using the 
Cβ-Cβ Euclidean distances [25]. It is defined as: 
1
( , ) /
L
i ii
Dist C C L
 , where L is the 
number of top-ranked couplings, iC  and iC  are two residue positions in the i
th
 top-
ranked long-range coupling. For evaluation purposes, the number of top-ranked 
couplings predicted by individual methods was set to L/2 or L [63]. A lower value of 
average Euclidean distance indicates better prediction performance of a method.  
Chapter 5: Ensemble coevolution system 
  
178 
Jaccard and association coefficients: To quantify the predictive heterogeneity of 
sequence-based methods, Jaccard and association coefficients were calculated 
between the top-ranked long-range couplings predicted by different sequence-based 
methods. Given two coupling sets X and Y, Jaccard and association coefficients are 
defined as | |/X Y X Y   and |/ min )( , || |X Y X Y , respectively [64]. 
 
 
 
Figure 5.1: Schematic view of ensemble coevolution system 
(A) Workflow of coevolution prediction. Input data: a multiple sequence alignment 
dataset Dj and one phylogenetic tree constructed using Dj. (1) Preprocessing of input 
Chapter 5: Ensemble coevolution system 
  
179 
datasets, the method-specific input formats are preprocessed and imported into 
individual sequence-based methods ( 1,..., 27)iM i  . (2) Execution of sequence-based 
methods, sequence-based methods are applied to predict coevolving positions using 
the parallel computation. Each method predicts a list of coevolving positions with 
estimated coevolution scores. Given the sequence-based method Mi and the sequence 
dataset Dj, coevolution scores of coevolving positions are normalized and exported 
into the matrix C*(Mi, Dj). (3) Combiner, given a chosen combination of sequence-
based methods, coevolution scores of predicted coevolving positions are assembled 
through the combiner, which provides the assemble strategies such as majority voting, 
Borda count and weighted voting. Coevolving positions are ranked and exported as 
outputs with corresponding coevolution scores. 
(B) Workflow of our procedures that optimize the combination of sequence-based 
methods. Input data: inputs of multiple MSAs are processed by sequence-based 
methods (see (A)). The validation datasets (e.g. experimental and clinical data) are 
also prepared for the method evaluation. Coevolution scores of ranked coevolving 
pairs in C(Mi, Dj) are collected after applying the sequence-based method Mi to the 
sequence dataset Dj. (1) Linear transformation, the coevolution scores are linearly 
transformed between 0 and 1. (2) Ensemble learning, a heuristic algorithm identifies 
the combination of sequence-based methods with improved prediction performance 
(Text S1). Each circle represents a single method and the combination of different 
methods is demonstrated in a group of colored circles. Using the validation datasets, 
prediction performance is evaluated (e.g. AUC) for the ranked statistical couplings 
assembled from the corresponding method combination. When adding a new method 
will not improve the prediction performance, the learning procedure stops and an 
optimized method combination is identified. Using the identified method combination, 
coevolving pairs are predicted as in (A) and returned as outputs. 
(C) Correlation-based networks of sequence-based methods. Seven major 
methodologies are summarized, including mutual information, machine learning 
(random forest, support vector machine, neural networks), Pearson coefficient, 
entropy theory, graphical models (Bayesian networks, singly connected spanning 
trees, mutagenetic trees), phylogenetic models and physicochemical property models. 
Methods are represented by cones (see abbreviations in Table 5.1) and the same color 
is given to sequence-based methods designed from similar methodologies (e.g. APC 
used MI as a part of its design, phylogenetic trees are used in Spidermonkey, CTMP 
and CoMap). 
 
Ensemble coevolution system (ECS) 
To provide robust position-specific coevolution predictions, we designed an ensemble 
coevolution system by integrating 27 sequence-based methods published in the last 
decade (Table 5.1). Inspired by the ensemble principle [65], ECS’s workflow 
includes: (1) inputs of MSAs and their corresponding phylogenetic trees, (2) 
execution of sequence-based methods, (3) a method combiner which integrates 
prediction results from different methods. Figure 5.1A shows the schematic overview 
of ECS and its model is described as follows. Suppose we have a set of sequence-
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based methods, denoted as 1 2{ , ,..., }NM M M M  and multiple sequence datasets, 
denoted as: 1{ ,..., }TD D D , where N is the number of methods (N = 27 in our study) 
and T is the number of sequence datasets (T = 7 in our study).  
Execution of sequence-based methods: Given a dataset jD , the method iM  
quantifies a coevolution score for the statistical coupling between the n
th
 and the m
th
 
positions ( , {1,..., }n m L ), where L is the number of amino acid positions in jD . The 
higher the score, the higher the statistical significance based on the method-specific 
measurements. This process generates a scoring matrix ( , )i jC M D  which has at most 
L×L pairs. The coevolution scores in ( , )i jC M D  are then linearly transformed 
between 0 and 1 ( *( , ) [ ( , ) min( )] / [max( ) min( )]i j i jC M D C M D C C C   ), where the 
higher the score, the higher the statistical significance. For each MSA evaluated by 
each method, the normalized coevolution scores in the scoring matrix are ranked with 
the highest score being the top ranked (see section 2 in Text S1). 
Method combiner: Users can choose any individual methods to combine, or use 
three implemented assemble strategies (majority voting, Borda count, weighted 
voting)[65]. For the majority voting, the combiner outputs the predicted coevolving 
residues if they were predicted in the (L or L/2) top-ranked predictions by more than 
half of the 27 sequence-based methods. For the Borda count, the combiner outputs 
only the coevolving residues if they were predicted in the (L or L/2) top-ranked 
coupling predictions by all the 27 sequence-based methods. For weighted voting, 
ranking is done after collecting the weighted votes. The weighted votes are collected 
as follows: 
Suppose a combination of methods is denoted by Ω, | |  is the number of methods in 
the method combination  , and iw is the weight of sequence-based method iM  
contributed to the coevolution scores. All methods contribute equally when every iw
equals to 1. The normalized coevolution scores *, ( , )n m jC D  is defined as: 
* *
, ,
1
( , ) ( , )
| |
i
n m j i n m i j
M
C D w C M D

  

  
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*
, ( , )n m jC D is thereafter ranked and exported as outputs. Notably,   can either 
contain a single method or a combination of methods, which can be selected based on 
the performance evaluation (see next section).  
Identification of method combinations using a heuristic algorithm 
Using validation datasets to evaluate the method performance, we proposed a 
heuristic algorithm to optimize a method combination. Given a performance 
measurement f  (e.g. AUC), 
* ,( ( ))jf DC   
measures the statistical performance of 
the method combination  applied to the dataset jD . To identify an optimized 
combination of methods, an objective function ( , )F D  is defined by a linear 
function [66]: 
*
,
1
( , ) ( , ))(
T
j n m j
j
F D u C Df

     
Where ju  is the weight of the training dataset jD contributed to the objective function. 
All datasets are treated equally if every ju equals to 1.  
Based on the objective function, an optimized combination of methods, denoted as 
 , is obtained by max ( , )
M
F D

   . Given the 27 known sequence-based methods, 
we aimed at identifying a method combination  to achieve a high prediction 
performance, preferably combining only a small number of methods. The reason for 
this is twofold. Firstly, some coevolution methods are computationally heavy. 
Secondly, it is hard to implement and apply an ensemble system integrating many 
complex methods. To simplify the optimization procedure, we also assumed that all 
training datasets contributed equally ( 1ju  ) and sequence-based methods contribute 
equally in a method combiner when selected ( iw equals to 1 or 0). Inspired by the 
forward selection and backward elimination approach [67], we designed a heuristic 
algorithm to identify the smallest method subset that maximizes the objective 
function. Text S1 clarifies this heuristic algorithm with more mathematical details. 
Here we provide an overview of the underlying principle. 
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Our heuristic algorithm begins with the independent predictions of the 27 sequence-
based methods applied on the MSA inputs (Figure 5.1B). For each method with a 
MSA input, statistical couplings in the scoring matrix are ranked according to the 
method-specific significance measurements (Text S1, Section 2). In the next step, the 
forward selection each time visits all methods but only adds the method with the 
largest increase in performance into the method subsets and assembles the coupling 
predictions for evaluation. The procedure ends when adding a method does not further 
improve the best performance score. Similar to forward selection, the backward 
elimination is performed (see Text S1). To evaluate the performance of the score, 
AUC is used because it is a statistical measurement independent of the cutoffs of the 
top-ranked predictions. 
 
5.4 Results 
Estimate HIV-1 coevolution using a new ensemble coevolution system (ECS) 
From the Los Alamos database, we retrieved 3171 nucleotide sequences of HIV-1 
subtype B Gag and protease, resulting in five intra-protein datasets (matrix, capsid, 
nucleocapsid, p6, protease) and two inter-protein datasets (protease-p6, protease-
GCS). We calculated protein contact maps based on the Euclidian distance between 
amino acids in the protein structures of matrix, capsid, nucleocapsid, p6 and protease. 
A Euclidian distance of less than 8 Å between residue pairs was considered as a 
biological measure of intra-protein coevolution [25]. We also performed a literature 
search of associated Gag and protease residues to identify inter-protein couplings 
confirmed by experimental and clinical studies. These data obtained from protein 
structure and literature review was used to validate true positive predictions of 
statistical couplings generated by sequence-based methods. We then designed an 
ensemble coevolution system (ECS) which integrates 27 sequence-based methods 
published between 2004 and 2013 (Figure 5.1, Table 5.1). Thereafter, we designed a 
heuristic algorithm to optimize the combination of sequence-based methods, which 
were evaluated by AUC (see Methods). Given our seven HIV-1 sequence datasets, 
this heuristic algorithm identified an optimized method combination, so-called CNPR, 
for the prediction of HIV-1 intra- and inter-protein coevolution (see section 1 of Text 
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S1). This CNPR combination comprised of four known methods (CMPro [39], NCPS 
[48], PhyCMAP [51] and RCW [52]), weighted equally (see section 1 in Text S1). 
 
CNPR outperforms 27 known sequence-based methods in detecting HIV-1 
coevolution 
We found that CNPR outperformed each of the 27 sequence-based methods in the 
prediction of HIV-1 intra- and inter-protein coevolution using four statistical 
measurements (Figure 5.2A). All the 27 methods and the CNPR combination were 
evaluated and ranked for 7 HIV-1 sequence datasets, displayed in Figure 5.2A. 
Firstly, CNPR achieved the best average ranking (2.07) followed by CMPro (5.71) 
and PhyCMAP (6.87) based on the AUC measurement (Table S 5.2). Secondly, 
CNPR achieved the highest average accuracies for both the L/2 and L top-ranked 
predictions (average accuracy = 0.35, 0.27, respectively) (Table S 5.2). Comparing 
CNPR to the second best method NNcon, average accuracies for the L/2 and L top-
ranked predictions increased by 0.061 (17.6%) and 0.031 (11.5%), respectively 
(Table S 5.2, Table S 5.3). Thirdly, we measured the harmonic distance Xd on the 
five intra-protein datasets. CNPR reached the second (Xd = 0.78) and the first ranking 
(Xd=0.66) on the L/2 and L top-ranked predictions, respectively (Table S 5.2, Table 
S 5.4). Fourthly, the L top-ranked long-range predictions of CNPR had the lowest 
average Euclidean distances (mean Euclidean distance: 11.52Å, 95% confidence 
interval: 4.64-20.85Å, Figure 5.2B). The L/2 top-ranked long-range predictions of 
CNPR had the second lowest average Euclidean distances (mean Euclidean distance: 
10.14Å, 95% CI: 4.53-17.43Å). 
 
Table 5.2: Performance of sequence-based methods in detecting HIV-1 protein 
coevolution 
Method Area-under-curve (AUC)  Accuracy Harmonic distance Euclidean distance 
MA CA NC p6 PR p6-PR CSM-PR  L/2 L L/2 L L/2 L 
APC 0.57 0.55 0.59 0.71 0.57 0.62 0.66 0.108 0.086 0.039 0.027 17.38 18.6 
ASC 0.56 0.53 0.59 0.75 0.59 0.63 0.62 0.15 0.117 0.051 0.028 16.41 18.69 
BN 0.71 0.55 0.62 0.69 0.75 0.54 -* 0.059 0.052 0.009 0.008 19.94 20.13 
CMPro 0.75 0.66 0.85 0.76 0.74 0.68 0.72 0.289 0.225 0.166 0.13 10.05 11.77 
CTMP 0.54 0.52 - - 0.57 0.69 - 0.033 0.033 0.004 0.004 16.98 16.98 
CoMap 0.52 0.52 0.61 - 0.55 - 0.5 0.039 0.043 0.029 0.029 16.85 17.14 
Complementary 0.52 0.52 0.57 0.54 0.53 0.53 0.55 0.04 0.047 0.008 0.003 19.08 20.01 
DCA 0.55 0.55 0.59 0.78 0.51 0.64 0.67 0.092 0.071 0.03 0.023 17.43 18.45 
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DNcon 0.5 0.51 0.66 - 0.61 - 0.77 0.165 0.113 0.093 0.07 13.66 15.11 
GREMLIN 0.56 0.54 0.6 0.81 0.6 0.6 0.63 0.138 0.095 0.04 0.024 17.14 18.77 
Interdependency 0.63 0.58 0.68 - 0.66 - - 0.073 0.07 0.028 0.026 18.4 18.58 
LogR 0.55 0.54 0.54 0.8 0.55 0.58 0.55 0.114 0.083 0.024 0.015 18.44 19.32 
MI 0.51 0.54 0.58 0.84 0.58 0.81 0.79 0.179 0.126 0.043 0.026 17.6 18.96 
MIBP 0.57 0.5 0.57 0.67 0.53 0.62 0.7 0.045 0.053 0.021 0.023 17.8 18.12 
Mutagenetic 0.53 0.66 0.71 - 0.64 0.86 0.6 0.159 0.159 0.027 0.027 19.13 19.13 
NBZPX2 0.56 0.52 0.54 0.55 0.54 0.51 0.5 0.061 0.052 0.011 0.005 19.51 20.2 
NCPS 0.58 0.51 0.54 0.83 0.56 0.86 0.83 0.17 0.116 0.018 0.011 19.37 20.27 
NNcon 0.68 0.72 0.78 - 0.78 - - 0.286 0.238 0.148 0.132 11.25 12.01 
PCC 0.53 0.56 0.55 - 0.51 0.54 0.61 0.07 0.05 0.013 0 18.63 20.2 
PSICOV 0.56 0.58 0.54 0.55 0.51 0.51 0.53 0.084 0.062 0.016 0.012 18.63 18.79 
PhyCMAP 0.76 0.7 0.72 0.65 0.72 0.8 0.55 0.194 0.172 0.118 0.107 11.83 12.55 
PhysicoMI 0.61 0.56 0.52 0.84 0.5 0.72 0.64 0.071 0.046 0.009 -0.001 20.46 21.06 
RCW 0.54 0.53 0.58 0.82 0.56 0.8 0.78 0.123 0.109 0.044 0.032 16.88 18.12 
SCA 0.54 0.54 0.56 0.53 0.58 0.77 0.77 0.157 0.108 0.027 0.016 18.26 19.08 
SVMcon 0.71 0.73 0.67 - 0.77 - - 0.246 0.183 0.14 0.111 11.42 12.65 
Spidermonkey 0.58 0.55 0.63 0.67 0.52 0.51 0.57 0.065 0.057 0.018 0.01 18.89 19.77 
ZRES 0.56 0.53 0.59 0.73 0.56 0.61 0.68 0.12 0.107 0.046 0.032 16.65 18.08 
CNPR 0.75(2.5) 0.7(3.5) 0.83(2) 0.84(1) 0.77(2.5) 0.87(1) 0.88(1) 0.347(1) 0.269(1) 0.155(2) 0.132(1.5) 10.14(2) 11.52(1) 
*: AUC was not evaluated due to the lack of long-range couplings predicted. For each 
column, the numbers in bold indicate methods with the best score among the 28 
methods. The ranking of CNPR for each dataset is provided in brackets (see others in 
Table S 5.2). Ranking numbers in decimals are results from the average rankings (see 
examples in Table S 5.2). Four statiscal measurements (AUC, accuracy, harmonic 
distance, Euclidean distance) are defined in Methods. For the latter 3 methods, the L 
or L/2 top-ranked predictions were compared and the average scores over the 7 HIV-1 
datasets were listed (see performance evaluation per method per dataset in Table S 
5.3-Table S 5.5). 
Chapter 5: Ensemble coevolution system 
  
185 
 
Figure 5.2: Evaluation of sequence-based methods in predicting HIV-1 intra- and 
inter-protein coevolution 
(A) Evaluation of the method combination CNPR and the 27 individual methods 
applied to the 7 HIV-1 datasets. The x-axis indicates the 28 assessed methods which 
are ordered according to their performance ranking (CNPR with the best ranking is 
positioned on the left). The y-axis indicates four statistical measurements (AUC, 
accuracy, harmonic distance, Euclidean distance) used for the assessment of 
coevolution predictions given 7 HIV-1 datasets. The L and L/2 top-ranked predictions 
are evaluated by the measurements of accuracy, harmonic distance and Euclidean 
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distance. The z-axis indicates the performance ranking of individual methods, where 
one method with the best ranking has the shortest bar. Based on the performance 
ranking, bars are colored by green (ranking: 1-5), yellow (ranking: 6-10), orange 
(ranking: 11-15), blue (ranking: 16-20) and red (ranking: 21-28). Grey cones are used 
when long-range couplings were not predicted by the corresponding sequence-based 
methods (e.g. AUC is not evaluated for NNcon in predicting long-range couplings in 
the p6 protein). Ranking data is provided in Table S 5.2. 
(B) Distribution plots of Euclidean distance between position pairs in the L top-
ranked couplings predicted by individual methods. X- and y-axes indicate the 
estimated Euclidean distances and the percentage of top-ranked couplings, 
respectively. Black lines indicate the mean values of Euclidean distances calculated 
using the L top-ranked couplings. For any method, a lower value of average 
Euclidean distance indicates that predicted coevolving pairs are in proximity, showing 
a better prediction performance. 
 
Sequence-based methods cluster according to their methodology 
We hypothesized that methods designed from a similar underlying methodology may 
output similar predictions. To measure the prediction similarities between the 
sequence-based methods, we calculated Jaccard and association coefficients for the 
top-ranked predictions between every two methods applied to the 7 HIV-1 datasets. 
CNPR shared the highest Jaccard and association coefficients with CMPro and 
PhyCMAP among the 27 sequence-based methods (Figure 5.3A). This observation 
was independent of the prediction cutoffs (Figure 5.4). Our hierarchical clustering 
analysis on the Jaccard and association coefficients revealed four clusters, each of 
which contained methods generating similar predictions (Figure 5.3B). Among the 
four methods integrated in CNPR, CMPro and PhyCMAP shared the same cluster 
with CNPR, while NCPS and RCW were individually located in the other two clusters 
(Figure 5.3C). Moreover, 15 out of 19 methods grouped in the method network were 
designed using similar methodologies, indicating that methods designed from a 
similar methodology tend to generate similar predictions. 
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Figure 5.3: Prediction similarity of sequence-based methods and method 
clustering 
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(A) Jaccard and association coefficients between the L top-ranked couplings predicted 
by 28 sequence-based methods. 
(B) Hierarchical clustering analysis of Jaccard (bottom) and association (left) 
coefficients between the 28 sequence-based methods. The heat-map distinguishes the 
smallest (green) and highest (red) coefficients between the 28 sequence-based 
methods. 
(C) Four method clusters identified commonly by the two clustering trees in (B). The 
arrows connect four methods (CMPro, NCPS, PhyCMAP, RCW) integrated in CNPR. 
Methods designed based on mutual information are colored in green, phylogenetics in 
grey, machine learning in pink. 
 
 
Figure 5.4: Jaccard and association coefficients between CNPR and 27 sequence-
based methods. The x-axis indicates the cutoff of the top-ranked couplings used for 
the calculation of Jaccard and association coefficients, where L is the number of AA 
sequence in the sequence inputs. 
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Detection of HIV-1 intra-protein coevolution 
Using HIV-1 sequence datasets, we applied CNPR to investigate coevolution within 
each HIV-1 protein. In this section, the predicted coevolving residues refer to the L 
top-ranked long-range couplings predicted by CNPR. 
Of the 132 predicted coevolving residues in the HIV-1 matrix protein (L = 132), 
30.3% were true positives (thus accuracy equals 30.3%), 56.8% were between two 
helix structures (helix-to-helix), 40.9% involved one position in the third (positions: 
47-67) and 50.1% one position in the fourth (positions: 73-90) helix structures 
(Figure 5.5A). The average Euclidean distance of the predicted coevolving residues 
was 9.97Å compared to 19.22Å between all residue pairs. As an example, CNPR 
predicted a true positive coupling A45+E74 (Euclidean distance: 5.69Å) within the 
inter-domain interaction interfaces involving with the third and the fourth random-coil 
structures in the matrix protein (Figure 5.5B). 
Of the 231 predicted coevolving residues in capsid (L=231), 21.2% were true 
positives, 9.5% were between two random-coil structures (coil-to-coil) and 52.8% 
were helix-to-helix couplings involving heavily 4 of the 11 helices (helix 3: 16.9%, 
helix 7: 15.2%, helix 11: 19.1%, helix 12: 18.6%) (Figure 5.5C). Average Euclidean 
distance of the predicted coevolving residues was 12.78Å compared to 26.07 Å 
between all residue pairs. CNPR also predicted the capsid coupling S41+T54 (7.22Å) 
within the inter-domain interaction interfaces located between N-terminal domains 
(NTDs) (Figure 5.5D). 
Of the 99 predicted coevolving residues in protease (L=99), 44.4% were true 
positives, 79.8% were between two beta-strands (strand-to-strand), 6.1% were coil-to-
coil couplings. Many predicted coevolving residues involved one position in the 
fourth (25.3%), the fifth (52.5%) and the sixth beta-strands (44.4%) (Figure 5.7). 
Average Euclidean distance of the predicted coevolving residues was 9.87Å 
compared to 17.61Å between all pairwise residues. CNPR did not detect inter-domain 
couplings between two monomers in protease.  
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Regarding the coevolution predictions in nucleocapsid (L=52) and p6 (L=55), 100% 
and 67.05% were in the random-coil structures, respectively. No inter-domain 
couplings were detected since both nucleocapsid and p6 are monomers. 
 
Figure 5.5: Intra-protein couplings of HIV-1 matrix and capsid predicted by 
CNPR 
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(A) Contact map of HIV-1 matrix protein and intra-protein coevolving pairs predicted 
by CNPR. Five helices (H1 to H5) and random-coil secondary structures are aligned 
to the x-axis. At the bottom right, protein contact map is colored according to the 
Euclidean distances between two amino acid positions in the 3D structure. 
Coevolving pairs are colored blue if Euclidean distances were less than 8Å, otherwise 
gradient from yellow to red. At the upper left, the predicted coevolving residues are 
marked as asterisks. Green asterisks indicate true positive couplings falling within the 
black contours of protein contact map. 
(B) Cartoon representation of HIV-1 matrix structure. The predicted intra-domain 
coupling between the residues A45 and E70 is annotated. PDB code: 1HIW. 
(C) Contact map of HIV-1 capsid protein and intra-protein coevolving pairs predicted 
by CNPR. Figure captions are the same as in (A). 
(D) Cartoon representation of HIV-1 capsid hexamer with 6 identical units. The 
predicted intra-domain coupling between the residues A42 and T54 is annotated. PDB 
code: 3H4E. 
The intra-protein couplings predicted by all 28 methods in HIV-1 proteins are shown 
in Figure S 5.1-Figure S 5.4. Visualization: PyMOL V1.5(http://www.pymol.org/). 
 
 
 
Figure 5.6: Structural representation of gag and protease proteins 
(A) Top and side views of the residue positions (T4, L10, I54, L63, V8, L90) in HIV-
1 protease. (B) Gag cleavage sites in the 3D protein structure of gag proteins. Gag 
cleavage sites are annotated in boxes and amino acid positions (V128, S373-T375, 
V431, F448-P453) are colored in red. PDB code: 1HIW (matrix), 3NTE (capsid), 
1U57 (p2), 2M3Z (nucleocapsid),2C55(p6). Visualization software: PyMOL V1.5 
(http://www.pymol.org/). 
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Figure 5.7: HIV-1 protease coevolving pairs predicted by CNPR. (a) The contact 
map of HIV-1 protease (bottom right) and the predicted coevolving pairs (top left) are 
illustrated. Green dots indicate true positive predictions in the protein contact map. 
The random-coil (e.g. L1-L2), beta-strand (e.g. β1-β3) and helix (e.g. H1) secondary 
structures are shown along the x- and y-axes. (b) The top (right) and side (left) view 
of HIV-1 protease structure with 2 symmetrical units colored blue and red, 
respectively. PDB code: 1TW7. Visualization software: Matlab and PyMOL V1.5. 
Detection of HIV-1 inter-protein coevolution 
We applied CNPR to investigate HIV-1 inter-protein coevolution using the protease-
p6 and protease-GCS sequence datasets. In this section, the predicted coevolving 
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residues refer to the L top-ranked long-range couplings predicted by CNPR. Of the 
151 predicted protease-p6 couplings (L=151), 17.9% were true positives, 21.8% were 
located in the coil-to-coil couplings, 53.3% were coil-to-strand couplings, 28.5% 
involved 5 protease positions (T4, L10, L63, V82, L90), 76.2% involved either 
protease cleavage sites Q450-P453 or protease-p6 overlapping positions (Gag 
positions: S489-Q500) (Figure 5.6), 58.9% had either Gag or protease positions 
identified in experimental studies (Table S 5.1). 
Of the 149 coevolving residues predicted between protease and GCS (L=149), 28.9% 
were true positives, 84.6% had either Gag or protease positions identified in the 
experimental and clinical studies, 25.5% were coil-to-coil couplings, 68.5% were the 
coil-to-strand couplings, 25.5% involved 4 protease positions (L10, I54, L63, V82), 
93.3% had GCS positions V128, S373-T375, A431 and F448-P453. Of interest, 
protease positions L10, I54, L63 and V82 are located near the protease active site 
(Figure 5.6). 
5.5 Discussion 
To our knowledge, this study presents the first ensemble coevolution system (ECS) to 
predict the position-specific coevolution in HIV-1 proteins. Ensemble systems with 
robust predictions have been applied previously [29-33, 68-71]. For instance, a super 
learner was created to improve the prediction of HIV-1 drug susceptibility using a set 
of machine learning algorithms [68]. As shown in our study, an ensemble approach 
can provide robust predictions of position-specific coevolution when different 
sequence-based methods predict different coevolving residues. The problem of 
discordant predictions has been reported previously. For instance, a significant 
variability in the performance of 13 sequence-based methods was shown using 
simulated and experimental MSAs [46]. A review which summarized the performance 
of 9 sequence-based methods also demonstrated different predictions of sequence-
based methods [24]. The aim of our study was to detect HIV-1 intra- and inter-protein 
coevolution using the ensemble learning strategy. For this reason, our study presents a 
new ensemble coevolution system that integrates 27 sequence-based methods 
published in the last decade. 
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An ensemble approach outperforms individual sequence-based methods in 
detecting HIV-1 coevolution 
Armed with our coevolution system, HIV-1 coevolving residues were predicted and 
the true positive predictions were evaluated using independent evaluation datasets. 
For HIV-1 intra-protein coevolution, we used protein contact maps to evaluate 
coevolving residues in close proximity within protein structures. For HIV-1 inter-
protein coevolution, we evaluated protease-GCS and protease-p6 couplings using the 
results reported in literature, summarized in our experimental and clinical datasets 
(Table S 5.1).  
We designed a heuristic algorithm to identify CNPR − a combination of four methods 
(CMPro [39], NCPS [48], PhyCMAP [51], RCW [52]). We found that CNPR 
outperformed any of the 27 individual methods in the prediction of HIV-1 intra- and 
inter-protein coevolution. Moreover, CNPR was mostly ranked first or second using 
four measurements (AUC, accuracy, harmonic distance, Euclidean distance) for 
performance evaluation (Table S 5.2). Interestingly, our clustering analysis showed 
that the four methods in CNPR originated from three method clusters (Figure 5.3C), 
suggesting that combining methods designed from different principles may establish a 
superior ensemble method [65]. This observation was supported by a recent study, 
showing that the combination of PSICOV and plmDCA can improve the prediction 
performance of either PSICOV or plmDCA alone [72]. Our heuristic algorithm used 
weighted voting as a combination strategy. During the design of our algorithm, we 
examined two other ensemble strategies, namely majority voting (predictions 
supported by more than 50% of the considered methods) and Borda count (predictions 
made by all the methods) [28], both of which yet failed to outperform individual 
methods (average rankings beyond the top 10, data not shown). Other advanced 
ensemble algorithms may provide alternative strategies with promising performance. 
Our study aimed at comparing sequence-based methods as accurately as possible, but 
five factors may limit our comparisons: (1) protein contact maps obtained from 
crystallized structures may reveal most but not all coevolving residues. The contact 
map evaluation assumes that a destabilizing mutation at one position is compensated 
for a mutation at the other position in contact [87], probably due to biochemical 
constrains (i.e. charge, volume and polarity) [94]. Yet, two residues that are in close 
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contact may not always coevolve [73, 74]. Coevolving residues are not necessarily in 
physical contact due to protein dynamics in various contexts [16, 20, 75]. Despite 
these, protein contact maps remain the most popular strategy to evaluate true positive 
predictions in position-specific coevolution [22]. (2) Default parameters of sequence-
based methods were mostly applied in our study but the optimization of parameters 
adapted to the HIV-1 datasets may provide better predictions. For instance, 
phylogenetic methods usually require high computation and memory consumption, 
forcing less optimized parameters to be used [22]. (3) Experimental and clinical 
studies provide some but not complete data to evaluate all true positive predictions. 
(4) The power of position-specific methods relies on the number of mutations 
observed in MSA inputs, limiting the prediction of coevolution occurring at highly 
conserved residues [76]. (5) Besides the above factors, phylogenetic bias, indirect 
coupling and stochastic effects can affect coevolution prediction [46, 50]. 
HIV-1 intra-protein coevolution detected by the method combination CNPR 
We applied the method combination CNPR to investigate HIV-1 intra-protein 
coevolution in Gag and protease proteins, which play important roles in HIV-1 
morphogenesis [1]. While CNPR was selected because it had the highest number of 
true positive predictions, we also found other interesting observations among the 
predicted co-evolving residues. 
In our analysis of matrix intra-protein coevolution, 30.3% of the predicted coevolving 
residues were true positives − a promising accuracy which represents a three-fold 
enrichment compared to a random prediction (average percentage of residue pairs in 
contact: 10.5%, see Table 5.3). Most predicted coevolving residues were located 
between the third (positions: 47-67) and the other helices in matrix, suggesting a role 
of the third helix in viral assembly. Previously, positions 54 and 68 were found to be 
important for matrix assembly [77]. Many positive predictions had residue positions 
between 45-47 and 68-74 (e.g. A45+E74), formed as two short random-coil loops in 
the matrix protein. As illustrated in Figure 5.5B, these two loops are in contact and 
located in the inter-domain interaction interface of the matrix trimeric complex. 
Matrix mutations near this interaction interface can alter the intra-domain interactions, 
resulting in the impairment of viral assembly and Env incorporation [78, 79]. 
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Table 5.3: Summary of long-range residue contacts derived from HIV-1 Gag and 
protease protein structures 
Protein 
Number of intra-domain long-range contact 
(1) 
Number of inter-domain long-range contact 
(2) Percentage(3) 
helix-helix strand-strand helix-strand others(4) helix-helix strand-strand helix-strand others 
Matrix    346 0 0 277 0 0 4 23 650/5995=10.46% 
Capsid (5) 520 15 22 680 46 0 19 8 1310/22993=5.59% 
Nucleocapsid 4 0 0 192 0 0 0 0 196/1225=14.78% 
p6 7 0 0 54 0 0 0 0 61/1081=5.19% 
Protease 3 233 42 248 0 0 13 8 547/4371=12.00% 
Total 880 248 64 1451 46 0 36 39 2764/36712=7.53% 
Long-range residues are defined as two residues have at least 6 amino acids apart in 
the protein sequence.Two residues are in contacts if the Euclidean distance of their Cα 
atoms is less than 8 Å in the protein 3D structure. 
(1) Intra-domain long-range contacts: the number of long-range contacts of residue 
pairs (see definitions in Methods) within a protein domain, which are classified 
according to the type of secondary structures involved (e.g. a helix-strand contact 
indicates contact between a protein residue in an alpha-helix structure and a protein 
residue in a beta strand structure). 
(2) Inter-domain contacts: residue contacts between different protein domains.  
(3) Percentage: the proportion of long-range residue pairs in contact, calculated using 
PDB data (e.g. for the matrix protein, 650/5995=10.46% indicates that 5995 possible 
long-range pairs of positions are resolved in the crystal structure and 650 of them are 
in direct contact).  
(4) Others: all the other residue contacts (helix-to-coil, strand-to-coil and coil-to-coil 
contacts) 
(5) Capsid contact map is based on crystalized hexamer.  
PDB code: 1HIW (matrix), 3H4E (capsid), 1A1T (nucleocapsid), 2C55 (p6), 1TW7 
(protease). 
 
 
In our analysis of capsid intra-protein coevolution, 21.2% of the predicted coevolving 
residues were true positives − a four-fold enrichment compared to a random 
prediction (the average percentage of residue pairs in contact: 5.6%, Table 5.3). Half 
(52.8%) of the long-range coevolving residues were found within helices, especially 
the helices 3, 7, 11 and 12 (Figure 5.5D). These helices near the capsid intra- and 
inter-domain interaction interfaces play a key role in the capsid assembly and stability 
[1, 80-82]. The helices 3, 4 and 7 in the N-terminal domain (NTD) and helices 8 and 
11 in the C-terminal domain (CTD) are essential for NTD-CTD interactions in the 
capsid hexamer [81-84]. When considering predicted intra-domain coevolving 
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residues in capsid, E71+L111 was previously predicted using a dataset of HIV-1, 
HIV-2 and SIV sequences [6]. In our analysis using CNPR, the predicted coupling 
S41+T54 was ranked higher than E71+L111. Moreover, the Euclidean distance 
between S41 and T54 (7.22Å) is shorter than that between E71 and L111 (9.85Å).  
In our analysis of protease intra-protein coevolution, 44.4% of the predicted 
coevolving residues were true positives − a four-fold enrichment compared to a 
random prediction (the average percentage of residue pairs in contact: 12%, Table 
5.3). Most statistical couplings (79.8%) were between beta-strand structures; 
particularly, the second, third and fifth beta-strand structures. Coevolving residue 
clusters in these beta-strand structures have been reported previously [85, 86].  
Besides the intra-protein coevolution reported here, other coevolution events in HIV-1 
Gag have also been reported. For instance, five groups of Gag positions were 
coevolving under multidimensional constraints and one of these groups contains 
positions in the capsid N-terminal helices [7]. Our coevolution analysis on HIV-1 
capsid also identified statistical couplings at the N-terminal helices near the inter-
domain interaction interface. In another study, phylogenetic dependency networks 
were used to infer patterns between human leukocyte antigen (HLA) alleles and HIV-
1 Gag residues, resulting in the prediction of 149 couplings between HLA alleles and 
Gag codons, as well as 1386 couplings within matrix and capsid [5]. Our study 
observed different predictions within matrix and capsid, possibly because we focused 
on HIV-1 subtype B, while the coevolution analysis in [5] used a mixed subtype B 
and C dataset. Further investigation needs to distinguish coevolving residues in HIV-1 
subtypes B and C. 
HIV-1 inter-protein coevolution estimated by the method combination CNPR 
We applied the method combination CNPR to investigate HIV-1 inter-protein 
coevolution. It is known that the open reading frame of p6 (nucleotides: 120-159) 
overlaps with protease (nucleotides: 1-40) in the viral genome and that Gag cleavage 
sites (GCS) interact with protease during the protease-mediated proteolytic processing 
[4, 87]. Since Gag cleavage sites interact with protease residues, mutations near Gag 
cleavage sites can be selected under the selective pressure of protease inhibitors [4, 
88]. CNPR predicted Gag cleavage sites 128, 373-375, 431 and 448-453 coevolving 
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with protease residues close to the active site. This is in agreement with previous 
findings that amino acid substitutions at these Gag cleavage sites are associated with 
PI resistance [4, 88]. 
In our analysis of p6-protease inter-protein coevolution, 17.9% of the predicted 
coevolving residues were true positives and 58.9% contained either a Gag or a 
protease position in HIV-1 clinical and experimental datasets. In the p6-protease 
overlapping region (Gag position: 487-500, protease position: 1-13. e.g. T4 and L10), 
many p6 residues (75.7%) were coupled with protease residues (e.g. T4), illustrating 
the HIV-1 coevolution in the p6-protease overlapping region. Moreover, p6 residues 
are mostly coupled with the protease position T4 and protease positions (L10, V82, 
L90) near the protease substrate-binding pocket (Figure 5.5A). Recognized by the 
known drug resistance algorithms (e.g. I S-US , HIVdb,  ega ) [89], all these 
protease positions are associated with PI drug resistance.  
Besides the protease-p6 and protease-GCS coevolution, other inter-protein 
relationships have been reported between Gag proteins. A recent study showed that 
the p6 residue S40 can partially rescue the negative effects of capsid mutants at the 
positions E207, A208 and P231 [90]. Matrix can fold back onto nucleocapsid to 
regulate Gag assembly by the lateral Gag-Gag inter-protein interaction [91]. While the 
matrix-nucleocapsid interaction interface remains unclear, residues between the 
matrix domain (positions: 114-126) were coupled with the nucleocapsid domain 
(positions: 379-383) in our prediction model. Since the predicted coevolving residues 
do not necessarily imply the spatial proximity or direct protein-protein interactions 
[24], structural experiments are still needed to clarify the matrix-nucleocapsid 
interaction domains. 
Limitations and future perspectives 
Our ensemble approach has its limitations. (1) ECS assembles individual methods so 
that combinations of methods cannot reveal coevolving residues that are absent in the 
predictions of individual methods. (2) For some datasets, the method combination 
CNPR does not always perform the best compared to individual methods. However, it 
does provide robust predictions with the highest overall ranking in our performance 
evaluation (Table S 5.2). (3) It can be computationally expensive to assemble 
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prediction results obtained from multiple methods, especially when phylogeny-based 
methods are integrated. According to our experience, it usually takes more than 30 
hours to test a single dataset using all 27 methods (system settings: Linux, CPU 
2.8GHz×4). High-standard file management is also needed to organize different 
inputs and outputs for the 27 methods.  
Our study aimed at detecting coevolution in different HIV-1 proteins and our 
performance comparison was restricted to HIV-1 datasets. Future analysis is still 
needed to improve the computation efficiency of ECS and to examine the 
performance of ensemble methods using large-scale protein family datasets. As new 
sequence-based coevolution methods continue to be reported [22], future studies also 
need to integrate new methods in the ensemble coevolution system. 
5.6 Conclusions 
Our study presents a new ensemble coevolution system that integrates multiple 
sequence-based methods to improve the prediction of HIV-1 position-specific 
coevolution. Using HIV-1 structural and experimental data, this ensemble system 
enabled us to identify a combination of 4 different methods that outperformed 27 
sequence-based methods for the prediction of HIV-1 inter- and intra-protein 
coevolution. We also investigated HIV-1 intra- and inter-protein coevolution by 
exploring coevolving residues in the HIV-1 Gag and protease proteins, which are 
responsible for virion morphogenesis. Overall, our ensemble coevolution system can 
detect HIV-1 intra- and inter-protein coevolution, leading to a better understanding of 
coevolution at the molecular level. 
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5.7 Additional file 1: Figures 
 
 
Figure S 5.1: Contact map of HIV-1 protease and coevolving pairs predicted by 
28 sequence-based methods. For each subplot, the protein contact map is shown at 
the bottom right and the top-ranked coevolving residues (L=99) predicted by 
sequence-based methods are shown as asterisk in the upper left side. True positive 
coevolving pairs are those falling within the contours of the protein contact map, and 
indicated as green asterisk. The others are red. 
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Figure S 5.2: Contact map of HIV-1 matrix and coevolving pairs predicted by 28 
sequence-based methods. For each subplot, the protein contact map is shown at the 
bottom right and the top-ranked coevolving residues (L=99) predicted by sequence-
based methods are shown as asterisk in the upper left side. True positive coevolving 
pairs are those falling within the contours of the protein contact map, and indicated as 
green asterisk. The others are red. 
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Figure S 5.3: Contact map of HIV-1 capsid and coevolving pairs predicted by 28 
sequence-based methods. For each subplot, the protein contact map is shown at the 
bottom right and the top-ranked coevolving residues (L=231) predicted by sequence-
based methods are shown as asterisk in the upper left side. True positive coevolving 
pairs are those falling within the contours of the protein contact map, and indicated as 
green asterisk. The others are red. 
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Figure S 5.4: HIV-1 nucleocapsid contact map and coevolving pairs predicted by 
28 sequence-based methods. For each subplot, the protein contact map is shown at 
the bottom right and the top-ranked coevolving residues (L=55) predicted by 
sequence-based methods are shown as asterisk in the upper left side. True positive 
coevolving pairs are those falling within the contours of the protein contact map, and 
indicated as green asterisk. The others are red. 
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5.8 Additional file 2: Tables 
Table S 5.1: Summary of PI-associated Gag and protease substitutions reported 
in in vitro or in vivo studies. 
Gag substitutions # Protease substitutions Ref 
L449F+P453T L10F+G16E+K20T+A28S+M46I+A71V [92] 
R452K Q58E+A71V [92] 
L449F L10F [93] 
L449F L10F+I84V [93] 
L449F L10F+M46I+I50V [93] 
L449F L10F+M46I+I47V+I50V [93] 
R452S L10F+K20I+M36I+M46I+I54V+L63P+A71V+G73S+I84A [94] 
L449F L10F+M46I+L63P+A71V+I84A [93, 94] 
A431V+L449Q L10V+M46I+L63A/P+A71V+I84A [94] 
A431V L10I+M46I+L63P+A71V+L76V+I84A [94] 
A431V+S451I L10F+L19I+M46I+I47V+I54V+L63P+A71V+I84A [94] 
A431V L10V+K20I+M36I+M46I+A71V+G73S+L76V+I84A [94] 
L449F L10I+M46I+L63P+A71V+V77I+I84A [94] 
A431V L10I+M46I+L63H+A71V+V77I+I84A [94] 
A431V+L449V+R452K L10F+K20I+M46I+I54M+L63P+A71V+G73T+V77I+I84A [94] 
A431V+L449F L10F+M46I+L63P+A71V+V77I+I84A [94] 
A431V+L449Q+S451T L10I+L33F+M46I+I54V+L63P+A71V+L76V+I84A [94] 
R452S L10F+K20I+M36I+M46I+I54V+L63P+A71V+G73S+I84A [94] 
S451N K20I+M36I+V82I+I84C [94] 
L449F L10I+L19I+L24I+L63H+I84C [94] 
A431V L10I+G16A+M46I+L63P+L76V+I84C [94] 
A431V+L449F L10F+L19V+L24I+M46L+L63P+I84C [94] 
A431V+L449F L10I+L24I+M46L+L63P+A71T+G73S+V77I+I84C [94] 
A431V M46I+L76V [95] 
A431V M46I [95] 
A431V L76V [95] 
P453L D30N+N88D [96] 
E12K+L75R+H219Q+V390D+R409K L10F+D30N+K45I+A71V [97] 
E12K+L75R+H219Q+V390D+R409K D30N+M46I+V77I [97] 
L75R+H219Q+V390D L10F+V32I+M46I+I84V [98] 
A431V L10F+K20T+L33F+M36I+M46I+I54V+L63P [99] 
A431V L10I+K20R+L33F+M46L+I54L+L63P+A71V+G73S+V82A+L90M [99] 
I437V L10I+G48V+I54V+L63P+V77I+V82A [99] 
L483P+K490R L10I+I15V+E34Q+M36I+T37N+I54A+Q58E+V82A [100] 
I376V+ L483P+K490R L10I+I15V+E34Q+M36I+T37N+I54A+Q58E+V82A [100] 
I376V+E398V+L483P+K490R L10I+I15V+E34Q+M36I+T37N+I54A+Q58E+V82A [100] 
L449P+P453L L19Ins+E21D+A22V+M46I/L63P+A71V+I84V+I93L [101] 
L449P+P453L M46I+L63P+A71V+I84V+I93L [101] 
L449F I50V [102] 
L449F M46I+I50V [102] 
P453L I50V [102] 
P453L M46I+I50V [102] 
A431V L90M [103] 
A431V N88D+L90M [103] 
A431V N88D [103] 
A431V D30N+N88D+L90M [103] 
A431V D30N+N88D [103] 
A431V I84V [103] 
A431V V82A [103] 
A431V I50L [103] 
A431V I84V+L90M [103] 
A431V V82A+L90M [103] 
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Gag substitutions # Protease substitutions Ref 
K436R L90M [103] 
K436R I84V+L90M [103] 
K436R I84V [103] 
K436R I50V [103] 
I437V D30N+N88D [103] 
I437V I50V [103] 
I437V I84V+L90M [103] 
I437V V82A [103] 
I437V V82A+L90M [103] 
I437V I84V [103] 
L449F D30N+N88D [103] 
L449F V82A [103] 
L449F I50V [103] 
L449F V82A+L90M [103] 
L449F L90M [103] 
L449F N88D [103] 
R452S I84V+L90M [103] 
R452S I84V [103] 
R452S L90M [103] 
P453L I84V [103] 
P453L I84V+L90M [103] 
P453L L90M [103] 
P453L V82A [103] 
P453L V82A+L90M [103] 
A431V M46I +L76V [104] 
P453L I84V [105] 
A431V M46I/L,V82A/F/T [105] 
I437A V82A [106] 
I437V G48V,I50V,I54A/V,V82A/T [106] 
P459Ins V82A/F/T/S [107] 
S451N L10I [108] 
I437T/V L76V [109] 
A431V M46I [110] 
N382A I15V [111] 
A431V M46L/I+I54V+ V82A [112] 
L449P,S451N,P453L D30N+N88D [113] 
A431V L24I+M46I/L+I54V+V82A [114] 
I437V I54V+V82F/T/S [114] 
L449V I54M/L/S/T/A [114] 
L449F+R452S+P453L D30N+I84V [114] 
P453L V82A [114] 
L449F,S451N/T D30N+N88D [115] 
A431V M46I/L,I54V,V82A/T/F [116] 
S373Q,L449P K20I/R/M,L89M/I [116] 
S125K+Y132F+G62R+I437V L10I+A71V+N88S [117] 
P453L N88D [118] 
#: Substitution: the symbol “+” indicates multiple amino acid substitutions observed 
simultaneously (e.g. Y79F+T81A indicates the presence of both Y79F and T81A). 
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Table S 5.2: Ranking of sequence-based methods using individual HIV-1 datasets 
Sequence-based 
method 
Area-under-curve (AUC) Accuracy(1) 
Harmonic 
distance(2) 
Euclidean 
distance(3) 
MA CA NC p6 PR PR-p6 PR-GCS L/2 L L/2 L L/2 L 
APC 11.5* 12.5 14.5 12 14.5 13.5 11 16 15 11.5 12.5 13 14 
ASC 15 20 14.5 10 11 12 14 11 8 7 10 7 15 
BN 4.5 12.5 10 13 4 18.5 0 24 22 26.5 23 27 24 
CMPro 2.5 5.5 1 9 5 10 7 2 3 1 3 1 2 
CoMap 25.5 23.5 11 0 19.5 0 22.5 27 27 14.5 9 9 8 
Complementary 25.5 23.5 19.5 19 22.5 20 19 26 25 26.5 26 23 23 
CTMP 21 23.5 0 0 14.5 9 0 28 28 28 24.5 11 7 
DCA 18.5 12.5 14.5 8 26 11 10 17 17 13 17 14 12 
DNcon 28 26.5 8 0 9 0 5.5 8 10 6 6 6 6 
GREMLIN 15 16.5 12 6 10 16 13 12 14 11.5 15.5 12 16 
Interdependency 7 7.5 6 0 7 0 0 19 18 14.5 12.5 18 13 
LogR 18.5 16.5 24.5 7 19.5 17 19 15 16 18 18.5 19 21 
MI 27 16.5 17.5 2 12.5 4 3 6 7 9.5 12.5 15 18 
MIBP 11.5 28 19.5 14.5 22.5 13.5 8 25 22 19 15.5 16 10.5 
Mutagenetic 23.5 5.5 5 0 8 2.5 16 9 6 16.5 12.5 24 20 
NBZPX2 15 23.5 24.5 17.5 21 22 22.5 23 22 23.5 24.5 26 25.5 
NCPS 9.5 26.5 24.5 4 17 2.5 2 7 9 20.5 20.5 25 27 
NNcon 6 2 3 0 1 0 0 3 2 3 1.5 3 3 
PCC 23.5 9.5 22 0 26 18.5 15 21 24 23.5 27 20.5 25.5 
PhyCMAP 1 3.5 4 16 6 5.5 19 5 5 5 5 5 4 
PhysicoMI 8 9.5 27 2 28 8 12 20 26 25 28 28 28 
PSICOV 15 7.5 24.5 17.5 26 22 21 18 19 22 20.5 20.5 17 
RCW 21 20 17.5 5 17 5.5 4 13 11 9.5 7.5 10 10.5 
SCA 21 16.5 21 20 12.5 7 5.5 10 12.5 16.5 18.5 17 19 
Spidermonkey 9.5 12.5 9 14.5 24 22 17 22 20 20.5 22 22 22 
SVMcon 4.5 1 7 0 2.5 0 0 4 4 4 4 4 5 
ZRES 15 20 14.5 11 17 15 9 14 12.5 8 7.5 8 9 
CNPR 2.5 3.5 2 2 2.5 1 1 1 1 2 1.5 2 1 
(1): Rankings are obtained by average accuracy of individual methods (Table S 5.3). 
(2): Rankings are obtained by average Harmonic distance of individual methods 
(Table S 5.4) 
(3): Rankings are obtained by average Euclidean distance of individual methods ( 
Table S 5.5).  
*: the average ranking of the method following the calculation procedures in [119]. 
We give a simple example to explain the calculation of this average ranking:  
 
                           AUC          Ranking                                  AUC             Ranking 
      Method 1:      0.9        =>    1                    Method 1:      0.8        =>   (1+2)= 1.5 
      Method 2:      0.8        =>    2                    Method 2:      0.8        =>   (1+2)= 1.5 
      Method 3:      0.7        =>    3                    Method 3:      0.7        =>    3 
 
For the example on the right side, the average ranking of the first and second methods 
is calculated as (1+2)/2 = 1.5.  For the method 3, it remains the same ranking as 3.  
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Table S 5.3: Accuracy of sequence-based methods on individual HIV-1 datasets  
Sequence-
based method 
Accuracy of the L/2 top-ranked long-range couplings Accuracy of the L top-ranked long-range couplings 
MA CA NC p6 PR PR-p6 
PR-
GCS Average MA CA NC p6 PR PR-p6 
PR-
GCS Average 
APC 9% 6.9% 17.9% 0%# 22% 9.2% 10.7% 10.8% 9% 4.3% 19.6% 0% 14% 4.6% 8.7% 8.6% 
ASC 7.5% 6.9% 21.4% 0% 20% 17.1% 32% 15% 6.8% 4.7% 17.9% 1.9% 19% 11.2% 20.7% 11.7% 
BN 6% 2.5% 7.1% 0% 16% 6.6% 2.9% 5.9% 5.6% 2.5% 6.5% 1.9% 11% 6.4% 2.9% 5.2% 
CMPro 41.8% 26.7% 64.3% 0% 64% 0% 5.3% 28.9% 30.8% 17.7% 50% 1.9% 49% 0% 8% 22.5% 
CoMap 7.5% 5.2% 10.7% 0% 0% 0% 4% 3.9% 6.8% 3.9% 8.9% 0% 4% 0% 6.7% 4.3% 
Complementary 4.5% 5.2% 7.1% 0% 6% 5.3% 0% 4% 6% 4.3% 3.6% 0% 6% 5.3% 8% 4.7% 
CTMP 9.3% 2.7% 0% 0% 0% 11.1% 0% 3.3% 9.3% 2.7% 0% 0% 0% 11.1% 0% 3.3% 
DCA 3% 9.5% 17.9% 3.7% 4% 5.3% 21.3% 9.2% 6% 6% 14.3% 1.9% 4% 3.9% 13.3% 7.1% 
DNcon 20.9% 18.1% 10.7% 0% 62% 0% 4% 16.5% 17.3% 14.2% 8.9% 0% 35% 0% 3.7% 11.3% 
GREMLIN 10.4% 5.2% 17.9% 0% 26% 13.2% 24% 13.8% 6.8% 3% 12.5% 0% 17% 9.2% 18% 9.5% 
Interdependency 4.5% 7.7% 11.1% 4.2% 20% 0% 3.3% 7.3% 5.7% 7.7% 11.1% 4.2% 171% 0% 3.3% 7% 
LogR 6% 7.8% 17.9% 0% 18% 9.2% 21.3% 11.4% 6% 5.2% 14.3% 0% 15% 5.3% 12.7% 8.3% 
MI 7.5% 5.2% 17.9% 7.4% 24% 23.7% 40% 17.9% 4.5% 3.9% 16.1% 3.8% 16% 18.4% 25.3% 12.6% 
MIBP 6% 0% 17.9% 0% 8% 0% 0% 4.5% 5.3% 1.7% 17.9% 0% 12% 0% 0% 5.3% 
Mutagenetic 10% 9.1% 20% 0% 22.2% 14.3% 35.7% 15.9% 10% 9.1% 20% 0% 222% 14.3% 35.7% 15.9% 
NBZPX2 10.4% 3.4% 7.1% 0% 14% 2.6% 5.3% 6.1% 6.8% 3% 8.9% 0% 10% 2% 6% 5.2% 
NCPS 0% 3.4% 17.9% 7.4% 12% 31.6% 46.7% 17% 0.8% 2.2% 10.7% 3.8% 14% 21.1% 28.7% 11.6% 
NNcon 37.2% 22.4% 67.9% 0% 70% 2.6% 0% 28.6% 37.2% 20% 44.6% 0% 62% 2.6% 0% 23.8% 
PCC 7.5% 3.4% 7.1% 0% 6% 7.9% 17.3% 7% 4.5% 4.3% 3.6% 0% 9% 3.9% 0.1% 5% 
PhyCMAP 34.3% 23.3% 28.6% 0% 44% 2.6% 2.7% 19.4% 33.8% 15.9% 30.4% 0% 33% 4.6% 2.7% 17.2% 
PhysicoMI 3% 0.9% 10.7% 7.4% 12% 5.3% 10.7% 7.1% 1.5% 0.4% 7.1% 3.8% 7% 5.3% 7.3% 4.6% 
PSICOV 10.4% 13.8% 10.7% 0% 4% 11.8% 8% 8.4% 7.5% 6.9% 5.4% 0% 9% 7.9% 6.7% 6.2% 
RCW 9% 6.9% 21.4% 0% 14% 13.2% 21.3% 12.3% 8.3% 4.3% 19.6% 1.9% 14% 10.5% 18% 10.9% 
SCA 7.5% 5.2% 10.7 0% 20% 28.9% 37.3% 15.7% 6% 3.9% 08.9% 0% 14% 17.8% 24.7% 10.8% 
Spidermonkey 4.5% 4.3% 14.3 0% 8% 2.6% 12% 6.5% 3.8% 3.4% 10.7% 0% 9% 2.6% 0.1% 5.7% 
SVMcon 47.8% 19.8% 46.4 0% 58% 0% 0% 24.6% 38.5% 18.8% 32.1% 0% 39% 0% 0% 18.3% 
ZRES 10.4% 6.9% 17.9 3.7% 16% 7.9% 21.3% 12% 8.3% 4.3% 19.6% 3.8% 13% 7.9% 18% 10.7% 
CNPR 38.8% 25% 57.1% 7.4% 56% 19.7% 38.7% 34.7% 30.3% 21.2% 42.9% 3.8% 44% 17.9% 28.9% 26.9% 
 
Table S 5.4: Harmonic distance of sequence-based methods using individual 
HIV-1 datasets 
Sequence-based 
method 
Harmonic distance of the L/2 top-ranked long-range 
couplings 
Harmonic distance of the L top-ranked long-range 
couplings 
MA CA NC p6 PR Average MA CA NC p6 PR Average 
APC 0.032 0.037 0.043 0.012 0.073 0.039 0.018 0.024 0.034 0.017 0.04 0.027 
ASC 0.025 0.029 0.066 0.057 0.078 0.051 0.015 0.02 0.024 0.022 0.058 0.028 
BN 0.014 0.004 0 -0.013 0.04 0.009 0.01 0.004 -0.01 0.002 0.035 0.008 
CMPro 0.177 0.161 0.222 0.07 0.198 0.166 0.139 0.113 0.175 0.064 0.16 0.13 
CoMap 0.033 0.023 0.032 0.078 -0.022 0.029 0.032 0.017 0.027 0.078 -0.007 0.029 
Complementary -0.003 0.034 -0.013 0.005 0.016 0.008 0.003 0.023 -0.025 0.001 0.01 0.003 
CTMP 0.045 -0.003 0 -0.038 0.017 0.004 0.045 -0.003 0 -0.038 0.017 0.004 
DCA 0.027 0.048 0.047 0.028 -0.003 0.03 0.023 0.037 0.045 0.007 0.002 0.023 
DNcon 0.119 0.103 0.059 0.003 0.182 0.093 0.104 0.086 0.054 -0.013 0.119 0.07 
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GREMLIN 0.034 0.024 0.041 0.015 0.087 0.04 0.019 0.005 0.023 0.009 0.061 0.024 
Interdependency 0.016 0.028 -0.022 0.046 0.071 0.028 0.016 0.028 -0.022 0.046 0.062 0.026 
LogR 0.012 0.037 0.029 -0.01 0.053 0.024 0.006 0.024 0.016 -0.007 0.037 0.015 
MI 0.017 0.017 0.023 0.078 0.08 0.043 -0.002 0.009 0.018 0.045 0.06 0.026 
MIBP 0.048 0.009 0.049 -0.016 0.017 0.021 0.041 0.013 0.057 -0.029 0.035 0.023 
Mutagenetic 0.029 0.016 0.034 -0.034 0.09 0.027 0.029 0.016 0.034 -0.034 0.09 0.027 
NBZPX2 0.031 0.018 -0.004 -0.011 0.023 0.011 0.009 0.017 -0.003 -0.011 0.011 0.005 
NCPS -0.013 -0.005 0.006 0.066 0.037 0.018 -0.018 -0.01 -0.007 0.038 0.053 0.011 
NNcon 0.134 0.135 0.197 0.064 0.209 0.148 0.134 0.116 0.146 0.064 0.2 0.132 
PCC 0.024 0.027 -0.003 0.008 0.008 0.013 0.001 0.02 -0.023 -0.01 0.011 0 
PhyCMAP 0.155 0.159 0.121 0.025 0.131 0.118 0.157 0.135 0.118 0.018 0.108 0.107 
PhysicoMI -0.002 -0.041 -0.016 0.051 0.052 0.009 -0.014 -0.029 -0.01 0.031 0.018 -0.001 
PSICOV 0.051 0.063 -0.022 -0.007 -0.003 0.016 0.032 0.036 -0.019 0 0.013 0.012 
RCW 0.03 0.042 0.048 0.057 0.042 0.044 0.02 0.024 0.04 0.03 0.043 0.032 
SCA 0.032 0.018 0.015 -0.008 0.079 0.027 0.015 0.007 0.004 0.001 0.052 0.016 
Spidermonkey 0.009 0.012 0.016 0.011 0.041 0.018 0.001 0.013 0.003 0.004 0.031 0.01 
SVMcon 0.192 0.128 0.152 0.037 0.189 0.14 0.165 0.124 0.113 0.027 0.128 0.111 
ZRES 0.034 0.044 0.053 0.061 0.041 0.046 0.022 0.024 0.037 0.044 0.035 0.032 
CNPR 0.175 0.155 0.19 0.08 0.178 0.155 0.144 0.137 0.16 0.068 0.152 0.132 
 
Table S 5.5: Average Euclidean distance of the top-ranked long-range couplings 
predicted by sequence-based methods 
Sequence-based 
method 
Average Euclidean distance of the L/2 top-ranked 
long-range couplings (Å) 
Average Euclidean distance of the L top-ranked long-
range couplings (Å) 
MA CA NC p6 PR Average MA CA NC p6 PR Average 
APC 16.45 21.64 14.74 20.81 13.25 17.38 17.72 22.9 16.69 20.65 15.06 18.6 
ASC 16.69 22.84 13.53 16.67 12.31 16.41 17.73 23.54 17.63 20.54 14.01 18.69 
BN 18.27 25.53 17.65 23.8 14.46 19.94 18.92 25.53 19.09 22.34 14.76 20.13 
CMPro 9.01 11.19 7.47 14.2 8.38 10.05 10.51 14.7 8.8 15.33 9.49 11.77 
CoMap 15.63 21.88 14.56 14.31 17.87 16.85 15.95 22.87 15.14 14.31 17.46 17.14 
Complementary 19.27 20.32 19.32 20.95 15.52 19.08 18.82 22.6 19.91 22.35 16.37 20.01 
CTMP 15.36 27.88 0 27.72 13.91 16.98 15.36 27.88 0 27.72 13.91 16.98 
DCA 15.41 20.27 14.53 19.76 17.18 17.43 16.52 21.6 15.18 21.96 17 18.45 
DNcon 11.18 15.69 12.55 19.74 9.14 13.66 11.6 16.62 13.87 22.35 11.12 15.11 
GREMLIN 16.58 22.21 14.8 19.7 12.39 17.14 17.78 24.97 16.2 21.52 13.37 18.77 
Interdependency 17.87 23.22 20.34 17.54 13.02 18.4 18.41 23.22 20.34 17.54 13.38 18.58 
LogR 17.68 21.95 15.72 22.64 14.2 18.44 18.24 22.92 16.99 23.08 15.36 19.32 
MI 17.66 24.05 16.98 16.73 12.59 17.6 19.17 25.57 17.81 18.79 13.45 18.96 
MIBP 14.06 21.77 13.89 23.39 15.9 17.8 14.52 21.93 13.49 25.55 15.13 18.12 
Mutagenetic 17.43 23.12 15.53 27.77 11.82 19.13 17.43 23.12 15.53 27.77 11.82 19.13 
NBZPX2 16.52 23.51 17.53 23.77 16.23 19.51 18.22 23.68 18.31 24.03 16.76 20.2 
NCPS 19.91 26.33 19.29 16.98 14.34 19.37 20.6 27.69 19.87 19.63 13.57 20.27 
NNcon 10.87 14.15 8.35 15.26 7.6 11.25 10.87 15.52 10.46 15.26 7.93 12.01 
PCC 17.02 21.43 17.38 21.22 16.09 18.63 18.71 22.86 19.26 23.57 16.59 20.2 
PhyCMAP 9.58 11.17 10.11 17.6 10.7 11.83 9.55 12.21 10.39 19.01 11.6 12.55 
PhysicoMI 18.76 32.18 19.4 18.33 13.65 20.46 20.03 30.06 19.03 20.09 16.08 21.06 
PSICOV 14.74 19.37 19.22 22.49 17.33 18.63 16.18 20.36 18.15 22.48 16.77 18.79 
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RCW 16.71 21.14 15.21 16.67 14.67 16.88 17.36 22.56 15.93 20.07 14.66 18.12 
SCA 16.36 24.03 16.07 22.61 12.22 18.26 17.78 24.77 17.39 21.86 13.6 19.08 
Spidermonkey 17.81 24.4 16.88 20.56 14.83 18.89 19.06 23.98 18.15 22.24 15.41 19.77 
SVMcon 8.52 13.3 9.54 16.82 8.89 11.42 9.48 13.43 11.02 17.96 11.38 12.65 
ZRES 16.4 20.75 14.35 16.81 14.94 16.65 17.23 22.69 16.32 18.93 15.24 18.08 
CNPR 9 11.23 7.77 13.67 8.65 10.06 10.06 12.78 9.41 15 9.77 11.4 
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1 Ensemble coevolution system
IntroductionWe designed an ensemble coevolution system (ECS) to provide robust predic-
tions of coevolving residues. Ensemble learning systems which combine different prediction
methods have shown high prediction performance in many studies (see review in [27, 28]).
For instance, XCS was made to improve the self-adaptation of evolutionary algorithms [29].
LCSE enhances the rule-based classification through the combination of reinforcement learn-
ing, evolutionary computing and heuristic approaches [30]. GAssist improves the perfor-
mance of the ordinal classification through the assembling of several rule-based models [31].
A cascade generalization framework which combines naı¨ve Bayesian classifiers, linear dis-
criminant classifiers and decision trees could improve the classification accuracy compared
to individual classifiers [32]. An ensemble system has recently been developed to improve
the prediction of protein-protein interactions using the attributes collected mainly from gene
ontology annotations [33]. This ensemble system integrates four machine learning methods
(support vector machine, random forest, decision tree and naı¨ve Bayesian network) based on
the majority voting strategy [33]. Recently, an ensemble method which combines PSICOV
and machine learning classifiers can improve the prediction of transmembrane inter-helix
contacts [34].
An ensemble learning system is usually built to combine a set of prediction models and
is popular when the prediction variability between prediction models (classifiers) is high
[28]. Ensemble learning is not needed if all models predict the same results [28]. Ensemble
learning systems usually comprise of three parts: (1) data sampling/selection, (2) model
prediction, (3) a combiner. The combiner plays a key role to determine the strategy of how
different predictions from various methods are integrated. There are many popular ensemble
strategies such as: majority voting (predictions supported by more than 50% of methods),
weighted voting (predictions are weighted according to the importance of models) and Borda
count (predictions consistently obtained by all the models) [27, 28].
Inspired by the principle of ensemble learning, we endeavored to build a software system
which integrates known sequence-based methods for coevolution prediction. It turned out to
be difficult for several reasons. Firstly, there is a lack of gold standard datasets for training
the ensemble learning system. Secondly, sequence-based methods predict different scores
for statistical couplings and mostly do not predict true negatives, which limits our choices
on data sampling and ensemble strategies. Thirdly, some sequence-based methods require
heavy computational time, a limit which may restrain a broad application of ensemble learn-
ing on large protein families. For the above reasons, the potential ensemble coevolution
system should provide robust predictions while combining the number of sequence-based
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methods as few as possible. Moreover, we considered the design of an ensemble coevolu-
tion system as an optimization problem, where the objective function was defined as a linear
function (see Methods). Here, we describe the details of our heuristic algorithm which we
designed to identify the combination of sequence-based methods which improves the pre-
diction performance.
Algorithm 1 A heuristic algorithm for identifying the combination of sequence-based meth-
ods
Require: As inputs, a set of sequence-based methodsM = fMiji = 1; :::; Ng and multiple
sequence datasets D = fDiji = 1; :::; Tg.
Ensure: As an output, the optimized method combination 
+.
1: 
 = ; fInitiate the method set 
 as empty.g
2: f(
; D) = 0; fInitiate the performance score of 
 as 0 given the datasets D.g
3: i = 0; i = 0; :::; N ; fInitiate the performance increase as 0 for each method.g
4: Step 1: Apply sequence-based methods and perform the linear transformation.
5: for i = 1 to N do
6: for j = 1 to T do
7: Obtain the coevolution scoring matrix C(Mi; Dj);
8: Linear transformation: C(Mi; Dj) =
C(Mi;Dj) min(C(Mi;Dj))
max(C(Mi;Dj)) min(C(Mi;Dj)) ;
9: end for
10: end for
11: Step 2: Optimization of method combination.
12: while 
 =  ormax() > 0 do
13: for i = 1 to N do
14: 
 = 
 [Mi whereMi 2M=
 ; fAdd the unvisited methodMi to 
.g
15: for j = 1 to T do
16: C(
; Dj) =
P
Mk2

wk;j C(Mk; Dj); fIntegrate the coevolution predictions.g
17: end for
18: i =
1
T
TP
j=1
f(C(
; Dj))  f(
; D); fIncrease of average performance score.g
19: end for
20: ifmax() > 0 then
21: M = argMimax(); fAmethod with the highest increase of performance score.g
22: 
 = 
 [M; fUpdate the best method subset.g
23: f(
; D) = f(
; D) +max(); fUpdate the best performance score.g
24: end if
25: end while
26: Return 
 as 
+.
Methodology M = fMiji = 1; :::; Ng represents a set of sequence-based methods Mi and
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D = fDjjj = 1; :::; Tg represents sequence datasets, where N is the number of methods
and T is the number of sequence datasets. Given a training dataset Dj , the sequence-based
methodMi predicts a coevoltuion score for each statistical coupling. This coevolution score
is normalized in the matrix with L  L elements, denoted as C(Mi; Dj), where L is the
length of residue positions in Dj . Every non-empty element in this matrix represents the
coevolution score of the statistical coupling between the positions n andm. To contend with
varied statistical measurements used by different methods, four normalization strategies have
been previously proposed [13]. Given a continuous variable x as an input, the normalized
variable y satisfies:
(1) Linear transformation: y = x min(x)
max(x) min(x) .
(2) Power transformation: y = 10(max(x) x)(max(x) min(x)).
(3) Binary transformation: if Rank(n;m) < , then y = 1; otherwise y = 0. The cutoff 
is the number of top-ranked couplings ( = L in our analysis).
(4) Log transformation: y = b  xa where Vmax = log10[max(x)], Vmin = log10[min(x)],
if min(x);max(x) > 0, then a = K=(Vmax   Vmin); b =  K  Vmax=(Vmax   Vmin), and
K = 5 as default.
We compared these four strategies and chose linear transformation as our normalization
strategy because linear transformation performed the best using HIV-1 datasets (data not
shown). Based on the normalized coevolution scores, the coupling (n;m) in the entire ma-
trix is ranked, denoted as Rank(n;m). Given a statistical measurement f (e.g. AUC), the
performance of the sequence-based methodMi is measured by f(C(Mi; Dj)). Suppose wi
and uj denotes the weight of the method Mi and the weight of the Dj , respectively. The
objective function for the ensemble learning is defined as:
F (
; D) =
TX
j=1
uj
j
j
X
Mi2

wi  f(Cn;m(Mi; Dj))
An optimized combination of methods 
+ is identified when 
+ = max

2M
F (
; D). To
simplify the learning procedure with a small number of training datasets, our study assumed
that uj = 1 and wi equals to 1 or 0. We therefore designed a heuristic algorithm (Algorithm
1) that provides a suboptimal solution to identify 
+ by maximizing the performance scores.
Specifically, we used the forward selection to improve the prediction performance because
of the high computational complexity. The forward selection each time adds one method
into the optimized method set if the added method increases the performance score. Our
heuristic algorithm begins with the initiation of global variables (line 1-3). The coupling
predictions of sequence-based methodsM are performed given the sequence datasetD (line
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5-10, T = 7; N = 27 in our analysis). Given each method with a sequence dataset, statistical
couplings in the scoring matrix C(Mi; Dj) are obtained according to method measurements
(line 7). The scores are then linearly transformed between 0 and 1 (line 8). Thereafter,
the forward selection adds one method into the method subset 
 at each loop (line 14). It
also assembles the statistical coupling predictions for the AUC evaluation (line 16, see AUC
definition in Methods). The increase of performance score i is calculated for each method
Mi when added into the method subset 
 (line 18). In each round, one method that increases
the highest performance score is added into the method subset 
 (line 20-24). The procedure
ends when adding any method does not improve the best performance score (line 12). The
method subset 
 is returned as the optimized method combination 
+ (line 26).
The forward selection algorithm can be easily adapted into the backward elimination,
which requires the initiate parameter 
 = f1; :::; Ng and line 14 in the algorithm should
remove a single method instead of adding a method. In order to achieve a promising opti-
mization, we implemented both forward selection and backward elimination approaches. In
our experiments, we found that both strategies identified the method set 
 with four methods
(NCPS, RCW, PhyCMAP, CMPro), suggesting a convergence of the heuristic search. Over-
all, our heuristic algorithm offers a fast computation to identify a method combination with
improved prediction performance using a local optimization procedure.
Our parameter settings: Parameters of sequence-based methods were initialized according
to individual methods (see parameter settings in the next section).
Software availability Our toolbox.
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Table 1. Summary of 27 sequence-based methods integrated in ECS
Method Methodology Software availability Year Ref
ASC Mutual information Our toolbox 2011 [10]
APC Mutual information Our toolbox 2011 [10]
BN Bayesian network https://code.google.com/p/bright/ 2007 [22]
CTMP Markov model, phylogenetic tree http://www.stat.sinica.edu.tw/chyeang/ 2007 [24]
CoMap Compensation coefficient, phylogenetic tree http://gna.org/projects/comap 2007 [25]
Complementary Complementary matrix, Pearson coefficient Our toolbox 2006 [11]
CMPro Neural network http://scratch.proteomics.ics.uci.edu/ 2012 [19]
DNcon Deep network, Bolzmann machine http://iris.rnet.missouri.edu/dncon/ 2012 [18]
GREMLIN Maximum entropy function http://openseq.org/ 2013 [26]
Interdependency Entropy, mutual information http://www.uhnresearch.ca/labs/tillier/depend2 2004 [5]
LogR Bayesian network, APC Author’s generosity 2010 [13]
MI Mutual information Our toolbox - [1]
MIBP MI, physicochemical property http://www.biomedcentral.com/1471-2105/12/206 2011 [7]
Mutagenetic Maximum likelihood mixed tree http://mtreemix.bioinf.mpi-inf.mpg.de/ 2005 [21]
NBZPX2 Normal binary Toolbox in [6] 2012 [6]
NCPS Mutual information, sequence similarity Our toolbox 2009 [9]
NNcon Neural network http://casp.rnet.missouri.edu/nncon.html 2009 [17]
PCC Mutual information, Pearson coefficient Our toolbox 2010 [12]
PhyCMAP Random forest, integer linear programming http://raptorx.uchicago.edu/ 2013 [20]
plmDCA Maximum entropy function http://plmdca.csc.kth.se/ 2013 [35]
PSICOV Sparse inverse covariance http://bioinfadmin.cs.ucl.ac.uk/downloads/PSICOV/ 2012 [15]
PhysicoMI MI, AA substitution matrix Our toolbox 2012 [8]
RCW Mutual information Our toolbox 2007 [3]
SCA Statistical free energy coupling http://systems.swmed.edu/rr lab/sca.html 2009 [10]
Spidermonkey MCMC Bayesian network, phylogenetic tree http://www.hyphy.org/w/index.php/Main Page 2008 [23]
SVMcon Support vector machine http://casp.rnet.missouri.edu/svmcon.html 2006 [16]
ZRES Mutual information Toolbox in [6] 2009 [4]
2 Position-specific sequence-basedmethods in the last decade
This section provides more details about the 27 sequence-based methods (Table 1). For each
method, we begin with a simple introduction and then briefly describe their key mathemat-
ical models. Lastly, we explain the parameter settings used in this study and the software
availability. We order these methods according to their methodology so that methods with
similar methodologies are described together.
2.1 MI: mutual information [1]
IntroductionMutual information (MI) measures the contribution of the knowledge of vari-
able X’s information in the redution of the uncertainty of the other variable Y [36]. For its
simplicity, MI has been adapted to predict coevolving positions and protein contact map [37].
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It was proposed based on the hypothesis that coevolving residues or residues in contact tend
to share a high mutual information [1].
Methodology Let variablesX; Y represent two protein positions in multiple sequence align-
ment (MSA) from a protein (family), X = x indicates that the position X takes the amino
acid x which is one of amino acid forms in MSA, P (X = x) represents the marginal proba-
bility of the position X taking the amino acid form x in MSA. Likewise, P (X = x; Y = y)
is the joint probability that the position X takes amino acid form x and Y takes amino acid
form y simultaneously. The mutual information between X = x and Y = y is defined as:
MI(X = x; Y = y) = P (X = x; Y = y) log
P (X = x; Y = y)
P (X = x)P (Y = y)
(1)
Furthermore, the mutual information between two positions X; Y is the sum of mutual
information of all possible configurations at the position X and Y , defined as:
MI(X;Y ) =
X
x
X
y
P (X = x; Y = y) log
P (X = x; Y = y)
P (X = x)P (Y = y)
(2)
Our parameter settings In cases where the marginal probability P (X = x) or P (Y = y) in
the denominator was zero causing the impossible infinity in the log function of MI, Laplace
smoothing was used by adding 1 into the both denominator and the numerator of the marginal
probability P (X) (P (X = x) = n=N ! P (X = x) = (n + 1)=(1 +N)) [38]. Gaps from
the positions of interest were ignored in the calculation of probabilities [1]. To solve the
heavy computation in large protein families, a fast parallel programming code is provided in
our Toolbox.
Software availability Our toolbox and toolbox in [6].
2.2 ASC and APC: average sum and product correction [2] (2008)
Introduction In this study, two statistical methods were proposed to estimate the background
MI in the process of protein evolution. The background MI was defined as the average MI
over all position pairs [2]. The average sum correction (ASC) was defined as the sum of MI
calculated at the positions i and j minus the background MI [2]. Similarly, the average prod-
uct correction (APC) was defined as the product of MI calculated calculated at the positions
i and j divided by the background MI.
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Methodology Based on mutual information described in the previous section, the back-
ground mutual information in ASC [2] is defined as:
ASCBackgroud(i; j) =
1
2n
X
X
[MI(i;X) +MI(X; j)]  1
n2
X
X
X
Y 6=X
MI(X;Y ) (3)
Suppose i and j are two residue positions of interest and n is the number of the overall
protein positions. Given an input MSA, the second part of above formula is a constant so
that the ASC correction for mutual information is defined as:
ASCMI(i; j) = MI(i; j)  1
2n
X
X
[MI(i;X) +MI(X; j)] (4)
Assuming that the background dependency is a product of independent factors associated
with two positions, the average product correction (APC) is defined as:
APCMI(i; j) = MI(i; j) 
P
X
MI(i;X)P
X
MI(X; j)P
X;Y
MI(X; Y )
(5)
Parameter settingsWe used the same parameter settings as the mutual information.
Software availability Our toolbox.
2.3 RCW: row and column weighted MI [3] (2007)
Introduction Similar to the methodology of ASC and APC, the method RCW takes the
average mutual information as the ”weight” for the pairwise dependency. Given simulated
datasets, RCW outperformed MI, logarithm correlation and multi-dimensional amino acid
representation [3].
Methodology Let i and j be the positions of interest,MI(i; j) denotes the mutual informa-
tion between the positions i and j. The mean value of mutual information at the position i is
calculated as MIi =
Pn
j=1MI(i; j)=(n   1), then RCW between the position pair (i; j) is
defined as:
RCW (i; j) =
MI(i; j)
MIi +MIj   2MI(i; j)=(n  1)
(6)
Our parameter settings We used the same parameter settings as those in mutual informa-
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tion.
Software availability http://www.cbs.dtu.dk/services/InterMap3D/.
2.4 ZRES: Z-residue score [4] (2009)
Introduction This study provided a method which refines MI by removing strong non-
coevolutionary influence and accounting for the position variability. The method is built
based on the linear regression between the mutual informationMIij andMIiMIj . Using
protein sequences from 1592 protein families in the Pfam database (http://pfam.sanger.ac.uk/),
this study showed that predicted coevolving positions tend to be in a close physical proxim-
ity [4].
Methodology As the stochastic and phylogenetic bias may affect the performance of MI,
ZRES uses the linear regression to fit the mutual information MIij with MIi MIj . By
doing so, the biases can be measured by Resij = MIi MIj    MIij , where  is the
estimated coefficient in the linear regression. Based on this principle, the statistical coupling
between the positions i and j is quantified by the Z-score, denoted as ZRes(i; j):
ZRes(i; j) =
(Resij   1n
nP
j=1
Resij)(Resij   1n
nP
i=1
Resij)s
nP
i=1
(Resij   1n
nP
j=1
Resij)2
s
nP
j=1
(Resij   1n
nP
i=1
Resij)2
(7)
The higher the Z-score ZRes(i; j), the higher the chance that two positions i and j are
coevolving.
Our parameter settingsWe used the default parameter settings in the ZRES toolbox [6].
Software availability Toolbox in [6].
2.5 Interdependency V2.1 [5] (2004)
Introduction To reduce phylogenetic bias, the statistical couplings in this method were
quantified by the statistical interdependency ratio, which measured the differences between
the observed residue interdependency and the expected residue interdependency [5].
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Methodology The expected independency is estimated by the likelihood of equivalent residues
compared to all residues at other positions. Let N be the number of non-gap residues at the
position Xi, the expected interdependency of the position Xi is defined as:
MS(Xi) =
1
N
X
j 6=i
X
xi;xj
log
P (Xi = xi; Xj = xj)
P (Xi = xi)P (Xj = xj)
(8)
The interdependency is proposed using the entropy weight based on the hypothesis that
residue positions do not increase the dependency when no functional correlation exists [5].
To quantify the amino acid variation at the position Xi, the entropy function H(Xi) is mea-
sured through H(Xi) =  
P
xi
P (Xi = xi) logP (Xi = xi). Based on the mutual infor-
maiton and the entropy function, the interdependency ratio is defined as:
R(Xi; Xj) =
MI(Xi; Xj)H(Xi)H(Xj)
MS(Xi) +MS(Xj)
[1 H(Xi)H(Xj)] (9)
Our parameter settingsWe performed the analyses using the default statistical parameters.
Software availability http://www.uhnresearch.ca/labs/tillier/depend2/dependency.html
2.6 NBZPX2: normal binary ZPX2 [6] (2012)
Introduction The method NBZPX2 which is an adaption of ZRES improves the perfor-
mance of ZRES by refining the MSA inputs. The refinement strategy uses the data transfor-
mation called the normal binary [6].
Methodology The workflow of this method can be simply described by three steps. (1) The
sequences in the MSA inputs are reordered using the sequence similarity, i.e. the 1st and 2nd
sequences are the most similar sequences and the 3rd sequence is the the closest one to the
2nd, etc. This reordering process terminates until all sequences have been visited. (2) The
MSA input is transformed into a binary dataset through AA comparisons of two subsequent
sequences. Specifically, the binary value 1 indicates that two AAs are identical, otherwise 0.
(3) The ZRES algorithm is applied using the transformed dataset.
Our parameter settingsWe used the default parameter settings.
Software availability Toolbox in [6].
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2.7 MIBP: MI with physicochemical property [7] (2011)
Introduction This study proposed a covariation model which uses mutual information ac-
counting for residue physicochemical properties [7]. Ten groups of amino acids were classi-
fied according to physicochemical properties. The key concept of this model is to calculate
the mutual information between amino acid groups, while taking into account the back-
ground amino acid distribution. Performance of this model was compared to MI and ELSC
using three protein families (1JXA-A, 1B93-A and PF01053).
Methodology Based on MI, the MIBP covariation between the positions i and j is defined
as:
MIBP (i; j) =
X
an
X
bm
P (xi 2 an; xj 2 bm) log P (xi 2 an; xj 2 bm)
Pb(xi 2 an)Pb(xj 2 bm)
Where xi and xj are residues at the positions i and j in the MSA input, an (n=1...10) and bm
(m=1...10) denotes the AA functional group at the positions i and j, respectively. Ten residue
groups include hydrophobic (A, G, C, T, I, V, L, K, H, F, Y, W, M), aromatic (F, Y, W, H),
aliphatic (I, V, L), tiny (A, S, G, C), small (P, N, D, T, C, A, G, S, V), proline (P), charged (K,
H, R, D, E), negative (D, E), polar (N, Q, S, D, E, C, T, K, R, H, Y, W) and positive (K, H,
R). Based on BLOSUM62 substitution matrix, Pb(xi 2 an) is the background distribution of
physicochemical properties and is defined as:
Pb(xi 2 an) = P (xi 2 an)=B(an)P
an
P (xi 2 an)=B(an)
WhereB(an) denotes the BLOSUM62 constants for functional groups (hydrophobic: 0.504,
aromatic: 0.132, aliphatic: 0.111, tiny: 0.243, small: 0.6632, charged: 0.226, negative:
0.117, positive: 0.507, proline: 0.244, polar: 0.043) [7].
Our parameter settingsWe used the default parameters in the original python implementa-
tion.
Software availability http://www.biomedcentral.com/1471-2105/12/206.
2.8 PhysicoMI: physico-chemical corrected MI [8] (2012)
Introduction PhysicoMI was proposed to calculate residue similarities taking into account
physical-chemical properties. In this method, MI and AA frequency are corrected using the
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BLOSUM62 substitution matrix [8].
Methodology Suppose x; y are two AAs at the positionsX and Y respectively, the corrected
joint probability of X in the presence of Y is modeled as:
f(X = x; Y = y) =
n(x; y) +
P
(x0;y0) 6=(x;y) n(x
0; y0)S(x; x0)S(y; y0)=
p
N
N +
p
N
(10)
Where n(x; y) is the number of residues x at the position X and y at the position Y .
S(x; x0) is the substitution score when amino acid x0 is replaced by x. In the same fashion,
the corrected marginal probability is defined as:
f(X = x) =
n(x) +
P
x0 6=x n(x
0)S(x; x0)=
p
N
N +
p
N
(11)
In the final measurement, both marginal and joint probabilities are corrected by physical-
chemical properties:
MIPhysico(X; Y ) =
X
X=x
X
Y=y
f(x; y) log
f(X = x; Y = y)
f(X = x)f(Y = y)
(12)
Our parameter settingsWe used the default parameter settings.
Software availability Our toolbox.
2.9 NCPS: normalized coevolutionary pattern similarity [9] (2009)
Introduction To identify coevolving positions by MI can be complicated due to common
ancestry and stochastic noise [9]. NCPS was therefore proposed to normalize sequence sim-
ilarities by reducing the background noise in the correlated mutation analysis. This study
showed that the background noise could be reduced using three coevolution analyses: M-
cBASC, OMES and MI [9].
Methodology Suppose CM(i; j) represents the correlated mutation score between the posi-
tions i and j. The coevolutionary pattern similarity (CPS) between the positions i and j is
modeled by the dot product of two vectors. Let n be the number of overall residue positions
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in the sequences, CPS(i; j) is defined as:
CPS(i; j) =
1
n  2
X
k 6=i;j
CM(i; k)CM(j; k) (13)
Secondly, the coevolutionary pattern similarity is normalized as follows:
NCPS(i; j) =
CPS(i; j)r
1
n(n 1)
P
i;j
CPS(i; j)
(14)
Thirdly, the NCPS score is proposed by removing the background noise.
aMIc(i; j) =
1
2
"
MI(i; j) NCPS(i; j)
max[MI(i; j) NCPS(i; j)] +
E(i; j)[MI(i; j) NCPS(i; j)]
max [E(i; j)[MI(i; j) NCPS(i; j)]]
#
(15)
Where E(i; j) = H(i)H(j)[1 H(i)H(j)] is the entropic factor [9].
Our parameter settingsWe used the default parameter settings.
Software availability Our toolbox.
2.10 SCA: statistical coupling analysis [10] (2009)
Introduction Statistical coupling analysis (SCA) has been shown to reveal allosteric com-
munications by the energetically coupled positions in the PDZ protein family [39]. Later
studies showed that SCA could discover evolutionary networks which mediate the allosteric
communications [40]. Moreover, SCA can be useful for protein design. For instance, artifi-
cial WW domains were designed based on the statistical couplings predicted by SCA. The
artificial WW domains can be folded and bind with peptides in high affinities as natural WW
domains [41].
Several follow-up studies have been devoted to improve the performance of SCA using
different protein families [10,42,43]. The SCA toolbox written in Matlabr has been updated
to Version 5.0, including different functions such as coupling prediction, independent com-
ponent analysis and spectral decomposition. The latest version of SCA is available online.
Methodology SCA measures the statistical couplings observed in the functional interactions
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of protein families [39]. The hypothesis relies on the observation that the distribution of
amino acids in one position shifts due to the changes of amino acid distribution at another
position. The degree of evolutionary dependence is quantified by the statistical coupling
energy based on the Boltzmann equation [39]. The high coupling energy corresponds to
the increased dependence between coevolving residues. Specifically, the statistical coupling
energy between the positions i and j, denoted as Gi;j , is modeled as:
Gi;j =
sX
x
(lnP xijj   lnP xi )2 (16)
Where P xi is the probability of the residue x at the position i; P
x
ijj is the probability
of the residue x at the position i given the perturbation position j. The method in SCA
V5.0 extends the coevolution estimation by the covariance analysis and principle component
analysis [42]. Briefly, the pairwise correlation C(ab)ij between the residue a at the position i
and the residue b at the position j is modeled as:
C
(ab)
ij = ln
hf (a)i (1  q(a))
(1  f (a)i )q(a)
i
(f
(ab)
ij   f (a)i f (b)j ) ln
hf (b)j (1  q(b))
(1  f (b)j )q(b)
i
(17)
Where f (a)i is the frequency of having the residue a at the position i, f
(ab)
ij is the joint fre-
quency of having the residue a at the position i and the residue b at the position j, q(a) is
the background probability of residue a in all proteins and q = (0.073, 0.025, 0.050, 0.061,
0.042, 0.072, 0.023, 0.053, 0.064, 0.089, 0.023, 0.043, 0.052, 0.040, 0.052, 0.073, 0.056,
0.063, 0.013, 0.033) (alphabetic order for the 20 amino acids).
Our parameter settingsWe used default parameter settings in the SCA toolbox V5.0 [42].
Software availability http://systems.swmed.edu/rr lab/sca.html.
2.11 Complementary: complementarymatrix in Pearson coefficient [11]
(2006)
Introduction To predict inter-protein residue coevolution, this study proposed a method
which calculates Pearson’s coefficients accounting for the complementary residues between
protein interaction interfaces [11]. It is known that residue frequencies and residue pairs at
protein-protein interfaces follow certain complementary patterns [44]. For instance, abun-
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dant hydrophobic residue pairs are often found at large protein interaction interfaces, while
polar residue pairs usually occur at small interfaces [44]. Integrated into Pearson’s coeffi-
cients, the complementary information was proven useful for inter-protein coevolution pre-
dictions. A promising performance of this method was found in the comparison with four
other methods (MI, SCA, ELSC and OMES) using a sequence dataset containing 224 protein
families in the Pfam database.
Methodology Let N be the number of sequences in the MSA input, Si be the AA exchange
matrix at the position i, Si(k; l) be the exchange score between the kth and lth residues at
position i, Si and i be the mean and the standard deviation of residues in the exchange
matrix Si at the position i, respectively. Given the kth sequence, Ci(k);j(k) is the estimated
complementary value between the kth residues at the position i and j [44]. The corrected
Pearson’s coefficient between the position i and j, termed ri;j , is modeled as:
ri;j =
1
N2
NX
k;l=1
(Si(k;l)   Si)(Sj(k;l)   Sj) Ci(k);j(k)  Ci(l);j(l)
ij
(18)
Our parameter settings The complementary matrix of 20 amino acids in [44] was used and
the other parameters were default.
Software availability Our toolbox.
2.12 PCC: Pearson correlation coefficient [12] (2010)
Introduction To reduce background noise and phylogenetic bias, this study proposed Pear-
son’s correlation coefficients (PCC) for statistical coupling predictions [12].
Methodology Suppose N is the number of sequences in the MSA input, Si is the exchange
matrix at the position i, Si(k; l) is the AA exchange score between the kth and the lth residues
at the position i, Si and i are the mean and standard deviation of residues in the exchange
matrix Si, respectively. The Pearson’s coefficient between the positions i and j, termed ri;j ,
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is proposed as:
r(i; j) =
1
N2
NX
k;l=1
(Si(k;l)   Si)(Sj(k;l)   Sj)
ij
(19)
Si =
1
N2
NX
k;l=1
Si(k;l); i =
vuut 1
N2   1
NX
k;l=1
[Si(k;l)   Si]2 (20)
Using the ASC to reduce the phylogenetic bias, the significance of statistical coupling is
modeled as:
PCC(i; j) = r(i; x) + r(j; x)  r (21)
r(i; x) =
1
N
NX
j=1
r(i; j); r =
1
N
NX
i=1
r(i; x) (22)
Our parameter settingsWe used the default parameter settings.
Software availability Our toolbox.
2.13 LogR: disentangling direct coupling analysis [13] (2010)
Introduction The sequence-based method LogR was proposed to model the weighted co-
variations by disentangling indirect statistical dependencies from direct dependencies. Specif-
ically, it quantifies the statistical couplings by estimating the weights of pairwise edges in
Bayesian spanning trees, which can model the dependencies between residue positions [13].
In this study, the coevolving residue chains were found to travel through spatial distances in
protein 3D structures, indicating the indirect (or transitive) statistical dependencies. To re-
duce phylogenetic biases, LogR used the phylogenetic correction proposed by APC . More-
over, the statistical dependency was estimated using informative prior and conservation in-
formation, both of which could improve the accuracy of contact predictions [13].
Methodology Suppose the number of residue positions is N given the MSA input D. Mea-
sured through Dirichlet prior, P (Di;j) is the joint probability of the position i and j. The
statistical dependency between the ith and jth positions, termed as Ri;j , is defined by the
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joint probability P (Di;j) divided by the marginal probability P (Di) and P (Dj).
Ri;j =
P (Di;j)
P (Di)P (Dj)
(23)
To avoid the existence of 0 in the statistical independency, logRi;j is shifted to a non-
negative value by dividing the minimal value of logRi;j , which is Si;j = log(Ri;j=minRi;j).
The APC phylogenetic correction is then calculated as:
log(RCi;j) = Si;j  
NP
n=1
Sn;i
NP
m=1
Sm;j
NP
n=1
NP
m=1
Sn;m
(24)
To disentangle the statistical couplings, the weight of the edge j  (j) in the entire
spanning tree space is estimated using the priors P (), where (j) is the parent node of the
jth position in the spanning tree . The weighted correlation for the positions j and (j) is
measured as:
Mj;(j) = (R
C
j;(j))
 j;(j)
1  j;(j) (25)
Where (j) is the neighboring node of the node jth in the spanning trees and j;(j) is
the probability of the edge j   (j) in random spanning trees.
Our parameter settingsWe used the default parameter settings in the software.
Software availability Author’s generosity.
2.14 DCA: direct coupling analysis [14] (2011)
Introduction This study aimed at the prediction of residue couplings in the spatial proximity
given folded proteins [14]. Specifically, it approximates the maximum entropy by exploring
the pairwise couplings given a MSA input. The implementation in [14] was proven to be fast
compared to a message-passing algorithm published in an early study [45]. Moreover, the
true positive rates of the new DCA has been shown to be better than MI and LogR using 131
domain families collected from the Pfam database.
Methodology Suppose P (X1; X2; :::; Xn) is the join distribution given the MSA input with
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the residue positionsXi from 1 to n. Given a maximum-entropy function, the optimization of
the joint distribution is approximated by the marginal and the pairwise dependencies using
the Lagrange transformation. Specifically, the approximation strategies (i.e. independent
positions, mean-field approximation) are used to determine parameters in the Gibbs potential
functions. Similar to mutual information, DCA models the pairwise couplings using the
direct information (DI):
DIij =
X
xi
X
xj
P
(dir)
ij (xi; xj)  log

P
(dir)
ij (xi; xj)P
xi
P
(dir)
ij (xi; xj) 
P
xj
P
(dir)
ij (xi; xj)

(26)
Where xi is the residue at the position i, P
(dir)
ij (xi; xj) is estimated through the following
Gibbs potential function:
P
(dir)
ij (xi; xj) =
1
Zij
exp[  (fij(xi; xj)  fi(xi)fj(xj)) 1(xi; xj) + ehi(xi) + ehj(xj)] (27)
Where fi is the marginal probability function of the position ith in the MSA input and fij
is the joint distribution between the positions i and j. ehi(xi) is the parameter that imposes
the empirical single-residue counts of residue xi at the position i. Zij is the normalization
parameter. (fij   fifj) 1(xi; xj) is the element in the inverse of an empirical correlation
matrix derived from the MSA input.
Our parameter settingsWe used the default parameter settings.
Software availability http://plmdca.csc.kth.se/.
2.15 PSICOV: precise structural contact prediction [15] (2012)
Introduction PSICOV uses a graphical Lasso approach with a sparse inverse covariance
estimation to reduce prediction biases, caused by functionally related residue chains in pro-
tein structures [46]. The rationale of the sparse inverse covariance method relies on the fact
that residue contacts are sparse in the known protein structures. Specifically, the non-zero
terms in the sparse inverse covariance matrix represent coupling positions and the zero terms
indicate that two positions are conditionally independent, assuming that the underlying dis-
tribution follows a multivariate Gaussian distribution [46].
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Methodology The methodology of PSICOV can be simply described as:
 = [  diag(X1; :::; XN) + (1  )  Cov(X; Y )] 1 (28)
Where N is the number of residues in a sequence, Cov(X;Y ) is the covariance matrix
over all positions X; Y in the MSA input,  is the concentration matrix,  2 [0; 1] is the
shrinkage parameter which targets diagonal values in diag(X1; :::; XN) and Xi denotes the
mean of diagonal values in the covariance matrix. The inverse covariance matrix estimates
the significance of the positions i and j in contact through the function SCij =
P
abjabij j,
where a and b are two residues at the position i and j, respectively. The correction of phylo-
genetic bias has also been taken into account in the PSICOV score:
PCij = S
C
ij  
NP
i=1
SCij 
NP
j=1
SCij
NP
i=1
NP
j=1
SCij
(29)
Our parameter settings Recommended by the software manual, the parameter  r and  i
were set to 0.005 and 62, respectively. Other parameters were default.
Software availability http://bioinfadmin.cs.ucl.ac.uk/downloads/PSICOV/.
2.16 SVMcon: support vectormachine contact map predictor [16] (2007)
Introduction SVMcon was designed to predict residue-residue contacts using support vector
machines (SVM). It was ranked as the second best method in the 7th critical assessment of
structure prediction (CASP7). SVMcon also outperformed CMAPpro using the benchmark
datasets.
Methodology SVMcon begins with the assessment of five input features for each residue pair
at the positions i and j. Using over 310000 training data points, the input features include the
local window features, pairwise information features, residue type features, central segment
window features and protein information features. Thereafter, the classification function of
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the SVM learner f(x) is defined for contact predictions:
f(x) =
X
xi2S+
i K(x; xi) 
X
xi2S 
i K(x; xi) + b (30)
K(x; xi) = e
 0:0025jjx xijj2 (31)
Where xi is the data point in a support vector, b represents the estimation bias, i is a non-
negative weight assigned to the training data point xi by minimizing a quadratic objective
function. S+ indicates the data point of residue pairs in contact and S  indicates that the data
point of a residue pair which is not in contact. A new data point x is predicted to be positive
if f(x) > 0. K(x; xi) is the Gaussian radial basis kernel and the inverse of the variance
parameter is optimized to be 0.0025.
Our parameter settingsWe used the default parameter settings.
Software availability http://casp.rnet.missouri.edu/svmcon.html
2.17 NNcon: neural network-based contact map predictor [17] (2009)
Introduction The 2D-Recursive Neural Network (2D-RNN) models were trained to predict
residue-residue contacts using a sequence dataset consisted of 482 protein families.
Methodology Ten 2D-RNNs are trained and validated using the 10-fold cross-validation on
a sequence dataset with 482 proteins. These 10 models are assembled to predict residues in
contact. The residue contacts are those residue pairs which have the Euclidean distance of
their C atoms less than 8 or 12 angstroms. Given a protein sequence with the length of n
amino acids, the 2D-RNN constructs a n  n input matrix and outputs a probability matrix
with n n contact elements.
Our parameter settingsWe used the default parameter settings.
Software availability http://casp.rnet.missouri.edu/nncon.html
2.18 DNcon: neural network contact prediction [18] (2012)
Introduction DNcon was proposed to improve the predictions of residue-residue contacts
based on deep networks and boosting techniques [18]. Using the standard back propagation
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algorithm, the weights of multiple layers in deep networks were trained based on the pre-
dicted secondary structures, solvent accessibility, amino acid features and position-specific
scoring matrix [18]. The method was evaluated using the D329 dataset containing 329 pro-
teins, the SVMCON TEST dataset containing 48 proteins and the CASP9 dataset containing
16 proteins. The comparison experiments showed that DNcon outperformed two other meth-
ods, ProC S3 and SVMcon.
Methodology Amino acid features (e.g. electrostatic charge, codon diversity, volume, po-
larity, secondary structure) are modeled in deep network classifiers with the combination of
restricted Bolzmann machines. The short, medium and long range residue-residue pairs are
sampled from a large database, which is used to train deep network classifiers with the im-
proved prediction power. The final contact predictions are evaluated by the scoring function.
Our parameter settings We used the software server with the option of the top 5L predic-
tions where L is the length of amino acids given an input sequence.
Software availability http://iris.rnet.missouri.edu/dncon/.
2.19 CMPro: 2D recursive neural network [19] (2012)
Introduction This study proposed a contact prediction architecture based on neural network-
s and structural alignment models. Using both CASP8 and CASP9 datasets, performance of
CMPro was shown to outperform PSICOV and other methods which were tested in CASP8
and CASP9 contact prediction [19].
Methodology Neural network prediction models are constructed in three steps. Firstly, the
coarse contacts and the orientations between secondary structure elements are predicted us-
ing 2D recursive neural networks. The probability of parallel contact, anti-parallel contact or
no-contact is estimated using feature variables extracted from protein secondary structures
and amino acid compositions in the sequence input. Secondly, the energy-based method
is used to optimize the amino acid alignment of strand - strand and helix-helix secondary
structures. The log-likelihood objective function is defined as:
EA =  
nX
i=1
logPA(a^i; ^i) (32)
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Where n is the number of anti - parallel (or parallel) contacting residue pairs, a^i and ^i are
the true shift and phase for the ith example, respectively. Thirdly, a deep neural network
architecture refines the prediction of residue contacts. Deep NN architecture has k layers
and each layer contains 2592 residue features, 377 coarse features, 477 align-
ment features and 81 temporal features. Due to the heavy computation of backpropagated
gradients in multi-layered neural networks, an incremental approach has been proposed to
train the weights of neural networks. The prediction performance is further improved using
10-fold cross-validation.
Our parameter settingsWe used the default parameter settings.
Software availability http://scratch.proteomics.ics.uci.edu/
2.20 PhyCMAP: random forest, integer linear programming [20] (2013)
Introduction This study proposed a sequence-based method PhyCMAP, which integrates
both evolutionary and physical restraints using random forests and integer linear program-
ming approach [20]. The performance comparison showed that PhyCMAP outperformed
NNcon, CMAPpro and DCA given the CASP10 dataset.
Methodology PhyCMAP has two components. The first component predicts the probability
score of the residue contacts using random forests. The contact score for the position pair
(i; j) is defined as:
HPS(i; j) =
X
h2H
PSbeta(a
h
i ; a
h
j ) + PShelix(a
h
i ; a
h
j ) (33)
Where ahi is the residue in a homology sequence h aligned to the residue i in the query
sequence, PSbeta(ahi ; a
h
j ) is the probability of a residue pair (a
h
i ; a
h
j ) forming a contact in
the -sheet structure, PShelix(ahi ; a
h
j ) is the probability of residues a
h
i ; a
h
j forming a contact
connecting two helix structures. Both PShelix(ahi ; a
h
j ) and PSbeta(a
h
i ; a
h
j ) are obtained from
protein structures in the training dataset containing 900 non-redundant protein structures
The second component selects a set of top-ranked contacts by using the integer linear pro-
gramming, which maximizes accumulative probabilities under a set of physical constraints.
max
X;R
X
6j i
(Xi;j HSP (i; j))  g(R) (34)
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Where Xi;j is a binary variable and Xi;j = 1 if the position pair (i; j) are in contact.
g(R) =
P
Rr is a linear penalty function with the parameter r defined over 8 hard and
soft constrains. These constraints are mainly proposed based on the observations of residue
contacts between two -strand structures or between two -helix structures.
Our parameter settingsWe used the default parameter settings.
Software availability http://raptorx.uchicago.edu/
2.21 Mutagenetic: mutagenetic tree mixture model [21] (2005)
Introduction Mutagenetic tree models have been designed to investigate the accumulation
of drug resistance-associated mutations in HIV-1 proteins [21]. It was shown that mutage-
netic tree mixture models could identify many parallel or confluent mutation pathways using
sequence datasets of HIV-1 protease [21]. This method has also been applied to the field of
tumor development [47, 48].
Methodology The mutagenetic tree model is built using a set of directed weighted trees.
This model can approximate the joint probability distribution consisting of a set of muta-
tional events. Based on a similar methodology proposed in the mixed tree probabilistic
models [49], EM algorithm can be used to maximize the log-likelihood function. Suppose a
mutagenetic tree is denoted as T = (V;E) with the set of vertices V and the set of edges E,
x = fxi; :::; xNg represents the mutation pattern. Given one mutagenetic tree model T , the
likelihood of a pattern x in T can be modeled as:
L(xjT ) =
Y
e2E(V (x))
P (e)
Y
e2E(V V (x))
(1  P (e)) (35)
The mixed tree model is defined by M =
PK
k=1 kTk, where k 2 [0; 1] is the weight
of the kth tree Tk and
PK
k=1 k = 1. The likelihood of the trained mutagenetic tree M is
defined as:
f(x1; :::; xN jM) =
NX
i=1
log
KX
k=1
kL(xijTk) (36)
The parameters k and Tk are thereafter optimized by the EM algorithm [49].
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Our parameter settings For each input sequence dataset, one mutagenetic tree was created
using default settings.
Software availability http://mtreemix.bioinf.mpi-inf.mpg.de/.
2.22 BN: Bayesian network [22] (2007)
Introduction Bayesian networks (BNs) have been used to model mutational pathways in
HIV-1 proteins [22, 50, 51]. It was shown that Bayesian networks could be useful for im-
proving drug resistance predictions [52].
Methodology Bayesian networks are trained based on methods adapted from the Bright soft-
ware [53]. Given a MSA input, this method maximizes the posterior probability of Bayesian
networks whose variables are residues or therapies. The robustness of Bayesian networks
is examined by a non-parametric bootstrap resampling using 100 replicates. In a consensus
Bayesian network, edges between variable nodes are considered as robust if their bootstrap
supports are above 65%. Different amino acids at the same position may cluster together due
to the presence of strong antagonistic effects.
Our parameter settings We used the default parameters as indicated in [22] (bootstrap re-
sampling: 100 replicates, bootstrap support: 65%). In order to compare results of Bayesian
networks with other coevolution methods, we extracted position pairs of adjacent variables
in the trained Bayesian networks.
Software availability https://code.google.com/p/bright/.
2.23 Spidermonkey [23] (2008)
Introduction In the software platform Spidermonkey, coevolving positions are modeled us-
ing Bayesian networks trained using reconstructed ancestral sequences from a phylogenetic
tree [23]. More specifically, Spidermonkey uses MCMC-based algorithms to model con-
ditional dependencies between the non-synonymous positions in Bayesian networks. The
advantage of this method relies on the fact that Bayesian networks can model high order
interactions using ancestral sequences, for coevolving positions may have high-order inter-
actions in protein families [23]. However, the convergence of MCMC in the process of
Bayesian network training requires large sequence datasets and a heavy demand of compu-
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tation power. As a compromise between computing power and prediction accuracy, Spider-
monkey allows for at most two parent nodes of variables in Bayesian networks [23].
Methodology Given a sequence dataset, Spidermonkey estimates a substitution model and
reconstructs ancestral sequences in the phylogenetic tree using a strategy of maximum-
likelihood optimization. The statistical dependencies between protein positions in Bayesian
networks are modeled using a MCMC-based algorithm [23].
Our parameter settings In our analysis, we used parameter settings as follows: (1) nu-
cleotide model 012345, MG94x; (2) treatment of ambiguities: averaged; (3) the number
of positions with substitution values: default, (5) maximum parents: 2; (6) the number of
MCMC chains: default (100000); (7) the number of burn-in steps before the main chain:
default (10000); (8) the number of ancestral samples: default (100).
Software availability http://www.hyphy.org/w/index.php/Main Page.
2.24 CTMP: continuous time Markov process [24] (2007)
Introduction This study proposed a continuous-timeMarkov process model augmented with
the phylogenetic information [24]. To identify sequence coevolution in different protein fam-
ilies, the model was applied to screen all position pairs of inter- and intra-domains in the pro-
tein families [24]. The majority of coevolving protein domains was found near functionally
important positions, providing an interesting information of protein structural and functional
constraints in the sequence coevolution [24].
Methodology Four steps are performed to measure the residue coevolution. Firstly, the ma-
trix of coevolutionary rates corresponding to amino acid changes is obtained by reweighting
the independent coevolutionary rates. Secondly, sequences from different protein domains
are mapped to the leaves of phylogenetic trees shared with the same topology. Thirdly, the
log-likelihood ratio is measured by the likelihood of observed sequences in the coevolution
model compared to the null model. By doing so, the joint probability of residue positions
is approximated by the singlet and pairwise terms of aligned positions among all states of
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internal nodes in the phylogenetic tree. The CTMP model is simplified as:
P (x1(t); :::; xn(t)jx1(0); :::; xn(0)) =
Q
xi xj2
P (xi(t); xj(t)jxi(0); xj(0))
nQ
i=1
P (xi(t)jxi(0))di 1
(37)
Where xi(t) is the sequence composition at the ith position with the sampling time t
given the phylogenetic tree  and the MSA input. The position pair xi(t); xj(t) is observed
on the leaves of the phylogenetic tree .
Lastly, the false positive rates of coevolving position pairs are evaluated by multiple hy-
pothesis tests using the simulated datasets.
Our parameter settings We used maximum 500 sequences for our CTMP analysis due
to limited computation power. The maximum-likelihood phylogenetic trees were trained
using RAxML V7.0.4. The threshold on the fraction of sequences coevolving with non-
overlapping states was set to 1, as well as the threshold on the fraction of conserved se-
quences. The penalty parameter () of the CTMP model was set to 0.25 according to the
manual.
Software availability http://www.stat.sinica.edu.tw/chyeang/.
2.25 CoMap [25] (2011)
Introduction CoMap V1.4.1 uses Markov models to identify residue coevolution based on
the phylogenetic tree [25]. This model takes into account the uncertainty of ancestral states
and among-site rate variations given the phylogenetic tree inputs [25]. As an advantage,
CoMap can work on both nucleotide and amino acid sequence datasets. Using a ribosomal
RNA dataset including 79 bacteria species, this method identified more than 95% intra-
protein predictions based on protein contact maps [25].
Methodology Firstly, for each residue position, CoMap creates a substitution vector which
contains posterior estimates of the substitutions at each branch given a phylogenetic tree. By
accounting for position variations, this substitution vector is defined as:
vi;b =
X
c
X
xp
X
xq
nxp;xq(t  rc) P (xp; xq; rcjDi;) (38)
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Where Di is the ith position of the MSA input D, a is the number of internal nodes in the
phylogenetic tree and b is a branch in the phylogenetic tree, rc is the rate of class c,  is
the set of parameters including branch lengths, substitution matrices and rate distribution
parameters. nxp;xq(t  rc) is the conditional observation of substitutions expected on the
branch with its branch length t and the states xp; xq.
Secondly, the Pearson’s correlation coefficient between two substitution vectors is:
i;j =
Cov(Vi; Vj)
(Vi)(Vj)
(39)
Where Vi = (vi;1; :::; vi;b; :::; vi;m) is obtained in the first step and (Vi) is the standard
deviation of Vi.
Thirdly, to show the statistical significance, p-values are measured by comparing the
conditional observations of substitutions with the expectation of the null hyphothesis of in-
dependence. The null distribution is estimated by simulating 100000 independent pairs [25].
Our parameter settings We used pairwise analysis to calculate the compensation coeffi-
cient for each position pair in CoMap V1.4.1 [54]. Due to the limitation of our computation
power, the number of sequences in the input datasets was restrained to be less than 500 se-
quences. In the first round, CoMap reported varied positions in the maximum likelihood phy-
logenetic tree. We thereafter removed positions reported with infinite maximum likelihood
according to the software manual. In the second round, the maximum-likelihood phyloge-
netic trees were prepared using RAxML V7.0.4. As suggested in the software manual, we
used the following parameters: (1) nijt aadist.sym=no, (2) aadist.type=grantham, (3) statis-
tic=Compenstation, (4) model=LG08, (5) statistic.null=yes, (6) statistic.null.compute pvalue=yes,
and (7) statistic.null.nb rep CPU=8. The coevolving residues were collected if their p-values
were less than 0.05.
Software availability http://gna.org/projects/comap.
2.26 GREMLIN: generative regularized models of proteins [26] (2013)
IntroductionGREMLIN was originally proposed to learn an undirected probabilistic graph-
ical model of the amino acid compositions given the inputs of MSA [55]. GREMLIN out-
performed hidden Markov models using the datasets of 71 protein families extracted from
the PFAM database [55]. As sequence-based methods usually require a large amount of se-
quences to achieve robust predictions, this paper contributes to incorporate prior information
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on residue pairs so that fewer sequences are needed for robust coevolution predictions [26].
Performance of GREMLIN was compared to MI, PSICOV, DCA, plmDCA and MIc using a
large sequence dataset with 329 protein families.
MethodologyMarkov random field is used to model the probability distribution given a set
of independent sequences X = fX1; X2; :::; XNg in the MSA input. Due to the intractable
computation of the global maximum likelihood function, the pseudo-likelihood function is
proposed for the efficient approximation to make the problem solvable. Specifically, the
pseudo-likelihood is defined as:
pll() =
1
N
X
Xi2X
NX
j=1

log j(X
i
j) +
X
k2ne(Vj)
log jk(X
i
j; X
i
k)  logZj

(40)
Where X ij is the residue at the j
th position of the ith sequence given the MSA input, j
is the potential function of the position j, jk is the potential function for the edge j   k, Zj
is a local normalization constant, ne(Vj) is the set of vertices connected with the node j in
the undirected graphical model.
For both structure learning and parameter estimation, the L1 regularization is used for
the optimization based on the projected gradients.
max; pll()  node
NX
s=1
jjV sjj22 edge
NX
s=1
NX
t=s+1
st (41)
subject to : 8(1  s < t  N) : st  jjW stjj2 (42)
Where node and edge are regularization parameters that determine the weights of the
penalty level. st is the differentiable proxy of jjW stjj2, which solves the calculation using a
smooth convex optimization.
Our parameter settingsWe used the default parameter settings.
Software availability http://openseq.org/.
3 Implementation and software manual
Several sequence-based methods (e.g. SCA, LogR, DCA, GREMLIN, ZERS, NBZPX2)
were designed using Matlab, we thus decided to build up the ensemble coevolution system
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in Matlab by integrating the available methods and implementing 7 methods without public
sources. We newly implemented 7 methods in our toolbox including ASC, APC, Comple-
mentary, NCPS, PCC, PhysicoMI and RCW. The other methods designed in non-Matlab
platform were requested from the authors or downloaded from public sources (see Table 1).
Due to the copy right issue, users who wish to test methods implemented in other pub-
lications need to install software independently. Nevertheless, our toolbox offers users the
platform to prepare the input files, the command lines (if any), the extraction of output results
and the assembly of all 27 methods integrated in our system. Currently, the toolbox V0.1
has only been tested in Linux (Ubuntun 12.04, 64-bit). If system comparability or other is-
sues were encountered, please write an email to liguangdi.research@gmail.com to obtain the
latest version.
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6.1 Summary 
HIV-1 infected patients who failed protease inhibitor (PI) treatment can harbor viral 
strains with Gag mutations. Yet, the coevolution between HIV-1 protease and its 
substrate Gag under PI selective pressure is still not fully understood. This study 
investigates the coevolution network between HIV-1 subtype B Gag and protease 
under PI selective pressure, and to evaluate its impact on current Gag inhibitors and 
HIV-human protein interactions. We sequenced the Gag and protease regions from 
531 patients in our Leuven cohort, and extracted 514 genomic and 3171 Gag-protease 
sequences from public resources. Using an ensemble coevolution method, 31 Gag-
protease coevolving pairs of amino acid positions were predicted, 13 of them were 
evaluated as true positives by in vitro and in vivo data. All predicted coevolving pairs 
harbored Gag-protease mutations whose prevalence significantly differed between the 
PI-resistant and the PI-susceptible sequence populations (p-value<0.01). HIV-1 Gag-
protease coevolution networks consisted of 29 Gag positions associated with 30 
protease positions. Among these 29 PI-associated Gag positions, 13 positions also 
interacted with human proteins (e.g. APOBEC3G, Cyclophilin A); while only 6 
positions interacted with 8% of 50 Gag experimental inhibitors. Moreover, 62.1% of 
29 PI-associated Gag positions and 80% of 10 Gag mutations identified in our Leuven 
cohort were located within either Gag cleavage sites or Gag C terminus (positions: 
362-500). Genome-wide sequence analysis independently showed that the amino acid 
diversity of drug-targeted regions and Gag cleavage sites and C terminus was 
significantly associated with drug selective pressure (p-value<0.01). HIV-1 can 
escape PI selective pressure by selecting protease drug resistance and Gag mutations 
mainly located at Gag cleavage sites and C terminus. HIV-1 Gag-protease coevolution 
takes place in the presence of human proteins, but it is unlikely to affect Gag 
experimental inhibitors. 
6.2 Introduction 
HIV is a retrovirus that produces up to 10 billion viral particles within a single patient 
per day. Immature HIV virions released from human cells are transformed into mature 
virions after the protease-mediated proteolytic cleavage of Gag and Gag-Pol 
polyproteins. This process leads to the morphogenesis of structural proteins (matrix, 
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capsid, nucleocapsid (NC), p6), enzymatic proteins (protease, reverse transcriptase, 
integrase) and spacer peptides (p1, p2) [1] (Figure S 6.1). HIV protease recognizes 
Gag and Gag-Pol cleavage sites through conserved structural conformations [2]. 
Proteolytic processing proceeds in a relatively strict order at a rate that varies between 
cleavage sites, and is susceptible to the surrounding contexts [3]. Since this 
proteolytic mechanism plays a major role during the viral maturation, protease 
represents an attractive anti-HIV drug target [4]. Many FDA-approved protease 
inhibitors (PIs) have been designed to competitively bind the protease catalytic pocket 
[5]. However, PI drug resistance can be caused by the evolutionary flexibility of HIV-
1 protease and protease substrates [6]. 
Position-specific coevolution is the reciprocal evolutionary process of amino acids, 
often observed within interacting protein positions [7, 8]. While position-specific 
coevolution on the conserved surface of transient protein-protein interactions is 
relatively slow [9, 10], HIV protease and its substrate Gag may coevolve much faster 
due to the high mutation rate via the error-prone reverse transcription [11]. Since PIs 
target protease positions that interact with protease substrates, amino acid 
substitutions in protease and Gag selected for in response to these drugs may cause 
conformational changes that affect binding affinity and impair viral replication [6]. 
Residues surrounding Gag cleavage sites may compensate for these conformational 
changes to maintain viral productivity [12]. 
Protease structures have been crystallized with peptide analogs of protease substrates 
(approximately 10 amino acids, Figure S 6.1). Weak bindings [13], low interaction 
energies [14] and reduced van der Waals contacts [15] can affect the interactions 
between drug-resistant protease mutants and natural substrate peptides. NC-p1 peptide 
substrates in the presence of Gag mutation A431V bind to protease V82A mutant 
more tightly than wild-type protease, because of increased hydrogen bonds and van 
der Waals contacts [16]. Nevertheless, a macromolecular Gag-protease complex has 
not been crystallized owing to the flexible nature of Gag inter-domain links [17]. 
Taken together, current structural evidence has shown that some cleavage site 
mutations (CSMs) in Gag can compensate for the reduced Gag-protease interactions 
[8]. However, lack of structural information on the macromolecular Gag-protease 
Chapter 6: HIV-1 Gag-protease coevolution networks 
  
249 
complex imposes a challenge to explore the coevolution between the full-length Gag 
and protease. 
Previous clinical studies have analyzed different patient cohorts (e.g. AREVIR [18], 
NARVAL [19], RESINA [20]) to identify HIV-1 Gag mutations (e.g. A431V, I437V, 
L449V) emerging during PI-based regimen, mostly in the presence of protease 
mutations (e.g. M46I, L76V, V82A). In the absence of protease mutations, Gag 
mutations may cause partial PI resistance, but these occurrences are low [21, 22]. As 
HIV-1 Gag mutations are associated with PI drug resistance, the coevolution between 
the full-length Gag and protease warrants a comprehensive investigation. 
This study investigates the coevolution between the full-length Gag and protease of 
HIV-1 subtype B under PI selective pressure. HIV-1 Gag-protease coevolution 
networks were constructed using sequence-based methods that detect coevolving pairs 
of amino acid positions in the full-length Gag and protease. To evaluate our networks, 
we reviewed in vitro and in vivo studies to collect a comprehensive list of documented 
Gag-protease mutation patterns associated with PI susceptibility. We then presented 
longitudinal data of our Leuven patient cohort to show Gag substitutions emerging 
during PI treatment. We also explored the potential impact of Gag-protease 
coevolution on Gag inhibitors and HIV-human protein interactions.  
6.3 Materials and Methods 
Dataset of PI-susceptible and PI-resistant Gag-protease sequences 
We retrieved 11812 nucleotide sequences of HIV-1 subtype B Gag and protease 
proteins from the Los Alamos HIV database (parameters: HXB2 nucleotide region: 
790-2550, minimum nucleotide length: 300, one sequence per patient). We thereafter 
selected 9320 sequences containing the full-length protease and the partial or full-
length Gag. Sequences were then aligned against the HXB2 reference and manually 
curated using Seaview V4.3 [23]. Sequence subtypes were assessed using the 
subtyping tools of Rega V3.0 [24] and COMET V1.0 (http://comet.retrovirology.lu/). 
To improve sequence quality, we excluded sequences with ≥99% similarity, 
hypermutations, stop codons or discordant subtype classifications [25]. This 
procedure resulted in the Gag-protease sequence dataset containing 3171 HIV-1 
subtype B Gag and protease sequences. 
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For these 3171 sequences, patient treatment information was collected from the 
original publications. Approximately 90% of Gag-protease sequences were sampled 
from treatment-naïve patients, while detailed treatment information of PI-treated 
patients (e.g. drug combination, therapy duration, treatment outcome) was largely 
lacking. For this reason, we used the drug resistance interpretation algorithms, HIVdb 
V6.0 [26] and Rega V9.1 [27], to assess PI susceptibility levels and to deduce 
assumed PI exposure. We defined two subsets of Gag-protease sequences based on 
the predicted PI activity. The Gag-protease PI-susceptible dataset contained 1820 Gag 
and protease sequences, which were sampled from PI-naïve patients and were 
interpreted as susceptible to all PIs by both interpretation algorithms. The Gag-
protease PI-resistant dataset contained 434 Gag and protease sequences, which were 
predicted to be (partially or fully) resistant against at least one common PI by both 
algorithms. For our Gag-protease coevolution analysis, we further selected full-length 
Gag and protease sequences, leading to 759 PI-susceptible and 168 PI-resistant 
sequences in the so-called “full-gagpro-susceptible” and “full-gagpro-resistant” 
datasets, respectively. Merging these two latter datasets led to the “full-gagpro” 
sequence dataset. Given the full-gagpro-susceptible sequence dataset, intra-subtype 
sequence diversity was calculated at each amino acid position of Gag and protease 
using our method described previously [25]. 
Amino acid diversity in the HIV-1 B full-length genome 
We retrieved 672 full-length subtype B genomic sequences from the Los Alamos HIV 
database (one genome per patient). Following similar procedures described above 
(sequence alignment, sequence quality control, drug susceptibility tests), we obtained 
a subtype B genomic dataset including 94 drug-resistant and 420 drug-susceptible 
genomic sequences, respectively. Drug resistance interpretation algorithms HIVdb 
V6.0 [26] and Rega V9.1 [27] were used to perform drug susceptibility tests on three 
drug classes: PI, RTI (reverse transcriptase inhibitor) and INI (integrase inhibitor). 
Next, we concatenated amino acid sequences of 15 HIV-1 proteins in the full-length 
genome. Using bootstrap resampling with 1000 replicates, pairwise amino acid 
diversity at each position was calculated using drug-susceptible and drug-resistant 
genomic sequence datasets [25]. Mann–Whitney U test was then performed to 
compare the distributions of amino acid diversity. A significant difference was 
detected if a p-value was lower than 0.05. 
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Sequence and treatment information of Leuven longitudinal dataset 
We collected 637 Gag and protease sequences from 531 subtype B infected patients, 
attending the University Hospital of Leuven. Sequences were obtained during clinical 
follow-up between 1996 and 2013. Our sequencing protocol and quality control 
procedures were described previously [25, 28, 29]. We extracted patient information 
(history of antiretroviral treatment, sampling time, viral load) from our Leuven 
database [30]. Of these 637 Gag-protease sequences, all contained the protease region, 
22 had the full-length Gag and the remaining 615 sequences contained the Gag C 
terminus. To identify amino acid substitutions that emerged during PI-based regimen, 
we prepared the longitudinal dataset of 44 patients who had taken at least one PI for 
more than four weeks, and had more than one Gag-protease sequences sampled 
during PI treatment. 
Documented Gag-protease mutation patterns in literature 
We reviewed journal articles to collect the in vitro and in vivo data of Gag-protease 
mutation patterns documented in HIV-1 subtype B. We searched for English articles 
in PubMed published between January 1983 and September 2013 using the keywords 
(“HIV Gag mutation”, “HIV Gag protease”, “HIV protease mutations Gag”, “HIV 
Gag evolution”, “HIV protease cleavage”). English articles were also reviewed if they 
were referenced in literature or published full-length Gag sequences. Table S 6.1 
summarizes the documented Gag-protease mutation patterns, in vivo data (patient 
treatments, sampling size, study cohort) and in vitro data (viral replication capacity, 
drug susceptibility to the following 8 PIs: TPV, SQV, APV, DRV, NFV, IDV, RTV, 
ATV). 
HIV-1 PDB and protein secondary structures 
From the RCSB Protein Data Bank (www.pdb.org), we collected the PDB data of 
HIV-1 matrix, capsid, p2, nucleocapsid, p6, protease and PI-protease complexes. The 
quality of PDB data was assessed using PDBREPORT [31] (default parameters). We 
used PSIPRED [32] and 2Struc [33] to determine protein secondary structures (e.g. 
alpha-helix, beta-strand, random-coil); consensus results were used for our analysis. 
Gag experimental inhibitors, HIV-human protein interactions and human 
CD4/CD8/antibody epitope positions 
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Three datasets were prepared as follows. (A) We retrieved 137 drug binding positions 
of 50 Gag experimental inhibitors from our recent study [25]. (B) From the NCBI 
HIV human protein interaction database [34], we collected information on direct 
interactions between 46 human proteins and 4 HIV-1 Gag proteins (matrix, capsid, 
nucleocapsid, p6). Table S 6.2 summarizes the information of HIV-human protein 
interaction. (C) We collected human CD4 T cell and antibody epitopes from the HIV 
Los Alamos database [35]. For human CTL/CD8 T cell epitopes, we included the A-
list which comprised the best-defined CTL/CD8 epitopes described by Llano et al [35] 
(Table S 6.3). 
Ratio of synonymous and non-synonymous substitution rate (dN/dS) 
Given the full-gagpro-resistant sequence dataset, we constructed a maximum-
likelihood phylogenetic tree using FastTree V2.1 [36] (parameters: continuous gamma 
distribution, fully optimized generalized time-reversible (GTR) model). Provided with 
the constructed phylogenetic tree and the full-gagpro-resistant sequence dataset, we 
then applied HyPhy V2.1.0 [37] to estimate the ratio of non-synonymous and 
synonymous rates (dN/dS). We employed the single likelihood ancestor counting 
(SLAC) model with the optimized GTR [37]. Ambiguous nucleotides were resolved 
by averaging over all possible states for the ancestral sequence reconstruction [37]. 
Statistical significance of dN/dS was measured by the continuous extension of 
binomial distributions (significance level: 0.01) [37]. 
Prevalence of HIV-1 subtype B Gag-protease mutations 
We calculated the prevalence of Gag-protease mutations in the PI-susceptible 
(n=1820) and PI-resistant (n=434) sequence datasets described above. Two-tailed 
Fisher’s exact tests were performed to examine the statistical significance of mutation 
prevalence differed between these two sequence datasets. The adjusted p-values were 
obtained using multiple testing correction via the false discovery rate approach [38]. 
Odds-ratio (OR) test was used to determine the odds of a Gag-protease mutation 
being in the PI-resistant sequence dataset relative to the odds of the mutation being in 
the PI-susceptible sequence dataset. Specifically, for a Gag mutation X and a protease 
mutation Y, OR is defined as: 
Re Re[ / (1 )] / [ / (1 )]s s Sus SusOR P P P P   , where PRes(X,Y) and 
PSus(X,Y) represent the probability of Gag-protease mutation (X,Y) in the full-gagpro-
resistant and the full-gagpro-susceptible datasets, respectively. Zero values in the OR 
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contingency tables were replaced with 0.5 to avoid an impossible infinity [39]. The 
95% confidence interval of OR was determined using standard procedures [40]. 
 
Construction of Gag-protease coevolution networks 
Provided with the full-gagpro-resistant and full-gagpro-susceptible sequence datasets, 
we used our ensemble coevolution system (ECS) to predict coevolving pairs of amino 
acid positions, so-called coevolving pairs. Given an input of multiple sequence 
alignments (MSAs), ECS detects coevolving pairs in a three-step process (Figure 
6.1A): (1) Sequence datasets are prepared by bootstrap resampling with 100 
replicates. (2) Resampled sequence datasets are imported into four sequence-based 
methods (CMPro [41], NCPS [42], PhyCMAP [43], RCW [44]), each of which 
estimates a statistical score for a coevolving pair. (3) The combiner assembles 
predictions of coevolving pairs from the four sequence-based methods, treated with 
equal weights. Thereafter, coevolving pairs with their statistical scores are ranked and 
exported as outputs. 
A four-step process constructed HIV-1 Gag-protease coevolution networks (Figure 
6.1B). (1) The full-gagpro-resistant (so-called D1) and the full-gagpro-susceptible 
(so-called D2) sequence datasets were imported into ECS for the prediction of 
coevolving pairs. The outputs of top-ranked coevolving pairs predicted from D1 and 
D2 were collected into the output datasets O1 and O2, respectively. Predicted 
coevolving pairs between a Gag position and a protease position, termed Gag-protease 
coevolving pairs, were separated from those coevolving pairs of positions within 
individual Gag and protease proteins. 
(2) Differential predictions between O1 and O2, denoted as O1-O2, were 
distinguished to identify top-ranked Gag-protease coevolving pairs that were 
associated with genotypic PI resistance. The threshold of top-ranked predictions was 
set to 3×L, where L was the number of amino acid positions in the MSA (L=599 in 
our datasets). 
(3) Top-ranked Gag-protease coevolving pairs were considered as significant if they 
contained any Gag-protease mutation that met two conditions: (a) Prevalence of the 
Gag-protease mutation was higher than 1% in the full-gagpro-resistant dataset. (b) 
Prevalence of the Gag-protease mutation differed significantly between the full-
gagpro-resistant and the full-gagpro-susceptible datasets (p-value < 0.01). 
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(4) HIV-1 Gag-protease coevolution networks were constructed. A top-ranked Gag-
protease coevolving pair was considered as a true positive if it contained one of the 
Gag-protease mutation patterns documented in the in vitro and in vivo datasets (Table 
S 6.1). Apart from the true positives, the unconfirmed predictions and the unpredicted 
positives (documented Gag-protease mutation patterns but not predicted) were also 
mapped. 
 
 
Figure 6.1: (A) Schematic view of ensemble coevolution system (ECS). Three major 
components are illustrated: (1) Input data, one MSA. (2) Bootstrap resampling, 100 
sequence datasets are generated by the bootstrap resampling with 100 replicates. (3) 
Sequence-based methods, resampling sequence datasets are imported into four 
sequence-based methods (CMPro [41], NCPS [42], PhyCMAP [43], RCW [44]); each 
predicts a coevolution score for a coevolving pair of amino acid positions. (4) 
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Combiner, for each coevolving pair predicted by individual sequence-based methods, 
coevolution scores are averaged over 100 resampling sequence datasets and 
normalized between 0 and 1. Given the equal weights of individual sequence-based 
methods, coevolving pairs are ranked based on normalized coevolution scores. 
(B) Workflow of coevolution network construction. Five steps are processed. (1) 
Predictions of coevolving pairs, the PI-resistant and PI-susceptible datasets are 
imported into ECS (see (A)) for the detection of coevolving pairs of amino acid 
positions. The prediction outputs from PI-resistant and PI-susceptible datasets are 
denoted as O1 and O2, respectively. (2) Disentangle top-ranked coevolving pairs, top-
ranked predictions from the output O1 are disentangled from the output O2. (3) 
Statistical test, top-ranked predictions in the disentangled dataset O1-O2 are further 
selected if they have a high prevalence in D1 (≥1%) and a prevalence differed 
between D1 and D2 (p-value < 0.01). (4) Prediction evaluation, true positives of 
predicted coevolving pairs are evaluated using the in vitro and in vivo datasets (Table 
S 6.1). (5) Construction of Gag-protease coevolution networks. Gag-protease 
mutation patterns in the coevolution networks are classified into three categories: (a) 
true positives, predictions confirmed by in vitro or in vivo datasets; (b) unconfirmed 
positives, predictions that are not identified by either in vitro or in vivo datasets; (c) 
unpredicted positives, position pairs in in vitro or in vivo datasets that are not 
predicted. (6) Evaluation of coevolving Gag and protease positions in a six-step 
process. (a) The PDB dataset is used for analyzing the location of these positions in 
the HIV-1 protein structures. (b) The sequence and treatment data of 44 patients in the 
Leuven cohort is analyzed to identify Gag substitutions emerging during PI treatment. 
(c) The 137 drug binding positions of 50 Gag inhibitors are compared with the 29 PI-
associated Gag positions in the Gag-protease coevolution networks. (d) HIV-1 Gag 
positions that interact with human proteins (Table S 6.2) are compared with the 29 
PI-associated Gag positions. (e) Human CD4/CD8/antibody epitope positions in the 
HIV-1 Gag (Table S 6.3) are compared with the 29 PI-associated Gag positions. (f) 
The amino acid diversity of 420 drug-susceptible and 94 drug-resistant genomic 
sequences is compared to identify regions in the HIV-1 full-length genome associated 
with drug selective pressure. 
 
6.4 Results 
The Gag-protease coevolution networks 
We modeled the Gag-protease coevolution networks using the full-length Gag and 
protease sequence datasets. Thirty-one Gag-protease coevolving pairs were predicted 
by a combination of four sequence-based methods (CMPro [41], NCPS [42], 
PhyCMAP [43], RCW [44]). Thirteen predictions were confirmed as true positives by 
the independent in vitro and/or in vivo datasets (A431+I54, A431+L10, A431+A71, 
A431+V82, A431+L33, L449+L10, A431+K20, A431+M46, A431+L90, L449+G16, 
A431+M36, I437+I54, L449+I54). For the other 18 coevolving pairs of Gag and 
protease positions, each harbored at least one Gag-protease mutation pattern (e.g. 
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A431V+I54V), whose prevalence differed significantly between the full-gagpro-
resistant and the full-gagpro-susceptible datasets (p-value<0.01, Table S 6.7). Figure 
6.2 maps Gag-protease coevolving pairs, protein secondary structures, dN/dS, intra-
subtype sequence diversity, human CD4/CD8/antibody T cell epitopes, Gag drug 
binding positions and Gag positions involved in the HIV-human protein interactions. 
 
Figure 6.2: HIV-1 subtype B Gag-protease coevolution networks. Eight layers 
indicate: Layer 1: Gag-protease coevolving positions. Red lines indicate true positive 
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predictions confirmed by in vitro or in vivo datasets. Black lines indicate unconfirmed 
predictions. Green lines indicate position pairs in the in vitro or in vivo datasets that 
are not predicted. The index of Gag and protease positions are also annotated. 
Layer 2: Drug binding positions of Gag experimental inhibitors (red dots). 
Layer 3: Three sub-layers from outside to inside denote human antibody (grey), CD4+ 
(green) and CD8+ (blue) T cell epitopes, respectively. 
Layer 4: Protein secondary structures. Colored regions indicate alpha-helix (blue), 
beta-strand (grey) and random-coil (orange) secondary structures. 
Layer 5: Index of HIV-1 protein positions based on the HXB2 reference. 
Layer 6: HIV-human protein interaction domains (skyblue). 
Layer 7: dN/dS. Red dots indicate positively selected positions (dN/dS>1, p-values < 
0.01); others are colored green. 
Layer 8: Amino acid diversity of Gag and protease positions. 
Visualization software: Circos (http://circos.ca/). 
Gag-protease coevolution networks included 29 Gag positions associated with 30 
protease positions. Among these 59 positions, 61.0% were highly variable (intra-
subtype sequence diversity > 0.1) and 11.9% were under positive selection (dN/dS > 
1, p-value < 0.01). Moreover, 22.0%, 33.9% and 44.1% of these 59 positions were 
located within alpha-helix, beta-strand and random-coil secondary structures, 
respectively (Table S 6.5). The top-ranked Gag-protease coevolving pairs included 4 
Gag cleavage positions (A431, I437, L449, P453) that were previously confirmed by 
at least five studies, as well as 7 protease positions (L10, G16, I54, L63, A71, V82, 
L90) containing PI resistance mutations in four HIV-1 drug resistance interpretation 
algorithms (Table S 6.4). Moreover, a significant association was not found between 
PI-associated Gag positions and human antibody, CD8+ and CD4+ T cell epitopes (p-
value>0.1), suggesting that immune selective pressure was unlikely to impact on the 
Gag-protease coevolution. 
Four non-cleavage site positions (S111, V218, T401, F463) were newly identified to 
coevolve with protease residues (Table S 6.5). (1) For S111, Gag-protease coevolving 
pair S111+L63 harbored two mutation patterns (S111C+L63A, S111C+L63A) 
significantly associated with genotypic PI resistance (p-value<0.005). (2) For V218, 
four Gag-protease coevolving residues (V218P+L10I, V218P+V82A, V218P+A71V, 
V218P+L90M) had a high prevalence in the PI-resistant sequences (>1%, Table S 
6.5). (3) For I401, coevolving pattern I401T+G16E was found in 3.29% of PI-
resistant sequences, but was completely absent in the PI-susceptible sequences (p-
value<0.01). (4) For F463, F463L+A71V was significantly associated with genotypic 
PI resistance (p-value < 0.0001). 
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HIV-1 Gag and protease mutations associated with PI drug susceptibility 
We collected in vitro and in vivo data documented in literature to show the PI drug 
susceptibility of Gag and protease mutation patterns (Table S 6.1). Most Gag 
mutations (88.6%, 39/44) were associated with PI drug susceptibility in the presence 
of protease mutations (fold change IC50 > 1 or EC50 > 1, Figure 6.3).  
Figure 6.3: PI susceptibility associated with HIV-1 Gag-protease mutation patterns. 
X-, y- and z-axes represent Gag mutation patterns, protease mutation patterns and the 
level of PI susceptibility, respectively. The PI drug susceptibility of these Gag and 
protease mutation patterns are either reported in in vitro studies (fold change IC50 > 3 
or EC50 > 3) or in vivo studies (Table S 6.1). Eight PIs extracted from crystallized 
structures of protease-inhibitor complexes are shown next to the z-axis. Red spheres 
indicate in vivo data and spheres in other colors indicate in vitro data. The legend 
indicates the degrees of PI susceptibility conferred by in vitro studies. PDB codes 
used for structural visualization: 1SDU (PI: IDV), 3EKX (NFV), 2NNP (SQV), 2Q5K 
(LPV), 3OXX (ATV), 2O4N (TPV), 3OXW (DRV), 3OXV (APV). 
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Figure 6.4: (A) Prevalence of Gag-protease mutation pairs in the HIV-1 subtype B 
Gag-protease sequence dataset. Gag and protease mutations are listed vertically and 
horizontally, respectively. Prevalence of Gag-protease mutations is colored according 
to the legend. Red asterisks indicate Gag-protease mutation pairs documented in in 
vitro or in vivo datasets (Table S 6.1). 
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(B) Association between CSMs and protease mutations in HIV-1 subtype B. Red 
circles indicate that the prevalence of CSM-protease mutation patterns is significantly 
differed between the PI-resistant and PI-susceptible sequence datasets (p-value<0.01). 
Other Gag-protease mutation patterns are indicated in black (p-values > 0.01) with 
scaled concentric green circles (1≤OR≤5) or full green circles (OR ≥5). 
 
Of the 244 Gag-protease mutation pairs documented by in vitro (fold change IC50 > 1 
or EC50 > 1) or in vivo dataset (mutations selected under PI selective pressure), 
27.2% had a prevalence of less than 0.1% (Figure 6.4A). Of the 105 CSM-protease 
mutation pairs whose prevalence differed significantly between the PI-resistant and 
PI-susceptible sequence datasets (Figure 6.4B, p-value < 0.01), 44 were also 
documented in the in vitro and in vivo datasets. Particularly, seven Gag mutations 
(V128I, R380K, A431V, I437V, L449F/V, P453L) were strongly associated with 
protease mutations L24I, L33F, M46I, I54V, V82A, I84V and L90M (p-value < 0.01). 
Gag substitutions emerging under PI selective pressure 
To assess our Gag-protease coevolution networks, we used our Leuven patient cohort 
to report Gag amino acid substitutions that emerged after PI exposure. A longitudinal 
dataset of 44 patients who received PI-based regimens for at least 4 weeks was 
analyzed. Viruses in 6 patients developed Gag substitutions in the presence or the 
absence of protease substitutions (Figure 6.5). HIV-1 subtype B viruses from 3 PI-
treated patients (ID: 133, 268, 290) developed Gag substitutions in the presence of 
protease substitutions. For patient 133 who received PI-based regimen for 65 weeks, 
two matrix substitutions V46T and Q63K emerged along with protease substitution 
T74S. For patient 268 who received PI-based regimen for 408 weeks, Gag 
substitution T470A emerged in the presence of protease substitution D30N. For 
patient 290, two Gag substitutions A431V/P453L and three protease substitutions 
L10F/I54V/V82A reverted back to wild type residues when a LPV/r-based regimen 
was interrupted for 21 weeks. On the other hand, viruses in 3 PI-treated patients (ID: 
289, 314, 681) developed Gag substitutions in the absence of protease substitutions 
(Figure 6.5). For patient 289 who received PI-based regimen for 21 weeks, Gag 
substitutions N382H/S473A emerged while L483M reverted to wild type L483. Gag 
substitutions I401T/H421P/D425E/E482D were found in patient 314 who received a 
LPV/r-based regimen for 52 weeks. Gag substitution P478T was found in patient 681 
who received PI-based regimens for 172 weeks. 
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Figure 6.5: HIV-1 subtype B Gag and protease substitutions emerging during PI 
treatment. Each of six subplots shows emerging Gag-protease substitutions, viral 
loads and therapy records in a patient. The x- and y-axes display treatment time 
(weeks) and plasma viral load (log10 copies/mL), respectively. A colored box 
encompasses treatment time for each therapy regimen. Wild-type residues and 
substitutions in HIV-1 Gag and protease are annotated at the sampling date of 
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sequences. For convenience, the slash symbol “+” indicates multiple substitutions (e.g. 
I401T/H421P indicates the presence of both I401T and H421P). The plus symbol “+” 
separates Gag and protease substitutions (e.g. Q63K+T74S indicates Gag substitution 
Q63K and protease substitution T74S).  
 
Gag C terminus and drug-targeted regions associate with drug selective pressure 
The Gag C terminus (positions: 362-500) contains 18 (62.1%) of 29 PI-associated 
Gag positions, 24 of the 31 predicted Gag-protease coevolving pairs and 8 of the 10 
Gag substitutions identified in our Leuven cohort. A significant difference of amino 
acid diversity between the 420 drug-susceptible and 94 drug-resistant genomic 
sequences was found at Gag cleavage sites (positions: 128-137, 359-368, 373-382, 
428-437, 444-453) (p-value=0.0052), but not in the full-length Gag (p-value = 0.17). 
As shown in Figure 6.6, the amino acid diversity of Gag C terminus, protease and RT 
(position: 362-819) was significant higher in the drug-resistant (mean: 9.71%) than in 
the drug-susceptible genomes (mean: 7.39%, two-sample t-test, p-value = 1.2×10-62). 
Amino acid diversity of other genomic regions did not differ significantly (13.57% vs. 
13.83%, p-value = 0.104). 
 
Figure 6.6: Distribution plots of amino acid diversity in the HIV-1 subtype B 
genome. Using bootstrap resampling with 1000 replicates, amino acid diversity of PI-
susceptible and PI-resistant genomic sequences is calculated and colored in blue and 
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red, respectively. Protein names are indicated beneath the plots and concatenated 
protein regions are mapped based on the HXB2 reference. 
 
Figure 6.7: Structure representations of HIV-1 Gag and protease proteins. 
(A) Mapping of PI-associated positions at the protein structures of HIV-1 protease 
(top) and Gag (bottom). The Cα atoms of amino acid positions are colored as red 
spheres (true positive predictions), green spheres (unconfirmed predictions) and blue 
spheres (positions from in vitro or in vivo datasets that are not predicted). 
(B) Gag positions under positive selection (dN/dS>1, p-value<0.01).  
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(C) Gag substitutions identified after PI exposure in our Leuven cohort. Eleven Gag 
substitutions are annotated and the corresponding positions are colored in grey. 
(D) HIV-human protein interaction domains. Skyblue spheres indicate amino acid 
positions in Gag that interact with human proteins (see summary in Table S 6.2). 
(E) Drug binding positions of Gag experimental inhibitors. Red spheres map 137 drug 
binding positions in the full-length Gag. Three Gag inhibitors (PF-3450074, CAI and 
CAA) are annotated near their drug binding positions (see others in [25]). 
PDB codes of Gag and protease proteins: 1HIW (matrix), 3NTE (capsid), 1U57 (p2), 
2M3Z (nucleocapsid), 2C55 (p6), 1TW7 (protease). PDB codes of Gag inhibitors: 
2BUO, 2L6E, 2XDE, 4E91, 4E92, 2JPR and 4INB. Visualization software: PyMOL 
V1.5 (http://www.pymol.org/). 
 
 
 
Half PI-associated Gag positions interact with human proteins 
Using the dataset of HIV-human protein interaction positions documented in literature 
(Table S 6.1), we identified 13 of 29 PI-associated Gag positions in the Gag-protease 
coevolution networks that interacted with human proteins (E12, L75, R76, S111, 
S125, Y132, V218, H219, T401, R409, P453, P459, P484) (Figure 6.7D). For 
instance, position E12 interacts with embryonic ectoderm development protein, 
position R76 interacts with PI(4,5)P2 and 5 positions (S125, Y132, H219, P453, P459) 
interact with Cyclophilin A (Figure 6.7). Of the 50 Gag cleavage sites, 6 positions 
(V128-Y132, Q135) interact with Cyclophilin A and 5 positions (A364-S368) interact 
with APOBEC3G (Figure 6.7). 
Most PI-associated Gag positions do not interact with Gag experimental 
inhibitors 
We compared 29 PI-associated Gag positions with 137 drug binding positions of 50 
Gag experimental inhibitors. As illustrated in Figure 6.7E, only 6 PI-associated 
positions (L75, R76, T81, V390, T401, R409) interacted with two matrix inhibitors 
(Compound7 [45], TD1 [46]) and two nucleocapsid inhibitors (CAA [47], 
Compound6 [48]). Note that only the CA-p2 site in five Gag cleavage sites is targeted 
by Bevirimat and its analogs [49, 50], while the other cleavage sites that interact with 
human proteins are not the drug targets (Figure 6.7E). 
6.5 Discussion and conclusions 
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To our knowledge, this study presents the first model of HIV-1 Gag-protease 
coevolution networks under PI selective pressure. Our findings demonstrate that Gag 
positions mostly in the cleavage sites and C terminus coevolve with protease drug 
resistance positions. Amino acid substitutions at coevolving Gag and protease 
positions can be selected during PI-based regimens (Figure 6.5). Moreover, the 
selective pressure of anti-HIV inhibitors could impact the sequence variability of Gag 
C terminus and drug-target regions in the subtype B genome. Surprisingly, many PI-
associated Gag positions interact with human proteins, while only a few bind with 
Gag experimental inhibitors. Overall, our study contributes to the understanding of 
HIV-1 Gag-protease coevolution under PI selective pressure, shedding light on the 
impact of protein-protein coevolution in HIV-1 drug resistance. 
HIV-1 Gag-protease coevolution provides a novel substrate-based mechanism for 
virus to escape PI selective pressure [5]. Documented by previous studies, a few Gag 
mutations (e.g. CSMs) can increase or decrease PI susceptibility, mostly in the 
presence of protease resistance mutations [6]. This process depends on the mutation 
combinations and the type of protease inhibitors (Figure 6.3). We mapped the 
coevolving Gag positions to protein secondary structures and found that 23 (79.3%) 
of the 29 PI-associated Gag positions were located in the flexible random-coil 
structures (Table S 6.5), supporting our hypothesis that the flexible Gag structure may 
play a crucial role in the HIV-1 Gag-protease coevolution. Our sequence-based 
method estimated 13 (41.9%) of 31 predictions as true positives, though some 
documented Gag-protease patterns were not predicted. Three factors may limit our 
predictions: (1) our sequence datasets did not contain all Gag-protease patterns 
reported by in vitro or in vivo studies (Table S 6.1). (2) Sequence-based methods 
mostly predict pairs of coevolving residues and underestimate high-dimensional 
associations between multiple residues [7]. (3) Sequence-based methods may fail to 
detect significant coevolving residues at highly conserved positions [51]. 
We showed that HIV-1 subtype B Gag and protease substitutions emerged under PI 
selective pressure using the longitudinal sequence data from our Leuven patient 
cohort. We found that 11 Gag substitutions in 13.6% (6/44) of subtype B infected 
patients who received PI-based regimens for at least 4 weeks. Of these 11 Gag 
substitutions, A431V and P453L were known and nine substitutions (N382H, I401T, 
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H421P, D425E, A431V, P453L, T470A, S473A, E482D) were located within the Gag 
C terminus. Our genome-wide sequence analysis further demonstrated that the amino 
acid diversity of Gag C-terminal domains and drug-target proteins was associated 
with genotypic PI resistance. This supported our findings in the Gag-protease 
coevolution networks that most PI-associated Gag mutations were located in the Gag 
C terminus. It also confirms the knowledge that drug resistance mutations in HIV-1 
drug-target regions can be selected under antiviral treatments, causing a higher 
genetic diversity in viral sequences [52, 53]. While we did not detect significant 
variations of sequence diversity outside the Gag and Pol regions, it is possible that 
other regions may play a role in PI drug resistance due to genome-wide interactions. 
For instance, the interaction between matrix and GP41 may affect PI drug resistance – 
a hypothesis supported by the observation in two HIV-infected patients that some 
mutations at the GP41 cytoplasmic tail may confer PI drug resistance [54]. Our study 
could not perform a comparison analysis because the information of subtype and 
mutation was lacking in [54]. Despite these, our Gag-protease coevolution networks 
included two matrix mutations (L12E, Q62R), which involved with Env incorporation 
to nascent viral particles [55]. Interestingly, both matrix mutations can affect PI drug 
susceptibility in vitro [56, 57], while their roles in matrix-GP41 coevolution require 
further investigations. 
We found that half (13/29) PI-associated Gag positions were located within the HIV-
human protein interaction domains (Figure 6.7). Previous studies showed that Gag 
mutants have lower affinities to interact with human proteins compared to wild-type 
strains [58, 59]. It is possible that Gag positions exposed on the protein surface are 
accessible for protease binding and human protein interactions, since many human 
proteins interact with Gag proteins to stabilize viral proteins [1]. Future studies need 
to address the impact of Gag-protease coevolution on the HIV-human protein 
coevolution and vice versa. 
More than 50 Gag experimental inhibitors have been published to date, and some 
have been under clinical trials [25]. Our coevolution analysis revealed that most Gag 
drug binding positions (95.6%, 131/137) were not coupled with protease residues, 
except a few detected at drug binding positions of Bevirimat (H358, L363, A364, 
A366, Q369, A370, T371) [49] (Figure 6.7E). Despite this, drug binding positions of 
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the promising capsid inhibitors (e.g. PF-3450074[60]), which target the conserved 
interaction interfaces of capsid N and C terminus, are unlikely to coevolve with 
protease residues (Figure 6.7). This supports the hypothesis that conserved N- and C-
terminal domains in capsid can be potential drug targets for novel inhibitors [25]. 
Predicted Gag-protease coevolving pairs do not necessarily imply protein interaction 
positions; neither do they directly predict PI treatment failure. The limited number of 
PI-treated patients restricted our analysis from identifying all PI-associated Gag 
mutations, and the impact of individual Gag mutations on PI resistance and viral load 
response. Future studies need to investigate the role of the identified Gag substitutions 
in PI treatment failure. While we attempted to be as comprehensive as possible, 
additional in vitro and in vivo studies on Gag-protease mutations may have been 
reported, but major changes of known Gag-protease mutations are not expected. Since 
our study focused on the Gag-protease coevolution in the HIV-1 subtype B due to 
data availability, future studies are needed to characterize non-B subtypes. Besides the 
Gag-protease coevolution, other coevolution in the HIV-1 genome may have affected 
PI resistance. Future investigations of genome-wide analysis on HIV-1 drug 
resistance are still required. 
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6.6 Additional figures and tables 
 
Figure S 6.1: Protease cleavage sites in the HIV-1 genome and protein structures 
of HIV-1 protease and its substrate peptides. (A) Schematic view of protease 
cleavage sites in the HIV-1 genome. HIV-1 full genome encodes 15 HIV-1 proteins 
and 3 space peptides in three open reading frames (ORFs). Protease cleavage sites are 
marked with red rings. (B) Protease structures crystalized with its substrate peptides. 
Subfigures from ① to ⑥ visualize the crystalized protease structures with substrate 
peptides derived from Gag cleavage sites (amino acid number: 10). Two units of HIV-
1 protease dimers are colored blue and green, respectively. Upstream and downstream 
amino acids of Gag cleavage site are colored red and yellow, respectively. PDB codes 
used in the ① to ⑥ subfigures: 1KJ4, 1KJ7, 1TSQ, 1KJF, 1KJG and 1KJH. (C) 
Structure representations of wild type protease (left) and protease- darunavir complex 
(right). Visualization software: PyMOL V1.5. 
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Figure S 6.2: Distribution of conservation scores in HIV-1 subtype B Gag and 
protease. (A) Conservation scores at individual Gag and protease proteins. The x- and 
y-axes represent Gag or protease HXB2 positions and conservation scores, 
respectively. For each Gag position, conservation scores calculated for PI-susceptible 
and PI-resistant sequences are shown symmetrically to the x-axis [25]. (B) 
Proportions of conservation scores in HIV-1 Gag proteins using PI-susceptible (top) 
and PI-resistant (bottom) sequences. 
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Table S 6.1: PI drug susceptibility of Gag and protease mutations measured using in vitro experiments 
Gag mutations (1) PR mutations (1) RC% Measure(2) TPV SQV APV DRV NFV IDV LPV RTV ATV Clone Ref 
R76K None  FC EC50   ~1.5  ~1.2 ~1 ~0.9  ~1.3 HXB2 [61] 
Y79F None  FC EC50   ~1.2  ~1 ~0.8 ~0.8  ~1.1 HXB2 [61] 
T81A None  FC EC50   ~2.5  ~2.1 ~1.6/1 ~1.2  ~2.9 HXB2 [61] 
Y79F+T81A None  FC EC50   ~2.7  ~3.7 ~4 ~2.3  ~3.9 HXB2 [61] 
R76K+T81A None  FC EC50   ~3.8  ~3.6 ~2.4 ~2.1  ~7 HXB2 [61] 
R76K+Y79F None  FC EC50   ~2.3  ~1.9 ~1.7 ~1.6  ~2.2 HXB2 [61] 
R76K+Y79F+T81A None  FC EC50 ~1.8(3) ~2.7 ~5.7 ~2 ~7.5 ~3.5 ~3.5  ~5.3 HXB2 [61] 
L449F+P453T L10F+G16E+K20T+A28S+M46I+A71V  FC IC50  2 8.7  5 55 15  1 HXB2 [62] 
R452K Q58E+A71V  FC IC50  1.1 0.4  1.0 0.9 1.0  1.4 HXB2 [62] 
L449F L10F 36 FC IC50  1.3 1.8  1.3 1.5 1.6 1.1  NL4-3 [63] 
L449F L10F+I84V 4 FC IC50  3.7 8.4  3.4 3.2 7.7 4.0  NL4-3 [63] 
L449F L10F+M46I+I50V 6 FC IC50  1.3 21  2.9 1.6 19 5.2  NL4-3 [63] 
L449F L10F+M46I+I47V+I50V 4 FC IC50  2.0 48  4.1 2.4 31 6.5  NL4-3 [63] 
R452S L10F+K20I+M36I+M46I+I54V+L63P+A71V+G73S+I84A 5.7 FC IC50  1000 43  196 178 50 400 700 Isolate A13 [64] 
L449F L10F+M46I+L63P+A71V+I84A 2.5 FC IC50  241 32  600 58 14 42  Isolate A4 [63, 
64] 
A431V+L449Q L10V+M46I+L63A/P+A71V+I84A 18 FC IC50  256 28  600 53 9.0 54  Isolate A5 [64] 
A431V L10I+M46I+L63P+A71V+L76V+I84A 1.0 FC IC50  24 21  64 38 14 34  Isolate A6 [64] 
A431V+S451I L10F+L19I+M46I+I47V+I54V+L63P+A71V+I84A  FC IC50  1000 74  600 92 124 141  Isolate A7 [64] 
A431V L10V+K20I+M36I+M46I+A71V+G73S+L76V+I84A 6.4 FC IC50  265.5 252  600 400 94 86  Isolate A8 [64] 
L449F L10I+M46I+L63P+A71V+V77I+I84A 64 FC IC50  1000 33  600 138 16 167 52 Isolate A9 [64] 
A431V L10I+M46I+L63H+A71V+V77I+I84A 41 FC IC50  1000 32  600 73 10 60 38 Isolate A1 [64] 
A431V+L449V+R452K L10F+K20I+M46I+I54M+L63P+A71V+G73T+V77I+I84A 27 FC IC50  1000 400  600 400 59 400 700 Isolate A10 [64] 
A431V+L449F L10F+M46I+L63P+A71V+V77I+I84A 31 FC IC50  1000 47  600 73 14 73 63 Isolate A11 [64] 
A431V+L449Q+S451T L10I+L33F+M46I+I54V+L63P+A71V+L76V+I84A 16 FC IC50  1000 400  600 400 210 400 25 Isolate A12 [64] 
R452S L10F+K20I+M36I+M46I+I54V+L63P+A71V+G73S+I84A 5.7 FC IC50  1000 43  196 178 50 400 700 Isolate A13 [64] 
S451N K20I+M36I+V82I+I84C 11 FC IC50  14 5.4  59 1.3  8.6  Isolate C2 [64] 
L449F L10I+L19I+L24I+L63H+I84C 8.9 FC IC50  56 8.6  74 4.1 1.6 10  Isolate C3 [64] 
A431V L10I+G16A+M46I+L63P+L76V+I84C 13.0 FC IC50  24 64  144 63 47 22  Isolate C6 [64] 
A431V+L449F L10F+L19V+L24I+M46L+L63P+I84C 0.6 FC IC50  92 10  395 11 3.1 9.1  Isolate C4 [64] 
A431V+L449F L10I+L24I+M46L+L63P+A71T+G73S+V77I+I84C 1.2 FC IC50  1000 23  600 42 7.2 60  Isolate C7 [64] 
A431V M46I+L76V 10 FC IC50 0.7 0.3 6.6 1.4   10.6  0.4 HXB2 [65] 
A431V M46I  FC IC50 ~3 ~1.1 ~3 ~1.0   ~3  ~1.2 HXB2 [65] 
A431V L76V  FC IC50 ~0.5 ~0.5 ~5.5 ~1   ~11.5  ~0.5 HXB2 [65] 
P453L D30N+N88D  FC IC50     0.91     NL4-3 [66] 
N165K None  FC IC50 ~3/1.4(4) ~2.8/2 4/3 ~2/1.2 ~6/3 ~6/2 ~4/2 ~4.5/3 ~3/2 Gag5(01AE) [67] 
E12K+L75R+H219Q+V
390D+R409K 
L10F+D30N+K45I+A71V  IC50 nM   0.64  11     NL4-3 [56] 
E12K+L75R+H219Q+V
390D+R409K 
D30N+M46I+V77I  FCIC50    0.15   8     NL4-3 [56] 
E12K+L75R+H219Q+V
390D+R409K 
None  IC50 nM  23 32  28 32  32  NL4-3 [56] 
L75R+H219Q+V390D L10F+V32I+M46I+I84V  FC p24   >1       NL4-3 [68] 
K436E+I437T None  FC IC50 ~3.5 ~3.9 ~4.3  ~5 ~3.5 ~4.7 ~3.3 ~3.3 HXB2 [5] 
I437V None  FC IC50 ~2.7  ~2.7    ~5  ~4.4 HXB2 [5] 
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I437T None  FC IC50 ~3.8  ~3.8    ~5.5  ~4.3 HXB2 [5] 
A431V L10F+K20T+L33F+M36I+M46I+I54V+L63P ~130 IC50 nM   ~1250/400   ~1200/400 ~800/400   NL4-3 [69] 
A431V L10I+K20R+L33F+M46L+I54L+L63P+A71V+G73S+V82A
+L90M 
~70 IC50 nM   ~210/50   ~1000/150 ~170/40   NL4-3 [69] 
I437V L10I+G48V+I54V+L63P+V77I+V82A ~24 IC50 nM   ~350/220   ~40/11 ~130/70   NL4-3 [69] 
L483P+K490R L10I+I15V+E34Q+M36I+T37N+I54A+Q58E+V82A 42 IC50 nM      260/30  1650 /870  D1.10 [70] 
I376V+ L483P+K490R L10I+I15V+E34Q+M36I+T37N+I54A+Q58E+V82A 10 IC50 nM      110/30  60 /870  D1.10 [70] 
I376V+E398V+L483P+
K490R 
L10I+I15V+E34Q+M36I+T37N+I54A+Q58E+V82A 14 IC50 nM      200/30  5150/870  D1.10 [70] 
K494R None 103 IC50 nM      10/30  9/870  D1.10 [70] 
L449P+P453L L19Ins+E21D+A22V+M46I/L63P+A71V+I84V+I93L ~30 FC IC50  46 17  >290 16 3.8 94 8.9 NL4-3 [71] 
L449P+P453L M46I+L63P+A71V+I84V+I93L ~100 FC IC50  3.3 3.0  10 1.3 1.8 8.5 2.6 NL4-3 [71] 
 L19Ins+E21D+A22V  FC IC50  1.1 0.4  4.4 0.6 0.3 2.4 0.5 NL4-3 [71] 
 M46I+I50V 6 FC IC50   10.8    6.4   HXB2 [72] 
L449F I50V 1 FC IC50  0.7 10.2  0.7 0.7 3.5 2.7  HXB2 [72] 
L449F M46I+I50V 16 FC IC50  1.0 15.2  3.8 1.8 7.8 6.8  HXB2 [72] 
P453L I50V <1 FC IC50  1.0 10.8  1.3 1.3 4.8 3.7  HXB2 [72] 
P453L M46I+I50V 6 FC IC50  1.0 15.9  3.3 1.6 7.8 6.9  HXB2 [72] 
K436E+I437T None  FC EC50 ~3.4      ~4.6 ~3.5  HXB2 [73] 
G435R+K436E+I437T None  FC EC50 ~1.1      ~1.2   HXB2 [73] 
K436E+I437T+W438R None  FC EC50 ~1.3      ~2.4   HXB2 [73] 
A431V None  FC EC50 ~1.8      ~2.6 ~3.9  HXB2 [73] 
I437V None  FC EC50 ~1.1      ~1.9   HXB2 [73] 
I437T None  FC EC50 ~1.1      ~1.5   HXB2 [73] 
A431V L90M 602 FC IC50 10.31/4.59 79.98/26.4 44.1/17.2  114.55/29.7 78.48/16.52 108.87/25.56 200.53/49.64 77.76/25.62 NL4-3 [74] 
A431V N88D+L90M 48 FC IC50 11.0/4.5 471.0/125.0 26.0/18.4  451.0/230.0 62.9/17.3 48.7/20.1 139.0/53.1 217.9/46.1 NL4-3 [74] 
A431V N88D 138 FC IC50 5.1/1.9 185.0/30.2 14.1/5.1  293.0/109.0 27.3/5.8 25.5/5.6 58.2/13.4 106.7/17.2 NL4-3 [74] 
A431V D30N+N88D+L90M 103 FC IC50 11.7/3.8 572.2/135.8 28.3/21.3  555.1/305.9 70.5/17.4 45.5/15.5 121.4/38.3 258.2/52.1 NL4-3 [74] 
A431V D30N+N88D 122 FC IC50 1.5/5.0 27.3/196.8 4.7/14.2  117.2/320.7 5.2/26.8 4.1/21.9 9.0/44.5 16.9/112.4 NL4-3 [74] 
A431V I84V 1957 FC IC50 16.4/12.6 403.7/302.9 89.4/66.7  117.3/67.5 77.0/43.9 125.9/80.7 239.8/180.7 178.1/114.6 NL4-3 [74] 
A431V V82A 1775 FC IC50      41.4/47.9 90.4/102.2   NL4-3 [74] 
A431V I50L 58 FC IC50   5.5/2.0  9.9/3.5 3.9/1.3 4.8/0.9 9.0/1.9 123.4/42.8 NL4-3 [74] 
A431V I84V+L90M 1439 FC IC50 16.1/12.4 497.0/374.7 98.4/76.0  137.1/81.1 90.0/51.0 136.5/91.7 263.3/202.9 205.6/131.3 NL4-3 [74] 
A431V V82A+L90M 871 FC IC50 5.6/4.3     52.9/61.6  264.7/233.3  NL4-3 [74] 
K436R L90M 189 FC IC50 10.22/5.59 56.83/35.48 44.8/20.88  63.37/45.94 47.38/27.8 69.62/40.46 134.29/77.05 56.97/34.66 NL4-3 [74] 
K436R I84V+L90M 167 FC IC50        280.9/230.1 236.5/166.7 NL4-3 [74] 
K436R I84V 229 FC IC50        254.7/207.9  NL4-3 [74] 
K436R I50V 60 FC IC50  453.5/244.0   93.1/40.1 96.4/37.2 273.4/171.3   NL4-3 [74] 
I437V D30N+N88D 80 FC IC50 5.3/1.7 64.4/47.9 9.1/5.1  221.7/137.2 17.8/6.7 9.6/5.6 21.9/12.4 42.7/26.6 NL4-3 [74] 
I437V I50V 104 FC IC50 2.4/1.2 516.7/197.6 124.0/87.7  104.4/30.2 119.8/24.7 286.4/156.2 305.0/191.4 65.7/19.1 NL4-3 [74] 
I437V I84V+L90M 347 FC IC50 19.1/13.5 504.3/426.7 108.8/83.9  141.2/108.1 94.8/68.0 140.4/111.3 284.1/225.7 220.9/164.7 NL4-3 [74] 
I437V V82A 635 FC IC50 5.2/3.2 147.6/63.9 37.4/28.7  97.2/59.2 64.5/40.5 130.2/89.1 237.6/178.7 109.3/58.0 NL4-3 [74] 
I437V V82A+L90M 378 FC IC50 6.9/4.5 284.1/238.0 48.4/40.7  120.0/82.6 75.1/52.5 147.6/111.1 284.1/238.0 130.1/82.0 NL4-3 [74] 
I437V I84V 495 FC IC50 21.3/13.5 413.8/345.8 99.1/74.8  118.2/92.0 84.3/58.3 136.5/99.7 261.8/202.6 192.9/143.1 NL4-3 [74] 
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L449F D30N+N88D 296 FC IC50  39.3/72.0 4.4/8.4   5.9/11.0    NL4-3 [74] 
L449F V82A 321 FC IC50 3.4/4.4 69.0/160.9 29.1/37.1  59.8/119.1 40.0/75.5 91.0/129.0 182.6/243.4 62.7/99.7 NL4-3 [74] 
L449F I50V 181 FC IC50      30.8/51.5 147.4/200.6 163.3/241.5  NL4-3 [74] 
L449F V82A+L90M 179 FC IC50 4.8/6.1 95.0/233.5 40.7/52.1  82.0/154.9 50.8/93.4 111.1/157.5 240.1/311.6 85.0/129.5 NL4-3 [74] 
L449F L90M  FC IC50  66.24/33.22 38.49/21.45  81.39/44.12    69.05/33.06 NL4-3 [74] 
L449F N88D 320 FC IC50 76.19/39.72 76.19/39.72 8.26/4.96  164.59/119.52 11.89/6.51   40.1/22.72 NL4-3 [74] 
R452S I84V+L90M 517 FC IC50  546.8/408.3 96.6/85.9  143.9/105.4 92.0/67.3 138.1/110.6 255.4/229.2 194.8/167.0 NL4-3 [74] 
R452S I84V 649 FC IC50  466.5/329.2 92.3/75.6   81.9/57.9 134.3/98.8 237.8/205.3 176.1/144.6 NL4-3 [74] 
R452S L90M  FC IC50  49.2/36.69        NL4-3 [74] 
P453L I84V 2948 FC IC50  372.6/276.0 81.4/68.3  101.7/78.3     NL4-3 [74] 
P453L I84V+L90M 2255 FC IC50  446.0/364.3   116.7/98.4     NL4-3 [74] 
P453L L90M 722 FC IC50 7.21/5.56  38.45/16.64   40.71/27.49 58.59/38.4 101.3/75.45 54.27/32.29 NL4-3 [74] 
P453L V82A 759 FC IC50 3.5/3.7 77.3/91.5 28.3/34.8  61.7/83.0 41.0/56.3 91.7/110.7 179.2/223.9 65.5/75.3 NL4-3 [74] 
P453L V82A+L90M 465 FC IC50  107.8/121.9     112.3/132.9 238.1/276.8  NL4-3 [74] 
(1) AA mutations: the symbol “+” indicates multiple mutations presented simultaneously (e.g. “Y79F+T81A” indicates the presence of both 
mutation Y79F and T81A). (2) The susceptibility to TPV, SQV, APV, DRV, NFV, IDV, RTV and ATV is presented from column 5 to 13 (empty 
values indicate unavailable data). The measurements used for analyzing drug susceptibility are shown in column 4. (3) For publications in which 
raw data were not presented in tables or texts, the symbol “~” preceding the approximate values indicates data collected from figures (e.g. “~5” 
RC% indicates that the replication capacity is approximately 5%). (4) The symbol “/” separates HIV-1 Gag-protease mutant’s drug susceptibility 
from that of the protease mutant (only specific mutations present in the protease but not in the Gag). For instance, 1250/400 IC50 (nM) indicates 
that the IC50 of the corresponding Gag-protease mutant is 1250nM, and the IC50 of wild type is 400nM. 
 
Table S 6.1 (B): HIV-1 Gag and protease mutations identified in patient cohort studies 
Gag mutations Protease mutations Treatment Number of 
subtype B 
infected patients 
Study cohort Ref 
A431V NA (1) DRV/r 124  [22] 
A431V M46I +L76V LPV 15 AREVIR [18] 
A431V, I437V, L449F, R452S, 
P453L 
NA  313 (160N)(2) DHCS/Danish 
HIV Database 
[75] 
P453L I84V 48 IDV,57 RTV,22 
NFV, 42SQVr 
102(16N)  [76] 
A431V M46I/L,V82A/F/T 48 IDV,57 RTV,22 
NFV,42 
SQV+RTV+NFV 
102(16N)  [76] 
A374G/T/N/P/S, Y484G/I/P/S NA LPV/r 56 MONARK [77] 
K436R, I437V, L449F, P453L NA LPV/r 56 MONARK [77] 
G435E,K436N,I437V,L449V, 
L449F,S440C 
NA ≥ 1 PI 953(628N) RESINA [20] 
I437A V82A ≥ 1 PI 953(628N) RESINA [20] 
I437V G48V,I50V,I54A/V,V82A/T ≥ 1 PI 953(628N) RESINA [20] 
P459Ins V82A/F/T/S APV 84 NARVAL 
(ANRS 088) 
[78] 
S451N L10I SQV, RTV 42  [79] 
I437T/V L76V DRV 43  [80] 
A431V M46I IDV+RTV/SQV 28  [81] 
V128T/A/del,L449F,I437V NA FPV+ATV/r, 
SQV+ATV/r 
29 2IP-ANRS 127 [82] 
N382A I15V SQV+ATV+RTV 1 2IP-ANRS 127 [83] 
S373P, A374del, T375N, 
R380K 
NA  2 2IP-ANRS 127 [83] 
A431V M46L/I+I54V+ V82A IDV 8  [84] 
L449P,S451N,P453L D30N+N88D NFV 21 clones from a 
patient 
 [85] 
A431V L24I+M46I/L+I54V+V82A HAART 500(275N) RESINA [86] 
I437V I54V+V82F/T/S HAART 500(275N) RESINA [86] 
L449V I54M/L/S/T/A HAART 500(275N) RESINA [86] 
L449F+R452S+P453L D30N+I84V HAART 500(275N) RESINA [86] 
P453L V82A HAART 500(275N) RESINA [86] 
L449F,S451N/T D30N+N88D  196(B>90%) NARVAL [19] 
A431V M46I/L,I54V,V82A/T/F SQV+RTV 98  [87] 
S373Q,L449P K20I/R/M,L89M/I SQV+RTV 98  [87] 
S125K+Y132F+G62R+I437V L10I+A71V+N88S LPV+ATV 98  [57] 
P453L N88D NFV 36(6N)  [88] 
(1) NA: data is not available. (2) An upper case “N” in superscript indicates the number of PI-naïve 
patients enrolled in the study. 
 
Table S 6.1 (C): Kinetic parameters for the protease-mediated hydrolysis of HIV-1 
subtype B Gag and protease mutants. 
Gag mutations PR mutations Experimental values 
A431V I84V 5.9/2.6/1.6/1.0 
A431V L90M 9.6/2.6/2.5/1.0 
A431V M46L 2.4/2.6/0.3/1.0 
A431V V82A 2.1/2.6/0.7/1.0 
Q430R+A431V I84V 7.9/20.1/1.6/1.0 
Q430R+A431V L90M 45.4/20.1/2.5/1.0 
Q430R+A431V M46L 11.7/20.1/0.3/1.0 
Q430R+A431V V82A 1.1/20.1/0.7/1.0 
F448Y M46L 2.6/1.3/0.6/0.8 
F448Y V82A 2.2/1.3/1.2/0.8 
L449F M46L 8.7/7.6/0.6/0.8 
F448Y V82A 2.2/1.3/1.2/0.8 
L449F L90M 22.3/7.6/2.1/0.8 
Experimental values are specificity constant Kcat/Km for protease-mediated hydrolysis of HIV-1 
HXB2 clones, derived from reference [89]. The symbol “/” separates experimental values obtained 
from clones with a/b/c/d: (a) Gag + PR mutations, (b) Gag mutations, (c) protease mutations, and (d) 
wild type (e.g.  5.9/2.6/1.6/1.0 for HIV-1 strains with Gag A431V and protease I84V mutations 
indicate Kcat/Km = 5.9 for A431V+I84V mutations, Kcat/Km=2.6 for A431V mutant, Kcat/Km=1.6 
for I84V mutant, Kcat/Km=1.0 for wildtype HXB2).  
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Table S 6.1 (D): Literature reports of HIV-1 Gag mutations in the absence of protease 
mutations 
Gag mutations Literature summary Ref 
P455TAP Duplication of P455TAP motif in p6, prevalent in NRTI-treated but not in naive 
patients, improves virion packaging resulting in more infectious variants [90, 91]. Gag P455TAP 
insertions may be related to sequence variations in HIV-1 envelope [92]. In a cohort of 547 drug-
naïve and 213 HAART failure isolates, P455TAP accumulated for longer lengths and at higher 
frequencies in subtype C patients than in subtypes B and F1 [93]. 
[90, 91], 
[92], [94], 
[93] 
M377I M377I near p2/NC site can block downstream p2/NC cleavage, resulting in faster cleavage of the 
CA/p2 site and less infectious virions. 
[95] 
A431V, R429K Treatment-associated CSMs in a drug-naïve cohort could lower the genetic barrier of first-line PI 
therapy. A431V in the absence of PR mutations was significantly associated with R429K. A431V 
and R452S were correlated with primary PI resistance in drug naive HIV-1. 
[96] 
Q369A/H,T371A  Q6A/H, V7A/M and T8A near p1 can confer different levels of resistance to maturation inhibitor 
bevirimat (BVM). 
[97, 98] 
Q369,V370,T371 Natural polymorphisms near the CA-p1 link (at positions 358, 363, 364, 366, and 369-371) 
caused BVM drug resistance in 389 subtype B patients. 
[99] 
Q7,L33,N37,L63,C67,H
69 in p6* 
Gag residues Q7, L33, N37, L63, C67 and H69 at non-active site near p6* may  influence 
catalytic site conformation and regulate protease-substrate specificity. 
[100] 
Y132I Gag mutation Y132I near the MA-CA link can abolish viral infectivity compared to the wild type 
NL4-3. 
[101] 
N394F/G Gag N17F/G modulates NC cleavage during late viral infection by decreasing infectivity and 
exhibiting H9 replication defects. 
[102] 
L363M, A364M Gag L363M,A364M cause resistance to protease inhibitor DSB (3-O-(3’,3’-dimethylsuccinyl)-
betulinic acid), which delays cleavage of CA-SP1 in Gag. 
[103] 
MA/CA, p1/p6 Insertions (TGNS, SQVN, AQQA, SRPE, APP, and/or PTAPP) near MA-CA and p1-p6 links 
can restore the enzymatic activity of mutant protease. 
[104] 
Cleavage site mutations Using 30 and 25 full genome sequences in subtype B and C respectively, 7 of 12 CSMs were 
more diverse in subtype C than in  subtype B [105]. Amino acid context near the cleavage sites in 
Gag and Gagpol are crucial to determine Gag cleavage rate [12]. Natural polymorphisms in NC 
and C-terminal cleavage sites can affect protease processing activity. Polymorphisms in sites 374 
to 380 may delay the dissociations between PR and Gag [106]. CSMs influence the drug 
resistance and viral fitness in patients treated with PIs [107]. CSM emergence was not associated 
with virological rebound among patients treated with LPV/RTV in the OK04 clinical trial [108]. 
[105] 
NC-p1 HIV-1 protease variants that evolved in reaction to treatment with RTV had 1.2-fold increased 
mean fitness, increased susceptibility to 2 NRTIs and SQV, and impaired replication capacity, 
correlated with reduced Gag NC-p1 processing. 
[109] 
Mutant Gag  Mutant Gags, derived from one patient with multi-PI drug-resistance, acted synergistically with 
mutant protease to reduce PI susceptibility while maintaining replication capacity. Non-CSM 
mutations in  Gag alone can also reduce susceptibility to 
APV,ATV,DRV,IDV,LPV,NFV,SQV,TPV.  
[110] 
Gag and env mutations Gag and env mutations are associated with PI antiviral treatment failure. [111] 
MA and CA mutations Mutations in MA and parts of CA can reduce PI susceptibility and restore the loss of replication 
capacity of protease mutant. 
[61, 110, 
112] 
 
Table S 6.2: Summary HIV-1 Gag-human protein interactions with identified 
binding domains 
HIV-1 
proteins 
HIV-1 binding domains Human host factors Interaction function Reference 
Matrix 8-43[113],W16,W36[59] ubiquitous calcium-sensing 
calmodulin (CaM, CAMI) 
Gag intracellular Trafﬁcking in 
cytoplasm 
[113],[59],[114],[1
15] 
R4-L13,R20-E40[116] embryonic ectoderm development 
(EED) protein 
Transcriptional regulation 
within nucleus 
[116],[117] 
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S9-K28 IL-8 chemokine receptors  
CXCR1(IL-8RA)/CXCR2 
Endothelial cells proangiogenic 
activation, monocyte migration 
[118],[119],[120] 
K26-K28 elongation factor 1-alpha (EF1a) Inhibition of translation [121] 
121-132 Cyclophilin A(CypA) Enhance CA- CypA interaction [122] 
15-32 Chromosome maintenance region 
1 (CRM1,exportin 1, XPO1) 
MA nuclear export signal  [123] 
24-31, 110-114[124] Importin α1 (karyopherin α2, 
Rch1/SRP1α/KPNA2) 
PIC nuclear import to nucleus [124] 
Y132 clathrin adaptor complex 2 AP-2, 
μ2 subunit (AP50) 
Gag intracellular Trafﬁcking [125] 
5-8,13-16 TIP47 (tail-interacting protein of 
47 kDa, perilipin 3, PLIN3 ) 
Env packaging into virions [126],[127] 
K26,K27 HO3 histidyl-tRNA synthetase 
(HARS2) 
HO3 packaging into virions [128] 
9,67,72,77[129] mitogen-activated protein 
kinase (MAPK/ERK-2) 
Phosphorylation of matrix 
during early uncoating, 
MAPK/ERK-2 incorporats to 
virions 
[129],[130],[131] 
L41,F44,V46,I60,L64,L75 PS/PE/PC (phosphatidylserine, 
phosphatidylethanolamine,phosph
atidylcholine) 
Gag binding to membrane [132],[133] 
113-122 Mab 3H7 antibody PIC integration [134] 
S111 protease kinase C (PKC) matrix translocation to 
membrane 
[135],[136] 
25-34,109-115 Heparin(HSPG analog) Prevent p17 binding to 
chemochine receptor 
[137] 
86-115 neutralizing monoclonal antibody 
(MAb 1575) 
 [138] 
S6[139],R22,K26,K27,W36,R76[
140]  
phosphatidylinositol-(4,5)-
bisphosphate PI(4,5)P2 
Target Gag to membrane rafts [140],[141] 
     
Capsid P85-
I91[142],T54,A92,R132[143],A9
2E,G94D[144],H219[145],P221,P
222[146],N74D[147],P85-
A88,A92,P93,G94 
Cyclophilin A(CypA) Viral core uncoating, 
incorporate into virions 
[148],[142],[149],[
143],[150],[151] 
N53,L56,N57,M66,Q67,K70,I73,
N74,A105,T107,S109,Y130 
CPSF6 (CFIm) CPSF6 binds CA in post-entry 
stages before 
Uncoating, nuclear import 
[152],[153] 
G89[154],H87[155],P38[156], 
V83,G89,H120,P122,W117, 
Y130,W133[157] 
TRIM5α TRIM5α promotes capsid 
disassembly during viral 
uncoating in cytoplasm 
[158],[154],[159],[
155],[156],[160],[1
61],[157] 
E45,T54,N57,Q63,Q67,N74,A10
5[162] 
Transportin3(TNPO3,TRN-SR2) PIC nuclear import [162], [163], [164] 
N74 Nucleoporin NUP98 PIC nuclear import [165],[166],  
N57,Q67,K70,N74[167] Nucleoporin NUP153 PIC nuclear import [168] ,[167], [169] 
G89,P90,I91[170] Nucleoporin NUP358 (RanBP2) PIC nuclear import [170],[171],[165],[
172] 
S16,P17 peptidyl prolyl-isomerase PIN1 CA core uncoating in cytoplasm [173] 
V3 clathrin adaptor complex 2 AP-2, 
μ2 subunit 
Gag  intracellular Trafﬁcking [125] 
V3 adapter protein complex 2 AP-2, 
α1 subunit 
Nuclear translocation of viral 
DNA in cytoplasm or 
perinuclear region 
[174] 
177-231 lysyl-tRNA synthetase LysRS LysRS packed into virions [175] 
     
Nucleocapsid K34,C49,N55 Moloney leukemia virus 10  
(MOV10) 
MOV10 packaging during 
virion budding 
[176],[177] 
R3,R7,R10,K11,K14,K20,R26[58
] 
ALIX (AIP-1) Recruit Gag to plasma 
membrane in viral budding 
[58],[178],[179],[1
80],[181],[179] 
M1-K11[182],R29-K34[183] APOBEC3G (A3G) A3G incorporation to virions in 
viral budding 
[182],[184],[185] 
Y36-P49 mRNA binding protein 1 (IMP1) Impedes Gag assembly, keep 
immature virus  on cellular 
membranes 
[186] 
C15-C49 double-stranded RNA-binding 
protein Staufen 1 (Stau1) 
Stau1 packed into virions, 
influences Gag multimerization 
[187] 
K14,K20,R26,R29,K33,K34,K38,
K41,K47 
ATP-binding protein ABCE1 
(HP68) 
capsid assembly [188] 
43-48 Topoisomerase I(TOP1) Enhancing reverse transcription [189] 
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K14,K20,R26,R29,K32-
K34,K38,K41,D48 
Elongation factor 1-alpha (EF1a) Inhibition of translation [121] 
R3,R7,R10,K11,K14,K20,R26 Nedd4-like ubiquitin ligase, 
Nedd4-1 
Viral release [179] 
     
p6 Y36-
L41[190],E34,L35,P37,L41,R42[
191] 
ALIX (ALG-2 interacting host 
protein, AIP-1) 
HIV-1 buds via the Alix driven 
pathway, ALIX incorporates 
into virions 
[58],[192], 
[179],[180],[191] 
P7-P10, Tumor susceptibility gene 
101(TSG101) 
Form viral budding machinery 
to bud from plasma membrane 
[58], [193] 
K27 small ubiquitin-like modifier 
SUMO-1 
ESCRT-III recruitment to viral 
budding 
[194] 
K27 Ubc9 ESCRT-III recruitment to viral 
budding 
[195], [194] 
K27 Daxx ESCRT-III recruitment to viral 
budding 
[194] 
T23 mitogen-activated protein 
kinase (MAPK/ERK-2) 
P6 phosphorylation within HIV-
1 virion 
[196] 
L35-L38 Nedd4-like ubiquitin ligase, 
Nedd4-1 
Viral release [179] 
P5,P7,P10,P11,P24,P30,P37,P49 Cyclophilin A(CypA) Catalyzes prolyl cis/trans 
interconversion of p6 Pro 
residues 
[197] 
K27,K33 Ubiquitin assembly and budding [198] 
Note that positions in HIV-1 binding domains are referred to HXB2 reference at 
individual Gag protein. Information on space peptide p1 and p2 is not available, for 
we could not find human factors bind to them. 
 
Table S 6.3: Summary of human antibody, CD4+, CD8+ T cell epitopes in HIV-1 
Gag 
HIV-1 protein Antibody epitope position CD4+ epitope position CD8+ epitope position 
Matrix 20-31 1-107,118-132 11-44,74-101,124-132 
Capsid 64-75 1-231 3-56,61-92,94-104,108-117,121-153,161-189,197-205,217-231 
p2  1-14 1-10 
Nucleocapsid  1-55 28-36,50-55 
p1  1-16 1-10 
p6  1-43 33-41 
Protease  53-70 3-11,30-42,57-66,68-90,99 
 
Table S 6.4: HIV-1 protease positions in HIV-1 genotypic drug resistance 
interpretation algorithms 
Expert rules Protease positions Version Year Reference 
IAS-USA  10,11,16,20,24,30,32,33,34,36,43,46,47,48,50,53,54,58, 
60,62,63,64,69,71,73,74,76,77,82,83,84,85,88,89,90,93 
March,2013 2013 [199] 
HIVdb 10,11,20,24,30,32,33,35,36,43,46,47,48,50,53, 
54,58,63,71,73,76,77,82,83,84,85,88,89,90,93 
6.2.0  2012 [200] 
Rega 10,11,20,24,30,32,33,35,36,43,46,47,48,50,53,54,58, 
62,63,64,71,73,74,76,77,82,84,85,88,89,90,93,95 
9.1 2013 [201] 
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ANRS 10,15,20,24,30,32,33,36,46,47,48,50,53,54,62,63, 
71,73,76,77,82,84,88,90 
22 2012 [202] 
Protease positions are listed in the HIV-1 genotypic drug-resistance interpretation 
algorithms, which can be found via the following links: 
(a) IAS-USA: https://www.iasusa.org/content/hiv-drug-resistance-mutations 
(b) HIVdb: http://hivdb.HIVdb.edu/DR/cgi-bin/rules_comments_hivdb.cgi?class=PI 
(c) Rega: http://rega.kuleuven.be/cev/avd/software/rega-algorithm 
(d) ANRS: http://www.hivfrenchresistance.org/. 
 
Table S 6.5: Summary of HIV-1 Gag and protease positions reported by literature or 
our study 
Gag 
protein 
Position Proportions of Gag mutations 
(1) 
Closest Gag 
cleavage sites (2) 
Intrasubtype 
Diversity(3) 
dN/dS(4) Secondary 
structure 
Reference(5) 
Matrix 12 E12K(24.65%) 
 
0.6007 8.37(p<0.01) Alpha-helix [56] 
Matrix 62 G62R(4.04%) 
 
0.5183 5.27(p<0.01) Alpha-helix [57]  
Matrix 75 L75R(0.32%) 
 
0.2387 0.502(p=0.949) Alpha-helix [56] 
Matrix 76 R76K(51.86%) 
 
0.5193 2.11(p=0.0393) Alpha-helix [6] 
Matrix 79 Y79F(40.70%) 
 
0.4908 1.32(p=0.31) Alpha-helix [61] 
Matrix 81 T81A(8.82%) 
 
0.1929 6.52(p<0.01) Alpha-helix [61], our study 
Matrix 111 S111C(5.22%), S111G(1.07%) 0.2518 0.971(p=0.631) Alpha-helix Our study 
Matrix 125 S125K(1.81%) 
 
0.5351 3.15(p<0.01) Random-coil [57] 
Matrix 132 Y132F(5.01%) MA-CA 0.1075 0.701(p=0.841) Random-coil [57], our study 
Capsid 218 V218A(3.69%), V218P(4.20%)  0.2083 1.23(p=0.308) Random-coil our study 
Capsid 219 H219Q(20.90%) 
 
0.4244 3.32(p=0.0208) Random-coil [56] [68] 
P2 
370 V370A(14.34%),V370I(2.27%),
V370M(4.99%)  0.486 2.72(p<0.01) Random-coil 
[99] 
P2 373 S373Q(1.53%) P2-NC 0.5305 4.44(p<0.01) Random-coil [83], [87] 
P2 374 
A374G(1.46%),A374N(6.02%),
A374P(4.74%),A374S(2.64%),A
374T(13.86%),A374V(2.01%) P2-NC 0.5507 1.41(p=0.109) Random-coil 
[83] [77]  
P2 375 T375N(18.82%) P2-NC 0.6015 1.62(p=0.0361) Random-coil [83] 
NC 390 V390D(<0.1%),V390I(12.55%) 
 
0.2828 1.56(p=0.232) Random-coil [56] 
NC 
401 T401L(7.24%),T401T(1.48%),T
401V(2.36%)  0.2763 2.99(p=0.221) Random-coil 
our study 
NC 409 R409K(<0.1%) 
 
0.079 0.0145(p=1) Random-coil [56] 
NC 410 K410R(2.77%) 0.048 0.67(p=0.829) Random-coil our study 
NC 431 A431V(2.11%) NC-p1 0.0398 4.12(p<0.01) Random-coil 
[64] [65] [73] 
[74] [22] [18] 
[75] [76] [81] 
[86] [87], our 
study 
P1 435 G435E(0.25%),G435R(<0.1%)| NC-p1 0.0211 0.5(p=0.889) Random-coil [20] [73] [203] 
P1 436 
K436E(<0.1%),K436N(<0.1%),
K436R(4.73%) NC-p1 0.1248 0.0811(p=1) Random-coil 
[5] [73] [74] [77] 
[20] 
P1 437 
I437A(<0.1%),I437T(<0.1%),I4
37V(2.87%),I437L(2.28%) NC-p1 0.1039 0.967(p=0.621) Random-coil 
[5] [73] [74] [75] 
[77] [20] [80] 
[82] [86], our 
study 
P1 438 W438R(0.25%) 
 
0.0119 0.066(p=0.997) Random-coil [73] 
P1 440 S440C(<0.1%) 
 
0.0375 0.47(p=0.931) Random-coil [20] 
P6 449 
L449F(1.36%),L449P(7.26%),L4
49Q(<0.1%),L449V(1.49%) p1-p6 0.1984 0.551(p=0.979) Random-coil 
[63] [64] [71] 
[72] [74] [204] 
[75] [77] [20] 
[82] [85] [86] 
[19] [87], our 
study 
P6 451 
S451I(0.13%),S451N(14.60%),S
451T(0.38%),S451G(1.56%) p1-p6 0.3258 Inf(p<0.01) Random-coil 
[79] [19] 
P6 452 R452K(0.75%),R452S(0.79%) p1-p6 0.1278 0.203(p=1) Random-coil 
[62] [64] [74] 
[86] 
P6 453 
P453L(7.79%),P453T(4.79%),P4
53S(1.68%) p1-p6 0.245 Inf(p<0.01) Random-coil 
[62] [65] [71] 
[72] [74] [75] 
[76] [77] [85] 
[86], our study 
P6 459 P459I(<0.1%) 
 
0.1217 0.25(p=0.963) Random-coil [78] 
P6 463 F463L(3.44%)  0.1101 3.98(p=0.121) Random-coil Our study 
P6 484 
Y484G(0.13%),Y484I(<0.1%),Y
484P(0.60%),Y484S(0.35%),Y4
84H(1.05%)  0.088 0.53(p=0.872) Random-coil 
[77] 
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Protease 
protein 
Positions Proportion of protease 
mutations 
Drug resistance 
interpretation 
rules (6) 
Intrasubtype 
diversity 
dN/dS Secondary 
structure 
Reference 
Protease 10 
L10F(1.61%),L10I(10.47%),L10
V(2.71%) 
IAS,HIVdb,Rega,
ANRS 0.1517 0.757(p=0.9) Beta-strand 
[62] [63] [64] 
[79],our study 
Protease 16 G16A(0.63%),G16E(4.54%) IAS 0.0536 0.167(p=1) Random-coil 
[62] [64], our 
study 
Protease 19 L19I(7.60%),L19V(2.11%)  0.14 1.57(p=0.149) Beta-strand [71] [64] [71] 
Protease 20 
K20I(0.63%),K20M(1.07%),K20
R(3.60%),K20T(0.66%) 
IAS,HIVdb,Rega,
ANRS 0.0624 0.587(p=0.97) Beta-strand 
[62] [64] [87], 
our study 
Protease 21 E21D(<0.1%)  0.0022 0.332(p=0.95) Beta-strand [71] 
Protease 22 A22V(<0.1%)  0.0009 0.111(p=1) Beta-strand [71] 
Protease 24 L24I(0.95%) 
IAS,HIVdb,Rega,
ANRS 0.011 0.804(p=0.752) Beta-strand 
[64] [86] 
Protease 28 A28S(<0.1%)  0.0013 Inf(p=0.667) Random-coil [62] 
Protease 30 D30N(1.01%) 
IAS,HIVdb,Rega,
ANRS 0.0107 Inf(p=0.118) Random-coil 
[65] [74] [204] 
[85] [86] [19] 
Protease 32 V32I(1.26%) 
IAS,HIVdb,Rega,
ANRS 0.0142 0.254(p=0.999) Beta-strand 
[137] 
Protease 33 
L33F(2.14%),L33I(1.07%),L33V
(1.73%) 
IAS,HIVdb,Rega,
ANRS 0.0495 1.65(p=0.123) Beta-strand 
[71] [69], our 
study 
Protease 36 M36I(16.65%),M536L(1.23%) 
IAS,HIVdb,Rega,
ANRS 0.1867 1.13(p=0.668) Random-coil 
[64] [69] [70],our 
study 
Protease 37 
S37D(10.00%),S537C(1.51%),S537S
(16.11%),S537T(2.62%),S537H(1.42
%)  0.356 7.23(p<0.01) Random-coil 
[70] 
Protease 45 K45I(<0.1%),K545R(1.89%)  0.0199 0.446(p=0.929) Beta-strand [56], 
Protease 46 
M46I(3.78%),M46L(1.32%),M4
6P(<0.1%) 
IAS,HIVdb,Rega,
ANRS 0.0514 0.634(p=0.862) Beta-strand 
[62] [63] [64] 
[65] [68] [71] 
[72] [89] [18] 
[76] [81] [86] 
[87],our study 
Protease 47 I47V(0.60%) 
IAS,HIVdb,Rega,
ANRS 0.0091 Inf(p=0.594) Beta-strand 
[63] 
Protease 48 G48V(0.54%) 
IAS,HIVdb,Rega,
ANRS 0.0091 0.401(p=0.985) Beta-strand 
[20] 
Protease 50 I50L(0.16%),I50V(0.16%) 
IAS,HIVdb,Rega,
ANRS 0.0038 Inf(p=0.709) Random-coil 
[20, 63] [72] [74] 
Protease 54 
I54A(<0.1%),I54L(0.60%),I54M
(0.19%),I54S(<0.1%),I54T(0.16
%),I54V(3.50%) 
IAS,HIVdb,Rega,
ANRS 0.0454 2.12(p=0.0721) Beta-strand 
[20, 64] [70] [84] 
[86] [87],our 
study 
Protease 58 Q58E(1.17%) IAS,HIVdb,Rega 0.0117 0.499(p=0.96) Beta-strand [62] [70] 
Protease 63 
L63A(5.42%),L63H(1.80%),L63
P(55.41%) 
IAS,HIVdb,Rega,
ANRS 0.4185 1.04(p=0.497) Beta-strand 
[64] [71] ,our 
study 
Protease 71 A71T(8.34%),A71V(8.53%) 
IAS,HIVdb,Rega,
ANRS 0.1721 2.99(p<0.01) Beta-strand 
[62] [64] [71],our 
study 
Protease 73 G73S(1.17%),G73T(0.25%) 
IAS,HIVdb,Rega,
ANRS 0.0174 2.3(p=0.136) Beta-strand 
[64] 
Protease 76 L76V(0.57%) 
IAS,HIVdb,Rega,
ANRS 0.0063 0.417(p=0.952) Beta-strand 
[65] [18] [80] 
Protease 77 V77I(33.79%) 
IAS,HIVdb,Rega,
ANRS 0.3391 6.01(p<0.01) Beta-strand 
[64] [56] [69] 
Protease 82 
V82A(3.41%),V82F(0.28%),V82
I(1.64%),V82S(0.13%),V82T(0.
25%) 
IAS,HIVdb,Rega,
ANRS 0.0584 4.09(p<0.01) Random-coil 
[62] [74] [89] 
[76] [20] [78] 
[86] [87],our 
study 
Protease 84 
I84A(<0.1%),I84C(<0.1%),I84V
(2.34%) 
IAS,HIVdb,Rega,
ANRS 0.0259 Inf(p=0.31) Beta-strand 
[63] [64] [68] 
[71] [74, 86] [89] 
[76] 
Protease 88 N88D(0.98%),N88S(0.25%) 
IAS,HIVdb,Rega,
ANRS 0.013 0.331(p=0.998) Alpha-helix 
[65] [74] [204] 
[85] [19] 
Protease 89 L89I(0.16%),L89M(0.98%) IAS,HIVdb,Rega 0.02 0.552(p=0.954) Alpha-helix [87] 
Protease 90 L90M(5.49%) 
IAS,HIVdb,Rega,
ANRS 0.0562 2.07(p=0.0307) Alpha-helix 
[74] [89] 
[204],our study 
Protease 93 I93L(35.42%) IAS,HIVdb,Rega 0.3586 4.83(p<0.01) Alpha-helix [71] 
(1) Proportions of mutations at the corresponding Gag or protease positions in our HIV-1 Gag-protease 
sequence dataset (the most prevalent amino acids are considered as wild type amino acids, others are 
mutations). (2) The closest Gag cleavage sites are indicated if Gag positions are less than 5 amino acids 
away from the cleavage sites. (3) Intra-subtype sequence diversity (see Methods). (4) dN/dS, the ratio 
of non-synonymous and synonymous rates at a residue position (see Methods). If dS=0, then dN/dS is 
infinite, denoted as “Inf”. (5) Reference, the list of publication that reported the Gag or protease 
positions, the results from our study are indicated by “our study”. (6) HIV-1 drug resistance 
interpretation algorithms that reported protease drug resistance mutations. 
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Table S 6.6: Summary of Gag, protease and RT substitutions in 6 patients of the 
Leuven cohort. 
Patient 
ID 
Sampling 
day 
Gag substitution Protease variants and 
PI resistance mutations 
RT variants and RTI 
resistance mutations 
133 2000-03-06  L33V+I64V M184V 
2000-10-30  L10[I,L]+L24I+L33V 
+I64V+V82A 
K103[K,N]+ M184V 
2002-10-21 V60T+G55E+Q63K+ 
K76R+V159I+H441Y 
L10I+L24[I,L]+I62[I,V] 
+I64V+T74S+V82A 
M184V+T215Y 
 
268 1996-07-10  L10[I,L]+L63[Q,H,P] E40F+M41L+D67N+V106[I,V] 
+V179I+L201W+T215Y 
2005-05-18 T469A+S473P L10[I,L]+D30N+M46[M,V,L] 
A71[T,I,A,V]+N88D 
E40F+M41L+D67N+V179I+ 
M184V+L210W+T215Y+K219E 
 
289 1997-09-24  I64V V90[I,V] +I179[I,V] 
2000-02-09 R380K+N382H+ 
S473A+M483L 
 V90I+V179I 
 
290 2006-03-07  L10F+K20R+D30N+ 
L33[I,L,F]+I54V 
+A71V+V82A+N88D 
D67N+K70R+L100I+K103N 
2006-09-21 S385N+V431A K20R+D30N+ 
A71[A,V]+N88D 
D67N+K70R+T215[T,I] 
+K219[Q,E] 
 
314 2005-07-18  L33V+I64V K166R 
2008-03-31 G412A+H421P+ 
D425E+E482D 
L33V+I64V K166[K,R] 
 
681 2009-08-19  I62V+A71T V108[I,V] 
2010-12-20  I62V+A71T V108[I,V] 
2012-12-20 P478T I62V+A71T V108[I,V] 
For the first sequence, PR and RT drug resistance mutations, detected by in the drug 
resistance interpretation algorithms HIVdb v7.0 [26] and/or Rega V9.1 [27], are colored red. 
For the subsequent sequences, the amino acid changes regarding to the first sequence are 
displayed (emergence and disappearance of amino acids). Ambiguous nucleotide letters are 
translated into amino acids, which are indicated by brackets. Gag substitutions and PI 
mutations are mapped in Figure 6.5 according to the sampling time. 
Table S 6.7: Coevolving residue pairs in the HIV-1 Gag-protease coevolution networks 
Position 
pair 
Coevolution 
score 
Mutation pattern Proportion* P-value Odds-ratio Confirmed by 
literature 
New Gag-protease coevolving pairs predicted by our sequence analysis 
81+10 0.144 T81A+L10I 3.28%/0.31% 0.0036 10.7059  
  T81A+L10F 2.46%/0 0.0003 91.05  
  T81A+L10V 1.64%/0.47% 0.0676 3.5041  
81+71 0.138 T81A+A71V 3.31%/0.31% 0.0036 10.7966  
81+54 0.129 T81A+I54V 2.46%/0 0.0003 91.05  
  T81A+I54L 4.10%/0 <0.0001 154.322  
  T81L+I54V 1.64%/0 0.0026 60.1983  
111+63 0.148 S111C+L63A 4.10%/0.32% 0.0015 13.3475  
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  S111C+L63S 1.64%/0 0.0025 60.1983  
132+82 0.125 Y132F+V82A 4.96%/0 <0.0001 188.3793  
218+10 0.181 V218P+L10I 4.92%/0 <0.0001 186.7692  
218+82 0.171 V218P+V82A 4.13%/0 <0.0001 155.641  
218+90 0.154 V218P+L90M 3.28%/0 <0.0001 122.4202  
  V218A+L90M 1.64%/0 0.0024 60.1983  
218+71 0.129 V218P+A71V 4.13%/0.30% 0.0012 14.188  
401+16 0.166 I401T+G16E 3.29%/0 <0.0001 123.0405  
453+54 0.155 P453L+I54V 7.35%/0 <0.0001 288.0678  
  P453L+I54L 1.84%/0 <0.0001 67.984  
  P453T+I54V 1.31%/0 0.0002 48.3024  
463+71 0.153 F463L+A71V 3.40%/0.17% <0.0001 20.6784  
Gag-protease coevolving pairs identified by both our sequence analysis and literature results 
132+10 0.128 Y132F+L10I 5.74%/0 <0.0001 219.7759  
431+54 0.184 A431V+I54V 7.06%/0 <0.0001 274.8679  
  A431V+I54L 2.35%/0 0.0001 87.2335  
431+10 0.174 A431V+L10I 8.24%/0 <0.0001 324.7643 [64] 
  A431V+L10F 2.35%/0 0.0001 87.2335 [64] 
  A431V+L10V 1.18%/0 0.0036 43.1006 [64] 
431+71 0.161 A431V+A71V 5.33%/0 <0.0001 203.5901  
  A431V+A71T 1.78%/0 0.0006 65.4251  
  A431V+A71I 1.18%/0 0.0036 43.3571  
431+82 0.149 A431V+V82A 7.69%/0 <0.0001 301.5669 
[74],[76],[84], [86], 
[87] 
  A431V+V82T 1.18%/0 0.0036 43.3571  
431+33 0.146 A431V+L33F 6.47%/0 <0.0001 250.3875 [62], [63] 
431+20 0.144 A431V+K20R 4.12%/0 <0.0001 155.4512  
431+46 0.141 A431V+M46I 5.92%/0 <0.0001 227.625 
[64],[65],[18],[76], 
[81],[84],[86],[87] 
  A431V+M46L 2.96%/0 <0.0001 110.3636 [76],[89],[84],[86],[87] 
431+90 0.138 A431V+L90M 8.07%/0 <0.0001 317.7584 [74] 
431+36 0.129 A431V+M36I 8.38%/0 <0.0001 331.0909  
437+10 0.187 I437V+L10I 5.36%/0.26% <0.0001 21.9375  
  I437V+L10F 1.79%/0 0.0006 65.8193  
437+54 0.127 I437V+I54V 4.17%/0 <0.0001 157.3704  
449+10 0.145 L449V+L10I 3.46%/0 <0.0001 130.0714  
  L449F+L10I 1.86%/0 <0.0001 68.9027  
  L449F+L10F 1.06%/0 0.0008 39.0563 [62], [63] 
453+10 0.153 P453L+L10I 5.48%/0.58% <0.0001 9.9866  
  P453L+L10F 4.96%/0 <0.0001 189.5836  
  P453L+L10V 1.83%/0 <0.0001 67.6233  
  P453A+L10I 1.04%/0 0.0009 38.3368  
  P453T+L10I 1.57%/0.29% 0.0045 5.496  
453+20 0.14 P453L+K20R 3.70%/0.14% <0.0001 26.6384 [87] 
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  P453L+K20T 1.59%/0 <0.0001 58.5845  
453+71 0.13 P453L+A71V 8.71%/0.43% <0.0001 21.8732  
  P453L+A71T 3.43%/0.43% <0.0001 8.1471  
  P453L+A71I 1.06%/0 0.0008 38.7447  
  P453A+A71V 1.32%/0 0.0002 48.56  
  P453T+A71V 1.58%/0.29% 0.0044 5.5428  
  P453T+A71T 1.32%/0.22% 0.0066 6.1467  
Gag-protease coevolving pairs identified by in vitro and in vivo studies 
12+30 0.066 E12K+D30N 2.46%/0 0.0003 91.05  
373+20 0.154 S373P+K20R 2.10%/0 0.0004 77.4894  
  S373P+K20I 1.40%/0 0.0029 51.2958  
  S373P+K20T 1.40%/0 0.0029 51.2958  
431+76 0.084 A431V+L76V 1.76%/0 0.0006 65.0357  
431+88 0.058 A431V+N88D 1.24%/0 0.0034 45.525  
431+84 0.11 A431V+I84V 6.47%/0 <0.0001 250.3875 [64], [74] 
436+90 0.036 K436R+L90M 1.24%/0 0.0034 45.525  
436+84 0.044 K436R+I84V 1.18%/0 0.0036 43.1006  
437+82 0.12 I437V+V82A 4.19%/0 <0.0001 158.3478  
437+84 0.076 I437V+I84V 1.79%/0 0.0006 65.8193  
449+82 0.121 L449F+V82A 1.07%/0 0.0008 39.2668  
  L449V+V82A 1.87%/0 <0.0001 69.2772  
449+90 0.091 L449F+L90M 4.36%/0 <0.0001 165.5455  
  L449P+L90M 1.63%/0 <0.0001 60.3646  
  L449V+L90M 3.00%/0 <0.0001 112.2185  
449+88 0.084 L449F+N88D 1.64%/0 <0.0001 60.5319 [74] 
449+54 0.125 L449F+I54V 1.60%/0 <0.0001 59.2195  
  L449V+I54V 1.87%/0 <0.0001 69.2772  
451+10 0.14 S451N+L10I 4.77%/0.67% <0.0001 7.3833  
  S451N+L10F 1.33%/0 0.0002 48.8204  
  S451T+L10I 1.33%/0 0.0002 48.8204  
452+84 0.056 R452S+I84V 2.62%/0 <0.0001 97.6408 [64] 
452+90 0.049 R452S+L90M 2.67%/0 <0.0001 99.7808 [74] 
453+50 0.051 P453L+I50V 1.05%/0 0.0009 38.438  
453+84 0.093 P453L+I84V 9.69%/0 <0.0001 389.4624 [71], [74], [76], [86] 
  P453A+I84V 1.05%/0 0.0009 38.438  
453+90 0.089 P453L+L90M 11.50%/0 <0.0001 471.7048 [74] 
  P453A+L90M 1.87%/0 <0.0001 69.2772  
  P453T+L90M 2.41%/0 <0.0001 89.5574  
453+82 0.119 P453L+V82A 2.62%/0 <0.0001 97.9032 [74], [86] 
459+82 0.046 P459S+V82A 0.50%/0 <0.0001 0 [78] 
*: Proportions of Gag-protease amino acid patterns were calculated using the PI-
susceptible and PI-resistant Gag-protease sequence datasets. 
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Table S 6.8: The list of software used in this study 
Software Software function used in 
our study 
Software availability Input Ref 
Circos Network visualization http://circos.ca/  [205] 
COMET Subtype classification http://comet.retrovirology.lu/ MSA  
HyPhy v2.1.0 Positive selection pressure http://hyphy.org/w/index.php/Main_Page MSA,Tree [37] 
Hypermut V2.0 Hypermutation sequence test http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html MSA [206] 
MUSCLE Sequence alignment http://www.drive5.com/muscle/ MSA [207] 
MultipleTest Bergmann-Hommel’s tests http://sci2s.ugr.es/keel/multipleTest.zip  [208] 
Matlab 2012a Statistical tests http://www.mathworks.com/products/matlab/   
PSIPRED V3.3 Secondary structure prediction http://bioinf.cs.ucl.ac.uk/psipred/ MSA [32] 
PDBREPORT PDB quality control http://swift.cmbi.ru.nl/gv/pdbreport/ PDB [31] 
ProtTest3 AA substitution test http://darwin.uvigo.es/software/prottest3/prottest3.html MSA [209] 
PyMOL V1.5 Protein visualization http://www.pymol.org/ PDB [210] 
PreRec V1.04 Precision-recall curve http://www.mathworks.com/matlabcentral/fileexchange/29250  [211] 
PSIPRED Secondary structure  
prediction using MSA 
http://bioinf.cs.ucl.ac.uk/psipred/ MSA [32] 
2Struc Secondary structure  
prediction using PDB 
http://2struc.cryst.bbk.ac.uk/twostruc PDB [212] 
RAxML V7.0.4 ML phylogenetic tree http://www.exelixis-lab.org/software.html MSA [213] 
Rega subtype 
tool 
Subtype classification http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0.2/hiv/typingtool MSA [24] 
Seaview V4.3.2 Sequence editor http://pbil.univ-lyon1.fr/software/seaview.html MSA [23] 
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Chapter 7: Learning ancestral polytrees
7.1 Summary
Causal polytrees are singly connected causal models and they are frequently applied in prac-
tice. However, in various applications, many variables remain unobserved and causal poly-
trees cannot be applied without explicitly including unobserved variables. Our study thus
proposes the ancestral polytree model, a novel combination of ancestral graphs and singly
connected graphs. Ancestral graphs can model causal and non-causal dependencies, while
singly connected models allow for efficient learning and inference. We discuss the basic
properties of ancestral polytrees and propose an efficient structure learning algorithm. Ex-
periments on synthetic datasets and biological datasets show that our algorithm is efficient
and the applications of ancestral polytrees are promising.
7.2 Introduction
Causal graphical models have been proposed to explicitly convey causal relations between
causes and their effects in reasoning tasks [1]. As a special class, polytrees are singly con-
nected graphical models where each pair of variables is connected through at most one
path [2]. Since Rebane and Pearl introduced polytree-like Bayesian networks [3], called
dependency polytrees, further research has shown that, (1) belief propagation can be per-
formed computationally efficiently in polytrees [4]. (2) Learning the maximum likelihood
dependency polytrees was proven to be NP-hard [5]. (3) Polynomial algorithms were pro-
posed to learn causal polytrees via conditional independence (CI) tests [2, 6]. (4) Based on
independency properties of isomorphic polytrees [7], a sound and complete criterion was
proposed to read independence relations from minimal directed independence maps [8].
Insofar, many variables remain unobserved in many applications, which have driven us to
design robust causal models bearing unobserved (synonymous with latent and hidden) vari-
ables. However, learning large Bayesian networks is slow [6] and causal polytrees cannot
express causal flows without explicitly including unobserved variables, causing the increased
complexity of causal reasoning, structure learning and inference. The drawbacks above mo-
tivate us to introduce ancestral polytrees (APs) with a fast structure learning algorithm and
we show this new model can be used to learn many biological systems.
Polytree models have been applied in real world applications. For example, dependency
polytrees were efficiently implemented to enhance caching strategies in distributed databas-
es [10]. Based on dependency polytrees, an inference framework was successfully designed
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(a) An NF-kB protein signaling pathway (b) A polytree network with 21 vertices
Figure 1. (a)An NF-kB protein signaling pathway (adapted from [9]). IL-1 and TNF- are
transmitted to IL-1 receptors and TNF- receptors due to extracellular signals. These
receptors then activate TAK1, which immediately activates the I-kB kinase. The I-kB
kinase phosphorylates two serine residues in the I-kB, allowing for the further binding of
the E3 ligase to trigger the degradation of I-kB and NF-kB. Thereafter, NF-kB is
transported into nucleus and activates gene transcription. Twisted red arrow indicates that
there is still an unknown mechanism which cooperates with TAK1 to activate the I-kB
kinase. (b) A polytree network with 21 vertices.to
optimize hardware components according to the performance and price of both tradition-
al and nanotechnology architectures [11]. Moreover, protein signaling pathways might be
modeled by causal polytrees. For instance, Figure 1 illustrates an NF-kB protein signaling
pathway, which activates mammalian immune system cells to produce antibodies against in-
flammation [9]. In this example, causal flows are indicated by red arrows and the activation
or inhibition of involved proteins represent cause or effect events.
Protein signaling pathways can be aptly modeled in cases where protein signalling data
have been collected, for instance, using multiparameter flow cytometry [12]. So far, many
proteins in protein signaling pathways remain unobserved, which have driven us to design
robust causal models bearing latent variables. However, causal polytrees cannot express
causal flows without explicitly invoking latent variables, causing the increased complexity
of causal reasonings. Fortunately, ancestral graphs (AGs) have been proposed to model latent
variables without invoking any additional variables [13]. This has motivated us to introduce
ancestral polytrees (APs) as the extensions of causal polytrees.
In ancestral graphs, every missing edge indicates an independence relation [14]. Besides
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the lack of any directed cycles in both DAGs and AGs, AGs contain directed edges, bidi-
rected edges and undirected edges, in contrast to DAGs, which only permit directed edges.
AGs are refined surrogates for DAGs even in the presence of unobserved variables and se-
lection effects [15]. Since causal polytrees are the offsprings of DAGs and singly connected
networks, APs are the progenies of AGs and singly connected networks. This merit allows
for APs to inherit the merits of both AGs and singly connected networks. On the one hand,
APs can express causal diagrams without invoking additional variables in the presence of
unobserved variables. On the other hand, due to their simplified structures, APs might guar-
antee a fast structure learning and inference compared to DAGs and general AGs. However,
this inheritance in turn demands a strong assumption — that is, the underlying reasoning
diagrams of APs must be singly connected.
This paper begins with basic definitions. We then characterize the properties of APs re-
garding Markov equivalence, essential graphs and factorization. We thereafter introduce a
structure learning algorithm. In the experiments, we compare the performance of our algo-
rithm with other state-of-the-art methods on synthetic datasets. We also apply our model to
investigate the protein signalling pathways and HIV-1 mutation pathways using three biolog-
ical datasets.
7.3 Definitions and properties
Most notations in this section have been adapted from [13]. For a graph G = (V;E) we
denote with V (G) the set of vertices of G and with E(G)  V  V the set of edges of G,
where E  f op y j ;  2 V ^ op 2 f ;!;$; gg. The symbols   ,    
and  $  denote the directed, undirected and bidirected edges between vertices  and ,
respectively. GU = (V;EU) represents the undirected version of G called skeleton. The
endpoint > of an edge is called an arrowhead, or the endpoint   is a tail. The symbol  is
used if the endpoint of an edge is either an arrowhead or a tail. For instance,     means
either  !  or    , and  !  means either  !  or  $ . The parent set
of a vertex  is Pa()  f j  ! g; the neighbor set is Ne()  f j    g; the
spouse set is Sp()  f j  $ g; the descendant set is De()  f j  !    ! 
or  = g; the ancestor set is An()  f j  !    !  or  = g; the anterior set is
Ant()  f j           or  = g; the archaic set is Ar()  f j  !     ! 
or  = g. A path ; refers to a sequence of edges from  to  without duplicate edges.
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The ; is a directed, undirected or bidirected path if it only contains directed, undirected,
or bidirected edges, respectively. A path            is called a triple if  and 
are disjointed. A vertex  is called a collider on a path if and only if the path contains a
triple  !   , so called -structure. The ; is an inducing path if its internal
vertices are all colliders and ancestors of either  or , or both (see examples and properties
of inducing paths on the page 2815 of [13]). An undirected subgraph comprises vertices
linked by undirected paths alone, whereas a bidirected subgraph comprises vertices linked
by bidirected paths alone.
Given the polytree graph in Figure 1(b), we provide several examples of above defi-
nitions: Pa(X5) = fX6g; Ne(X2) = fX1g; Sp(X4) = fX5g; De(X3) = fX3; X4; X9g;
An(X4) = fX2; X3; X4; X8; X10g;Ant(X4) = fX1; X2; X3; X4; X8; X10; X11; X15g;Ar(X4)
= fX2; X3; X4; X5; X6; X8; X10g; X2 ! X3  X10 and X3 ! X4 $ X5 are -structures;
X3, X4, X17, X20 are colliders; X10;X16 is an undirected path; X10;X9 is a directed path;
X17;X21 is a bidirected path; an undirected subgraph contains X1; X2 and a bidirected sub-
graph contains X17; X20; X21.
Let X; Y; Z be variables or sets of variables, hX;Y jZi denotes that X and Y are condi-
tionally independent given Z; otherwise, hX; Y - Zi. hX; Y i refers to the fact that X and
Y are marginally independent; otherwise, hX; Y - ;i. We use CI tests to determine the con-
ditional independence. In ancestral graphs, independency relations can be identified using
m-separation [14].
Definition 1. m-separation. Two vertices  and  are m-separated given Z in G— denoted
as h; jZim —where Z  V (G)nf; g if and only if every path between  and  contains
either one triple from (1) !  ! , $  ! ,   ! ,   ! ,   , and
 2 Z, or one triple from (2) !   , $   , $  $ , and De() \ Z = ;.
Two vertex sets X; Y are m-separated given Z if all the paths from X to Y are m-
separated byZ. Figure 1(b) indicates the examples that hX2; X4jX3i, hX2; X4 - ;), hX2; X8i,
hX2; X8 - X3i, hX3; X5i, hX3; X5 - X4i, hX2; X9jX3; X4i and hX3; X6 - X4; X5i.
Definition 2. Ancestral graph (AG) [13]. A graph G is an ancestral graph if and only if
three conditions hold: (i) there are no directed cycles; (ii) if there is an undirected edge
   , then  and  have neither spouses nor parents; (iii) wherever there is a bidirected
edge $ , no directed path passes from  to , or from  to .
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The attributes and examples of AG, as well as the difference between AGs and Bayesian
networks, have been clarified in [13, 14]
Definition 3. Maximal ancestral graph (MAG) [13]. An ancestral graph is maximal if
and only if there exists Z such that h; jZi for any un-adjacent pair ;  2 V (G), where
Z  V (G)nf; g.
In ancestral graphs, vertices represent observed variables and edges represent causal re-
lations. Many examples of AGs and MAGs were provided in [13,15]. The polytree network
in Figure 1(b) is an AG. Regarding the interpretation of directed, undirected and bidirect-
ed edges: (1)  !  indicates that the appearance of  cultivates  which might be due
to a direct cause [4]; (2)  $  indicates that an unobserved variable L exists in the path
  L ! , whereas neither  causes  nor  causes  [15]; (3)     indicates that
 is associated with  with no certainty whether  causes  or vice-versa, due to selection
bias [15].
7.4 Ancestral polytree models
In this section, we present our ancestral polytree models, which combine the concept of
ancestral graphs with the idea of polytree structures.
Definition 4. Ancestral polytree (AP). A graphical model G(V;E) with E  f op  j
;  2 V ^ op 2 f ;!;$; gg is an ancestral polytree if and only if two conditions hold:
(i) it is singly connected; (ii) if it has an undirected edge    , neither  nor  has any
spouse or parent.
Figure 1(b) demonstrates an example of AP. Moreover, it has been proven that an AG is
maximal if and only if there is no inducing path between any non-adjacent vertices (Corollary
4.4, [14]). Since APs are singly connected, the conditions (i) and (ii) in the definition of AGs
are guaranteed so that any AP is also an AG. Because there is no inducing path in singly
connected AP so that any AP is an MAG.
As the subgraphs of causal polytrees, causal basins start with -structures, and continue
in the direction of directed paths to traverse the children’s descendants and the direct parents
of these descendants [4]. For instance, the vertices fX2; X3; X4; X8; X9; X10g in Figure 1(b)
form a causal basin (also see examples on page 393 of [4]). We herein introduce ancestral
basins in ancestral polytrees.
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Definition 5. Ancestral basin. A subgraph of an ancestral polytree G is an ancestral basin
GB if it starts with a -structure containing a starting collider, and continues in the direction
of directed or bidirected paths to pass every linked vertex, whose archaics include at least
one collider, or being a parent of a collider.
Definition 6. Simple ancestral polytree (SAP). Ancestral polytree G is a SAP if and only if
its edges are either in ancestral basins or in undirected paths.
Proposition 1. Both ;  are colliders if  $  2 E(GS).
Proof. Ar() contains at least one collider since GS is a SAP. If Ar()  fg, then  itself
is a collider; if Ar()  fg, at least one vertex  2 Ar() satisfies  !  $ . It
ensures that  is a collider, so is .
A starting collider, also termed as a multi-parent node [4] or articulation point [6], rep-
resents the vertex  on a path containing   !    , where an ancestral basin be-
gins. For instance, the subgraph containing fX2; X3; X4; X5; X6; X8; X9, X10g in Figure
1(b) is an ancestral basin whose starting collider is X3. Yet, neither the subgraph containing
fX11; X12; X13, X14g nor the one containing fX15; X17; X18; X19; X20; X21g is an ancestral
basin, because there is no starting collider in both subgraphs, and neither the parents of
X11; X19 nor the anteriors of X11; X19 contain any collider. The AP in Figure 1(b) becomes
an SAP after replacing X12 ! X13, X19 ! X18 with X12  X13, X19  X18, respectively.
Let H(G) represent the independency in a causal diagram:
H(G)  fhX;Y jZi j Disjointed subsets X; Y; Z  V (G)g
Definition 7. Markov equivalence [13]. Two ancestral graphs G1 and G2 are Markov e-
quivalent, G1  G2, if H(G1) = H(G2).
Proposition 2. G1  G2 if and only if APs G1 and G2 have the same skeletons and -
structures.
Due to limited space, a concise proof includes two parts. (Necessary) Note that both
APs G1 and G2 are also MAGs. If G1; G2 are MAGs and G1  G2, then G1; G2 have the
same adjacencies and -structures (Proposition 3.6 in [13]). (Sufficient) It was proven that
if MAGs G1; G2 share the same skeleton and colliders with order, then G1  G2 (Theorem
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3.7, [13]). If APs G1 and G2 have the same -structures, they have the same colliders with
order because there is no discriminating path (definition 3.8 and 3.11, [13]) in any AP.
Above proposition leads to a sufficient and necessary condition to identify Markov equiv-
alent APs. However, instead of investigating all equivalent structures, it is vital to identify
one essential graph which is sufficient to represent all Markov equivalent structures.
Definition 8. Essential graph. Let [G] denote Markov equivalence class of ancestral poly-
tree G, whose conditional independencies are identical. MG is the essential graph of G if
and only ifMG satisfies two conditions, (i)MG shares the same skeleton with all APs in [G];
(ii) any directed or bidirected edge exits inMG if and only if it is shared by all APs in [G].
Note that essential graphs are equivalent to partial ancestral graphs [15] if AGs are re-
stricted to be polytrees. Let GS be a SAP, due to the condition (ii) above, GS 2 [G] guar-
antees that GS includes all directed and bidirected edges inMG. This fact leads to the next
proposition.
Proposition 3. MG is a simple ancestral polytree.
The factorization of acyclic directed mixed graphs with directed and bidirected edges
was studied in [16]. The factorization of Gaussian distribution in MAG can be decom-
posed as f(XV ) = f(XunG)f(XV nunG j XunG), where unG and V nunG contain vertices of
undirected and directed subgraphs in MAG, respectively [14]. To assess structure learning
and inference, the next proposition clarifies the factorization of joint probability of ancestral
polytrees.
Proposition 4. Given an ancestral polytree G = (V;E), the joint probability of random
variables can be decomposed into products of conditional probability distributions as:
PG(XV ) =
1
Z
Y
Xi Xj2E(SU )
 (Xi;Xj)
Q
b2SB P (XbjAnt(Xb))
Q
X2SD P (XjAnt(X);Ar(X))
Where SB is the set of subgraphs containing bidirected edges, SU is the set of subgraphs con-
taining undirected edges, SD is the set of subgraphs containing directed edges,  is a factor
potential of a clique formed with edge     as a non-negative function, the normalization
coefficient is defined as Z =
R
X
V (SU )
Q
 2SU  (; )dX .
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Proof. Firstly, given any undirected subgraph s in SU and any bidirected subgraph b in SB,
the factorization can be expressed as
Q
c2C(s)  c(X)=Z
, where C(s) is the set of cliques in s
and Z is the normalization coefficient. Note that undirected subgraphs in SU are disjointed
and cliques in singly connected SU contain two neighbouring nodes ;  on an undirected
edge   . Therefore, the factorization of SU is:
P (XSU ) =
Y
s2SU
1
Z
Y
c2C(s)
 c(X) =
1
Z
Y
c2C(SU )
 c(X) =
1
Z
Y
Xi Xj2E(SU )
 (Xi; Xj)
Secondly, Theorem 4 in [16] reveals the factorization of bidirected subgraphs as:
P (XSB jNe(XSB); XSU ) =
Y
b2SB
P (Xb j Pa(Xb); V (SU)) =
Y
b2SB
P (Xb j Ant(Xb))
Thirdly, the factorization of directed subgraphs is:
P (XSD jNe(XSD); XSU ) =
Y
X2SD
P (X j Pa(X); V (SB); V (SU)) =
Y
X2SD
P (X j Ant(X); Ar(X))
The proof is complete by multiplying three parts:
PG(X) = P (XSU )P (XSB ; XSD jXSU )
= P (XSU )P (XSB jNe(XSB); XSU )P (XSD jNe(XSD); XSU )
Particularly, if the entire ancestral polytree G is an ancestral basin, we have SU =
;; SD = V   V (SB); Ant(X) = Ar(X). Mimicking each vertex in SD as an entire bidi-
rected subgraph, the factorization of ancestral basin GB is:
PGB(XV ) =
Y
X2V V (SB)
P (X j Ant(X))
Y
b2SB
P (Xb j Ant(Xb))
=
Y
b2SB[(V V (SB))
P (Xb j Ant(Xb))
Examples in Figure 2 include: V (SU) = ffX1; X2g; fX6; X7g; fX10; X11; X15; X16gg; V (SB)
= ffX4; X5g; fX17; X20; X21gg; V (SD) = ffX9g; fX12; X13; X14g, fX3; X8g; fX18; X19gg.
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The factorization of AP with configuration X = x in Figure 2 is: P (X = x) = [1=Z
 (x1; x2) (x6; x7) (x10; x11) (x11; x15) (x15; x16)][p(x19)p(x18jx19)p(x13jx12)p(x14jx12)
p(x3jx1; x2; x8; x9; x10; x11; x15; x16)p(x12jx10; x11; x15; x16)] [p(x4; x5jx3; x6; x7)
p(x17; x20; x21jx10; x11; x15; x16; x18)]
7.5 Learning ancestral polytrees
Given a training dataset, the methodology of training causal polytrees usually involves t-
wo stages. Firstly, undirected skeletons are trained either by maximum weighted spanning
trees [4] or by CI tests [2]. Secondly, the directionality of edges in undirected skeletons are
recovered by orienting principles [4, 6] including two rules. Rule 1: for all        and
h; i, orient        into  !   . Rule 2: for remaining  !     , orient
 !     into  !  ! . Based on the m-separation, orienting principles for learning
ancestral polytrees rely on the orienting principles of ancestral polytree (OPAP), which also
includes two rules:
Rule 1 : for all          and h; i, orient          into  !   .
Rule 2 : for remaining  !    , orient  !     into  !  ! .
Based on the OPAP, we have designed a structure learning algorithm using three tips: (1)
search colliders through visiting inner vertices from the one with the most undirected edges
to the one with the least, because every collider is an inner vertex. (2) For each selected
inner vertex, examine CI test h; i on the triplet        first, and examine CI test on
   !  last (because it is comparatively rare for both  and  to be colliders). (3)
Distinguish bidirected from undirected edges by withdrawing detected bidirected edges, and
recover them back into the oriented structure.
Algorithm: Learning Ancestral Polytree (LAP)
Input: A training dataset and a polytree skeleton GU .
Output: A partially oriented ancestral polytree G.
Abbreviations: UV, the set of unvisited inner vertices; CS, the set of colliders; BA, the
set of bidirected edges; VIn, the set of inner nodes; CI, the set of CI test.
Initiate CI = BA =;, UV = VIn; G = GU .
While UV 6= ;
 = argmax
v2UV
jNeG(v)j; UV = UVnfg;
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For all       2 E(G) and (; ) 62 CI
Do CI = CI [ f(; )g; if h; i, orient        into  !    and
CS = CS [ fg;
End for
For all      2 E(G) and (; ) 62 CI
Do CI = CI [ f(; )g; if h; i, orient       into  !    and
CS = CS [ fg;
End for
For all    !  2 E(G) and (; ) 62 CI
Do CI = CI [ f(; )g; if h; i, orient     !  into  !  $  and
CS = CS [ fg,E(G) = E(G)nf $ g;BA = BA [ f(; )g;
End for
For all   !  2 E(G) and (; ) 62 CI
Do CI = CI [ f(; )g; if h; i, orient    !  into  $  $  and
CS = CS [ fg, E(G) = E(G)nf$ ;  $ g;BA = BA [ f(; ); (; )g;
End for
For all !     2 E(G)
Do orient !  ! ;
End for
End while
For all  2 CS, create an empty queue Q, push(Q;);
While Q 6= ;
 = pop(Q);UV = UVnfg;
For all  2 UV;     2 E(G)
Do orient     into   , push(Q; );
End for
End while
End for
For all (; ) 2 BA
Do E(G) = E(G) [ f$ g.
End for
Return G
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LAP has two major parts. The first part in the ”while” loop and the second part in the
”for” loop orient the unvisited edges based on the rule 1 and rule 2 of OPAP, respectively.
Using CI tests, each of the five ”for” loops in the first part orients       ;      
;     ! ;    !  and  !    , respectively. The visited edges and nodes are
recorded to avoid repeating tests. The second part uses the depth-first traversal to visit all
colliders in ancestral basins and to orient the undirected edges subsequently.
Ideally, consider there is an oracle to provide CI information from a faithful ancestral
polytree G, denoted as GT . An algorithm is sound if it outputs a predicted G that G 2 [GT ],
and algorithm is complete if it predicts a maximally informativeG for [GT ] [15]. The sound-
ness and completeness of 11 orientation rules have been proven to train ancestral graphs [15].
These 11 orientation rules can be simplified into OPAP if AGs are singly connected, which
ensures the soundness and completeness of LAP. Remind that two OPAP rules were also
included in the Fast Causal Inference algorithm (FCI) [17] and the augmented FCI [15],
both of which can model equivalent structures as LAP if underlying structures were singly
connected.
Many studies have endeavored to learn polytree skeletons and well-known algorithm-
s for maximum-likelihood learning of tree distributions have achieved the complexity of
O(n2 log(n)) [18]. Herein we analyze the computational complexity of LAP to show that
LAP can achieve a fast structure learning using refined orienting procedures.
Proposition 5. Suppose skeleton GU is an undirected tree which has one root with K adja-
cent vertices, and has inner vertices all with K+1 adjacent vertices. Let N be the number of
vertices in GU , the number of required CI tests R(GU) satisfies:
R(GU)  (K + 1)(N   1)=2 K
Proof. Let H be the depth of tree GU , we have N =
PH
i=1K
i 1 = (KH   1)=(K   1).
Therefore,
PH 1
i=2 K
i 1 = (KH 1 K)=(K 1) = (N 1)=K 1. The number of required
CI tests is maximal if we test h; i in all triplets formed as     . Consider every inner
vertex has K(K + 1)=2 pairs of adjacent vertices except the root, the summation of CI tests
over all inner vertices satisfies:
R(GU)  K(K   1)=2 +K(K + 1)PH 1i=2 Ki 1=2 = (K + 1)(N   1)=2 K.
Proposition 5 analyzes the complexity of LAP for a special case of skeleton GU . For the
general cases, we then consider the average CI tests regarding the entire space of the set of
313
Chapter 7: Learning ancestral polytrees
marginally independent tests T , denoted as 
. Given an arbitrary GU , let f(n) count the
number of T that requires n CI tests to train GU . In fact, the set of f(n) has k(k   1)=2  
dk=2e + 1 elements where n = dk=2e; dk=2e + 1;    ; k(k   1)=2 and dk=2e denotes the
upper bound of integer upon k=2 (e.g. d3=2e = 2). The average CI tests of inner node v is:
E[R(GUv )] =
1
j
j
k(k 1)=2X
n=dk=2e
[n f(n)]
To date, we have not found any simple formula to decode f(n) whose experiment data is:
f(2)=f1g,f(3)=f2,6g,f(4)=f16,8,8,14,18g,f(5)=f128,192, 192,224,104,72,62,50g, f(6)=f4096,
4096,4096,3584,3584, 3968,3520,2560,1776,744,392,222,130g, f(7)=f131072,262144, 327680,
311296,262144,233472,169984,123904,88064,66560, 50048,33856,19808,10480,3944,1672,
702,322g, f(8)=f16777216,25165824, 29360128,29360128,27787264,25165824, 22413312,
18874368,14680064,10485760,7061504,4673536, 2883584,1775616,1086464,681728,415488,
233792,116128,51248,17384,6152,2046, 770g.
Even so, we have observed that regression methods can estimate E[R(GUv )] sufficiently.
Particularly, we have found similar results using both least square and robust linear regres-
sions based on iteratively re-weighted least squares. The output of least square regression is:
E[R(GUv )] =  1:3439 + 1:3425K, where the root mean square error is " = 0:2652 and the
maximum residue at K = 5 equals to "max = 0:3126. Based on the above estimation, we
have:
E[R(GU)] =
X
Vi2VIn
[
1
j
j
X
T2

R(GUVi ; T )] =
X
Vi2VIn
E[R(GUVi)]
If K = maxv2V jNeGU (v)j 8, E[R(GU)]  jVInj(1:3425K   1:3439 + "max). In other
words, the average CI tests for each inner node are bound by 1.3425K-1.0313 if the maximal
graphical degree meets the condition of K8.
7.6 Experiments
Four experiments were carried out in this study: (1) we compared LAP with both the causal
Polytree Recovery Algorithm (PRA) [4] and the Polytree-Depth-First-Search (PDFS) algo-
rithm [6] using a synthetic dataset, (2) we applied LAP to model protein signaling pathways
using a human immune cell dataset [12], (3) we explored the HIV-1 resistance mutation path-
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ways by LAP using the HIV-1 protease inhibitor nelfinavir (NFV) dataset [19], and (4) we
used LAP to model the interaction networks in the HIV-1 capsid protein.
In our experiments, the algorithm performance was evaluated using structure accuracy
defined as: Acc = (jf(X;Y )j(X;Y ) 2 E; (X;Y ) 2 E; (Y;X) =2 Egj)=(jV j 1), where
G = (V;E) and G = (V;E) are the known and the predicted structures, respectively. We
used non-parametric bootstrapping with 100 replicates to cultivate polytree skeletons from
the undirected maximal spanning tree algorithm based on mutual information [20]. We used
Fisher’s exact test for CI tests (confidence level: 95%) and Laplace smoothing for probability
calculations.Our algorithm implementation is available at http://www.mathworks.com/
matlabcentral/fileexchange/40126-ancestral-polytree.
In the first experiment, we compared LAP with two causal polytree algorithms PDFS
and PRA using a synthetic dataset. The synthetic data contained 6000 random polytrees
with variable numbers (ranging from 20 to 49) and CI sets randomly generated. For each
variable number, 200 unique skeletons were randomly sampled for our analysis. Figure 2(a)
illustrates the comparison results, showing that LAP (average structure accuracy: 82.72%)
performs better than the PDFS (64.6%) and PRA (49.54%) algorithms. We also compared
the number of CI tests required by the polytree algorithms, illustrated in the Figure 2(b).
The average CI tests for PDFS, LAP and PRA were found to be 49.51, 47.53 and 37.02,
respectively. This suggests that the weak structure accuracies of PRA are compromised by
the least CI tests, and LAP performs better than PDFS.
In the second experiment, LAP was applied to flow cytometry datasets of human T cell
protein signaling pathways [12]. The data was collected through intracellular multicolor
flow cytometry, which measures the protein expression levels of 11 proteins with single-cell
data points [12]. We first removed the outliers whose values were 3 times larger than the
mean values and discretized the continuous data using an information preserving algorithm
[21]. By doing so, 500 datasets were created containing data for 400 cells each. Using 100
bootstrap samples on each dataset lead to 500 trained APs. Figure 2(c) shows a consensus
AP which recovers 10 out of 14 expected signaling pathways, while BN analysis recovered
12 [12]. Note that the bidirected edge PIP2$PIP3 was recovered assuming that the protein
PI3K was observed.
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Figure 2. Average structure accuracy (a) and number of CI tests (b) required by LAP, PDFS
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and PRA on the a synthetic dataset.(c) Human T cell protein signaling pathway network
modeled by LAP. Pink circles and blue triangles represent activators and inhibitors respec-
tively. Other nodes represent proteins in the signaling pathways. Red arrows are faithfully
predicted edges, black arrows are undetected edges but reported by biological studies and
blue arrows are recovered assuming that the protein PI3K is observed [12]. (d) Ancestral
polytree network of HIV-1 protease mutations selected by the protease inhibitor NFV. N-
FV is colored yellow and colored squares distinguish protease drug resistance mutations
from wild type residues. Mutations from the same residue position are clustered and mu-
tual information is notified on edges. (e) HIV-1 protease structure. The residue positions
are annotated accordingly. The PDB data of HIV-1 protease is 2QAK and the visualization
software is PyMOL v1.5. (f) Ancestral polytree modeling of residue interaction networks in
HIV-1 capsid. Green and pink indicate residue positions in the loop and helix structures of
capsid, respectively. Circle, square and triangle represent positions in the C-terminal (1-84),
middle (85-145) and N-terminal (146-231) domains. Red edges indicate positions whose C
atoms are closer than 10A˚ of the Euclidean distance in the capsid structure. (g) HIV-1 cap-
sid structure (PDB:3P05, visualized by PyMOL v1.5). The residue positions 41, 120, 132,
136 across different functional domains are annotated, as well as major clusters in two loop
regions (positions: 1-16 and 85-100). Yellow links indicate the associations between residue
positions 136, 132, 41 and 120, predicted by our ancestral polytree model. (h) Position 6 in
the structure of HIV-1 capsid hexamer (PDB:3H4E, visualized by Chimera v1.7).
In the third experiment, we modeled the interaction network of HIV-1 protease mutations
selected by the protease inhibitor nelfinavir (NFV). We trained polytree networks using the
HIV-1 NFV dataset, which includes 1307 HIV-1 protease amino acid sequences sampled
from 967 drug-naive and 340 NFV-treated patients [19]. The trained polytree network is
illustrated in Figure 2(d). We mapped the mutation positions to the crystalized structure
of HIV-1 protease (Figure 2(e)). We found that for protease mutations that had less than 5
edges to the NFV in the consensus AP, the Euclidean distances of C atoms between these
mutations had less than 10 angstroms in the 3D structure. Moreover, our AP shared 38 out of
58 edges compared to the trained BNs, described previously in [19]. AP may help to study
the associations between HIV-1 drug resistance mutations, whereas causal effects in drug
resistance pathways and the impact of unobserved variables require further investigations.
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In our last experiment, we modeled the interaction networks of natural residues in HIV-1
capsid - a hexamer protein in the length of 231 residue positions. HIV-1 capsid is a key
protein to construct the structural surface of HIV-1 mature virions [22]. We followed the
procedure described in [22] to collect HIV-1 capsid sequences sampled from 787 treatment
naive patients in the HIV Los Alamos database. We removed both duplicate sequences and
sequences with stop codons. We aligned nucleotide sequences using Seaview v4.4.0. Figure
2(f) shows our consensus ancestral polytree for HIV-1 capsid. It suggests that positions
are clustered in AP regarding to the loop and helix regions in functional domains of capsid
(Figure 2(g)), except the positions 83 and 116. Being crucial for protein multimerization,
position 6 connected with many positions in AP (Figure 2(h)). Potentially, positions from
the same functional domains tempt to cluster in our causal network may explain the role of
structural constraints. As shown in our recent study [22], this information can be useful for
designing novel inhibitors targeting HIV-1 capsid.
7.7 Conclusions and future work
This study introduces ancestral polytrees and their simple structures which guarantee fast
learning algorithms. Our future study will focus on maximum likelihood and inference
problems. We will also apply polytree models to large biological networks such as genomic
interaction networks.
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Chapter 8 
General discussion and future perspectives 
 
 
                                ―If I have seen further it is by standing on the shoulders of giants.‖ 
                                                                                                              — Isaac Newton 
 
The contribution of my Phd thesis can be summarized in one sentence: it contributes 
to the understanding of HIV genome-wide diversity, interaction and coevolution. My 
research has been involved mainly with two topics: HIV genomic analysis and the 
development of computational methods. HIV genomic projects have been designed 
toward clinical applications (e.g. HIV drug resistance) as well as drug and vaccine 
development. I have developed computational methods for large-scale data analysis 
mostly based on the mathematical modeling. My software toolboxes have been shared 
as open sources in the journal websites and in the Matlab file exchange center (ID: 
45984). 
In the last chapter of my thesis, I will summarize the contributions of my Phd study 
and provide original ideas for future research. The strength and weakness of my HIV 
projects are also discussed. At the end of this chapter, my contributions on 
probabilistic graphical models and data visualization are briefly discussed as two side 
projects of my Phd study. Future perspectives of my genome-wide analysis on HBV 
and HCV are discussed as well. 
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 HIV-1 genetic diversity and drug resistance 8.1
In the past three decades, thousands of anti-HIV inhibitors have been proposed and 
more than 25 inhibitors in five drug classes have been approved by the FDA (Chapter 
1). Nevertheless, many HIV clinical studies have demonstrated that the efficiency of 
anti-HIV inhibitors have been hampered by drug resistance mutations emerging in the 
HIV genome [1]. Usually, anti-HIV drugs with low genetic barriers have higher 
tendency towards development of drug resistance, while those with higher genetic 
barriers have a lower tendency towards development of drug resistance [2]. All 
NNRTIs and most NRTIs are considered to have lower genetic barriers than protease 
inhibitors [2]. Previous HIV-1 studies have investigated the role of protease mutations 
in the drug resistance of protease inhibitors, which have relatively higher drug genetic 
barriers. As a new mechanism of drug resistance, HIV-1 Gag mutations have been 
found to cause drug resistance to protease inhibitors [3]. The presence of Gag 
mutations has been associated with protease drug resistance [4]. Nevertheless, large-
scale analysis on PI-associated Gag mutations is largely lacking. 
Many HIV drug resistance interpretation algorithms have been designed to estimate 
genotypic drug resistance using viral sequences. These algorithms are built on the 
drug resistance mutations reported in experimental and clinical studies. Currently, 
several drug resistance interpretation algorithms are widely used; for instance, the 
Stanford algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra), the Rega 
algorithm (https://rega.kuleuven.be/cev/avd/software/rega-algorithm), the ANRS 
algorithm (http://www.hivfrenchresistance.org/) and the drug resistance mutation list 
from International Antiviral Socienty-USA (https://www.iasusa.org/). HIV clinical 
guidelines from WHO and NIH have also been updated regularly 
(http://aidsinfo.nih.gov/). Overall, advancements on many aspects of detecting and 
monitoring drug resistance have been made. Improved HIV treatments have further 
prolonged the life expectancy of HIV infected patients [5]. 
Ideas of my HIV-1 diversity and drug resistance studies 
HIV gag gene encodes important structural proteins for viral morphogenesis (see 
Chapter 1). Gag polyproteins are cleaved into individual structural proteins during the 
protease-mediated proteolytic processing. Genetic diversity of Gag proteins can 
impact on the synthesis and maturation of viral structural proteins [6]. In my thesis, 
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Chapter 2 reports the genetic diversity of HIV-1 Gag and Chapter 4 investigates HIV-
1 Gag mutations associated with drug resistance of protease inhibitors. 
During the process of data collection and literature review, I found that many 
experimental inhibitors had been designed to target Gag but few studies had reported 
the genetic diversity of drug binding sites in the HIV-1 Gag. Since natural 
polymorphisms can affect the potential of experimental Gag inhibitors [7], I 
conducted large-scale sequence analysis to reveal the functional conservation of HIV-
1 Gag and to show all possible natural polymorphisms observed at the known drug 
binding sites (Chapter 2).  
In the meantime, Dr. Kristof Theys and Prof. Kristel Van Laethem helped to contact 
Dr. Jens Verheyen whose expertise is known in the field of HIV Gag mutations. After 
a few months, HIV-1 gag nucleotide sequences and clinical data from our Leuven 
patient cohort were available for me to identify HIV-1 Gag mutations emerging 
during the treatment of protease inhibitors. With the help of my colleagues, I drafted 
the manuscript about the drug resistance of HIV-1 Gag mutations (Chapter 4). 
Strength and weakness of my HIV-1 Gag studies 
Chapter 2 and 4 characterize genetic variations of HIV-1 Gag and its impact on the 
protease drug resistance. In these two studies, large-scale datasets were used in our 
statistical analysis. Previous studies have reported results only in small cohorts of 
patients, whereas I analyzed the data sampled from more than 10000 patients. Chapter 
2 provides the first study to show the functional conservation of HIV-1 Gag proteins. 
We showed natural variations at drug binding sites of over 50 Gag experimental 
inhibitors and revealed the N terminus of capsid as the most conserved drug target in 
HIV-1 Gag.  
Chapter 4 shows for the first time the prevalence of PI-associated Gag mutations in 
large-scale cohorts of patients infected with different HIV-1 subtypes. We showed 
that most Gag mutations were less prevalent than previously thought. Only a few 
significant Gag mutations were found in the C terminus of HIV-1 Gag. Our study thus 
contributes to the prevalence analysis of HIV-1 PI-associated Gag mutations in large-
scale patient populations.  
The progress of my HIV-1 Gag projects has faced many challenges. I was unable to 
further investigate and quantify the clinical impact of point mutations in HIV-1 Gag. 
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Owing to the limited resources, I was unable to perform the in vitro experiments to 
quantify the drug resistance levels of Gag mutations. Future perspectives of these two 
studies are associated with the development of new Gag inhibitors (Chapter 2) and the 
evaluation of clinical impact of PI-associated Gag mutations (Chapter 4). The former 
will take years to develop new HIV-1 Gag inhibitors; the latter will require large 
clinical and experimental data which is largely lacking to date. It remains a challenge 
to address the virological outcome of HIV-1 Gag mutations and the development of 
Gag inhibitors. In addition, different HIV-2 Gag mutations have been shown to 
associate with PI drug resistance compared to HIV-1 [8]. Further investigations on 
HIV-2 Gag mutations are still needed. 
 HIV genomic diversity 8.2
The HIV pandemic has been characterized by extensive genomic diversity caused by 
multiple factors including high evolutionary rates, sequence recombination and 
multiple zoonotic transmissions into human populations [9]. In the multi-national 
vaccine trial STEP, 252 full-length genome sequences of subtype B were sampled 
from 42 patients to show the genetic difference between the vaccine and the placebo 
groups [10]. In the Thai vaccine trial RV144, 359 full-length genome sequences of 
CRF01_AE were extracted from 49 patients to demonstrate that vaccine-induced 
immune responses were associated with residues in the variable regions of GP120 [11, 
12]. Moreover, HIV-1 transmission and viral evolution were characterized using 475 
subtype B genome sequences sampled from 11 American patients during acute HIV-1 
infection [13]. Subtype distributions in South Africa and Malaysia were assessed 
using 244 and 184 genome sequences, respectively [14, 15]. Investigations of HIV 
genome sequences sampled from less than 100 patients have also been reported [16-
25]. A few studies have also quantified the HIV genome-wide diversity using small 
sequence datasets [16-18]. Since HIV genome-wide diversity has a significant effect 
on the development of HIV drugs and vaccines [9], one of our objectives was set up 
to investigate the genome-wide diversity of HIV from a global perspective.  
Ideas of my HIV genome projects 
My idea to investigate HIV genome-wide diversity was inspired by HIV-1 Gag 
conservation study (Chapter 2). Most results of HIV-1 genome-wide diversity 
analysis are presented in Chapter 3. The original idea originated from conversations 
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with Dr. Kristof Theys a year ago. We had read that HIV genomic diversity reported 
discordantly by different publications, raising our interests to publish results about 
HIV genome-wide diversity. When this clear goal was set up, I proceeded to collect 
all full-length genomic sequences from public databases. During my previous projects, 
I developed the toolbox for genome sequence alignment and collected many genomic 
datasets (e.g. human T cell epitopes, HIV-human protein interaction, HIV-derived 
peptide inhibitors). After the initiation of my HIV genome diversity study, I applied 
my alignment toolbox and integrated the genomic datasets that I collected in my 
previous projects. 
Strength and weakness of my genomic studies 
I performed comparative analyses to accurately estimate HIV genomic diversity using 
large-scale genomic datasets (Chapter 3). I have further contributed to an open-source 
genomic toolbox developed for genomic analysis. However, due to limited time and 
resource, I could not use the information of HIV genomic diversity to improve current 
inhibitors and bring much improvement in the HIV clinical treatments and vaccine 
trials. 
Many technologies in the field of viral infectious diseases have been advanced in the 
past few years (e.g. high throughput genomic sequencing, database management, 
statistical methodology). It is my belief that the methods and software presented in 
this thesis will be useful for analysing genome-wide diversity, interaction and 
coevolution with broad applications to many viral infectious diseases. 
 HIV-1 protein coevolution 8.3
Study of the evolution theory, coevolution is essential for exploring the relationships 
between species in the complex ecological systems [26]. Recently, sequence-based 
methods have been established to use the phylogenetic information and to disentangle 
indirect relationships, leading to an improved prediction capacity [26]. Previous HIV-
1 coevolution studies revealed that functional communications of coevolving residues 
in the GP120-GP41 complex [27] and in the Matrix-GP41 complex [28], both of 
which help HIV to overcome major structural alterations during viral entry. As 
reviewed in Chapter 5, more than 27 sequence-based methods have been proposed in 
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the last decade, making the coevolution research one of the advanced areas in 
computational biology.  
To the best of our knowledge, no computational method has been proven efficient to 
model genome-wide coevolution. While many methods have been applied to a single 
protein, I realized that a standard method for investigating the coevolution between 
different HIV-1 proteins is still lacking. For this reason, I focused on developing a 
software system, which provided robust predictions of long-range coevolution within 
and between HIV proteins to the extent of coevolution in the HIV full-length genome. 
To meet this objective, I designed an ensemble coevolution system (Chapter 5). As 
my pilot study of HIV-1 genome-wide coevolution, Chapter 6 investigates the HIV-1 
Gag-protease coevolution. 
Ideas of my HIV coevolution projects 
Chapter 5 introduces a new coevolution system that integrates different sequence-
based methods to predict amino acid coevolution. While the original goal was to 
create a method for modeling the genome-wide HIV coevolution, it was not feasible 
due to several reasons. Firstly, no method has proven efficient in predicting genome-
wide residue coevolution. Secondly, no in vitro experiment has been developed to 
identify all the possible amino acid associations in the whole-length genome. Thirdly, 
biological mechanisms of genome-wide HIV coevolution have not been fully 
understood.  
At the beginning, I tried the structure-based methods, but the prediction results were 
not interpretable. I also applied many sequence-based methods, but prediction results 
were largely distinct, causing a problem for data interpretation. Thereafter, I began to 
investigate the HIV-1 Gag-protease coevolution because many experimental and 
clinical studies had provided data for the model validation. Designing a new method 
was still a challenge even though the goal was reset to investigate the HIV-1 Gag-
protease coevolution − one of the key coevolution events in the HIV-1 genome. 
Firstly, even after many hard-working days and nights, I failed to design a single 
prediction method that could outperform the 30 published methods. Secondly, 
discordance predictions were obtained from different methods with comparable 
prediction accuracy, making the data interpretation extremely hard.  
Chapter 8: General discussion and future perspectives 
  
327 
Acting on the contention that the performance of sequence-based methods varies, I 
came up with the idea of assembling different prediction models into one system, 
which was called ―ensemble coevolution system‖ (Chapter 5). In the meantime, I 
studied the known algorithms in the research field of ensemble learning [29, 30]. 
Algorithms such as AdaBoost were however not feasible for assembling the 
sequence-based methods, because sequence-based methods do not provide negative 
predictions so that true negatives cannot be evaluated and used in AdaBoost. For this 
reason, I used the incremental learning and the majority voting to integrate multiple 
sequence-based methods, resulting in the heuristic algorithm that I proposed in 
Chapter 5. Using the combination of individual sequence-based methods, 
combinations of methods could outperform any of the individual methods so that the 
prediction capacity was improved. Thereafter, I applied the ensemble coevolution 
system to model the HIV-1 Gag-protease coevolution networks (Chapter 6). 
Strength and weakness of my coevolution studies 
In Chapter 5 and 6, I proposed a software platform ECS to investigate the HIV-1 Gag-
protease coevolution networks, providing valuable insight on HIV genome-wide 
coevolution. Ensemble coevolution system is the first coevolution system proposed to 
investigate the residue coevolution given the 27 sequence-based methods. Regarding 
the weakness of my study, I have only evaluated method performance in HIV-1 
proteins. It is possible that different combinations of methods can be more efficient in 
other protein families. Since most sequence-based coevolution methods have been 
developed to predict coevolving residues in many protein families [31], as a future 
perspective, we still need to evaluate the performance of sequence-based methods 
using large-scale protein family datasets, for instance, using the benchmark datasets 
provided in the Critical Assessment of protein Structure Prediction (CASP, 
http://predictioncenter.org/). 
Recent studies have demonstrated that an accurate prediction of protein contact maps 
can improve the prediction of protein 3D structures [32]. In future, we will apply the 
ensemble coevolution system to predict large protein structures. Since new sequence-
based methods are continually being reported, it is also important to integrate new 
methods in our system for the improvement of prediction capacity. In addition, how to 
efficiently integrate multiple resources from in vitro experiments and prediction 
models remains a challenge in the research field of coevolution. 
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 Probabilistic graphical models 8.4
Probabilistic graphical models (e.g. Bayesian networks) have been applied in many 
fields for the knowledge discovery and inference [33]. Probabilistic graphical models 
provide powerful tools for biologists to infer cellular networks [34] and to study the 
possible evolutionary pathways [35]. During my Phd study, my work focused on three 
types of probabilistic graphical models: Bayesian networks, ancestral polytree models 
and multi-polytree graphical models. 
In Chapter 9, I have proposed novel graphical models called ancestral polytree models, 
which belong to the ancestral graphical models. The strength of these models relies on 
the fact that polytree models allow for fast learning and inference when large-scale 
variables are under investigation. Bayesian networks provide a higher order of 
probabilistic dependencies in modeling the possible relationships between observed 
variables. However, modeling large-scale networks demands a high computation, 
which limits a wide application of Bayesian networks in genome-wide analysis. In 
Chapter 9, I proposed ancestral polytree models and characterized the properties of 
ancestral polytrees regarding the Markov properties, the probabilistic factorization 
and the learning procedure. Using the synthesized and biological datasets, I showed 
that the promising applications of ancestral polytree models. Further investigations 
are still needed to solve the maximum likelihood inference in ancestral polytrees.  
As extensions of single polytree models described in Chapter 9, I worked on a new 
class of graphical models, called multi-polytree graphical models (manuscript in 
preparation). The multi-polytree models can construct a set of polytree models to 
improve maximum likelihood inference. I proposed the Expectation–maximization 
algorithm to learn the multi-polytree graphical models and solved the difficulty in 
identifying the number of variable clusters using fuzzy clustering. 
I have worked with Prof. Concha Bielza and Prof. Pedro Larrañaga on the projects of 
the multi-dimensional Bayesian network classiﬁcation (MBC) [36]. MBC has been 
proven useful when multiple target variables are required for robust predictions in 
many real-word applications [36]. In the past few years, a great number of 
publications have emerged to propose algorithms that provide accurate predictions of 
multiple class variables. Compared to single class prediction models (e.g. Naïve 
Bayesian classifiers), MBC has shown superior performance using both synthetic and 
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biological datasets. Under supervision from Prof. Concha Bielza and Prof. Pedro 
Larrañaga, I contributed to data collection, algorithm design and performance 
evaluations. I also contributed to the analysis of computational complexity of the 
inference and learning in MBC. 
 Data visualization 8.5
During my Phd study in an immunology and epidemiology lab, I realized the fact that 
beautiful mathematical equations are less appreciated than pictures. Although the 
lesson was difficult to take, the driving forces to improve my skills on data 
visualization have benefited my research. Here, I would like to share my visualization 
toolbox and my experience on several data visualization software. 
Visualization using my Matlab toolbox: I have developed the toolboxes for 
visualizing genomic diversity. Basic programming skills are needed to create pictures 
because the visualization purposes are usually different in individual projects. 
Examples of how to use my visualization toolbox are available in my Matlab space 
(http://www.mathworks.com/matlabcentral/fileexchange/authors/45984). Moreover, I 
worked on the visualization of geographical regions in the world map. While Google 
Map APIs have provided extensive functions, I have developed the geographical 
mapping tools in Matlab that provide the flexibility of visualizing the country-specific 
or region-specific information on the world map. 
Visualization of protein structure: I used three tools to visualize protein structures. 
(1) PyMOL (http://www.pymol.org/), designed by Dr. Warren L. DeLano. As my 
favorite structural visualization software, this software is user friendly and provides 
intuitive ways to visualize protein structures. Complex algorithms for making 
structural movies are available in the software. Various protein structure packages can 
be easily integrated using Python. (2) Chimera is supported by a team from the 
University of California, San Francisco (http://www.cgl.ucsf.edu/chimera/). This 
software is comprehensively documented and has an active user community, which is 
very helpful to solve problems of most structural analysis. This software is very user-
friendly and the implemented structural analyses are very easy to follow for beginners. 
(3) MOE (http://www.chemcomp.com/) is a famous structural tool utilized in the field 
of drug design. While many options and algorithms have been implemented in MOE, 
its license is expensive and the details of implemented algorithms are proprietary. 
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Among the above three tools, I favor Chimera for protein structural analysis, while 
PyMOL is better for creating publication pictures. I also tried other tools such as Jmol 
and Visual molecular dynamics (VMD), but they were not used often in my research.  
Visualization of protein-protein interaction (PPI) networks: I used three tools to 
visualize protein-protein interaction networks. (1) Geomi V2.0 is a 3D visualization 
software (http://sydney.edu.au/engineering/it/~visual/geomi2/), created by Dr. 
Seokhee Hong. I used this software to visualize HIV-human protein interaction 
networks (Chapter 3). This software provides many layout algorithms for the 
optimization of variable positions − a function which is not commonly optimized. 
This software requires basic programming skills to prepare the input files for 
visualizing large-scale datasets. (2) Cytoscape (http://www.cytoscape.org/) is user 
friendly and provides the impressive visualization of protein-protein interactions. 
Features of Cytoscape have been published in Nature Method [37]. (3) Graphviz 
(http://www.graphviz.org/) is a tool used to produce 2D graphical networks. This 
software is handy to standardize graphical outputs, but basic programming skills are 
needed to prepare the dot input files. Further reading about different PPI visualization 
software can be found in a recent article [38]. 
Visualization of genome-wide interaction networks: Circos (http://circos.ca/) is a 
visualization tool made by Dr. Martin Krzywinski. The concept of using circles to 
visualize genome-wide interaction networks is nothing new, but Circos is the best 
genome-wide visualization tool that I found. In my studies, I used Circos to visualize 
Gag-protease coevolution networks, HIV genome-wide diversity and HIV-1 inter-
protein interaction networks. This software provides many simple and efficient 
visualization strategies for genome-wide analysis. 
Visualization of schematic views of workflow and viral life cycle: I used four tools 
(Photoshop, Illustrator, Fireworks and PowerPoint) for the visualization of workflows 
and the viral life cycle. PowerPoint is my favorite software and provides simple and 
quick options for making pictures. Photoshop and Illustrator are professional 
visualization software, but require more time and training to master skills. 
Visualization of phylogenetic trees: Many visualization tools have been developed, 
but FigTree (http://tree.bio.ed.ac.uk/software/figtree/) has received the most attention. 
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Many nice features are provided in FigTree, such as the highlight of certain branches 
and various shapes of phylogenetic trees. 
 Future perspectives 8.6
8.6.1 Genome-wide interactions between HIV and human proteins 
More than 1000 human proteins have been found to interact with HIV proteins during 
the viral life cycle [39]. Based on the literature results, possible HIV-human protein 
interactions have been classified by the NCBI HIV-human protein interaction 
database (http://www.ncbi.nlm.nih.gov/projects/RefSeq/HIVInteractions/). According 
to the information extracted from the above database, human proteins can upregulate, 
downregulate, inhibit, disrupt, bind, inactivate, stimulate, enhance, activate, polarize, 
methylate, ubiquitinate, myristoylate, phosphorylate, dephosphorylate, deglycosylate, 
depolymerize, stabilize, cleave, re-localize, co-localize, export or import HIV proteins 
during viral infection and replication. The global landscape of HIV-human interaction 
system has thus been reconstructed for more than 1500 human proteins, which 
directly (e.g. bind) or indirectly (e.g. upregulate) interact with HIV proteins [40]. For 
instance, the human protein PAF1 [41] and APOBEC3G [42] can prevent HIV 
infection through HIV-human protein interactions during the viral life cycle. 
Understanding HIV-human protein interactions can be useful in the development of 
HIV drugs and vaccines. 
The NCBI HIV-human protein database has been criticized by the low quality of 
literature data, which contains a certain proportion of false-positive interactions due to 
different date ranges, a diverse array of experimental procedures, inconsistent and 
redundant annotations of interactions [43]. Different HIV-human protein interactions 
have also been reported in different subtypes, while this difference is hardly 
distinguishable in NCBI database. Several independent studies have been proposed to 
identify HIV-human protein interactions based on the siRNA gene knockdown 
screens [44, 45]. Despite this, a low coverage between different studies has been 
reported, largely due to differences in experimental procedures (e.g. cell-type, choice 
of time points analyzed and choice of filtering thresholds) [43]. In addition, siRNA-
based studies could not infer the detailed information about residue positions that are 
responsible for HIV-human protein interactions. Structures of HIV-human protein 
interaction are mostly lacking, nor the protein interaction positions. 
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Figure 8.1: HIV genome-wide conservation and HIV-human protein interaction 
domains. Layer 1: HIV-1 protein structures with the surface representation of HIV-human 
protein interaction domains. Layer 2: HBX2 reference index. Layer 3: mapping of the known 
HIV-human protein interaction positions. Layer 4-8: distributions of amino acid conservation 
index at the full-length genome across 5 major HIV-1 subtypes (A, B, C) and CRFs (01_AE, 
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02_AG). The list of PDB data is available in Chapter 3. Visualization software: PyMOL V1.5 
(http://www.pymol.org/), Circos V0.64 (http://circos.ca/).  
 
The NCBI HIV-human protein database has inspired me to understand the HIV-
human protein interactions. However, many redundant and confusing annotations 
have been observed in this database (approximately 5-10% based on my personal 
estimation). This database has indeed provided valuable information but scientifically, 
the data quality still needs improvement. While the NCBI database has been criticized 
by many false-positive protein interactions [43], previous siRNA-based studies only 
reported possible protein-protein interactions but not the interaction domains.  
I performed literature review to collect information about the HIV-human protein 
interactions and their protein interaction positions reported in experiments. Based on 
HIV publications in the last three decades, I conducted the literature review over 5000 
publications and had selected about 700 publications showing the experimental data 
of direct interaction positions between HIV and human proteins. This process took me 
a few months and enriched my knowledge about HIV and human proteins, which in 
turn enlightened me to outline my future project which aimed at identifying the 
human proteins that physically interact with HIV proteins during the viral life cycle. 
As a preliminary visualization result in Figure 8.1, the known HIV-human protein 
interaction positions and their amino acid conservation are mapped in the 5 major 
HIV-1 subtype and CRF genomes using 94560 sequences. Information of HIV-human 
protein interaction positions and amino acid sequence datasets has also been included 
in Appendix 1 and 2. Further work still need to investigate how human genomes 
coevolve with HIV genome, leading to one of the most complex virus-host interaction 
networks being identified.  
 
8.6.2 Comparison of HIV, HBV and HCV genomic diversity 
Inspired by my HIV projects, I will briefly highlight two side projects about HBV and 
HCV that I will cooperate with colleagues in my research lab. 
HCV is a RNA virus and belongs to the genus Hepacivirus in the Flaviviridae family. 
A HCV particle contains a single-stranded RNA genome that encodes 10 proteins in 
one open reading frame [46]. The HCV RNA genome has 9000 to 9100 nucleotides 
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depending on the HCV genotypes. Moreover, ten HCV proteins are classified as 
structural and non-structural proteins. HCV structural proteins include one core (Core) 
and two envelope proteins (E1, E2). HCV non-structural proteins include NS2, NS3, 
NS4A, NS4B, NS5A and NS5B. Notably, the NS3 protease and the NS5B polymerase 
are two important viral enzymes. Besides the structural and non-structural proteins, 
P7 is a membrane-associated oligomeric protein, whose ion channel activity is crucial 
for the assembly of HCV particles [46]. 
HBV is a DNA non-retroviral virus in the hepadnavirus family and has a circular 
genome of partially double-stranded DNA. HBV particles contain one full-length 
strand (3020 − 3300 nucleotides) and one short-length strand (1700 − 2800 
nucleotides)[47]. Four genes (P, S, C, X) in the HBV genome encode for viral 
proteins which play multiple roles during the HBV life cycle. (1) The HBV 
polymerase gene P encodes for the DNA polymerase which synthesizes DNA 
molecules by assembling nucleotides in the cytoplasm. (2) The S gene encodes for the 
surface antigen (HBsAg), which contains three sections (pre-S1, pre-S2, S). (3) The 
HBV core gene C encodes for the Core and Pre-C protein which construct the core of 
HBV particles. (4) The X gene encodes for a protein whose functions have not been 
fully understood [48]. 
I used the same method in Chapter 3 to quantify the nucleotide genomic diversity of 
HIV, HBV and HCV genomes. As my preliminary result visualized in Figure 8.2, 
two major observations were identified. (1) When comparing the intra-subtype 
diversity, HBV has the lowest genomic diversity compared to HCV and HIV. The 
intra-subtype diversity of HCV subtype 1b is comparable to HIV-1 subtypes, while 
HCV subtype 1a has a lower genomic diversity than HIV-1 subtypes. (2) When 
comparing the inter-subtype diversity, HCV has the highest inter-subtype genomic 
diversity compared to HBV and HIV. Distribution of HBV inter-subtype genomic 
diversity has two major peaks; the one with higher diversity is comparable to HIV-1 
inter-subtype genomic diversity. HCV inter-subtype genomic diversity has a similar 
distribution as the genomic diversity between HIV-1 group M and O/P. The genomic 
diversity between HIV-1 and HIV-2 is the highest among all analysed subtypes, 
groups and types in HBV, HCV and HIV. 
Overall, our comparative analysis suggests that the genomic diversity of three viruses 
follows the order as: HIV > HCV > HBV. 
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Figure 8.2: Distribution of HBV (A), HCV (B) and HIV (C) genomic diversity. The x- 
and y-axes demonstrate nucleotide genomic diversity and proportion, respectively. Different 
viral subtypes have been colored indicated by the figure legend. 
 
 Author’s words in the end 8.7
When I look back to my Phd study wondering around in the research area, I can not 
remember how many times I got excited with small results and how many times I got 
upset when my analyses failed. However, ―Failures are finger posts on the road to 
achievement.‖ − C. S. lewis.  
In fact, most of my projects failed during my Phd study. For instance, I failed to 
design a single sequence-based method to outperform all published methods. I was 
unable to design a software platform that integrates sequence and protein structural 
analysis. I failed to construct the structure of HIV integrase tetramer. I could not 
design any peptide or molecular inhibitor after many theoretical tries. I was unable to 
model the coevolution between HIV and human genomes. Although many of my 
projects have failed during my Phd, some might be achievable in the future. Many 
things that I wanted to do during my Phd but I could not do. For you, who can see any 
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value of this thesis, I wish you could stand on my shoulder to become a giant: ―If I 
have seen further it is by standing on the shoulders of giants‖ − Isaac Newton.  
My Phd thesis cannot be successfully presented without substantial advices from my 
Phd promoter, co-promoters, colleagues and jury members. It is therefore my sincere 
acknowledgement for their contributions. 
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 Summary of natural variations in the HIV-1 genome 9.1
In April 2014, I extracted 213428 HIV-1 sequences from the HIV Los Alamos 
database (www.hiv.lanl.gov/) to investigate the prevalence of natural variations in 
large-scale HIV-1 populations. One sequence per patient was extracted and these 
sequences contained at least one protein region. The quality criteria for removing 
misclassified sequences or sequences with hypermutations, stop codons, ambiguous 
nucleotides were described in Chapter 2. I also removed sequences conferred partial 
or full resistance to any of the protease inhibitors, RT inhibitors and integrase 
inhibitors using HIVdb V6.0 (http://sierra2.stanford.edu/sierra/servlet/JSierra). I 
further selected those subtype datasets that contained at least 50 sequences for each 
HIV-1 protein, resulting in 5 HIV-1 datasets (A1, B, C, D, CRF01_AE, CRF02_AG) 
(Table 9.1) with 94560 sequences in total. 
 
Table 9.1: Summary of HIV-1 sequence datasets 
 MA CA p2 NC p1 p6 PR RT IN Vif Vpr Tat Rev Vpu GP120 GP41 Nef Total 
A1 784 703 874 381 833 1046 4946 164 233 183 162 172 182 338 315 286 207 7126 
B 4725 4517 4068 3748 5494 5177 42070 2357 2510 1962 1847 2475 2619 1777 2302 2171 2434 56891 
C 2401 2190 2396 1929 2964 2733 11682 753 617 498 557 882 953 708 1539 1480 806 17149 
01_AE 1562 1316 1377 1342 1750 1784 5858 801 834 378 372 384 390 428 610 591 332 7851 
02_AG 133 371 633 187 659 712 4279 171 231 101 82 79 91 93 149 141 136 5543 
 
The figures in the following pages visualize natural amino acid variations at all 
positions of HIV-1 proteins. For each subtype, two pictures are available with the 
mapping of 15 HIV-1 proteins. The first amino acid position of each protein region is 
labeled with its protein name in a box. Annotated protein regions are shown as 
colored bars. HXB2 indices of individual proteins are shown on top of the colored 
bars. For each subtype, a consensus amino acid at each position is shown beneath the 
colored bar. Natural variations are shown below the consensus amino acids; 
proportions (%) are colored red if they were more than 5%; blue otherwise. 
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169| 180| 190| 200| 210| 220| 230| 10| 10| 20|
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Reverse transcriptase
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340
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P
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C
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R
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1| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
101| 110| 120| 130| 140| 150| 160| 170| 180| 190| 8|
9| 20| 30| 40| 50| 60| 70| 80| 90| 100| 7|
8| 20| 30| 40| 50| 60| 70| 80| 90| 100| 107|
108| 116| 10| 20| 30| 40| 50| 60| 70| 80| 9|
10| 20| 30| 40| 50| 60| 70| 80| 90| 100| 109|
110| 120| 130| 140| 150| 160| 170| 180| 190| 200| 209|
210| 220| 230| 240| 250| 260| 270| 280| 290| 300| 309|
310| 320| 330| 340| 350| 360| 370| 380| 390| 400| 409|
410| 420| 430| 440| 450| 460| 470| 480| 10| 20| 28|
29| 40| 50| 60| 70| 80| 90| 100| 110| 120| 128|
129| 140| 150| 160| 170| 180| 190| 200| 210| 220| 228|
229| 240| 250| 260| 270| 280| 290| 300| 310| 320| 328|
329| 340| 10| 20| 30| 40| 50| 60| 70| 80|
84| 90| 100| 110| 120| 130| 140| 150| 160| 170| 180|
184| 190| 200| 206|
Vif
Tat
Vpu
Nef
GP41
GP120
Rev
HIV-1 subtype A1 (continued)
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502| 510| 520| 530| 540| 550| 560| 10| 20| 30| 40|
42| 50| 60| 70| 80| 90| 100| 110| 120| 130| 140|
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N
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1| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
101| 110| 120| 130| 140| 150| 160| 170| 180| 190| 8|
9| 20| 30| 40| 50| 60| 70| 80| 90| 100| 7|
8| 20| 30| 40| 50| 60| 70| 80| 90| 100| 107|
108| 116| 10| 20| 30| 40| 50| 60| 70| 80| 9|
10| 20| 30| 40| 50| 60| 70| 80| 90| 100| 109|
110| 120| 130| 140| 150| 160| 170| 180| 190| 200| 209|
210| 220| 230| 240| 250| 260| 270| 280| 290| 300| 309|
310| 320| 330| 340| 350| 360| 370| 380| 390| 400| 409|
410| 420| 430| 440| 450| 460| 470| 480| 10| 20| 28|
29| 40| 50| 60| 70| 80| 90| 100| 110| 120| 128|
129| 140| 150| 160| 170| 180| 190| 200| 210| 220| 228|
229| 240| 250| 260| 270| 280| 290| 300| 310| 320| 328|
329| 340| 10| 20| 30| 40| 50| 60| 70| 80|
84| 90| 100| 110| 120| 130| 140| 150| 160| 170| 180|
184| 190| 200| 206|
Vif
Tat
Vpu
Nef
GP41
GP120
Rev
HIV-1 subtype B (continued)
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P
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R
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R
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1| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
101| 110| 120| 130| 10| 20| 30| 40| 50| 60| 68|
69| 80| 90| 100| 110| 120| 130| 140| 150| 160| 168|
169| 180| 190| 200| 210| 220| 230| 10| 10| 20|
24| 30| 40| 50| 10| 16| 10| 20| 30| 40| 50|
1| 10| 20| 30| 40| 50| 60| 70| 80| 90| 99|
2| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
102| 110| 120| 130| 140| 150| 160| 170| 180| 190| 200|
202| 210| 220| 230| 240| 250| 260| 270| 280| 290| 300|
302| 310| 320| 330| 340| 350| 360| 370| 380| 390| 400|
402| 410| 420| 430| 440| 450| 460| 470| 480| 490| 500|
502| 510| 520| 530| 540| 550| 560| 10| 20| 30| 40|
42| 50| 60| 70| 80| 90| 100| 110| 120| 130| 140|
142| 150| 160| 170| 180| 190| 200| 210| 220| 230| 240|
242| 250| 260| 270| 280| 288| 10| 20| 30| 40| 50|
54| 60| 70| 80| 90| 96|
Matrix
Capsid
p1
p2 Nucleocapsid
p6
Protease
Reverse transcriptase
Integrase
Vpr
HIV-1 subtype C
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T YWG
N3
L Q
H10
L 2
N1
T
P12
G E R
K 2
D
E38
A6
WH
Q2
L G H
N4
Q2
G V
A7
C 6
S I EWR
K 2
L
W4
F 2
M2
R
K19
G7
N1
R
K17
G5
S 3
E 2
Y
F 2
S
N5
R 1
T Q V
I10
D
E 9
P
G
D6
S 5
L
M2
A DQ L I HM
I 8
V 3
L 2
T 1
H
Y 6
Q1
Y F DC F A
T11
D
E16
G1
S A I R K
Q15
N2
R 2
A I
L12
L G H
Q6
E 2
I
R 5
V 3
L 1
V I
S20
T 7
F 6
N2
P
H5
S 2
R C D
E13
N2
Y Q
P14
A GH N
K 4
S 3
T 3
K
Q4
V G S L Q Y L A L T A L I
V 4
L 2
K P
T 2
K
R 4
K
R16
Q3
R
I39
T 3
K
R 2
P P L P S V
I17
L 1
R
K12
Q7
S 6
G1
K L V
A9
T 3
E D
N1
R
K 4
WNN
K41
E 3
D2
P
S 4
L 1
Q
R 2
K
R 5
T
I28
R
K 9
M1
G
D15
R
H13
R G
E 4
N
S 9
H
R 1
T
I 5
M
L 3
N
S 5
G HME
D6
P
L 2
Q1
V
I19
D
N1
P N
K 9
S 4
R 2
L
E
D1
PWN
K 8
H P G S Q P K
R11
E11
N3
T 3
T A
P35
C N
T13
S 1
N
K30
T10
S 5
P 2
C Y
F19
C K K
R23
H22
Y13
S 4
C S
C11
Y
F 1
H C L
P 5
Q5
I 2
V
A5
C F
L 1
Q
L11
H2
T
K41
R 4
K G L G
S 1
I S
Y 6
Y
H1
G R K K R
W4
R
G3
S 2
K 1
Q
R 2
K 1
P 1
R R
Q1
S
R11
N2
A
T28
S 1
P
S 3
H1
P
Q21
S 5
R 1
S
N2
R 2
G2
S
G3
N3
R 1
E
K14
A1
D
G2
N2
A1
HQN
D16
T 3
S 1
L
P38
S 3
F 2
H2
I
V19
L 6
S
P 9
K
E 2
Q P
S 3
A
T37
S11
P 1
S
P 8
T 3
A2
Q P
L12
S 7
H6
T 2
R
G4
S 1
G D
N3
P
Q3
S 2
T
A2
G P
Q10
K
E11
T 4
E
K 3
S
P 7
Q7
K
E 4
K
E 6
K
E 3
T 1
V
M2
E
A1
R
T 9
S 7
K 3
G2
E
K 9
A2
T
A4
E
K 4
A1
T
A10
P 2
K 1
D
H14
N1
P
Q12
V
D10
G10
F 9
E 7
D
H15
A15
N10
G3
M
I 1
A G R S G
E 3
D
V 1
S
N10
G1
D
E 3
E
A9
D1
K 1
A
E 9
T 2
V 1
L L
I 1
Q
R19
K 8
L 5
A
V 3
T 2
V
A3
I 3
R
K12
I
T15
A2
L 1
I K
R 6
I
L 3
V 1
L
I 2
Y Q S N P P
Y18
L10
C 1
P S
N18
K14
T 5
R 3
P
S11
T 6
Q3
L 2
E
R11
K 7
G2
A1
G T
S10
R Q
R 1
A R
Q2
R
K17
N R
Q5
R R RWR E
A27
Q7
K 2
R
K 3
Q R
K 3
N2
Q
H10
R 3
W1
I
L 1
R
D18
Q14
H11
N5
S
A13
T11
K 8
E 3
I
L21
V 2
F 2
S
G5
E
G37
A10
D7
Q2
W
R40
I
L 8
V 2
L
I 8
S
D7
N4
R 4
G3
T
N18
A4
D4
S 2
Y
C20
H18
F13
R 2
L G
D7
E 3
R
G3
P
S40
A
T27
E17
V 3
P 1
E
Q2
P
S 1
V P
S 6
H1
L
F10
Q
P 4
H3
L 1
L P P
S 2
L
I14
E
D2
R
G2
K 1
L T
H18
N4
S 2
L
I 3
D
N3
G1
C
S 2
S
N40
D4
R 3
C 2
E
K 4
D
G4
E 1
C
S 3
G1
G T
N5
D1
S
P 3
A2
G T Q
R 1
G V
L 1
E 1
G S
N21
R11
G11
T 6
P
S 5
T 3
Q
E 3
I
V31
L
S23
P 3
F 2
R 1
V
G13
L 3
E S
P 5
P
S18
A
T33
G9
V 5
P 4
V
I27
L E
G21
D11
S
P 9
T 2
E 1
G
R 2
T
D8
A5
N2
K
E 5
T 1
E
N11
K 4
D1
M
A2
V 2
I 2
L 1
R
K22
D9
E 8
G6
V
L13
I12
D2
Y 1
D
L 2
G1
K 1
S 1
Y
I 2
R
K12
A2
I 1
V 1
L
I23
V 8
G
A14
T 2
V 1
L 1
V
I14
G
A13
V 2
A L
F18
I
V10
L 8
T 3
A2
V
I40
L 2
A2
A
G2
V 1
L
F 5
I 3
V 1
A1
I
V 3
L 3
S 2
F 1
I
L20
A
V 6
T 4
I
V 1
V
I35
V
A1
WT
I32
S 3
V 2
I
L 5
V
A44
T 1
Y
F 2
I
L16
E Y R
K 3
K
R 5
L
V 4
I 4
W3
L
V45
R 3
K 2
I 2
R
K24
Q R
K14
K
R16
Q2
I
L 4
D
N6
W
R22
C 3
Q2
K 2
L
I 1
I
V17
L 1
K
E27
N3
R 2
R I R
G2
K 2
E R A
E 5
T 2
E D S G N E
D1
S E
D28
G D T
I12
V 4
A3
M2
E E
D2
L S
A37
E 3
− T
A4
M
L 7
V 2
V
G3
DM
V 4
L 2
G
E 8
H
N14
R12
Q5
Y 1
L
I 2
R
G4
L L
M2
V 1
D
G2
A1
V
A21
D17
N6
G6
N
D6
H5
I 4
A2
D
N22
E 6
G5
V 1
L
V10
I 2
M2
G1
−G
E13
K 4
R 2
N2
N
D6
K 5
S 4
G4
L
M5
S 3
R 2
WV T V Y
Y G V P VWK
R30
T 6
Q2
E
D7
A K
N3
T 1
T
A13
P 1
T
P 2
L F C A S D
N3
E 2
A K
R 2
A
S11
G5
Y
H2
E
D16
K 2
V 1
S 1
K
R28
T13
E 2
Q2
E V
A4
M2
H NV
I10
WA T H
Y 1
A C V P T D P N
S 7
D7
P Q
L 2
H1
R 1
EM
I32
L26
V 4
V
F 7
I 4
E 4
L 3
L
M5
E
G21
K10
V 3
A3
N V
I 1
T E N
S 2
D2
F N
D1
M
I 1
WK
E10
R 2
D1
ND
N3
Y 2
G1
E 1
MV
A3
D
E 7
N4
QMH
Q3
E
Q3
K 1
D I
V18
I S
N3
L
I 5
WD
E 2
Q
E14
S
G2
L K P C V K
R 1
Q1
L
M2
T P L C V T L N
K 7
E 7
T 4
D4
C T
S24
R 4
G4
K 4
N
D20
T11
E 4
K 4
V
A35
I 7
N4
Y 3
− − S
V14
N13
T12
A10
T
N42
S 8
K 2
D1
N
S14
V13
A11
D10
T
N15
A7
S 6
I 5
N
S15
T13
Y10
A7
N
S14
T 7
D5
G5
T
N16
S16
G13
A12
T
N21
S14
I 7
D3
− − − − − −K
N18
T14
R 8
E 6
− − I
M41
V 7
L 3
R 1
K
R12
Q4
T 2
N C S
T 7
F N
K 2
S 1
T
A26
I19
V16
M6
T
I 6
T
A1
S 1
E
V 4
D2
I
L39
V15
R
K15
T 2
I 2
S 1
D
N2
G1
K
R10
K
Q12
R 8
E 6
T 5
K
Q35
R14
H3
E 3
K
Q12
N10
R 5
T 4
E
V31
A14
Q3
M3
Y
H12
S 6
R 4
N3
A
S 2
L
I 2
F Y
H1
R
K35
S 2
N1
L
P13
S 8
I 2
T 2
D I
V21
L11
V
I 4
E 2
P
S12
Q7
K 1
L
I10
N
D22
E 8
S 8
K 7
E
G23
N18
K 9
D5
N
S16
D8
E 4
T 3
S
N21
F 8
Y 8
T 4
− E
S10
T 9
D7
K 7
Y
F 1
R
I26
V 3
L I N
S 5
H3
T 1
C N T
S 8
A2
S T
A30
V13
I
V13
L 4
M1
T
A 6
K 4
S 2
QA C P K V
I 5
S
T33
N4
F
W1
D
E11
P I P I
L 1
H Y
F 2
C A
T 7
P A G Y
F 9
A I
L 1
L K
R 2
C N
K 4
N
D15
K
E11
N3
R 1
T
K 4
A2
F N
S 3
T 1
G T
K 5
I 2
S 2
G P C
N
H16
Q9
T 8
K 6
N V
I 2
S T
S 2
V Q
L 1
C T HG I K
R 3
P V V
I 2
S T Q L L L NG S L
I 3
A
S 4
E
K 4
G1
E
G28
K15
D1
Q1
E
D14
G12
K 3
I
V 4
T 2
I
V11
M4
I
V 2
R
S 4
K 4
S
F 1
A1
E
K12
Q1
A1
N
D1
L
I10
M3
T
S 4
A2
D
N45
E 1
S 1
N
S 2
A
V36
T 9
I 5
G2
K
N2
R 1
T
I11
I I V
A2
I 1
H
Q19
L
F 7
N
K 8
D2
E
K16
Q7
D4
T 2
S
P12
T 3
A3
V
I18
L 1
E
K 7
Q5
N5
G4
I V
N24
E10
T 8
M4
C T
I15
V 4
A3
M1
R P N
G30
S 6
NN T
I 2
R K
R11
T 5
Q4
E 3
S
G3
R 1
I
V33
M7
R
G3
I − −G P GQ
R 2
T
A23
V 5
S 2
F
L 1
I 1
Y
F11
A
T 6
T
N8
A1
I 1
G
N13
D2
E 1
K 1
D
E18
A7
G7
N4
I
T 2
V 2
G D
N18
I R Q
K10
E 8
R 1
AH
Y20
C N
T 5
K 3
S 3
I 1
I
V 4
L 2
S
N16
T 6
E
K26
R16
G14
A6
E
S13
T13
G11
K11
K
N12
E10
D10
Q8
WN
E11
T 8
S 3
K 3
K
E20
T10
R 9
N8
T
A5
I 1
L
I 2
V 1
Q
E18
K 7
H4
R 3
R
K16
Q15
E 9
G6
V
I 5
S
G22
K21
R12
A4
K
E39
R 7
G3
N3
K
E 4
R 2
L K
R24
A16
E11
G7
E
K16
G4
H
Y13
L 7
Q2
R 2
F
Y 9
− P
N8
H3
S 3
L 1
N
G3
D3
K 2
S 2
K
R 8
T 5
S 2
N2
T
N7
S 3
I 2
K 2
I K
I17
E12
T11
N7
F N
A20
E16
K14
Q9
P
S23
Q17
N3
K 2
S
H17
P15
A5
S
A8
P 2
T 1
V 1
G G D L
P 8
I 2
E I
V16
T
V 2
I 2
A2
T
M5
S 1
H S
T 4
I 1
F N
T 1
C R
G28
K 2
Q1
M1
G E F F Y C N
D6
Y 1
T S
T22
K
G20
N12
D10
Q8
L F N
K 2
D1
S 1
T 1
− − − − − − − − S
N19
G18
D10
E 6
T
S14
N9
I 3
A 3
− S
N13
E11
G9
T 8
N
S23
T12
G4
A 4
− S
N23
D12
G10
T 6
T
S23
N5
Q3
P 2
− T
N19
S18
D7
G5
− − − I
L 3
T 2
T
I10
L
I19
P
Q22
S 1
L 1
C R
K14
I K
R 4
Q I
F 8
V 1
I
V10
N
R 2
M
L 3
WQ E
G32
K 9
R 4
Q3
V G R
Q11
K 5
AM
I12
Y A P
S10
P I
V 3
A
E22
K 5
R 2
Q1
G N
E10
S 4
K 4
I 3
I
L 2
T
I 3
K 1
A1
C K
N25
R11
T 7
I 6
S N
S16
T 3
K 2
D1
I T G L
I 9
L
I 4
L T
V20
L 5
E 2
R
W2
H2
DGG N
G14
T11
K10
E 7
N
T13
G11
D9
E 9
N
T12
S 9
K 6
E 6
N
S16
T12
D4
E 3
T
N17
E12
D10
G10
T
E13
N12
K 4
I 3
E T
I39
V 2
F R P G
A 8
E 6
I 3
Q2
G G D
N43
MR
K37
D
N10
NWR S
N6
E L Y K Y K V V
I 2
E I
V13
L 1
K
Q4
R 3
N3
E 2
P L G I
V33
L 4
A P T E
K29
G15
T 7
A5
A
S 3
K
R10
Q1
R R V V E
Q8
G2
K 2
D1
R
K 4
E
G3
Q2
K
R 4
R A V
A8
I 2
G
T 2
I
L23
M12
V 1
G A V
M11
L 6
A1
F
L20
I12
L
F12
G F
I 2
L G
S 2
A
T 3
V 3
AG S TMG A A S
A2
I
M11
V 6
L 5
T
A12
L T V
A7
QA
T 1
R
K 4
Q L
V 6
L S G I V QQQ S
N13
N L L R
K 9
A I E AQQHM
L18
L Q L T VWG I K Q L Q
R 2
A
T36
R V
I 2
L A I
L12
V 4
M3
E R Y L K
Q15
R 8
DQQ
R 1
L
F 1
L G I
L39
M12
WG C S G K
R 1
L
I 3
R 2
V 2
I C T
P 4
T A
N32
T 9
S 4
D2
V P
Y 4
S 2
A2
R 1
WN S
T 5
A4
N3
I 2
S
T 4
W S
N1
N
S 1
K
R13
S
T23
N4
Q
Y17
L11
E11
K 9
T
E20
D16
A11
N11
D
E35
Y 3
A2
Q2
I WD
N19
E15
G10
K 3
N
K 1
M
L 4
T 2
TWM
I 2
Q
E 7
WD
E12
R
K23
E I
V 6
S
N28
D13
N
K 1
Y
H1
T
S 4
D
N29
G18
S 5
E 4
T
I24
L 1
I Y R
K18
S10
Q7
N6
L L E
G2
E
D36
V12
K 4
I 2
S
A1
Q
H1
N
I15
T11
S10
K 5
QQ E
D2
K
Q20
R10
E 6
S 4
N E K
Q11
R 2
E 1
D
E10
L L A
E 6
S 1
L D
N4
G1
E 1
S
K21
R 3
N3
WN
K29
Q17
D4
A3
N
S23
D2
T 1
L WN
S29
T 5
W F D
S31
N20
G4
I T
S39
N
K32
T 5
R 4
H2
WLWY I K
R23
I
L 3
F I
V 5
M
I 9
I
V 3
V
I 5
G G L I
V 1
G L R I I
V 7
F
L 6
A
G12
T 4
C 1
S 1
V
I 2
L
I 5
F 2
S
A1
I
L15
V 6
V
I 5
N
K13
R 4
R
K 2
V R QG Y S P L S F
L12
Q T
I 1
L
P 2
T
I33
A2
N1
L 1
P
Q2
N
S10
T 6
H2
A2
P
Q9
S 5
R
G8
G
E34
P
L30
D
G1
R L
P16
G
E10
R 8
R
G37
E 3
I
T 3
E E E
G7
G G E
Q
R 1
P 1
D
G6
R
K25
N2
S 2
D
G11
N7
S 4
T 2
R
K 3
S I
V25
T 3
R L V
A3
S
N42
T 2
G F
L 1
L
F 9
A
S19
P 7
T 4
L
I 8
A
V15
F 8
I 4
WD
E 8
N1
D L R S
N13
L C L
I 2
F S
C12
L 3
I 1
Y H
R 5
R
Q23
H10
L 6
L R
T 1
D
N4
F
L12
C 4
I
T 9
L 7
V 2
L
S 5
I
V32
L 2
A
V27
T21
I 4
A
V13
T 7
G4
R A
V20
T 8
G2
V
A10
L 3
G1
E
G1
Q1
L
I 5
L G R
H12
Q7
Q
R 2
G
R12
E 8
S 1
WE
G1
K 1
T 1
A
I20
T11
V 6
L K Y L G
K 2
R 1
S
N25
G6
L
I 5
F 1
V
I 5
G3
A3
L 3
Q
L 6
YW
G2
G
V 2
S 2
C 1
L
Q4
R 1
E L
I 5
K K
R10
G3
S
R 1
G1
A I
V 6
T 3
S
N19
R 1
L L
F20
I 2
V 1
Y 1
D
N3
T
A5
S 3
I 2
F 1
I
L12
T10
V 5
A I
V 2
A
V12
T11
R 2
I 1
V
T 3
A
G3
E
G2
G
R 1
T D R I
V 3
L 1
I
L 9
E
D3
N2
A1
G1
L
V23
F22
I11
A4
I
V23
L22
A 5
G2
Q
L 6
R 3
R
G13
S 3
N2
I 2
I
F 8
L 7
V 4
T 2
C
G14
V 9
W6
F 4
R
G1
A
G6
I
F 2
V 2
R
L27
C19
Y12
I 1
N
H16
S 2
I
L 7
V 7
T 2
P R
T22
V 2
I 1
R I
V 4
L 2
R QG F
L14
A1
E A
T11
V 3
I 2
A
S 3
T 1
L L
Q46
MGG
S13
N12
A1
K
N1
W
L 3
C 1
S K S
C13
R 8
G3
S
R 2
K 1
C 1
N1
I
L 5
K 4
P 4
V 3
V
I 6
A3
S 3
G3
G
E 3
W P
S 5
A2
A
E13
D7
N6
T 5
V
I23
R E
D7
R
K 3
I
M35
L 8
R
K 2
R
Q13
K 6
T
A27
E
A6
Q5
D5
G3
P
A4
S 2
G2
T 2
A A E
V 3
A3
D1
G V G A
P 5
T 5
A
V 1
S Q
R22
K 1
D L D
E 7
A6
G2
K
R17
H
Y40
R 3
G A L
I 3
F 2
T S
T29
I 4
N2
S
N6
N T
S 1
A
P19
D12
V11
S 3
H
T27
A17
S 9
Q5
N
T25
S 3
NA
P 5
D2
E 1
D
A25
T 2
C
V 2
AW
R 2
L
V 2
Q
E42
R12
K 2
A1
A
T 3
Q E
Q2
E
D4
Q2
E
D9
G7
A7
T 2
E
D7
G5
V G F P V R
K 9
T 2
P QV P L
V 7
T 1
R PM
I 1
T Y
F16
K A
G47
S 2
E 2
A F
V13
L 2
D L S
G21
F
W1
F L K E
D2
K G G L E
D39
G L
I 1
I
V 6
T 1
Y
W15
H13
S K
Q9
R 7
K
R 9
Q8
R Q
K 3
E
D39
I L D L WV
I 1
Y
H2
H
N39
T QG F
Y45
F P DWQ
H3
N
C 4
Y T P
S 2
G P G V
T 8
I 8
R Y
F16
L 4
P L T F
L 1
GWC
P 6
L 1
F
Y22
K L V P V D
N1
P R
K15
S12
G8
E 5
E
D1
V
I 2
E E A
D8
N3
E 2
T 1
N
T 7
S 3
E
K40
Q4
T 2
N2
G
R 2
E 1
E
D4
N
D23
S 1
N
S 4
C
S 8
R 1
L L H PM
I18
V11
L 4
A1
S
C14
N4
H1
A1
Q
L25
H
Q2
Y 1
GM
I22
A3
V 2
E
D12
D E
A17
D9
P 6
T 3
D
E34
H28
R
G16
K 9
E V
I 2
L K
R15
Q15
M13
V 2
W
K
Q19
E10
V 9
R 2
F D S
I 4
S
Q15
H13
L 7
M2
L A R
H15
Y 2
L 2
R
K 6
T 2
HM
L37
I 7
V 7
R 3
A R E L
K22
Q4
I 3
M1
H
Y 2
P E
D4
Y
F33
W4
Y
F 2
K D
N8
C
1| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
101| 110| 120| 130| 140| 150| 160| 170| 180| 190| 8|
9| 20| 30| 40| 50| 60| 70| 80| 90| 100| 7|
8| 20| 30| 40| 50| 60| 70| 80| 90| 100| 107|
108| 116| 10| 20| 30| 40| 50| 60| 70| 80| 9|
10| 20| 30| 40| 50| 60| 70| 80| 90| 100| 109|
110| 120| 130| 140| 150| 160| 170| 180| 190| 200| 209|
210| 220| 230| 240| 250| 260| 270| 280| 290| 300| 309|
310| 320| 330| 340| 350| 360| 370| 380| 390| 400| 409|
410| 420| 430| 440| 450| 460| 470| 480| 10| 20| 28|
29| 40| 50| 60| 70| 80| 90| 100| 110| 120| 128|
129| 140| 150| 160| 170| 180| 190| 200| 210| 220| 228|
229| 240| 250| 260| 270| 280| 290| 300| 310| 320| 328|
329| 340| 10| 20| 30| 40| 50| 60| 70| 80|
84| 90| 100| 110| 120| 130| 140| 150| 160| 170| 180|
184| 190| 200| 206|
Vif
Tat
Vpu
Nef
GP41
GP120
Rev
HIV-1 subtype C (continued)
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MG A R A S V
I12
L S
T13
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GG K L D A
T 2
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2| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
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HIV-1 CRF 01_AE
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I
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D
N34
A
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V 7
A
T19
V 3
V
I 6
T 6
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A
G4
G
E 8
W
G2
T D R V
I10
I E V
A8
I 6
L 1
A
V 8
T 5
I 1
Q R
G23
A3
V 3
T 2
A
V 6
I 2
T 2
W
G9
C 4
R
K 1
A
I
F20
L12
V 5
L
I 7
C 1
H
N3
I P R R I R QG L
F16
A1
E R A
S 9
T 6
I 3
F 2
L L
V13
Q10
I 2
P 1
MGG
S26
N11
K
N1
W
C 2
S K S
R 4
G4
N3
S
C 3
R 2
I
K11
L 2
V 2
R 2
V
A4
E 3
R 2
G2
G
E 3
W P
S 3
T 2
Q
R 1
K 1
V
I11
R
M1
E
D6
R
K19
I
M3
L 2
R
K46
E 4
Q
R27
K 4
H1
T
A4
P
E 2
S 2
A1
G1
P
A9
S 4
T 2
G2
A A
T40
E
A2
K 2
G V G A V
A3
I 1
S Q
R 6
K 1
D L D
A6
E 4
K
R 2
H
Y 3
G A V
I26
T S
I 2
S
T 8
N2
N
K 1
−M
I17
V 3
L 1
−N
D2
N
S 2
A
D3
P 3
T 1
E 1
D
E 7
A6
S 1
C
S43
N5
R 1
Y 1
V
T 5
A4
I 3
WL R
E17
K 7
Q3
G3
A
T 2
Q
H3
E E
D13
E
D22
N2
E
G44
V G F P V R
K 7
M2
T 2
P QV P L R PMT Y
F49
K G
A10
E 6
D1
A F
V 1
D L S
G4
F F L K
R 8
E K
Q1
G G L D
E25
G L
M1
I
V10
Y
H3
W1
S K
R 6
Q5
E 1
K
R24
Q1
R Q
K 4
R 2
E
D11
I L D L WV Y
H4
N
H34
T QG F
Y11
F
L 1
P DWQ
H42
D5
N Y T P
S 2
G P G I
V17
T17
R Y
F25
L 1
P L C F GWC F
Y 2
K L V P V
I 1
D
N2
P
Q5
T 5
S 3
R
K15
G11
T 5
E 4
E
D6
A2
V
I 8
A4
E E
K 2
D
N17
E12
A7
L 1
N
T28
S 5
K
E 5
Q2
R 1
G
E13
R 1
E N
D4
S 1
N
S19
T 6
C
S 4
L L H PM
I 8
L 3
V 2
S
N25
Q
L 1
H
Q1
G I
M23
L 9
Q6
V 4
E
D32
G4
D E
D10
A5
P 3
G2
E
D23
H6
R
G15
K 9
E V L M
I 9
R 8
K 4
W
K
Q4
R 3
E 1
F D S
T 2
A
S21
G2
L A R K
R41
T 5
H I
L 6
V 6
T 5
R 3
A R E
D1
L
Q9
M9
K 7
R 4
H
R16
P E
D17
Q1
Y
F34
Y
F 6
K D
N1
C
1| 10| 20| 30| 40| 50| 60| 70| 80| 90| 100|
101| 110| 120| 130| 140| 150| 160| 170| 180| 190| 8|
9| 20| 30| 40| 50| 60| 70| 80| 90| 100| 7|
8| 20| 30| 40| 50| 60| 70| 80| 90| 100| 107|
108| 116| 10| 20| 30| 40| 50| 60| 70| 80| 9|
10| 20| 30| 40| 50| 60| 70| 80| 90| 100| 109|
110| 120| 130| 140| 150| 160| 170| 180| 190| 200| 209|
210| 220| 230| 240| 250| 260| 270| 280| 290| 300| 309|
310| 320| 330| 340| 350| 360| 370| 380| 390| 400| 409|
410| 420| 430| 440| 450| 460| 470| 480| 10| 20| 28|
29| 40| 50| 60| 70| 80| 90| 100| 110| 120| 128|
129| 140| 150| 160| 170| 180| 190| 200| 210| 220| 228|
229| 240| 250| 260| 270| 280| 290| 300| 310| 320| 328|
329| 340| 10| 20| 30| 40| 50| 60| 70| 80|
84| 90| 100| 110| 120| 130| 140| 150| 160| 170| 180|
184| 190| 200| 206|
Vif
Tat
Vpu
Nef
GP41
GP120
Rev
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229| 240| 250| 260| 270| 280| 290| 300| 310| 320| 328|
329| 340| 10| 20| 30| 40| 50| 60| 70| 80|
84| 90| 100| 110| 120| 130| 140| 150| 160| 170| 180|
184| 190| 200| 206|
Vif
Tat
Vpu
Nef
GP41
GP120
Rev
HIV-1 CRF 02_AG (continued)
349
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 Summary of HIV-human protein interactions 9.2
I performed literature review to collect information on HIV-human protein 
interactions. Publication selection criteria include: (1) direct HIV-human protein 
interactions must be reported; (2) interaction positions must be reported either in HIV 
proteins or in human proteins; (3) results in the latest publication are retained if 
disagreed results were reported. Subtype-specific information was also collected if it 
were available. Notably, HIV-human protein interactions may be subtype-specific (e.g. 
the Vpu-tetherin interaction occurs in group M, but not in group O [1, 2]). The HXB2 
reference is used to index the HIV-human interaction positions in HIV proteins. 
Table S9.2: Summary of HIV-human protein interactions 
HIV  
proteins 
HIV binding 
positions (1) 
Host factors in human Human protein 
binding domains 
Subtype Interaction function Reference 
Matrix 8-43[3], W16, W36 
[4] 
ubiquitous calcium-sensing 
calmodulin (CaM, CAMI) 
F19,G33,L48,E54,V
55,A57,F68,E82,L10
5,T110[5] 
HIV-1 Gag intracellular 
Trafﬁcking in cytoplasm 
[3],[4],[5],[6] 
 R4-L13,R20-E40[7] embryonic ectoderm development 
(EED) protein 
Q294-N309[8], 388-
403[7] 
Subtype B transcriptional regulation 
within the nucleus[7] 
[7],[8]  
 S9-K28 IL-8 chemokine receptors  
CXCR1(IL-8RA)/CXCR2 
 HIV-1 endothelial cells 
proangiogenic activation, 
monocyte migration 
[9],[10],[11] 
 K26-K28 elongation factor 1-alpha (EF1a) 1-74 Subtype B inhibition of translation [12] 
 121-132 Cyclophilin A(CypA)  HIV-1 Enhance CA- CypA 
interaction 
[13] 
 15-32 Chromosome maintenance region 
1 (CRM1,exportin 1, XPO1) 
 Subtype B MA nuclear export signal  [14] 
 24-31, 110-114[15] Importin α1 (karyopherin α2, 
Rch1/SRP1α/KPNA2) 
 HIV-1 PIC nuclear import to 
nucleus 
[15] 
 Y132 clathrin adaptor complex 2 AP-2, 
μ2 subunit (AP50) 
 HIV-1 Gag  intracellular 
Trafﬁcking 
[16] 
 5-8,13-16 TIP47 (tail-interacting protein of 
47 kDa, perilipin 3, PLIN3 ) 
 HIV-1 Env packaging into virions [17],[18] 
 K26,K27 HO3 histidyl-tRNA synthetase 
(HARS2) 
 HIV-1 HO3 packaging into 
virions 
[19] 
 9,67,72,77[20] mitogen-activated protein kinase 
(MAPK/ERK-2) 
201-255[21] HIV-1, 
SIV 
Phosphorylation of matrix 
during early uncoating in 
cytoplasm, MAPK/ERK-2 
incorporation to virions 
[20],[22],[21] 
 L41,F44,V46,I60,L6
4,L75 
PS/PE/PC (phosphatidylserine, 
phosphatidylethanolamine,phosph
atidylcholine) 
 HIV-1 Gag binding to membrane [23],[24] 
 113-122 Mab 3H7 antibody  HIV-1 PIC integration [25] 
 S111 protease kinase C (PKC)  Subtype B matrix translocation to 
membrane 
[26],[27] 
 25-34,109-115 Heparin(HSPG analog)  HIV-1 prevents p17 binding to 
chemochine receptor 
[11] 
 86-115 neutralizing monoclonal antibody 
(MAb 1575) 
   [28] 
 (HIV-1)S6[29], R22, 
K26, K27, W36, 
R76[30],(HIV-
2)L21,R22,K27,H33
,W35,K76,S77[31] 
phosphatidylinositol-(4,5)-
bisphosphate PI(4,5)P2 
 HIV-1, 
HIV-2 
targeting Gag to membrane 
rafts 
[29],[30],[31] 
  serine-threonine protein kinase 
PRP4 
687-1007 HIV-2 inhibit PRP4-mediated 
phosphorylation of SF2 
[32] 
  APOBEC3C R122[33] Subtype B A3C incorporation into 
virions 
[33, 34] 
  ATPase KIF4 601-702[35] HIV-1 Gag intracellular 
Trafﬁcking 
[35],[36] 
  virion-associated nuclear shuttling 
protein(VAN) 
312-637 Subtype B nucleocytoplasmic 
transport in nucleus 
[37] 
  eukaryotic initiation factor2α(IF2) 921-1220 HIV-1 inhibits translation [38] 
  Rch1(32AA N-terminally 
truncated form of Importin α1) 
244-529 Subtype B PIC nuclear import [39] 
       
Capsid P85- Cyclophilin A(CypA) W121Y,R55,F113[4 HIV-1, Viral core uncoating &  [48],[40],[49],
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I91[40],T54,A92, 
R132[41],A92E,G94
D[42], 
H219[43],P221,P222
[44], N74D[45],P85-
A88,A92,P93,G94 
6],54-126 FIV, 
SIV[47] 
incorporate into viral 
budding 
[41],[50],[51] 
 N53,L56,N57,M66,
Q67,K70,I73,N74,A
105,T107,S109,Y13
0 
CPSF6 (CFIm) V314,L315,F321 HIV-
1,HIV-
2,SIV,FIV 
CPSF6 binds CA in post-
entry stages before 
Uncoating, nuclear import 
[52],[53],  
 G89[54],H87[55], 
P38[56], V83, G89, 
H120, P122,W117, 
Y130,W133[57] 
TRIM5α Q109,E110,V114,I1
15,L118,E120,R121,
Q123,E124[58], 
R332P[59],W117,L1
18,R121 
HIV-1, 
HIV-2 
TRIM5α promotes capsid 
disassembly during viral 
uncoating in cytoplasm 
[60],[54],[61],
[55],[56],[58],
[59],[57] 
 E45,T54,N57,Q63,Q
67,N74,A105[62] 
transportin 3 (TNPO3 or TRN-
SR2) 
Last 93AA[63] HIV-1 PIC nuclear import [62], [63], 
[64],  
 N74 Nucleoporin NUP98  HIV-1 PIC nuclear import [65],[66],  
 N57,Q67,K70,N74[6
7] 
Nucleoporin NUP153 896-1475 HIV-1 PIC nuclear import [68] ,[67], 
[69] 
 G89,P90,I91[70] Nucleoporin NUP358 (RanBP2) V61,V113 HIV-1 PIC nuclear import [70],[71],[65],
[72] 
 S16,P17 peptidyl prolyl-isomerase PIN1  HIV-1 CA core uncoating in 
cytoplasm 
[73] 
 V3 clathrin adaptor complex 2 AP-2, 
μ2 subunit 
 HIV-1 Gag  intracellular 
Trafﬁcking 
[16] 
 V3 adapter protein complex 2 AP-2, 
α1 subunit 
 HIV-1 nuclear translocation of 
viral DNA in cytoplasm or 
perinuclear region 
[74] 
 1-110 ankyrin-1, Ank(GAG)1D4  HIV-1 Integration blockage at the 
post-integration phase 
[75] 
 177-231 lysyl-tRNA synthetase LysRS  HIV-1 LysRS packed into virions [76] 
  PDZD8 932-1119 Subtype B After viral entry in 
cytoplasm 
[77] 
  actin cross-linking protein filamin 
A (FLNa) 
2364–2647 Subtype B Gag  intracellular 
Trafﬁcking 
[78] 
       
SP1       
       
Nucleoca
psid 
K34,C49,N55 Moloney leukemia virus 10  
(MOV10) 
261–305 HIV-1 MOV10 packaging during 
virion budding 
[79],[80] 
 R3,R7,R10,K11,K14
,K20,R26[81] 
ALIX (AIP-1) F99-
A112[82],Q8,K11,K
48,R51,R56,K60[83] 
Subtype B Recruit gag to plasma 
membrane in viral budding 
[81],[84],[85],
[82],[83],[85] 
 M1-K11[86],R29-
K34[87] 
APOBEC3G (A3G) Y124-W128[88] HIV-1 A3G incorporation to 
virions in viral budding 
[86],[89],[88] 
  APOBEC3F(A3F) W126,R305,Y307 Subtype B A3F Incorporation [90] 
  APOBEC3A(A3A) Y130-W133 HIV-1 A3A incorporation [91] 
 Y36-P49 mRNA binding protein 1 (IMP1) 409-458,490-540 HIV-1 Impedes gag assembly, 
keep immature virus  on 
cellular membranes 
[92] 
 C15-C49 double-stranded RNA-binding 
protein Staufen 1 (Stau1) 
26-37 HIV-1 Stau1 packed into virions, 
influences gag 
multimerization 
[93] 
 K14,K20,R26,R29,K
33,K34,K38,K41,K4
7 
ATP-binding protein ABCE1 
(HP68) 
 HIV-1 capsid assembly [94] 
 43-48 Topoisomerase I(TOP1)  Subtype B enhancing reverse 
transcription 
[95] 
 K14,K20,R26,R29,K
32-
K34,K38,K41,D48 
Elongation factor 1-alpha (EF1a) 1-74 Subtype B inhibition of translation [12] 
 R3,R7,R10,K11,K14
,K20,R26 
Nedd4-like ubiquitin ligase, 
Nedd4-1 
L211-L214 Subtype B Viral release [85] 
       
SP2       
       
p6 Y36-L41[96], 
E34,L35,P37, 
L41,R42[97] 
ALIX (ALG-2 interacting host 
protein, AIP-1) 
F99-
A112[82],V498,F67
6,I683[96] 
Subtype B HIV-1 buds via the Alix 
driven pathway, 
ALIX  incorporates into 
virions 
[81], [98], 
[85],[82], ,[97
] 
 P7-P10,  Tumor susceptibility gene 
101(TSG101) 
391-510 HIV-1 Form viral budding 
machinery to bud from 
plasma membrane 
[81], [99],  
 K27 small ubiquitin-like modifier 
SUMO-1 
 Subtype B ESCRT-III recruitment to 
viral budding 
[100],  
 K27 Ubc9  Subtype B ESCRT-III recruitment to 
viral budding 
[101], [100], 
 K27 Daxx  Subtype B ESCRT-III recruitment to 
viral budding 
[100], 
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 T23 mitogen-activated protein 
kinase (MAPK/ERK-2) 
 Subtype B P6 phosphorylation within 
HIV-1 virion 
[102] 
 L52-H56 Clathrin  HIV-2, 
SIV 
clathrin incorporation [103] 
 L35-L38 Nedd4-like ubiquitin ligase, 
Nedd4-1 
L211-L214 Subtype B Viral release [85] 
 P5,P7,P10,P11,P24,
P30,P37,P49 
Cyclophilin A(CypA)  HIV-1 Catalyzes prolyl cis/trans 
interconversion of p6 Pro 
residues 
[104] 
 K27,K33 Ubiquitin  Subtype B assembly and budding [105] 
       
gag  tripartite motif containing 22 
TRIM22 
C15,C18 at RING 
domain 
HIV-1 Disrupt gag trafficking to 
extracellular membrane 
[106] 
  tripartite motif containing 21 
TRIM21 
T14-C59,C97-H129 HIV-1 TRIM21 incorporated to 
virions 
[107] 
       
Protease 32,71 focal adhesion plaque 
proteins(FAK,), beta 4 
integrin,alpha 3 integrin 
 HIV-1 Affect focal adhesion 
plaque integrity 
[108] 
       
Reverse 
transcript
ase 
G462,464-541 AKAP149(A-kinase anchoring 
protein 149, also AKAP1) 
375-645 Subtype B reverse transcription [109] 
 1-243 APOBEC3G (A3G)  65-132 HIV-1 A3G inhibits reverse 
transcription. 
[110] 
       
Integrase A128,A129,W131,
W132,I161-K173, 
T174,T125, 
LEDGF/p75 I365,D366,F406,K4
15,V408[111] 
HIV-1, 
HIV-2, 
FIV 
IN strand transfer activity [112],[113],[1
14], [115] 
 185-188,R262-
K264,266-269[116] 
Transportin-SR2 (TRN-
SR2,Transportin 3,TNPO3, 
importin 12) 
62-334[117], 
R400,R402,Q761[11
8] 
HIV-1 PIC nuclear import [116],[117],[1
18],[119] 
 161-173[120], 
K186-K189,K211-
K219[121] 
Importin α1 (karyopherin α2, 
Rch1/SRP1α/KPNA2) 
 HIV-1 PIC nuclear import [121], [120], 
[119], [122] 
 251-270 Importin α3  Subtype B PIC nuclear import [123] 
 K186-K189[122], Importin β1  Subtype B PIC nuclear import [122] 
 W235-G245,R262-
K266[124] 
importin 7 (IPO7)  HIV-1 DNA genome nuclear 
import 
[124],[125] 
 H12,K71,Q137,S147
,D202[126],E69G,K
71R[127] 
INI1(hSNF5, BAF47, 
SMARCB1) 
T213,D224,D226,S2
46 
HIV-1 Gag/gagpol trafficking to 
membrane, IN 
multimerization and 
integration 
[126],[128],[1
29],[130],[131
], 
 K264,K266,K273 Histone acetyltransferase 
p300/CBP 
 Subtype B lysine acetylation [132],[133] 
 Y15,V75,A76,K186,
L241,L242[134], 
survival motor neuron 
(SMN)-interacting protein 1 
(SIP1/Gemin2) 
137-238 Subtype B stimulate RT activity [135],[134], 
 43-195 von Hippel-Lindau binding 
protein 1(VBP1) 
 HIV-1 integrase degradation in 
integration-transcription 
transition 
[136] 
 50-211(CCD) Huwe1 1-3617 HIV-1 localization of gagpol 
precursor 
[137] 
 212-264[138] embryonic ectoderm development 
(EED) protein 
L96-H104,T224-
V232[8] 
HIV-1 DNA integration  in the 
nucleus and near nuclear 
pores 
[138],[8] 
 48-212 Heat shock protein HSP60  HIV-1 Stimulate IN activity 
within PIC 
[139] 
 L172,170-180[140] Uracil DNA glycosylase (UNG) 2 1-52[141] Subtype B UNG packed into new 
virions 
[140],[141]  
 K264, K266, K273 KAP1(TRIM28, Tif-1 β)  Subtype B KAP1 Inhibits HIV-1 
Integration 
[142] 
 K258, K264, K266, 
K273 
transcriptional activator GCN5   Subtype B acetylates IN leading to 
enhanced 3'-end and strand 
transfer activities 
[143], 
 230-288 Ku70(XRCC6) 1-430 HIV-1 Ku70 protects IN from 
proteasomal degradation 
[144] 
 N184,K185[145] clathrin  HIV-1 clathrin incorporation [103],[145] 
 Y23 peptidyl prolyl-isomerase PIN1  Subtype B controls IN stability during 
DNA integration 
[146] 
 K46,K136,K244 small ubiquitin-like modifier 
SUMO-1 
 HIV-1 IN SUMOylation, proviral 
integration 
[147] 
 K156-K159[148] Daxx 625-740[149] HIV-1 Viral DNA integration  [149],[148] 
 E87,V88,I89,P90,E9
6,Y99,F100,K103,K
173 
Sucrose  HIV-1  [150] 
 50-212 APOBEC3G (A3G)  104-156 HIV-1 Reduce reverse 
transcription of proviral 
DNA 
[151] 
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  HRP2(hepatoma-derived 
growth factor related protein 2) 
470-552[114] HIV-1 IN strand transfer activity [114],[152],[1
53] 
  Rad18 (RNF73) 65-226 HIV-1 integrase stabilization [154] 
  TTRAP(tyrosyl-DNA 
phosphodiesterase 2) 
146-362 HIV-1 integration [155] 
  Nucleoporin NUP153 896-1475[156] HIV-1 Integrase nuclear import  [156] 
  Nucleoporin 62 328-522 HIV-1 Integrase nuclear import  [157] 
       
Vif W5,W11,D14-
R17,W21,L24,V25,
W38,L64,I66,Y69,
W70,L72,W79,W89 
[158], S23-V25[159] 
APOBEC3C, E106-H111 HIV-1 APOBEC3C degradation [158],[160],[1
61], [159] 
 S23-V25[159], 
W5,W11,D14-
R17,W21,L24,V25,
W38,L64,I66,Y69,
W70,L72,W79,W89
[158] 
APOBEC3D(APOBEC3DE) L268,F271,C272,I27
5,L276,S277,Y282,
H307, E302,F303, 
E337 
HIV-1 APOBEC3D degradation [158], 
[159],[159] 
 K26,H27[162],K22,
Y40,E45[163],W11,
Q12,D14-
R17,V25,Y69-L72, 
T74-W79,L81-
G84,E171-
W174,I87,W89[164] 
APOBEC3F L255,F258,C259,I26
2,L263,S264,Y269, 
E289,F290, H294, 
E324[161] 
HIV-1 APOBEC3F  degradation [160],[161],[1
65],[166],[163
],[167] 
 W5,W21,K22,K26,
Y30,W38,Y40-
Y44,L59,L64,I66,Y6
9,W70,L72,W89[15
8],S23-
V25[159],N48[168], 
G84[164],L81,G82,I
87,W89[164] 
APOBEC3G (CEM15) D128-D130[88], 
[169] 
HIV-1, 
HIV-2 
APOBEC3G degradation [160], [166], 
[170],[171],[1
72],[168],[169
],[164],[167] 
 D14,R15,F39,R41,H
42,H48,L64,I66,Y69
,L72[158] 
APOBEC3H E121[173] HIV-1 APOBEC3H degradation [158] 
 L145,Q146,A149,L1
50[174],I120,A123,
L124[175],H108,C1
14,C133,H139,159-
173,P161-164,L169 
Cullin5 of E3 ubiquitin 
ligase(Cul5) 
Y75,F93,L103,A107
,C112[174] 
Subtype B Vif-mediated 
downregulation of 
APOBEC3 
[160],[172],[1
75],[176] ,[17
7]  
 4-22 MDM2 E3 ubiquitin 
ligase(Hdm2) 
168–320 Subtype B MDM2 reduces cellular 
Vif levels and reversely 
increases A3G levels 
[178] 
 20-128 E3 ubiquitin ligase Nedd4,AIP4 WW domains Subtype B Vif ubiquitination  [179] 
 P161-P164 [180] hemopoietic cell kinase HCK 66,68,75,93[180] Subtype B Vif represses the kinase 
activity of Hck 
[180],[181] 
 P161-P164 [177] Elongin B D101-K104[177],9-
14 [182] 
Subtype B Vif-mediated 
downregulation of 
APOBEC3 
[160],[177], 
[182] 
 S144-Q146,P161-
P164 
[177],V142,L145,L1
48,A149,A152,L153
,L163,V166,L169,R
173[176], L158, 
C162,V165,V166[18
3] 
Elongin C Y79,Y76,V73,I90,L
103,L104,N108, 
Subtype B Vif-mediated 
downregulation of 
APOBEC3 
[176], [177], 
[182], 
[184],[183] 
 96,165 mitogen-activated protein kinase 
(MAPK) 
 Subtype B MAPK phosphorylates and 
regulates Vif 
[185] 
 4-22 tumor suppressor protein p53 
(TP53) 
168-320 Subtype B Vif-mediated G2 cell cycle 
arrest 
[186] 
 W21,W38[187] CBF-β, core binding factor β  F68[188],D101-
K104[182],69-
90,129-140[187] 
Subtype B Essential for assembly of 
Vif–CUL5 E3-ubiquitin-
ligase complex 
[182],[187],[1
88] 
 12-23,43-59,73-
87,97-112 
nuclear body protein  Sp140 527-836 Subtype B Vif may enhance cytosolic 
retention of Sp140 
[189] 
       
Rev 35-50,75-84 LEDGF/p75 361-370,402-411 Subtype B promote dissociation of 
IN-LEDGF/p75 complex 
[190] 
 L78,L81[191],L75-
L83[192] 
RIP (Rev-interacting protein, 
REBP, Rev/Rex effector binding 
protein, Rab) 
148-271 (FG 
repeats) [193], 
HIV-1 Rev nuclear export [194],[193], 
[195], 
[192],[191] 
 9-14 heterogeneous nuclear 
ribonucleoproteins A1(hnRNP 
A1) 
R194,R196,R206,R2
28,R235R242 
HIV-1 Multiple functions [196] 
 L78,E79[197] Sam68 (Src-associated protein in 
mitosis) 
321-410[197] HIV-1 Rev nuclear export [197],[198] 
 18-50 Puralpha  73-123 HIV-1 enhance Rev-RRE 
binding in cytoplasm 
[199] 
 L75-L83 Chromosome maintenance region 
1 (CRM1,exportin 1, XPO1) 
D716 HIV-1 nuclear export to nuclear 
pore complex 
[200] 
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 10–
24[201],V16,I55[20
1] 
RNA helicase DDX1 370-373 HIV-1 Promote Rev 
oligomerization 
[202],[203],[2
04],[205],[201
] 
 59-116[206] Nucleoporin Nup98 493-920[206] Subtype B Rev nuclear export [206], ,[207] 
 L75-L83 Nucleoporin Nup214(CAN) 1691-1894[195] Subtype B Rev nuclear export [208], [195] 
 35-46[209] Importin beta (karyopherin β) 1-396[210] HIV-1 nuclear import into nuclei [210],[211],[2
09] 
 R38-R44 Importin 5  HIV-1 Rev nuclear import [210] 
 R38-R44 importin 7 (IPO7)  HIV-1 Rev nuclear import [210] 
 1-59 microtubules  HIV-1 Microtubule 
destabilization 
[212] 
 35-46 HIC (Human I-mfa domain-
Containing protein) 
144-246 HIV-1 Rev nuclear import [213] 
 R41-Q51 NAP1(nucleosome assembly 
protein 1) 
 HIV-1 Nap1 affects Rev 
multimerization & nuclear 
export 
[214] 
 37-47[215] Nucleolar phosphoprotein 
B23(NPM1, NO38, numatrin) 
187-255[216] HIV-1 Rev nuclear export in 
nucleus 
[217],[216],[2
15] 
 34-50 p32(splicing factor ASF/SF2-
associated protein) 
196-208 HIV-1 mediate Rev activity in 
RNA splicing in nucleus 
[218] 
 S5,S8[219],35-
50[220] 
protein kinase CK2 beta  HIV-1 CK2 phosphorylate Rev [220],[219] 
 73-84 Nuclear prothymosin alpha ProTa  HIV-1 Rev nuclear import [221] 
 75-83 NLP-1 (nucleoporin-like 
protein 1, hCG1,NUPL2) 
213-380 HIV-1 Rev nuclear export [222] 
 75-93[223] eIF-5A (eukaryotic initiation 
factor 5A) 
 HIV-1 Rev nuclear export [224],[225],[2
23] 
  HS1-associated protein X-1 (Hax-
1) 
176–260 HIV-1 inhibits Rev from binding 
to RRE RNA 
[226] 
  mRNA binding protein 1 (IMP1) 1-408 HIV-1 modulate RNA expression, 
relocate Rev from nucleus 
to  cytoplasm 
[227] 
  Transportin 1 1-517 HIV-1 Rev nuclear export [210], 
  RNA helicase DDX5 (p68) 248-251 Subtype B Rev nuclear export [228],[204],[2
05] 
  RNA helicase 
DDX3,DDX17,DDX21,DDX56 
11-21 HIV-1 Rev nuclear export [204],[205], 
       
       
Vpu 14,22,18[229],E15,V
19,V25 (group 
N)[1], 
Tetherin(BST-2, CD317, 
HM1.24) 
22-
46[230],9,17,43,52[2
31], 
34,37,41,45[232] 
Group 
M[2], 
group 
N,SIV[1] 
Vpu-mediated 
ubiquitination degrades 
BST-2  in the trans-Golgi 
network or in early 
endosomes 
[229],[230],[2
32] ,[1] 
 K31-Q35[233] SGT(glutamine-rich 
tetratricopeptide repeat protein, 
also vpu-binding protein UBP, 
VIP) 
84-210 Subtype B Viral release [234],[233] 
 L41,S52,S56,E57,D
79,D80 
CD4 414-419 Subtype B CD4 degradation in the 
endoplasmic reticulum 
[235], [236] 
 S52,S56 CK-2(casein kinase 2)  Subtype B Vpu phosphorylation [237],[238] 
 L45,I46,S52,G53,S5
6[239], S61 [240], 
Beta-transducin repeat-containing 
protein (Beta-TrCP) 
260-293 Subtype B 
Subtype C 
inhibit p53 ubiquitination, 
proteasomal degradation, 
CD4 degradation 
[235], 
[241],[239, 
240], [240] 
 S52,S56 Interferon regulatory factor 3 
(IRF3) 
 Subtype B Vpu redirects IRF3 to 
endolysosome for 
proteolytic degradation 
[242] 
  wik-related Acid Sensitive 
TASK-1 
1-40 HIV-1 transcription [243],[244] 
       
Vpr 17-
46[245],L23,K27,A3
0,F34[246] 
nucleoporin CG1 (hCG1, NLP-1) 94-170[245] HIV-1 Vpr interacts with NPC 
components at nuclear 
envelope 
[245],[246] 
 17-34,46-74[247] Importin α1 (karyopherin α2, 
Rch1/SRP1α/KPNA2) 
393-462[247], 404-
475[248] 
HIV-1 Vpr enters nucleus by 
interacting with 
nucleoporins at  nuclear 
pore 
[249] ,[250], 
[247], 
 17-34[250] Importin α3(Qip1,karyopherin α4 392-439 [248] HIV-1 PIC  nuclear import [248], [250] 
 17-34[250] Importin α5(NPI1,karyopherin α1 404-451 [248] HIV-1 PIC  nuclear import [248], [250], 
[247], 
 F72[251] Importin 5 (importin β3)  HIV-1 PIC  nuclear import [251], 
 17-34[250] Importin β (karyopherin β) 71-876[252] HIV-1 PIC  nuclear import [252],[251],[2
50], 
 65-85 Transcriptional coactivator  p300 2045-2191  activate HIV transcription [253] 
 W54,E25,N16-
W18[254], 
W54R,S79A 
uracil DNA glycosylase (UNG2) W222-W225[255] HIV-1 induce G2 arrest by 
proteasomal and 
polyubiquitination 
degradation in cytoplasm 
[254],[255],[2
56] 
 Q65R,[257],L60-
81[258] 
DCAF1(VprBP) 877-1365[259] Subtype B Vpr-induced G2 arrest [260],[257],[2
59],[258] 
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 71-96 HS1-associated protein X-1 
(HAX-1) 
118-141 Subtype B mitochondrion instability, 
Vpr proapoptotic activity 
[261] 
 71-82 adenine nucleotide translocator 
(ANT, component of permeability 
transition pore complex PTPC) 
104-116 HIV-1 modulate mitochondrial 
membrane 
permeabilization (MMP) 
[262], [263] 
 I74,I81 Wee1 291-369 HIV-1 Vpr-induced G2 arrest [264] 
 E25,H33,H45,G75[2
65] 
HHR23A(RAD23A) 319-
363[266],I324,A329,
L330,F332,P333,A3
53,F354,L356,F360[
267] 
Subtype B Involve cellular DNA 
repair pathway to induce 
life cycle G2 arrest at or 
about the nuclear 
membrane 
[265],[266],[2
67]  
 1-35[268],15-
77[269],R80[270] 
basal transcription factor TFIIB W52,F55[270] HIV-1 stimulate transactivation 
activity in nuclei 
[268],[208],[2
70] 
 L67,R80,R88 SAP145 426-563[271] HIV-1 Vpr-induced checkpoint 
activation and G2 arrest 
[271],[272] 
 H71,R90 CDC25c E352,K359 HIV-1 inactivation of the cdc2-
cyclin B kinase complex, 
promotes G2 arrest 
[273] 
 R80 14-3-3tau 190-210 Subtype B promotes G2 arrest [274] 
 L22-L26,L64-L68 Chromosome maintenance region 
1 (CRM1,exportin 1, XPO1) 
 Subtype B Vpr nuclear export 
nucleocytoplasmic 
shuttling 
[275] 
 L64 damaged DNA-binding protein 
(DDB1) 
 Subtype B Vpr-induced G2 arrest [276],[257] 
 L64-L68[268],L22-
L26,  
glucocorticoid receptor (GR)  HIV-1 Activate glucocorticoid 
signal transduction 
pathway 
[268],[277],[2
78] 
 H71,G75 replication protein A (RPA)  HIV-1 chromatin binding activity, 
induces ATR activation 
[279] 
 1-39 Lys-tRNA synthetase(LysRS)  Subtype B inhibits LysRS-mediated 
aminoacylation to affect 
initiation of reverse 
transcription 
[280] 
 Q60-P81 transcription factor  SP1  HIV-1 Vpr trans-activation of 
HIV-1 LTR promoter 
[281], 
 H71-G75 Chromatin-remodeling factor 
SNF2h 
 HIV-1 downregulate endogenous 
to induce SNF2h DNA 
double-strand breaks 
[282] 
 77-92[283] Protein phosphatase 2A1 (PP2A)  HIV-1 life cycle G2 arrest in 
cytoplasm 
[283],[284] 
  cyclin T1 300-479 Subtype B Viral transcription [285] 
  Nucleoporin Pom121 796-1199 Subtype B PIC nuclear import 
through NPC at nuclear 
envelope 
[286] 
  Glucocorticoid receptor p21 
(WAF1, Cip1) 
1-90,149-164 Subtype B Vpr alleviates p21-
mediated inhibition of cell 
departure from G1 phase 
[287] 
  VIP/mov34 225-341 HIV-1 Vpr-induced G2 arrest [288],[289] 
       
Vpx Q76[290],N12,E15,
E16,T17[291], 
SAMHD1 595-626[292] HIV-2, 
SIV 
Vpx induces proteolytic 
degradation of SAMHD1 
[290],[292],[2
91],[293] 
 101–112 alpha-actinin 1 346–892 HIV-2, 
SIV 
Vpx and PIC nuclear 
import 
[294] 
 61-112 heat shock protein 40, 
Hsp40/DnaJB6 
100-326 HIV-2 PIC nuclear import [295] 
 Q76,K77[296], 
W24,K68,K77[297], 
V29,I32,A36,V37,H
39,Q76,F80[293] 
E3 ubiquitin ligase DCAF1  HIV-2 Macrophage infection [296],[297],[2
93] 
 H82 APOBEC3A  HIV-2 Vpx counteracts 
APOBEC3A in cytoplasm 
[298] 
 103-106 Src-like tyrosine kinase Fyn SH3  HIV-2 PIC nuclear import [299] 
 Y66, Y69, 
Y71[299], 
mitogen-activated protein 
kinase (MAPK/ERK-2) 
 HIV-2, 
SIV 
Vpx phosphorylation [299],[300] 
  CD74(MHC II invariant chain, Ii) 134-216 HIV-2 Vpx may disrupt major 
histocompatibility 
complex class IIantigen 
presentation 
[301] 
       
Tat 24-36,45-72[302], 
49-86[303],52-
57[304] 
RNA polymerase  IIa 1325-1630[304] HIV-1, 
HIV-
2[304] 
induce CTD 
phosphorylation and 
transcription from HIV-1 
promoter 
[302],[305], 
[303],[304], 
[306],[304] 
 P18,C22,K41[307],3
,6,10,47 
cyclin T1 (CCNT1,a component 
of PTEFb, a heterodimer of 
CycT1 and CDK9) 
(CDK9=PITALRE=TAK) 
44,111,112,253–256 HIV-1, 
HIV-
2[308] 
transcription elongation to 
TAR RNA 
[302],[307], 
[309], [310], 
[311],[312],[3
08] 
 K28[313],K50,K51[
314],20-
Histone acetyltransferase 1542-
2412[317],F748,V75
HIV-1 Tat acetylation, 
transcriptional activation 
[317],[318],[3
21], 
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40[315],Y47,R53[31
6] 
p300/CBP-associated factor  
(P/CAF) 
2,Y802,Y809[318], 
1253-
1710[319],760,761[3
20], 
V763,Y802,Y809[31
6] 
[322],[313], 
[323],[314],[3
15],[316] 
 47-57[324] tumor suppressor protein 
p53(TP53) 
K351[325],E343, 
E349, 326-355[324] 
HIV-1 Tat-induced transactivation [325],[324] 
 K51,R52,D67 20S proteasome E235,K236,K239 HIV-1 Affect proteasome 
function(antigen 
processing 
[326] 
 R49-R57[327] IkappaB-α 263-269[328] HIV-1 NF-kappaB deregulation [327],[328] 
 K50,K51[329], 32-
48[330] 
splicing regulator p32(32-kDa 
protein, TAP) 
244-260[331] HIV-1 Tat acetylation affected 
splicing of HIV-1 genome 
[332],[329], 
[331],[330] 
 P3-P6, P81-P84 Grb2 (growth factor receptor-
bound protein 2) 
160-212 HIV-1 Inhibit Tat-mediated 
transactivation 
[333] 
 1-49[334] transcription factor E2F-4 1-184 HIV-1 transcriptional activity ,[334] 
 K41,K50,K51[335] human sirtuin 1 SIRT1 F414,V445,P447[33
5] 
HIV-1 Tat inhibits SIRT1 
deacetylase activity 
[335],[336] 
 21-47 HT2A (TRIM32) 526-653 HIV-1, 
HIV-2 
transactivation [337] 
 72,86 INI1(hSNF5, BAF47,SMARCB1) Rpt1(183-294) and 
Rpt2 domain 
HIV-1 transcriptional activation [338] 
 K41,K50,K51 BRG-1 (SWI/SNF chromatin-
remodeling complex) 
1400-1700[339] HIV-1 transcriptional activation [339],[340]  
 37-72 microtubule-associated protein 
LIS1 (a subunit of platelet-
activating factor acetyl hydrolase) 
WD domain 5 HIV-1 Tat-induced apoptosis to 
distortion of microtubules 
polymerization 
[341] 
 67-101[342], 18-
36,36-56[343] 
TAFII250 (TAF1 RNA 
polymerase II) 
848-1279,885-
984,1120-1279 
Subtype B Tat repression of 
MHC class I transcription 
[342],[343] 
 49-86 mammalian mRNA capping 
enzyme Mce1 
211-597 HIV-1 stimulates capping of TAR 
RNA during transcription 
[344] 
 22-48 histone acetyltransferase GCN5 111-251,389-476 Subtype B transactivation [345] 
 49-72[346] Puralpha  100-121[346] HIV-1 transcriptional 
activation[346], 
deregulation of NGF 
transduction pathway[347] 
[346],[348],[3
47] 
 48-72 Y-box protein YB-1 75-203 HIV-1 Tat-induced transactivation [349] 
 30-72 Dicer (ATP-dependent RNase III) 246-585 HIV-1 Tat-induced transactivation [350] 
 1-48 chicken ovalbumin upstream 
promoter transcription factor-
interacting protein 2 (CTIP2) 
145-434 Subtype B Tat inactivation through 
subnuclear relocalization 
[351] 
 1-27[352] NFAT1 (nuclear factor of 
activated T cells) 
1-96[352] HIV-1 NFAT1 inhibits Tat-
mediated activation of 
HIV-1 LTR transcription 
[352],[353] 
 R49-R57 NAP1(nucleosome assembly 
protein 1) 
162-290,290-391 HIV-1 Tat-induced transactivation [354] 
 R49-R57 Nucleolar phosphoprotein 
B23(NPM1) 
187-255  Rev nuclear export ,[216] 
 73-101(second exon) human translation elongation 
factor 1-delta (EF-1δ) 
144-280 Subtype B Repress RNA translation [355] 
 Q35-F38, V36,F38 serine-threonine protein 
phosphatase PP1γ 
RVXF motifs Subtype B stimulates Tat-mediated 
transactivation of HIV-1 
LTR promoter in nucleus 
[356] 
 1-40 p160 coactivator GRIP1 1-97 HIV-1 HIV-1 LTR 
Transactivation by Tat 
[357] 
 C30,C31[358],31-
61[359] 
N-methyl-D-aspartate receptors 
NMDAR 
C744[358] Subtype B neuropathogenesis  [359],[358] 
 36-50 TATA-binding protein (TBP) 
subunit of TFIID 
last 181 amino acids HIV-1 transcriptional activity [360],[361] 
 30,41,10-48 transcription factor TFIIB 27-103,148-163 HIV-1 Stabilize transcriptional 
initiation complex 
[362] 
 1-48 CDK7 in TFIIH kinase  HIV-1 Tat transactivation [363],[364] 
 K13, L18, K21, T26, 
I27, T29, G33, L39, 
A57 
calmodulin  HIV-1 control multiple metabolic 
pathways. 
[365] 
 1-45 Toll-like receptor 4 TLR4-MD2  HIV-1  [366] 
 C22,C25,C27[327] Transcriptional coactivator p65  HIV-1 NF-kappaB deregulation [327], 
 K50 Endogenous BRM(a DNA-
dependent ATPase subunit of 
SWI/SNF) 
 HIV-1 transactivation [367] 
 R49,R52,R53,R55,R
56,R57,R78-
D80[368] 
αvβ3 integrins  HIV-1 activate focal adhesion 
kinase in extracellular 
[368], [369] 
 G48-R57 α5β1 integrins  HIV-1 Activate adhesion kinase 
in endothelial cells 
[369] 
 45-86[370] α4β7 integrin  HIV-1 cell attachment to tat in 
extracellular 
[370], 
 22,30 TIP60 (Tat interactive protein, 60 
kDa) 
 HIV-1 transactivation [371] 
 15-24,36-49 CDK2/cyclin E  HIV-1 Cdk2 phosphorylates [302] 
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tat,transcription 
 1-48[372] TIP30(CC3,SDR44U1,HTATIP2)   HIV-1 transactivation [372],[373] 
 47-67 CCAAT/enhancer binding 
protein(C/EBPβ) 
 HIV-1 activation of MCP-1 
transcription 
[374] 
 46-60 VEGF receptor Flk1/KDR  HIV-1 Tat-induced angiogenesis [375] 
 24-51 β-chemokine receptors CCR2  HIV-1 Receptor activation in 
extracellular  
[376] 
 24-51 β-chemokine receptors CCR3  HIV-1 Receptor activation in 
extracellular  
[376] 
 24-51 CXCR4  Subtype B viral entry interference [377] 
 37-48 lipoprotein related protein 
receptor (LRP) 
 Subtype B neuropathogenesis  [378] 
 36-39 microtubule  αβ-tubulin  HIV-1 Tat-induced apoptosis [379] 
 R49-R57 Importin β  HIV-1 Tat nuclear import into 
nuclei 
[209] 
 49-57 heparan sulfate proteoglycans 
(HSPG) of syndecan-2, syndecan-
4, and CD44v3 
 HIV-1 Tat transduction in 
extracellular 
[380],[381] 
 R49-R57 vascular endothelial growth factor 
receptor type 2 (VEGFR2,KDR) 
 HIV-1 endothelial cell activation 
in extracellular 
[382] 
 F31-G60 dextrin-2-sulfate(D2S)  HIV-1 D2S inhibits tat 
transactivation 
[383] 
 C22 dopamine transporter (DAT)  HIV-1 Tat regulates DAT activity 
on plasma membrane 
[384] 
 48-60[385],46[386] protein kinase C- α(PKC- alpha)  HIV-1 inhibit PKC 
phosphorylation of 
ERK1/2 in cytoplasm 
[385],[386] 
 40-58[387] RNA-activated kinase PKR  Subtype B Phosphorylation of Tat by 
PKR, Tat inhibits PKR 
autophosphorylation 
[387],[388] 
 K71 MDM2 E3 ubiquitin ligase 
(Hdm2) 
 Subtype B Hdm2 ubiquitinates Tat [389] 
 R53-R56 furin   HIV-1 furin cleaves tat to 
inactivate extracellular tat 
[390] 
 1–22, 38–53, 93–101 MAb 7G12    [391] 
 E9-K12 Fab 11H6H1 antibody G91,Y58 HIV-1  [392] 
  Werner syndrome helicase 
(WRN) 
K577 HIV-1 Recruit transcription 
complex 
[393] 
  DDX3 536-661 HIV-1 transactivation [394],[395] 
       
GP120 101-120,160-
175,252-261,308-
328 
protein-disulfide isomerase (PDI) acidic C terminus Subtype B env biosynthesis in ER [396] 
 317,318,320,322 Salivary agglutinin gp340 (SAG) 33-36,73-76,94-97 Subtype B gp340 binds GP120 to 
inhibit coreceptor binding 
[397],[398],[3
99] 
 365-371,425-
430,112,255,256,257
,368-371,375-
377,382,384,427,473
,475 
CD4 Q40P, F43L,G47R 
[400],K29,K35,K46,
R59,F43[401] 
HIV-1 GP120-receptor binding [402],[403],[4
04],[405],[406
],[407],[400].[
401] 
 296-331(V3 domain) CCR5 2-15[404] HIV-1, 
HIV-2, 
SIV 
GP120-receptor binding [408],[409],[4
04] 
 296-331(V3 domain) CXCR4 E14,E15,D20,Y21,D
22,D187-
Y190,D193,D262, 
E268,E277,E282[40
8] 
HIV-1, 
HIV-2, 
SIV 
GP120-receptor binding [408],[409],[4
10],[411] 
 296-331(V3 domain) CCR3  HIV-1 GP120-receptor binding [412],[410],[4
13] 
 301-317 immunophilins FK506-binding 
protein (FKBP12) 
 Subtype B immunophilins binds 
gp120 in extracellular 
[414] 
 31-50,101-120,160-
175,308-324 
Calnexin(CNX)  Subtype B env biosynthesis in ER [396] 
 R508-R511[415] furin  HIV-1 Cleaves gp160 into gp120 
and gp41 in ER 
[415],[416],[4
17] 
 R419,K421,K432 heparan sulfate proteoglycans 
(HSPG,SDC2) 
 Subtype B co-receptor recognition in 
extracellular 
[418] 
 204,259,309 mannose-binding lectin 
Concanavalin A (ConA) 
 Subtype B  [419] 
 230,289,295,386,392
,448[420],234,241,2
89,339[421],262,332
[422] 
Lectin grifﬁthsin(GRFT) 30,70,112[423] A,B,C  [420],[424],[4
21],[422],[423
],[425] 
 230,234, 289, 295, 
332, 339, 
386,392,448[424],39
7[426],302,362,367,
376,418[419] 
mannose-binding lectin 
Cyanovirin-N 
2-3,7,23-27,93-
95,41-
44,50,53,56,57,74-
78,93 
A,B,C  [427], 
[424],[419], 
[428],[429],[4
30], [431] 
 332,392,339,295 mAb 2G12 19  Inhibit GP120-receptor 
binding[432] 
[433],[434], 
[435],[436],[4
37],[432] 
 197,301,364,369,372 mAb b12    [402],[438],[4
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,373[407] 39],[440],[407
] 
 334,386,392,397,450 mAb 17b[441]    [442],[439],[4
43],[440] 
 S256,T257,D368-
E370,K421,P470-
484[444] 
mAb F105  Subtype B  [445],[440],[4
44] 
 420–423 mAb E51    [443],[446],[4
47] 
 298,302,303,441 mAv 412d    [404], [443] 
 176,177,179,180,183
,184,192-194 
mAb 697-D  Subtype B  [448] 
  mAb 830A     
 510-516 mAb 1331A    [441] 
  mAb VH1-69     
 230,234,276 mAb 8ANC195    [449] 
 293,334,337,340,460 mAb 19.3H-L1,L3 295,333,335   [450] 
 119,199,207,298,366
,367,368,392,423,42
6,427,430,432,435,4
37,472,473 
mAb m6    [451] 
 227,229,233 mAb m9    [451] 
 227,233,234,423,432 mAb scFv X5    [451] 
 D368 mAb m43    [452] 
 295,332,392,386,448
[453] 
mAb 2G12  A,B,C  [440], [453], 
 F159,N160,L165-
D167,K169,K171 
mAb CAP256  A,B,C  [454] 
 309,312-317 F425-B4e8 (B4e8) 32,92,100 B,C,D  [455],[456] 
 K160,295,406,448,4
63 
3BC176, 3BC315  A,B,C  [457], 
 156,158-
160,162,173,176,181
,299 
PG9 96-102 A,B,C,D,
G,F,01_A
E,02_AG 
 [458],[459],[4
60],[461] 
 156,158-
160,162,173,176,181
,299,305,307,309,31
7,318 
PG16 96-102 A,B,C,D,
G,F,01_A
E,02_AG 
 [458], 
[461],[462]  
 301,332 PGT128    [463],[464] 
 127,159,160,168,169
,171,181 
CH01, CH02, CH03, CH04    [465] 
 D474,R476,M475,R
476[466] 
HJ16    [466],[467], 
 307-312,315-317 HGN194  Subtype C  [468],[469] 
 50,58,67,71,96,100 VRC01 276,279,280,456,459
,368 
  [402],[470],[4
71], [472] 
 S199,N276,D279,N2
80,I420,I423,D457,
N461,S463,R469 
PGV04(VRC-PG04）    [473],[474] 
 K305,H308,R315 Fab 268-D    [475] 
 308,309,312-318 Fab 1006 Y32,W91(light 
chain), 
D31,W33,Y52,P53,
D54,D56(heavy 
chain). 
A,B,C  [475], [476] 
 307-318 Fab 2219 Y32,W91(light),D31
,W33,Y52,P53,D54,
D56(heavy) 
A,B,C  [475],[476],[4
77]  
 304-309,312-318 Fab 2557 K31,Y32,W91-
L98(light), 
D31,W33,Y52, 
P53,D54,D56,H58,L
95,L97,N100(heavy) 
A,B,C  [475], [476] 
 307,309,313,317 Fab 3074 Y49(light),S30,Y53,
F96,E98-
Y100(heavy) 
A,B,C  , [476] 
 160,167,169,313,315 Fab 2909 95-100 SF162  [461],[478],[4
79]  
 R304,K305,I307-
I309,F317,Y318 
Fab 2558 N30,K31,Y32,W91(l
ight),D31,W33,D54,
D56(heavy chain) 
02_AG  [476] 
 R304,K305,I307-
I309,F317,Y318 
Fab 4025 N30,K31,Y32,W91(l
ight),D31,W33,D54,
D56(heavy chain) 
  [476] 
 305-309,312-315 Fab 447-52D W33,R50,K52,S100-
Y106(heavy 
chain),Y34,W93,A9
9,W101(light chain) 
A,B,C  [480],[481],[4
82],[483],[484
]  
 304-309,312-316 Fab 537-10D W33,W47,N50,Y61,
E91,Y95,D97,L99-
M108(heavy chain), 
N30,G31,Y34,Y93,P
99-V101 
A,B,C  [482] 
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 312-315 Fab 0.5β D30,Y32,Y49,E55,F
96 (light), H52, Y53, 
D55,D56,E61,Y96,Y
100(heavy) 
Subtype B  [485],[486] 
       
GP41 W597–W 611 CD74 72-232 Subtype B activation of ERK/MAPK 
pathway during viral entry, 
extracellular membrane 
[487] 
 790-811 P155-RhoGEF 860-913 Subtype B gp41C inhibited p115 
mediated actin stress fiber 
formation and SRF 
activation 
[488] 
 751-768 human bZIP transcription factor 
Luman 
100-314 HIV-1 TMgp41 inhibits 
transcriptional activation 
mediated by Luman fusion 
[489] 
 822-855 α-catenin 787-813 HIV-1 GP41 cytoplasmic domain 
binds to actin filaments 
[490] 
 670–677 Z13e1 30-33,50-58,97-100 HIV-1 GP41 neutralizing 
antibody 
[491],[492],  
 769–788, 826–
854(LLP-
1)[493],835,838[494
] 
ubiquitous calcium-sensing 
calmodulin (CaM, CAMI) 
 Subtype B Fas-mediated apoptosis [493],[495],[4
94] 
 W623-W631 Caveolin-1  Subtype B Env trafficking to 
membrane 
[496] 
 539-684 HSP60  HIV-1 ? [497] 
 E633–S650, D675–
K685 
Retrocyclin-1  Subtype B retrocyclin-1 prevented 6-
helix bundle formation 
[498] 
 618–623 gC1qR, receptor on CD4+ 
lymphocytes 
 HIV-1 induces NKp44L cell-
surface expression 
[499] 
 708-750 major histocompatibility complex 
class II MHC-II 
 Subtype B incorporation of HLA 
class II proteins 
[500] 
 650-685 galactosyl ceramide (GalCer)    [501] 
 762-773 TGF-beta-activated kinase 1 
TAK1 
 HIV-1 gp41CD-mediated NF-κB 
activation 
[502] 
 Y707-L710,Y763-
L766[503], Y712, 
Y721,L855-
L856[504], Y712-
Y715[505] 
clathrin adaptor complex 1 AP-1, 
μ1 subunit (AP47) 
 HIV-1, 
SIV,HTL
V-1 
Env trafficking [503], [504], 
[505], 
 Y712-Y715[505] clathrin adaptor complex 1 AP-1, 
μ2 subunit 
 HIV-1 Env trafficking [505] 
 (HIV-1)Y707-
L710,Y763-
L766[503], Y712-
Y715[505], G711-
715,L855,L856[506]
, Y712-L715,Y768-
L771[507], (HIV-
2)G706,Y707[508] 
clathrin adaptor complex 2 AP-2, 
μ1 subunit (AP50,mu2) 
 HIV-
1,HIV-2 
Env trafficking [503], [505], 
[506], [507], 
[508] 
 Y707-L710,Y763-
L766[503], 712-
715[504] 
clathrin adaptor complex 3 AP-3, 
μ1 subunit (mu3A adaptin) 
 HIV-1 Env trafficking [503], [504] 
 745-751 monoclonal antibody(mAb)SAR1    [509],[510] 
 662-670 mAb 2F5 F100B[511]   [511],[512],[5
13],[514],[515
],[516],[517], 
[518],[519],[4
91],[520] 
 647-682 mAb 1281    [441] 
 567-647 mAb 1367    [441] 
 735-752 mAb 1575    [28],[510] 
 746-750 mAb 1577, MAb 1583    [521] 
 671-676[522], 
679,680[523] 
mAb 4E10 31-33,47,50-58,91-
95,100 
A,B,C,D,
G,F,01_A
E,02_AG 
 [512],[514],[5
15],[524],[491
],[520] 
 N671,W672,F673,T
676,L679,R683 
mAb 10E8    [525] 
 672-676 mAb CAP206-CH12    [526] 
 664-666,669,671 mAb 13H11 94-96,101   [527] 
 564,567,568,571,573
-575,577,579, 
636,643 
mAb HK20 I53-N58[528]   [468] ,[528] 
 M593,G594,G597,G
600,L602,W610,V6
12,W614,K617,V61
9-W623,M626-D636 
mAb m44    [529] 
 569,675 mAb b12  B,C  [407] 
 Q563,H564,Q567,L
568,W571,I573,K57
4,Q575,Q577[528],
mAb D5 I52-N58[528]   [530],[528] 
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H564,L568,V570-
Q577,D632,N636,T
639,H643[530] 
 E560,H564,L565,Q5
67,L568,V570-
Q577,R579,M629,D
632,N636,S640,H64
3,I646,E647 
Fab 8066 P27,E30,Y31,Y48, 
N52,S92,M93,V95 
  [530] 
 E560,Q563,H564,L5
65,Q567,L568,V570
-Q577, R579, N636, 
H643, I646 
Fab 8062 E30,Y31   [530] 
 643-661 Fab 1281    [531] 
 E560,H564,W571,K
574,Q575 
Fab 3674    [532] 
 786~856 lipid rafts    [533],[534] 
 727-732 Chessie 8    [535] 
 741-751 EPES  Subtype B GP41 neutralizing 
antibody 
[536] 
 L799,L800 Prohibitin Phb1/Phb2 heterodimer  HIV-1 Phb-dependent cellular 
process 
[537] 
 750-763,764-785 Golgi retrieval signals    [538] 
 586–596 receptor protein P45  HIV-1 Gp41 binds receptor 
proteins during viral entry 
[539],[540] 
       
Nef P72-
P75[541],76,R77,86,
90, 
106,109,113,120 
Src family kinase Fyn R96,119,94-100 Subtype B suppress Fyn kinase and 
transforming activities, 
altered T cell receptor 
signaling 
[542],[543] ,[
544],[545] , 
[541], [546] 
 P72-P75 Src family kinase c-Src SH3 motifs HIV-1 actiate c-Src activity in 
transGolgi network 
[541] 
 E62-E65[547],P72-
P75,96[548], 
P72,V74,P75,R77[5
49], 
Src family kinase Hck SH3 D67,E69[548],72-
256[550] 
HIV-1 actiate Hck activity in 
transGolgi network 
[548], [550], 
[549], [541], 
[546], [547] 
 P72-P75[541],P69-
A83[551] 
Src family kinase LCK SH3 motifs Subtype B Nef decreases vitro kinase 
activity of Lck 
[551], [541] 
 1~30 N-myristoyl transfterase2(NMT2) 40-50,170-185 HIV-1 Nef is myristoylated by 
NMT2 
[552],[553] 
 109,110, p21-associated kinase 1(PAK1, 
NAK) 
83-149[554] Subtype B activation of a PAK-
related kinase 
[554], 
 57-
59,60,95,96,97,106, 
109,110[555],123[54
9],L164,L165[556] 
CD4 408-418 HIV-1 Nef downregulates CD4 [555], [549], 
[556] 
 57-59 CD28 191,185,193 HIV-1, 
SIV 
Nef downregulates CD28 [557] 
 149-155,174-
179[558],158-
178[559] 
NBP1, ATP6V1H, V1H unit of 
vacuolar ATPase 
133-363,402-
483[559] 
Subtype B endocytic trafﬁcking, 
Internalization of CD4 
 
[558],[560],[5
60], 
 2 ATP-binding cassette ABCA1 2225-2231[561] HIV-1 induces downregulation, 
redistribution of ABCA1 
to plasma membrane 
[561], 
 174,175,179 c-Raf1 kinase 33-38 Subtype B Activate c-Raf1-MAP 
kinase pathway 
[562] 
 72,75[563],F195[56
4] 
SH3 domain of Vav1 (Rho family 
of small GTPases) 
783–843[563] HIV-1, 
SIV 
nef recruits Vav1 to 
membrane microdomains, 
associate with PAK2 
activity 
[563],[564] 
 72-75 diaphanous interacting protein 
(DIP) 
SH3 domain HIV-1 activates p190RhoAGAP, 
downregulates RhoA 
[565] 
 72,75,78 Rack1(receptor for activated C 
kinase 1) 
181~317 Subtype B Rack1 acts as a Nef 
intracellular docking site 
[566] 
 69-83 mitogen-activated protein kinase 
(MAPK) 
69-71 Subtype B Nef decreases MAPK 
kinase activity in T cell 
[551] 
 158,177 Regulatory p85 subunit of PI3K 477-514 Subtype B activate p21-activated 
kinase (PAK) 
[567] 
 G2,R106 apoptosis signal-regulating kinase 
ASK1 
152-159[568] Subtype B Nef inhibits ASK1 pro-
apoptotic signals 
[568],[569] 
 E62-E65[570],P72-
P75,20,78,113 
PACS-1 (phosphofurin acidic 
cluster sorting protein-1) 
N188,K189,Q195 Subtype B downregulation of MHC-I 
to the trans-Golgi network  
[571], [572], 
[573],[570] 
 E62-E65, P72-P75 PACS-2 (phosphofurin acidic 
cluster sorting protein-2) 
 HIV-1 Nef action and Trafficking 
of itinerant membrane 
[574] 
 E62-
E65,P69,P72,P75,P7
8,D123[575],W13,V
16,M20[576], 
L164,L165[577], 
Y143,L181,F185[57
clathrin adaptor complex 1 AP-1, 
μ1 subunit (AP47, AP1M1) 
R303, K274E 
K298E K302E 
R303D,K374,R225,
R393,K396,R211,R2
46,218-231[575], 
F172,D174,V392,L3
Subtype 
B,SIV 
clathrin-associated sorting [580], [575], 
[577], [578] 
Appendix 9.2: HIV-human protein interaction 
  
361 
8] 95[579] 
 E160,L164,L165[58
1],17-26[582], 
adapter protein complex 1 AP-1, 
γ subunit 
 HIV-1 Nef interacts with γ-σ1 
complex [583] 
[581],[583],[5
77],[582], 
[584] 
 L164,L165[556] adapter protein complex 1 AP-1,  
β1 subunit (beta-adaptin) 
   [556] 
 E160,L164,L165[58
4], D174-
D175,E179[585] 
adapter protein complex 2 AP-2, 
α1 subunit 
K297,R340[586] Subtype B Nef stabilizes association 
of AP-1 α-σ2 complex 
with membranes 
[584], [585] 
 L164,L165[556], adapter protein complex 2 AP-2, 
β1 subunit (beta-adaptin) 
   [556] 
 E160,L164-
L165[587], 
clathrin adaptor complex 2 AP-2, 
μ1 subunit (AP50,mu2) 
 HIV-
1,SIV,HI
V-2 
CD4 downregulation[587] [587], [588] 
 L164-L165 clathrin adaptor complex 3 AP-3, 
μ1 subunit (mu3A adaptin) 
 Subtype B Nef stabilizes association 
of AP-1 and AP-3 with 
membranes 
[589], 
 E160,L164,L165 adapter protein complex 3 AP-3, 
δ subunit 
 HIV-1 Nef interacts with δ-σ3 
complex [583],Nef 
stabilizes association of 
AP-3 with membranes 
[581], [583], 
[584] 
 R17,R19,E154,E155
[590] 
Beta-COPI (component of non-
clathrin-coated vesicles) 
 Subtype B endosomal sorting [590],[591],[5
92] 
 67-69,72-
73,75,77,90[549], 
85,89,106,187,188,1
91[593],F191,F195[
594] 
p21 activated protein kinase 
PAK2 
 HIV-1 activate primary 
CD4/CD8+ T cells 
[593], 
[595],[594] 
 135-138 ALIX (ALG-2 interacting host 
protein, AIP-1) 
 Subtype B Proliferate multivesicular 
body in macrophages 
[596] 
 D174,D175 Beclin 1  HIV-1 Prevent autophagy 
degradation 
[597] 
 66-70[598] heat shock protein 
Hsp70(mortalin) 
 Subtype B exosomal Nef secretion [598],[599] 
 G2-S9 ubiquitous calcium-sensing 
calmodulin (CaM, CAMI) 
 HIV-1 Nef intracellular 
localization and membrane 
targeting 
[600] 
 62-65,72-75 Gαi2 (α subunits of G-protein Gi) HECT domain Subtype B nef recruits AIP4 E3 ligase 
to ubiquitinate Gαi2 for 
lysosomal degradation 
[601] 
 73-82 T Cell Receptor zeta chain(TCRξ)  Subtype B nef-TCR form signaling 
extracellular complex 
mediates fasL upregulation 
[602] 
 108,112,121-123 human thioesterase II 
(hTE,ACOT8) 
 Subtype B enhances hTE enzymatic 
activity 
[603],[604] 
 P72,P75,P106 DOCK2  HIV-1 activates Rac activity [605] 
 P72,P75,P106 ELMO1  HIV-1 activates Rac activity [605] 
 P72,P75,P106 Rac2  HIV-1 activates Rac activity [605] 
 1-57 Tumor suppressor protein 
p53(TP53) 
 Subtype B Inhibit p53-mediated 
apoptosis 
[606] 
 16-22 p62  Subtype B Nef phosphorylation [607] 
 186-191 β-catenin  HIV-1 Inhibit Wnt Signaling 
pathway 
[608] 
 112,121-123, 164, 
165 
dynamin 2 (Dyn2) GED domain HIV-1 Dyn2 enhances Nef 
activity 
[609] 
 6,1~35 protein kinase C- θ(PKC- theta)  HIV-1 Inhibit activated PKC 
binds to RACK 
[610],[611] 
 6 protein kinase C- δ(PKC- delta )  HIV-1 myristoylation of Nef and 
Pak2 activity 
[610],  
 14-23(alpha-
helix),138-211 
Embryonic ectodermal 
development (EED) 
 HIV-1 Nef recruits EED to 
plasma membrane 
[612] 
 12,13,140,141 Argonaute-2 (AGO2)  HIV-1 Nef inhibits RNA slicing 
activity of Ago2 
[613] 
 73-82 HLA-A3 heavy chains  HIV-1 T cell antigen receptor 
recognition 
[614] 
 G67,F68,P78,D123[
549],W13,V16[576],
10,17-
26,20,123,E62-
E65,72,75,P78,  
major histocompatibility complex 
class I MHC-I cytoplasmic 
domain 
327-
332,Y320,324,327 
HIV-1 Nef downregulate MHC-I [615], 
[616],[549], 
[575],[576], 
[580], 
 164,165,174,175 major histocompatibility complex 
class II MHC-II variant (Ii) chain 
 Subtype B Nef reduces mature MHC 
II 
[617], [618] 
  Naf1 (Nef-associated factor 1, 
VAN) 
94-412 HIV-1 CD4 down-regulation on 
plasma membrane 
[619] 
 A60-E65 tumor necrosis factor 
receptor-associated factor TRAF2 
R393,R403, 
F447,S454,F456 
Subtype B Activate TRAF/NF-kB and 
TRAF/IRF-3 pathway 
[620] 
 73~88 Actin    [621] 
 4,7,17-22 [622], 2-
27[623]  
cytoplasmic membrane    [622],[623], 
[624] 
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